



# Skin Melanoma Clinical Registry

of the Cancer Registry of  
Republic of Slovenia

2018-2022

report



## Report of the Skin Melanoma Clinical Registry of the Slovenian Cancer Registry 2018–2022

### Editorial Board

Vesna Zadnik, editor in chief  
Katarina Lokar, Sonja Tomšič, Tina Žagar

### Data Processing and Analysis

Katarina Lokar, Miran Mlakar, Tina Žagar, Nika Bric, Mojca Birk, Ana Mihor

### Design and Typesetting

Nika Bric

### Copy Editing

Soglasnik Language Cooperative

### Printing

Tisk Žnidarič d.o.o., Kranj

### Staff of the Skin Melanoma Clinical Registry

Laura Šeneker Zupanc, Polona Rus, Agata Čampa

### Expert Advisers

Marko Hočevar, Boštjan Luzar, Janja Ocvirk, Barbara Perić, Primož Strojman

### Employees of the Slovenian Cancer Registry that also contributed to data processing for 2018–2022

Frančiška Škrlec, Maruška Ferjančič, Andrej Krašovec, Martina Omerzo,  
Branka Pestotnik, Sabina Prvinšek, Polona Škulj, Urška Tomšič, Boštjan Zavratnik,  
Brigita Zore, Vesna Drolec, Katja Hribar, Katja Kolenc Mokotar

### Correspondence to

Slovenian Cancer Registry  
Institute of Oncology Ljubljana  
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija  
Phone: + 386 1 5879 450  
E-mail: [register@onko-i.si](mailto:register@onko-i.si)  
Websites: <https://www.onko-i.si/eng/rrs/cr> <http://www.slora.si/en>

Report of the

**Skin Melanoma  
Clinical Registry**

at the Slovenian Cancer Registry

for the 2018–2022 period



# Contents

|                                                                                                                                                                                                                 |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Editorial .....                                                                                                                                                                                                 | 10 |
| Data .....                                                                                                                                                                                                      | 12 |
| <b>Data Sources</b> .....                                                                                                                                                                                       | 12 |
| <b>Data Processing</b> .....                                                                                                                                                                                    | 13 |
| Tumour Site and Morphology .....                                                                                                                                                                                | 13 |
| Disease Staging .....                                                                                                                                                                                           | 13 |
| Treatment .....                                                                                                                                                                                                 | 14 |
| Survival and Time to Disease Progression .....                                                                                                                                                                  | 14 |
| <b>Terminology Used</b> .....                                                                                                                                                                                   | 15 |
| Burden of Skin Melanoma .....                                                                                                                                                                                   | 16 |
| Figure 1a: Estimated age-standardised incidence (new European standard) of malignant skin melanoma for both sexes combined in Europe 2022. ....                                                                 | 16 |
| Figure 1b: Estimated age-standardised mortality rate (new European standard) of malignant skin melanoma for both sexes combined in Europe 2022. ....                                                            | 17 |
| Figure 2: Map of malignant skin melanoma (C43) by electoral district; spatially smoothed standardised incidence rates, Slovenia 2005–2014. ...                                                                  | 18 |
| Figure 3a: Time trend of the crude and age-standardised incidence rate of malignant skin melanoma (C43) per 100,000 population. ....                                                                            | 19 |
| Figure 3b: Time trend of crude and age-standardised malignant skin melanoma (C43) mortality rate per 100,000 population. ....                                                                                   | 19 |
| Figure 4: Proportions of malignant and in situ skin melanoma (C43, D03) by site and sex, Slovenia 2018–2022. ....                                                                                               | 21 |
| Figure 5: Breslow tumour thickness proportions (mm) for malignant skin melanomas (C43) with mean annual change for the last 10 years, Slovenia 1999–2022. ....                                                  | 22 |
| Figure 6: Time trend of 5-year net survival of patients with malignant skin melanoma (C43) by stage, Slovenija 1998–2022. ....                                                                                  | 22 |
| Figure 7: Primary invasive skin melanoma (C43, C51, C60, C63) – age-standardised 5-year net survival in adults (15–99 years) by European countries and period of diagnosis 2000–2014: the Concord-3 study. .... | 23 |

## Patients and Disease Characteristics ..... 24

|           |                                                                                                                                                                                                |    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table 1:  | Incidence of skin melanoma (C43, C51, C60, C63, C77–C80, D03) by site, age, and sex with crude incidence rate (CR) per 100,000 population and cumulative rate (CumR), Slovenia 2018–2022. .... | 24 |
| Table 2:  | Prevalence of skin melanoma (C43, C51, C60, C63, C77–C80, D03) by site and sex, Slovenia 2018–2022. ....                                                                                       | 25 |
| Table 3:  | Skin melanoma (C43) mortality by age and sex with crude mortality rate (CR) per 100,000 population, Slovenia 2018–2022. ....                                                                   | 26 |
| Table 4:  | Skin melanoma (C43, C51, C60, C63, C77–C80, D03) incidence by site and sex, Slovenia 2018–2022. ....                                                                                           | 26 |
| Table 5:  | Number and proportion of primary invasive skin melanoma (C43, C51, C60, C63) per patient, Slovenia 2018–2022. ....                                                                             | 29 |
| Table 6a: | Number and proportion of primary invasive skin melanoma (C43, C51, C60, C63) by UICC stage, Slovenia 2018–2022. ....                                                                           | 29 |
| Table 6b: | Sites of distant metastases of primary invasive skin melanoma (C43, C51, C60, C63), Slovenia 2018–2022. ....                                                                                   | 30 |
| Table 7a: | Number and proportion of primary invasive skin melanoma (C43, C51, C60, C63) according to Breslow thickness, Slovenia 2018–2022. ....                                                          | 31 |
| Table 7b: | Number and proportion of primary invasive skin melanoma (C43, C51, C60, C63) with confirmed ulceration according to Breslow thicknesses, Slovenia 2018–2022. ....                              | 31 |
| Table 7c: | Number and proportion of Breslow thickness distribution in primary invasive skin melanoma (C43, C51, C60, C63) by sex and age, Slovenia 2018–2022. ....                                        | 32 |
| Table 8:  | Number and proportion of skin melanoma (C43, C51, C60, C63, C77–C80, D03) by histological type, Slovenia 2018–2022. ....                                                                       | 34 |

## Survival ..... 35

|           |                                                                                                                                                                                                                                                                          |    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table 9a: | One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by ICD classification and sex, Slovenia 2018–2022. .... | 35 |
| Figure 8: | Kaplan-Meier survival curve to first progress or death for patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by ICD classification and sex, Slovenia 2018–2022. ....                                                                                        | 35 |

|            |                                                                                                                                                                                                                                                                                      |    |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Figure 9:  | Kaplan-Meier observed survival curve for patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by ICD classification and sex, Slovenia 2018–2022. ....                                                                                                                      | 35 |
| Table 9b:  | One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by histological type, Slovenia, 2018–2022. ....                 | 36 |
| Figure 10: | Kaplan-Meier survival curve to first progress or death for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by histological type, Slovenia, 2018–2022. ....                                                                                                        | 36 |
| Figure 11: | Kaplan-Meier observed survival curve for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by histological type, Slovenia, 2018–2022, ....                                                                                                                          | 36 |
| Table 9c:  | One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by age group, Slovenia 2018–2022. ....                          | 37 |
| Figure 12: | Kaplan-Meier survival curve to first progress or death for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by age group, Slovenia 2018–2022. ....                                                                                                                 | 37 |
| Figure 13: | Kaplan-Meier observed survival curve for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by age group, Slovenia 2018–2022. ....                                                                                                                                   | 37 |
| Table 9d:  | One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by UICC stage (simplified classification), Slovenia 2018–2022. .... | 38 |
| Figure 14: | Kaplan-Meier survival curve to first progress or death for patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by UICC stage, Slovenia 2018–2022. ....                                                                                                                    | 38 |
| Figure 15: | Kaplan-Meier observed survival curve for patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by UICC stage, Slovenia 2018–2022. ....                                                                                                                                      | 38 |
| Table 9e:  | One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by Breslow thickness, Slovenia, 2018–2022. ....                 | 39 |
| Figure 16: | Kaplan-Meier survival curve to first progress or death for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by Breslow thickness, Slovenia, 2018–2022. ....                                                                                                        | 39 |

|            |                                                                                                                                                             |    |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Figure 17: | Kaplan-Meier observed survival curve for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by Breslow thickness, Slovenia, 2018–2022. .... | 39 |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----|

## Diagnostics ..... 40

|           |                                                                                                                                                                                          |    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table 10: | Health care institution that performed excisional biopsy (all lesions are included) to diagnose primary skin melanoma (C43, C51, C60, C63, D03), Slovenia 2018–2022. ....                | 40 |
| Table 11: | Histopathology laboratory that assessed the excisional biopsy specimens (all lesions are included) to diagnose primary skin melanoma (C43, C51, C60, C63, D03), Slovenia 2018–2022. .... | 42 |
| Table 12: | Type of biopsy for pathology report (all lesions are included) for primary skin melanoma (C43, C51, C60, C63, D03), Slovenia 2018–2022. ..                                               | 42 |
| Table 13: | Diagnostic histopathology of excisional biopsy specimens (all lesion excisions are included) in primary invasive skin melanoma (C43, C51, C60, C63), Slovenia 2018–2022. ....            | 43 |
| Table 14: | Diagnostic histopathology of surgically removed regional lymph nodes in the primary treatment of invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. ....          | 45 |
| Table 15: | Number of imaging tests in baseline staging of skin melanoma (C43, C51, C60, C63, C77–C80, D03) by UICC stage, Slovenia 2018–2022. ....                                                  | 45 |
| Table 16: | The presence of BRAF, NRAS and c-KIT mutation in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. ....                                            | 46 |
| Table 17: | Level of serum LDH in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. ....                                                                       | 46 |

## Treatment ..... 47

|            |                                                                                                                                                                |    |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table 18a: | Number and proportion of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by type of first treatment, Slovenia 2018–2022. ....               | 47 |
| Table 18b: | Number of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by UICC stage and type of first treatment, Slovenia 2018–2022. ....               | 47 |
| Table 18c: | Number and proportion of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by age group and type of first treatment, Slovenia 2018–2022. .... | 47 |

|            |                                                                                                                                                                                                                          |    |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table 19a: | Surgical treatment of regional lymph nodes for invasive skin melanoma (C43, C51, C60, C63, C77–C80) by treatment indication, Slovenia 2018–2022. ....                                                                    | 48 |
| Table 19b: | Number of patients with non-sentinel lymph node involvement after primary treatment with lymph node dissection in primary invasive skin melanoma (C43, C51, C60, C63), Slovenia 2018–2022. ....                          | 49 |
| Table 19c: | Amount and proportion of positive sentinel lymph nodes by Breslow thickness in patients with primary invasive skin melanoma (C43, C51, C60, C63) the course of first treatment, Slovenia 2018–2022. ....                 | 50 |
| Table 20:  | Radiotherapeutic treatment for invasive skin melanoma (C43, C51, C60, C63, C77–C80) by type of radiotherapy and treatment indication, Slovenia 2018–2022. ....                                                           | 51 |
| Table 21a: | Number of systemic treatments by regimen, therapeutic subgroups and administered drugs according to place in therapy in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. ....     | 52 |
| Table 21b: | Number of systemic treatments by regimen, therapeutic subgroups and administered drugs by treatment indication in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. ....           | 54 |
| Table 21c: | Number of systemic treatments by treatment type, medication group and administered medication by UICC stage at diagnosis in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. .... | 59 |
| Table 21d: | Number of systemic treatments by treatment type, medication group and administered medication by BRAF status in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. ....             | 64 |
| Table 21e: | Number of systemic treatments by treatment type, medication group and administered medication by age in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. ....                     | 68 |
| Table 22a: | Review of performing assessment of response to systemic treatment in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022. ....                                                        | 72 |
| Table 22b: | Assessment of response to treatment in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by systemic treatment regimen, Slovenia 2018–2022. ....                                                        | 72 |

|                                                                                                                                                                                                                                                     |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| <b>Adverse events</b>                                                                                                                                                                                                                               | 73 |
| Table 23: Adverse events* of systemic treatment in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), by treatment type, Slovenia 2018–2022.                                                                                       | 73 |
| <b>Conclusion of Systemic Treatment</b>                                                                                                                                                                                                             | 74 |
| Table 24: Reasons for systemic treatment discontinuation in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by treatment type, Slovenia 2018–2022.                                                                               | 74 |
| <b>Disease Recurrence</b>                                                                                                                                                                                                                           | 75 |
| Table 25: First recurrence of disease in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by primary disease site, recurrence type and time from start of primary systemic treatment and disease progression, Slovenia 2018–2022. | 75 |
| <b>Compliance with Guidelines</b>                                                                                                                                                                                                                   | 76 |
| Table 26: Adherence to clinical practice guidelines in diagnostics and primary treatment of patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by stage (excluding autopsy-only registered cases), Slovenia 2018–2022.                  | 76 |
| Table 27: Treatment of recurrence in patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by year of diagnosis (for progresses of main lesions up to and including Dec 31 2023), Slovenia 2018–2022.                                      | 96 |
| <b>Quality Indicators</b>                                                                                                                                                                                                                           | 98 |
| Table 28a: Quality indicators for skin melanoma, Slovenia 2018–2022.                                                                                                                                                                                | 98 |
| Table 28b: Calculation methodology of quality indicators for skin melanoma, Slovenija 2018–2022.                                                                                                                                                    | 98 |

In recent years, more than 15,000 Slovenians have been diagnosed with cancer every year, and more than 6,000 have died. There are currently more than 100,000 Slovenians who have ever been diagnosed with cancer. As it is more common in older people and the large post-war generation is approaching this age, it is expected that the burden of the disease will continue to increase, even if the exposure to risk factors remains the same as today. Over the last ten years, cancer incidence in Slovenia has increased by an average of 2% per year and mortality by just under 1% per year. A systematic and long-term reduction in the cancer burden is only possible through comprehensive disease management. To this end, the Republic of Slovenia launched the National Cancer Control Programme in 2010, in which goals were set for the period up to 2015. The third National Cancer Control Programme, launched in 2021, sets the strategic goals for the years 2022 to 2026 to reduce the incidence, increase survival and improve the quality of life of cancer patients.

The collection of data on cancer patients has a long tradition in Slovenia, as the Institute of Oncology Ljubljana (OI Ljubljana) has one of the oldest population-based cancer registries in Europe. The Cancer Registry of the Republic of Slovenia (SCR, the Registry) has been providing data on the incidence, prevalence and survival rate of Slovenian cancer patients without interruption since 1950. The cancer burden indicators are the starting point for evaluating the performance of primary and secondary cancer prevention, diagnosis, treatment, rehabilitation and palliative care, as well as for planning facilities and resources. Data on the amount of funding allocated to various programmes alone does not confirm that these resources are being used effectively and contributing to improving the health of the population.

Data on the diagnosis and treatment of cancer patients are scarce in population-based cancer registries. Therefore, the SCR only records a basic set of treatment-related data: the start of treatment and a rough specification of the type of treatment. This information usually only relates to the first treatment that a patient receives – progressions with their dates and therapies are usually not systematically followed up. Another problem concerns the time delay in reporting the indicators, as the SCR currently reports data with a one- to two-year delay compared to the planned time frame (i.e. with a two- to three-year delay compared to the incidence year) due to irregular notifying and the resulting time-consuming querying of the service providers. Short- and long-term monitoring of indicators for evaluating the quality of care for cancer patients is made possible by detailed data on the type of disease and the diagnostic process, as well as on treatment procedures and response to treatment, which are collected in so-called clinical registries. It makes sense to establish clinical registries in the setting of population-based cancer registries, as these already have population- and health system-specific knowledge on collecting, processing, storing and analysing data on cancer patients and, above all, already have a system for obtaining a core set of cancer cases. In addition, the SCR also has the appropriate legal basis for the acquisition, storage and linkage of all health data of oncology patients in Slovenia, as stipulated in the Act on databases in the field of healthcare.

In line with the goals of the National Cancer Control Programme 2017–2021, Slovenia is establishing clinical registries within the SCR for breast, prostate, colorectal, lung cancer and skin melanoma. These are the five most common types of cancer, accounting for more than half of all cancers in the Slovenian population. Clinical registries would monitor quality indicators for the diagnosis and treatment of common cancers, such as total time from diagnosis to treatment, compliance of treatment with current guidelines, number of annual admissions by individual providers, treatment complications, survival rates, etc. These data would make it possible to identify and correct systemic deviations or to verify whether the criteria for the planned networks of oncology centres are being met.

In 2018, the Institute of Oncology Ljubljana established the first national clinical oncology registry – the Skin Melanoma Clinical Registry (KrMel) – within the setting of the Cancer Registry of the Republic of Slovenia. It was in the case of skin melanoma that the professional community was the first to agree on a set of data to be collected to monitor the quality of care, and the establishment of KrMel was facilitated by the centralisation of care for patients with advanced melanoma in Slovenia. The rules and procedures for registering cases in KrMel are in line with the current principles of the population-based registry, allowing direct data transfer between the two registries and simultaneous reporting on both population-based cancer burden and quality of care indicators.

This is the sixth report compiled from the data of the Slovenian Skin Melanoma Clinical Registry. Following the example of the SCR annual reports and the OI Ljubljana hospital registry reports, the KrMel report begins with a presentation of the population burden of skin melanoma in Slovenia and compares it with the burden in other countries. This is followed by a description of the characteristics of the patients, their disease and their survival. The indicators for the quality of care are divided into diagnosis and treatment indicators. A very important part of the report is the set of indicators that address the compliance of patient care with the guidelines. In addition, we have defined 24 composite quality of care indicators, which are presented at the end of the report.



## Data Sources

Cancer registration has been mandatory and prescribed by law in the Republic of Slovenia since the establishment of the SCR (Official Gazette of the RS No 10/50, No 29/50, No 14/65, No 1/80, No 45/82, No 42/85; Official Gazette of the RS No 9/92, No 65/00, No 47/15 and No 31/18). All patients who have their permanent residence in the Republic of Slovenia at the time of diagnosis are registered in the SCR/KrMel. The main source of KrMel data are the pathohistological examinations with a diagnosis of skin melanoma, which are currently still sent to the registry in paper form by 11 Slovenian pathology laboratories. From them we extract the patient's personal data, information about the provider of surgical treatment and the pathohistological prognostic factors. Since the prognosis and possible additional treatment depend mainly on the prognostic factors of the primary tumour, in KrMel we record all data on the primary tumour defined in the standardised pathohistological report; for pathohistological reports that are not structured according to the current Slovenian Recommendations for the Treatment of Patients with Skin Melanoma, we extract and code the relevant data during the registration processes in KrMel.

The melanoma patients identified based on the pathohistological examinations are verified and, if necessary, supplemented with data on skin melanoma patients reported to the SCR by all hospitals and diagnostic centres in Slovenia through cancer notification forms. Another complementary source for the core set of patients in KrMel are the medical reports on the cause of death provided to us by the National Institute of Public Health of the Republic of Slovenia. In the present Report, no patients are included for whom information was obtained only from the cancer notification forms or from the report on the cause of death. Between 2018 and 2022, three melanomas were diagnosed at autopsy, all in 2021.

Almost all Slovenian patients with skin melanoma for whom lymph node surgery, systemic therapy or radiotherapy is recommended due to advanced disease are treated at OI Ljubljana. The genetic characterisation of melanoma patients in Slovenia is also centralised: BRAF, NRAS and c-KIT mutations are determined in the molecular diagnostics laboratory at OI Ljubljana for all patients requiring systemic therapy. The primary data source for the quality of care of melanoma patients are therefore the medical records of patients at OI Ljubljana: surgical reports, prescriptions for systemic therapy, discharge letters, records of outpatient and multidisciplinary board consultations, results from the molecular laboratory, etc. SCR/KrMel staff have access to all paper and electronic documents in OI Ljubljana for all patients registered in KrMel.

In order to calculate the prevalence and survival of patients, we need information called vital status (whether a person is alive, dead or their vital status is unknown on a given date). The Registry receives this information, updated daily, from the Central Population Registry for all persons included in the Registry.

## Data Processing

The data collected from all the above sources are coded by nurses with specialised knowledge in KrMel in accordance with the international and internal SCR rules for cancer registration. In addition, patients are grouped according to the Slovenian Recommendations for the Treatment of Patients with Skin Melanoma.

### Tumour Site and Morphology

The 10th revision of the International Classification of Diseases and Related Health Problems for Statistical Purposes (ICD-10) has been in force since 1997 for the classification of neoplasms according to their primary site. The classification of neoplasms according to their morphology, for which we use the morphological axis of the International Classification of Diseases for Oncology, is also crucial for the classification of malignant diseases. We have been using the third edition (ICDO-3) since 2012, with updates in 2011, and the new revision ICD-O-3.2 from 2020. All patients with skin melanoma who are registered in the SCR with the histological ICDO-3 codes for melanoma 8720 to 8780 and site according to ICD-10 are recorded in KrMel: skin (C43 and D03), vulva (C51), penis and scrotum (C60 and C63), secondary malignant tumours of lymph nodes or organs (C77, C78 and C79), and malignant neoplasms without specification of site (C80). All melanomas coded with C are invasive, and D03 represents skin melanoma in situ. Patients with multiple tumours of the same histological type that appear at the same time or at different times are registered only registered once. Patients who are initially diagnosed with melanoma in situ and later with an invasive melanoma are an exception: for these patients, two separate tumours are registered. If an individual has had multiple lesions detected, only the main (largest or first) lesion is included in the incidence, and the pathohistological and surgical parameters are monitored for all lesions. Mortality is presented using the ICD-10 codes as reported by the National Institute of Public Health (NIJZ). As there is often insufficient information on the disease available at the time of death, the only ICD-10 code used to represent a death due to skin melanoma is C43.

### Disease Staging

Several classifications are used to show the spread of disease at the time of diagnosis. The spread is defined on the basis of the findings of any recorded procedure – from surgery to autopsy record, if the patient has not received treatment beforehand.

- Stage according to the TNM classification (UICC, 8th revision): T for tumour, N for nodus (lymph node), M for metastasis. Tumour (T) is classified into 4 basic groups (T1 to T4) depending on its size, N usually has the value "0" if the lymph nodes are not affected, and N1 to N3 depending on the number of affected lymph nodes. The designation M0 means the absence of distant metastases and M1 their presence.
- The simplified staging is based on the TNM classification. A localised stage is defined as a case of disease in which the tumour is designated as T1, T2 or T3, the regional lymph nodes are not affected and there are no metastases in distant organs (N0, M0). In the regional stage, tumours are classified as T4 and/or the regional lymph nodes are also affected (N1) and there are no distant lymph node or organ metastases (M0). In the group of distant stage, we classify cases in which distant lymph node or organ metastases have been detected (M1).
- Tumour thickness according to Breslow: it is measured in mm and represents the distance from the granular layer of the epidermis (in the case of ulcerations, the distance is measured from the base of the ulceration) to the deepest growing tumour cell. In aggregated figures, it is indicated by median and mean values.

## Treatment

One of the central roles of the KrMel is the systematic recording of treatment data. In contrast to the SCR, clinical registries document both the first treatment and the treatment initiated after the disease progression. All treatments started in the first six months after diagnosis are defined as first treatments. Systemic treatment lines are recorded chronologically as neoadjuvant and adjuvant systemic therapy, first-line, second-line and subsequent lines (3+), regardless of whether the patient was treated as part of the first treatment or disease progression.

## Survival and Time to Disease Progression

Survival indicates the proportion of patients who are still alive after a certain period of time from diagnosis for a selected group of patients. There are several ways and methods of calculating survival. The most basic and simplest survival measure is the so-called observed survival, which includes in the calculation all deaths, including those not caused by cancer. In this report, we show observed survival calculated using the Kaplan-Meier method by sex, age, site, histological type and stage or tumour thickness at diagnosis. Only patients with invasive melanoma are included in the survival calculation (except for site and stage, where patients with melanoma in situ are added). If a patient has more than one melanoma in the selected time period, only the first tumour is included in the survival analysis. Also excluded from the analysis are patients in whom the melanoma was only diagnosed at the time of death. Patients lost from the Central Population Registry are included in the analysis until the last day of follow-up, at which they are censored.

We also estimate the time to disease progression using the Kaplan-Meier method. In this case, we define the event – disease progression – as local, regional, systemic or in transit recurrence or death of the patient.

## Terminology Used

Hereby we present an overview of included terms and subgroups by ICD-10 codes for skin melanoma (other synonymous terminologies are cutaneous melanoma, cutaneous malignant melanoma, melanoma skin cancer and malignant melanoma of skin).

| ICD-10 code                            | Primary site designation                    |
|----------------------------------------|---------------------------------------------|
| Vsi (C43, C51, C60, C63, C77–C80, D03) | Skin melanoma                               |
| C43, C51, C60, C63, C77–C80            | Invasive skin melanoma                      |
| C43, C51, C60, C63                     | Primary invasive skin melanoma              |
| C43, C51, C60, C63, D03                | Primary skin melanoma                       |
| C77–C80                                | Melanoma of secondary or unspecified origin |
| C43                                    | Malignant skin melanoma                     |
| D03                                    | Melanoma in situ                            |

Main lesions – all cases with single primary skin melanoma and melanoma lesion with highest baseline stage in multiple primary skin melanoma.

All lesions – all lesions of single and multiple primary skin melanoma cases.

# Burden of Skin Melanoma

Nearly 325,000 people are affected by malignant skin melanoma globally each year, according to estimates. The disease is more common in white people living near the equator, where UV radiation is stronger. The incidence is highest in Australia and New Zealand, followed by North America and Northern Europe, while it is lowest in Asia. In Australia, large-scale prevention measures were introduced after 1960 and soon proved successful: the burden of disease began to decline in women after 1985, and somewhat later in men and especially among younger people.




Figure 1a: Estimated age-standardised incidence (new European standard) of malignant skin melanoma for both sexes combined in Europe 2022.

In Europe, melanoma is less common than in Australia, and on average it is the sixth most common cancer in women and in men. The estimated average age-standardised incidence rate (new European standard) for 2022 in Europe was 21.5 cases per 100,000 inhabitants. With a rate of 29.8/100,000, Slovenia is well above the European average; in the European union (EU), the incidence rates were highest in Denmark and Sweden (53.3/100,000 and 50.5/100,000). The relatively low mortality rate indicates that the disease has a fairly good prognosis on average. Worldwide, 57,000 people die of skin melanoma every year. In the 27 EU countries, Slovenia and Poland have the highest age-standardised mortality rate with 5.4 deaths per 100,000 inhabitants.




Figure 1b: Estimated age-standardised mortality rate (new European standard) of malignant skin melanoma for both sexes combined in Europe 2022.

The geographical analysis of the Registry data shows that the population at the highest risk of malignant skin melanoma is the population of central Slovenia, especially Ljubljana and its surroundings, and Primorska. The development of malignant skin melanoma is equally associated with genetic susceptibility (fair-skinned people with a large number of pigmented lesions have a higher risk), environmental exposure (people living in the equatorial zone or under the ozone hole have a higher risk) and risky behaviour (frequent sunburn). Many studies cite socio-economic status as an indirect factor linking all three risk factors: people with a higher socioeconomic status have a higher risk of malignant skin melanoma. Successful people are more likely to engage in modern but risky behavioural patterns, the common denominator of which is occasional intense sun exposure (skiing in high mountain ski resorts, long holidays at the equator, etc.). Similarly to the rest of the world, part of the geographical differences in Slovenia can be explained by socio-economic inequality: it has been calculated that socioeconomic inequality in Slovenia is responsible for less than a fifth of all malignant skin melanomas.




Figure 2: Map of malignant skin melanoma (C43) by electoral district; spatially smoothed standardised incidence rates, Slovenia 2005–2014.

Malignant skin melanoma is one of the cancers with the steepest increase in incidence in recent decades. In Slovenia, the crude incidence rate has risen by 3.7% per year over the last ten years and the age-standardised rate by 0.2% (not statically significant). The number of new cases already exceeds 600 per year, making malignant melanoma of the skin the sixth most newly diagnosed cancer. In 2022, 888 people in Slovenia developed invasive skin melanoma. The mortality rate has remained stable over time. On average, around 130 people die of malignant skin melanoma every year.




Figure 3a: Time trend of the crude and age-standardised incidence rate of malignant skin melanoma (C43) per 100,000 population.




Figure 3b: Time trend of crude and age-standardised malignant skin melanoma (C43) mortality rate per 100,000 population.



Until a few years ago, about 10% more women than men were affected, but today there is no longer a gender difference. Today, more than 8,500 people live with a diagnosis of malignant skin melanoma (prevalence). More detailed epidemiological data for Slovenian patients with malignant skin melanoma diagnosed between 2018 and 2022 are presented in the table below.

Basic epidemiological data on malignant skin melanoma (C43), Slovenia 2018–2022.

| INCIDENCE (2018–2022 average)                                       | Males | Females | Both  |
|---------------------------------------------------------------------|-------|---------|-------|
| Number of new cases per year                                        | 351   | 326     | 678   |
| Percentage of all cancers (%)                                       | 5.3   | 5.2     | 5.2   |
| Rank by frequency among all cancers                                 | 5     | 5       | 6     |
| Percentage of all cancers other than skin cancer (%)                | 6.5   | 6.5     | 6.5   |
| Cancer risk by age 75 (cumulative risk) (%)                         | 1.9   | 1.8     | 1.8   |
| Crude incidence rate per 100,000                                    | 33.5  | 31.2    | 32.4  |
| Age-standardised incidence rate (ASR) per 100,000 (W)               | 17.6  | 17.3    | 17.2  |
| Estimated annual change of crude incidence rate latest 10 years (%) | 3.0*  | 4.5*    | 3.7*  |
| Estimated annual change of ASR latest 10 years (%)                  | 1.3   | 3.4*    | 2.3   |
| MORTALITY (2018–2022 average)                                       |       |         |       |
| Number of deaths per year                                           | 73    | 60      | 133   |
| Percentage of all cancer deaths (%)                                 | 2.0   | 2.1     | 2.1   |
| Risk of dying from cancer by age 75 (cumulative risk) (%)           | 0.3   | 0.2     | 0.3   |
| Crude mortality rate per 100,000                                    | 6.9   | 5.7     | 6.3   |
| Age-standardised mortality rate (ASR) per 100,000 (W)               | 3.1   | 2.0     | 2.5   |
| Estimated annual change of crude mortality rate latest 10 years (%) | 0.8   | 1.7     | 1.2   |
| Estimated annual change of ASR latest 10 years (%)                  | -1.8  | -1.3    | -1.6  |
| PREVALENCE (on 31 December 2022)                                    |       |         |       |
| Persons living with cancer at the end of 2022 (prevalence)          | 3971  | 4661    | 8632  |
| Persons living with cancer per 100,000 (prevalence rate)            | 374.9 | 444.1   | 409.3 |
| 1-year prevalence                                                   | 457   | 402     | 859   |
| 5-year prevalence                                                   | 1516  | 1462    | 2978  |

\*The mean annual change is statistically significant at a risk level of 0.05.

Since 1997, the Registry has not only recorded cases of invasive skin melanoma, but also melanoma in situ (D03 according to ICD-10). In recent years, around 370 new cases of melanoma in situ have been registered each year. Additionally around 30 melanomas occur annually on eyes and mucous membranes – these cases are not included in this report.

As shown in Figure 4, melanoma occurs most frequently on the trunk – in more than half of all new cases in men and in more than a third in women. The median age at diagnosis has risen by more than ten years over the last three decades and has reached 64 years in the past 5 years (median is 62 for women and 66 for men).




Figure 4: Proportions of malignant and in situ skin melanoma (C43, D03) by site and sex, Slovenia 2018–2022.

Tumour thickness at the time of diagnosis is a key determinant for the prognosis of the disease. In the last 30 years, the proportion of patients whose tumour is thinner than 0.8 mm at diagnosis has doubled – patients with melanomas thinner than 0.8 mm now account for almost half of all diagnosed melanomas (Figure 5).




Figure 5: Breslow tumour thickness proportions (mm) for malignant skin melanomas (C43) with mean annual change for the last 10 years, Slovenia 1999–2022.

The 5-year net survival rate for melanoma patients is increasing; from 57% for patients diagnosed in 1984–1986, it has risen to 91% for patients diagnosed in 2018–2022. The survival rate of women is slightly better than that of men, on average by four percentage points in 2018–2022. The time trend in survival of patients with malignant skin melanoma is improving in all age groups and in all tumour stages, except for the distant stage. In terms of age, the 5-year survival rate is worst in patients aged 65 and over at diagnosis, but even in this group it is already above 89%.




Figure 6: Time trend of 5-year net survival of patients with malignant skin melanoma (C43) by stage, Slovenia 1998–2022.

The 5-year net survival for patients with localised stage is now almost 100% and has improved by 5 percentage points over the last 20 years. The five-year net survival of patients with regional spread at diagnosis is 62%, and 21% for patients with disseminated disease at diagnosis (Figure 6).

Data from the EUROCARE and CONCORD surveys show that Slovenia is one of the countries where survival has improved most rapidly over the years. According to the results of the latest Concord-3 study, which compared the survival of 1,553,109 skin melanoma patients from 59 countries, Slovenia is in the group of 17 European countries with a five-year net survival of over 85%. The five-year net survival of patients diagnosed in 2000–2014 in 28 European countries is shown in the figure below. In the most successful countries, the five-year net survival is already over 90%.




Figure 7: Primary invasive skin melanoma (C43, C51, C60, C63) – age-standardised 5-year net survival in adults (15–99 years) by European countries and period of diagnosis 2000–2014: the Concord-3 study.

# Patients and Disease Characteristics

Table 1: Incidence of skin melanoma (C43, C51, C60, C63, C77–C80, D03) by site, age, and sex with crude incidence rate (CR) per 100,000 population and cumulative rate (CumR), Slovenia 2018–2022.

| Year        | ICD code           | Primary site                                | Sex | All ages | Age |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |      | CR   | CumR<br>0-74 |
|-------------|--------------------|---------------------------------------------|-----|----------|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|--------------|
|             |                    |                                             |     |          | 0-  | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80-  | 85+  |      |              |
| 2018        | All                | Skin melanoma                               | M+F | 940      | 0   | 0  | 0   | 2   | 5   | 9   | 26  | 48  | 62  | 80  | 80  | 64  | 110 | 117 | 89  | 117 | 65   | 66   | 45.4 | 2.6          |
|             |                    |                                             | M   | 476      | 0   | 0  | 0   | 1   | 2   | 3   | 8   | 20  | 22  | 30  | 46  | 41  | 59  | 60  | 45  | 70  | 38   | 31   | 46.2 | 2.6          |
|             | F                  | 464                                         | 0   | 0        | 0   | 1  | 3   | 6   | 18  | 28  | 40  | 50  | 34  | 23  | 51  | 57  | 44  | 47  | 27  | 35  | 44.6 | 2.7  |      |              |
|             | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 323      | 0   | 0  | 0   | 0   | 2   | 3   | 5   | 8   | 13  | 18  | 35  | 25  | 38  | 43  | 28  | 52  | 28   | 25   | 31.4 | 1.7          |
|             |                    |                                             | F   | 289      | 0   | 0  | 0   | 0   | 2   | 4   | 10  | 18  | 25  | 32  | 15  | 13  | 29  | 37  | 32  | 28  | 20   | 24   | 27.8 | 1.6          |
|             | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 4        | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 1   | 0   | 1   | 1    | 0    | 0.4  | 0.0          |
|             |                    |                                             | F   | 5        | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 0   | 0   | 1   | 1   | 0   | 0   | 1    | 1    | 0.5  | 0.0          |
|             | D03                | Melanoma in situ                            | M   | 149      | 0   | 0  | 0   | 1   | 0   | 0   | 3   | 12  | 9   | 12  | 11  | 16  | 20  | 16  | 17  | 17  | 9    | 6    | 14.5 | 0.9          |
| F           |                    |                                             | 170 | 0        | 0   | 0  | 1   | 1   | 2   | 8   | 10  | 15  | 17  | 19  | 10  | 21  | 19  | 12  | 19  | 6   | 10   | 16.3 | 1.0  |              |
| 2019        | All                | Skin melanoma                               | M+F | 1001     | 0   | 1  | 1   | 1   | 5   | 15  | 26  | 45  | 69  | 68  | 83  | 89  | 107 | 141 | 118 | 109 | 68   | 55   | 47.9 | 2.9          |
|             |                    |                                             | M   | 507      | 0   | 0  | 0   | 0   | 1   | 6   | 7   | 21  | 32  | 27  | 46  | 49  | 54  | 73  | 71  | 62  | 31   | 27   | 48.5 | 3.0          |
|             | F                  | 494                                         | 0   | 1        | 1   | 1  | 4   | 9   | 19  | 24  | 37  | 41  | 37  | 40  | 53  | 68  | 47  | 47  | 37  | 28  | 47.3 | 2.9  |      |              |
|             | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 320      | 0   | 0  | 0   | 0   | 1   | 4   | 5   | 13  | 16  | 18  | 33  | 32  | 29  | 47  | 40  | 39  | 27   | 16   | 30.6 | 1.8          |
|             |                    |                                             | F   | 321      | 0   | 1  | 1   | 0   | 3   | 7   | 13  | 13  | 20  | 28  | 20  | 30  | 36  | 42  | 30  | 29  | 26   | 22   | 30.8 | 1.8          |
|             | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 8        | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 2   | 4   | 1   | 0    | 0    | 0.8  | 0.07         |
|             |                    |                                             | F   | 4        | 0   | 0  | 0   | 0   | 0   | 0   | 2   | 0   | 0   | 0   | 0   | 0   | 1   | 0   | 1   | 0   | 0    | 0    | 0.4  | 0.03         |
|             | D03                | Melanoma in situ                            | M   | 179      | 0   | 0  | 0   | 0   | 0   | 2   | 2   | 8   | 16  | 9   | 13  | 17  | 24  | 24  | 27  | 22  | 4    | 11   | 17.1 | 1.1          |
| F           |                    |                                             | 169 | 0        | 0   | 0  | 1   | 1   | 2   | 4   | 11  | 17  | 13  | 17  | 10  | 16  | 26  | 16  | 18  | 11  | 6    | 16.2 | 1.0  |              |
| 2020        | All                | Skin melanoma                               | M+F | 997      | 0   | 0  | 0   | 6   | 8   | 11  | 27  | 39  | 55  | 70  | 100 | 92  | 76  | 106 | 129 | 132 | 75   | 71   | 47.5 | 2.7          |
|             |                    |                                             | M   | 523      | 0   | 0  | 0   | 2   | 2   | 5   | 12  | 14  | 22  | 26  | 50  | 51  | 46  | 62  | 88  | 72  | 41   | 30   | 49.6 | 2.9          |
|             | F                  | 474                                         | 0   | 0        | 0   | 4  | 6   | 6   | 15  | 25  | 33  | 44  | 50  | 41  | 30  | 44  | 41  | 60  | 34  | 41  | 45.3 | 2.5  |      |              |
|             | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 330      | 0   | 0  | 0   | 2   | 1   | 3   | 7   | 7   | 16  | 20  | 31  | 39  | 32  | 35  | 52  | 39  | 30   | 16   | 31.3 | 1.9          |
|             |                    |                                             | F   | 312      | 0   | 0  | 0   | 2   | 2   | 4   | 10  | 14  | 21  | 28  | 35  | 25  | 15  | 32  | 28  | 40  | 24   | 32   | 29.8 | 1.6          |
|             | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 11       | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 1   | 0   | 0   | 4   | 2   | 1    | 2    | 1.0  | 0.1          |
|             |                    |                                             | F   | 10       | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 0   | 0   | 2   | 0   | 1   | 1   | 1    | 3    | 1.0  | 0.04         |
|             | D03                | Melanoma in situ                            | M   | 182      | 0   | 0  | 0   | 0   | 1   | 2   | 5   | 7   | 6   | 6   | 18  | 11  | 14  | 27  | 32  | 31  | 10   | 12   | 17.3 | 1.0          |
| F           |                    |                                             | 152 | 0        | 0   | 0  | 2   | 4   | 2   | 5   | 11  | 11  | 15  | 15  | 16  | 13  | 12  | 12  | 19  | 9   | 6    | 14.5 | 0.9  |              |
| 2021        | All                | Skin melanoma                               | M+F | 1006     | 0   | 0  | 0   | 6   | 4   | 16  | 20  | 44  | 48  | 70  | 83  | 95  | 108 | 124 | 120 | 105 | 92   | 71   | 47.7 | 2.7          |
|             |                    |                                             | M   | 498      | 0   | 0  | 0   | 3   | 1   | 3   | 10  | 13  | 23  | 33  | 38  | 41  | 55  | 62  | 71  | 64  | 48   | 33   | 47.1 | 2.6          |
|             | F                  | 508                                         | 0   | 0        | 0   | 3  | 3   | 13  | 10  | 31  | 25  | 37  | 45  | 54  | 53  | 62  | 49  | 41  | 44  | 38  | 48.4 | 2.8  |      |              |
|             | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 322      | 0   | 0  | 0   | 2   | 1   | 3   | 9   | 8   | 16  | 22  | 25  | 27  | 37  | 35  | 48  | 36  | 33   | 20   | 30.4 | 1.7          |
|             |                    |                                             | F   | 307      | 0   | 0  | 0   | 2   | 0   | 6   | 9   | 18  | 12  | 27  | 26  | 30  | 31  | 36  | 35  | 24  | 24   | 27   | 29.3 | 1.7          |
|             | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 11       | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 1   | 1   | 1   | 2   | 1   | 1   | 2   | 0   | 2   | 0    | 0    | 1.0  | 0.1          |
|             |                    |                                             | F   | 8        | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 2   | 1   | 1   | 2   | 1   | 0   | 1    | 0    | 0.8  | 0.05         |
|             | D03                | Melanoma in situ                            | M   | 165      | 0   | 0  | 0   | 1   | 0   | 0   | 1   | 4   | 6   | 10  | 11  | 13  | 17  | 25  | 23  | 26  | 15   | 13   | 15.6 | 0.8          |
| F           |                    |                                             | 193 | 0        | 0   | 0  | 1   | 3   | 7   | 1   | 13  | 13  | 10  | 17  | 23  | 21  | 24  | 13  | 17  | 19  | 11   | 18.4 | 1.1  |              |
| 2022        | All                | Skin melanoma                               | M+F | 1401     | 0   | 0  | 0   | 5   | 6   | 10  | 25  | 61  | 102 | 119 | 122 | 141 | 142 | 167 | 173 | 138 | 104  | 86   | 66.4 | 3.8          |
|             |                    |                                             | M   | 736      | 0   | 0  | 0   | 3   | 2   | 5   | 10  | 21  | 41  | 48  | 63  | 81  | 85  | 103 | 100 | 75  | 55   | 44   | 69.5 | 4.1          |
|             | F                  | 665                                         | 0   | 0        | 0   | 2  | 4   | 5   | 15  | 40  | 61  | 71  | 59  | 60  | 57  | 64  | 73  | 63  | 49  | 42  | 63.4 | 3.7  |      |              |
|             | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 464      | 0   | 0  | 0   | 2   | 1   | 3   | 6   | 13  | 31  | 31  | 38  | 45  | 49  | 59  | 63  | 54  | 35   | 34   | 43.8 | 2.5          |
|             |                    |                                             | F   | 411      | 0   | 0  | 0   | 2   | 4   | 3   | 7   | 25  | 32  | 41  | 33  | 39  | 37  | 42  | 50  | 36  | 32   | 28   | 39.2 | 2.3          |
|             | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 6        | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 0   | 2   | 3   | 0   | 0    | 0    | 0.6  | 0.0          |
|             |                    |                                             | F   | 7        | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 1   | 2   | 0   | 0   | 2   | 1    | 0    | 0.7  | 0.0          |
|             | D03                | Melanoma in situ                            | M   | 266      | 0   | 0  | 0   | 1   | 1   | 2   | 4   | 8   | 10  | 17  | 25  | 35  | 36  | 42  | 34  | 21  | 20   | 10   | 25.1 | 1.6          |
| F           |                    |                                             | 247 | 0        | 0   | 0  | 0   | 0   | 2   | 8   | 15  | 29  | 30  | 25  | 20  | 18  | 22  | 23  | 25  | 16  | 14   | 23.5 | 1.4  |              |
| 2018 - 2022 | All                | Skin melanoma                               | M+F | 5345     | 0   | 1  | 1   | 20  | 28  | 61  | 124 | 237 | 336 | 407 | 468 | 481 | 543 | 655 | 629 | 601 | 404  | 349  | 51.0 | 14.7         |
|             |                    |                                             | M   | 2740     | 0   | 0  | 0   | 9   | 8   | 22  | 47  | 89  | 140 | 164 | 243 | 263 | 299 | 360 | 375 | 343 | 213  | 165  | 52.2 | 15.2         |
|             | F                  | 2605                                        | 0   | 1        | 1   | 11 | 20  | 39  | 77  | 148 | 196 | 243 | 225 | 218 | 244 | 295 | 254 | 258 | 191 | 184 | 49.8 | 14.5 |      |              |
|             | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 1759     | 0   | 0  | 0   | 6   | 6   | 16  | 32  | 49  | 92  | 109 | 162 | 168 | 185 | 219 | 231 | 220 | 153  | 111  | 33.5 | 9.5          |
|             |                    |                                             | F   | 1640     | 0   | 1  | 1   | 6   | 11  | 24  | 49  | 88  | 110 | 156 | 129 | 137 | 148 | 189 | 175 | 157 | 126  | 133  | 31.4 | 9.0          |
|             | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 40       | 0   | 0  | 0   | 0   | 0   | 0   | 0   | 1   | 1   | 1   | 3   | 3   | 3   | 7   | 11  | 6   | 2    | 2    | 0.8  | 0.3          |
|             |                    |                                             | F   | 34       | 0   | 0  | 0   | 0   | 0   | 0   | 2   | 0   | 1   | 2   | 3   | 2   | 7   | 3   | 3   | 3   | 4    | 4    | 0.7  | 0.2          |
|             | D03                | Melanoma in situ                            | M   | 941      | 0   | 0  | 0   | 3   | 2   | 6   | 15  | 39  | 47  | 54  | 78  | 92  | 111 | 134 | 133 | 117 | 58   | 52   | 17.9 | 5.4          |
| F           |                    |                                             | 931 | 0        | 0   | 0  | 5   | 9   | 15  | 26  | 60  | 85  | 85  | 93  | 79  | 89  | 103 | 76  | 98  | 61  | 47   | 17.8 | 5.3  |              |

Table 2: Prevalence of skin melanoma (C43, C51, C60, C63, C77–C80, D03) by site and sex, Slovenia 2018–2022.

| Year | ICD code           | Primary site                                | Sex | Prevalence* on 31 Dec in the relevant year |      |      |      |                     |
|------|--------------------|---------------------------------------------|-----|--------------------------------------------|------|------|------|---------------------|
|      |                    |                                             |     | Years after diagnosis                      |      |      |      | Complete prevalence |
|      |                    |                                             |     | <1                                         | 1–4  | 5–9  | 10+  | All                 |
| 2018 | All                | Skin melanoma                               | M+F | 922                                        | 2861 | 2696 | 3127 | 9606                |
|      |                    |                                             | M   | 461                                        | 1453 | 1251 | 1210 | 4375                |
|      |                    |                                             | F   | 461                                        | 1408 | 1445 | 1917 | 5231                |
|      | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 310                                        | 1006 | 869  | 989  | 3174                |
|      |                    |                                             | F   | 289                                        | 931  | 967  | 1605 | 3792                |
|      | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 2                                          | 7    | 4    | 3    | 16                  |
|      |                    |                                             | F   | 4                                          | 7    | 2    | 4    | 17                  |
|      | D03                | Melanoma in situ                            | M   | 149                                        | 440  | 378  | 218  | 1185                |
|      |                    |                                             | F   | 168                                        | 470  | 476  | 308  | 1422                |
| 2019 | All                | Skin melanoma                               | M+F | 977                                        | 3067 | 2712 | 3546 | 10302               |
|      |                    |                                             | M   | 495                                        | 1533 | 1315 | 1378 | 4721                |
|      |                    |                                             | F   | 482                                        | 1534 | 1397 | 2168 | 5581                |
|      | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 311                                        | 1042 | 926  | 1090 | 3369                |
|      |                    |                                             | F   | 311                                        | 978  | 949  | 1749 | 3987                |
|      | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 5                                          | 6    | 4    | 3    | 18                  |
|      |                    |                                             | F   | 2                                          | 9    | 2    | 4    | 17                  |
|      | D03                | Melanoma in situ                            | M   | 179                                        | 485  | 385  | 285  | 1334                |
|      |                    |                                             | F   | 169                                        | 547  | 446  | 415  | 1577                |
| 2020 | All                | Skin melanoma                               | M+F | 965                                        | 3238 | 2823 | 3863 | 10889               |
|      |                    |                                             | M   | 505                                        | 1586 | 1399 | 1511 | 5001                |
|      |                    |                                             | F   | 460                                        | 1652 | 1424 | 2352 | 5888                |
|      | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 318                                        | 1026 | 975  | 1194 | 3513                |
|      |                    |                                             | F   | 301                                        | 1035 | 958  | 1867 | 4161                |
|      | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 7                                          | 7    | 5    | 3    | 22                  |
|      |                    |                                             | F   | 7                                          | 6    | 4    | 4    | 21                  |
|      | D03                | Melanoma in situ                            | M   | 180                                        | 553  | 419  | 314  | 1466                |
|      |                    |                                             | F   | 152                                        | 611  | 462  | 481  | 1706                |
| 2021 | All                | Skin melanoma                               | M+F | 980                                        | 3316 | 2975 | 4242 | 11513               |
|      |                    |                                             | M   | 481                                        | 1638 | 1473 | 1685 | 5277                |
|      |                    |                                             | F   | 499                                        | 1678 | 1502 | 2557 | 6236                |
|      | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 310                                        | 1036 | 1013 | 1304 | 3663                |
|      |                    |                                             | F   | 300                                        | 1050 | 997  | 2000 | 4347                |
|      | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 6                                          | 8    | 5    | 3    | 22                  |
|      |                    |                                             | F   | 6                                          | 8    | 6    | 3    | 23                  |
|      | D03                | Melanoma in situ                            | M   | 165                                        | 594  | 455  | 378  | 1592                |
|      |                    |                                             | F   | 193                                        | 620  | 499  | 554  | 1866                |
| 2022 | All                | Skin melanoma                               | M+F | 1378                                       | 3435 | 3036 | 4627 | 12476               |
|      |                    |                                             | M   | 725                                        | 1702 | 1509 | 1847 | 5783                |
|      |                    |                                             | F   | 653                                        | 1733 | 1527 | 2780 | 6693                |
|      | C43, C51, C60, C63 | Primary invasive skin melanoma              | M   | 457                                        | 1060 | 1036 | 1397 | 3950                |
|      |                    |                                             | F   | 402                                        | 1061 | 999  | 2131 | 4593                |
|      | C77 - C80          | Melanoma of secondary or unspecified origin | M   | 4                                          | 8    | 8    | 3    | 23                  |
|      |                    |                                             | F   | 5                                          | 10   | 5    | 4    | 24                  |
|      | D03                | Melanoma in situ                            | M   | 264                                        | 634  | 465  | 447  | 1810                |
|      |                    |                                             | F   | 246                                        | 662  | 523  | 645  | 2076                |

\* A person diagnosed with more than one cancer is included as a prevalent case in each cancer site, but for all sites together each person is counted only once.

Table 3: Skin melanoma (C43) mortality by age and sex with crude mortality rate (CR) per 100,000 population, Slovenia 2018–2022.

| Year        | Sex | All ages | Age  |       |       |     | CR  |
|-------------|-----|----------|------|-------|-------|-----|-----|
|             |     |          | 0–19 | 20–49 | 50–74 | 75+ |     |
| 2018        | M+F | 131      | 1    | 9     | 59    | 62  | 6.3 |
|             | M   | 81       | 1    | 5     | 44    | 31  | 7.9 |
|             | F   | 50       | 0    | 4     | 15    | 31  | 4.8 |
| 2019        | M+F | 115      | 0    | 12    | 44    | 59  | 5.5 |
|             | M   | 56       | 0    | 7     | 24    | 25  | 5.4 |
|             | F   | 59       | 0    | 5     | 20    | 34  | 5.7 |
| 2020        | M+F | 141      | 0    | 12    | 62    | 67  | 6.7 |
|             | M   | 74       | 0    | 3     | 36    | 35  | 7.0 |
|             | F   | 67       | 0    | 9     | 26    | 32  | 6.4 |
| 2021        | M+F | 128      | 0    | 13    | 46    | 69  | 6.1 |
|             | M   | 76       | 0    | 9     | 30    | 37  | 7.2 |
|             | F   | 52       | 0    | 4     | 16    | 32  | 5.0 |
| 2022        | M+F | 148      | 0    | 10    | 69    | 69  | 7.0 |
|             | M   | 76       | 0    | 5     | 37    | 34  | 7.2 |
|             | F   | 72       | 0    | 5     | 32    | 35  | 6.9 |
| 2018 – 2022 | M+F | 663      | 1    | 56    | 280   | 326 | 6.3 |
|             | M   | 363      | 1    | 29    | 171   | 162 | 6.9 |
|             | F   | 300      | 0    | 27    | 109   | 164 | 5.7 |

Table 4: Skin melanoma (C43, C51, C60, C63, C77–C80, D03) incidence by site and sex, Slovenia 2018–2022.

| ICD code                    | Primary site                                              | Sex | Year |      |      |      |      | Mean of yearly values 2018–2022 |
|-----------------------------|-----------------------------------------------------------|-----|------|------|------|------|------|---------------------------------|
|                             |                                                           |     | 2018 | 2019 | 2020 | 2021 | 2022 |                                 |
| C43, C51, C60, C63, C77–C80 | Invasive skin melanoma                                    | M+F | 621  | 653  | 663  | 648  | 888  | 694.6                           |
|                             |                                                           | M   | 327  | 328  | 341  | 333  | 470  | 359.8                           |
|                             |                                                           | F   | 294  | 325  | 322  | 315  | 418  | 334.8                           |
| D03                         | Melanoma in situ                                          | M+F | 319  | 348  | 334  | 358  | 513  | 374.4                           |
|                             |                                                           | M   | 149  | 179  | 182  | 165  | 266  | 188.2                           |
|                             |                                                           | F   | 170  | 169  | 152  | 193  | 247  | 186.2                           |
| C43, C51, C60, C63          | Primary invasive skin melanoma                            | M+F | 612  | 641  | 642  | 629  | 875  | 679.8                           |
|                             |                                                           | M   | 323  | 320  | 330  | 322  | 464  | 351.8                           |
|                             |                                                           | F   | 289  | 321  | 312  | 307  | 411  | 328.0                           |
| C77–C80                     | Melanoma of secondary or unspecified origin               | M+F | 9    | 12   | 21   | 19   | 13   | 14.8                            |
|                             |                                                           | M   | 4    | 8    | 11   | 11   | 6    | 8.0                             |
|                             |                                                           | F   | 5    | 4    | 10   | 8    | 7    | 6.8                             |
| C43                         | Malignant melanoma of skin                                | M   | 321  | 320  | 330  | 322  | 464  | 351.4                           |
|                             |                                                           | F   | 286  | 319  | 310  | 307  | 410  | 326.4                           |
| C43.0                       | Malignant melanoma of lip                                 | M   | 0    | 0    | 1    | 0    | 0    | 0.2                             |
|                             |                                                           | F   | 1    | 1    | 0    | 0    | 0    | 0.4                             |
| C43.1                       | Malignant melanoma of eyelid, including canthus           | M   | 1    | 1    | 0    | 1    | 0    | 0.6                             |
|                             |                                                           | F   | 1    | 0    | 1    | 1    | 1    | 0.8                             |
| C43.2                       | Malignant melanoma of ear and external auricular canal    | M   | 3    | 9    | 7    | 3    | 4    | 5.2                             |
|                             |                                                           | F   | 3    | 5    | 6    | 3    | 4    | 4.2                             |
| C43.3                       | Malignant melanoma of other and unspecified parts of face | M   | 17   | 11   | 20   | 6    | 25   | 15.8                            |
|                             |                                                           | F   | 18   | 27   | 23   | 21   | 24   | 22.6                            |
| C43.4                       | Malignant melanoma of scalp and neck                      | M   | 37   | 28   | 18   | 23   | 26   | 26.4                            |
|                             |                                                           | F   | 15   | 17   | 13   | 16   | 19   | 16.0                            |
| C43.5                       | Malignant melanoma of trunk                               | M   | 187  | 171  | 195  | 194  | 287  | 206.8                           |
|                             |                                                           | F   | 101  | 105  | 96   | 115  | 153  | 114.0                           |

Continued. —>

Table 4: Continued.

| ICD code | Primary site                                                             | Sex | Year |      |      |      |      | Mean of yearly values<br>2018–2022 |
|----------|--------------------------------------------------------------------------|-----|------|------|------|------|------|------------------------------------|
|          |                                                                          |     | 2018 | 2019 | 2020 | 2021 | 2022 |                                    |
| C43.6    | Malignant melanoma of upper limb, including shoulder                     | M   | 34   | 49   | 42   | 46   | 72   | 48.6                               |
|          |                                                                          | F   | 69   | 79   | 65   | 53   | 88   | 70.8                               |
| C43.7    | Malignant melanoma of lower limb, including hip                          | M   | 33   | 43   | 41   | 41   | 46   | 40.8                               |
|          |                                                                          | F   | 73   | 80   | 99   | 94   | 117  | 92.6                               |
| C43.8    | Overlapping malignant melanoma of skin                                   | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C43.9    | Malignant melanoma of skin, unspecified                                  | M   | 9    | 8    | 6    | 8    | 4    | 7.0                                |
|          |                                                                          | F   | 5    | 5    | 7    | 4    | 4    | 5.0                                |
| C51      | Malignant neoplasm of vulva                                              | Ž   | 3    | 2    | 2    | 0    | 1    | 1.6                                |
| C60      | Malignant neoplasm of penis                                              | M   | 2    | 0    | 0    | 0    | 0    | 0.4                                |
| C63      | Malignant neoplasm of other and unspecified male genital organs          | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C77      | Secondary and unspecified malignant neoplasm of lymph nodes              | M   | 0    | 0    | 1    | 1    | 1    | 0.6                                |
|          |                                                                          | F   | 2    | 0    | 1    | 0    | 2    | 1.0                                |
| C77.0    | Lymph nodes of head, face and neck                                       | M   | 0    | 0    | 1    | 1    | 1    | 0.6                                |
|          |                                                                          | F   | 0    | 0    | 1    | 0    | 2    | 0.6                                |
| C77.1    | Intrathoracic lymph nodes                                                | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C77.2    | Intra-abdominal lymph nodes                                              | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C77.3    | Axillary and upper limb lymph nodes                                      | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C77.4    | Inguinal and lower limb lymph nodes                                      | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C77.5    | Intrapelvic lymph nodes                                                  | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C77.8    | Lymph nodes of multiple regions                                          | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 2    | 0    | 0    | 0    | 0    | 0.4                                |
| C77.9    | Lymph node, unspecified                                                  | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C78      | Secondary malignant neoplasm of respiratory and digestive organs         | M   | 0    | 0    | 1    | 1    | 0    | 0.4                                |
|          |                                                                          | F   | 0    | 0    | 1    | 0    | 0    | 0.2                                |
| C78.0    | Secondary malignant neoplasm of lung                                     | M   | 0    | 0    | 0    | 1    | 0    | 0.2                                |
|          |                                                                          | F   | 0    | 0    | 1    | 0    | 0    | 0.2                                |
| C78.1    | Secondary malignant neoplasm of mediastinum                              | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C78.2    | Secondary malignant neoplasm of pleura                                   | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C78.3    | Secondary malignant neoplasm of other and unspecified respiratory organs | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C78.4    | Secondary malignant neoplasm of small intestine                          | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C78.5    | Secondary malignant neoplasm of large intestine and rectum               | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C78.6    | Secondary malignant neoplasm of retroperitoneum and peritoneum           | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                          | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |

Continued. —&gt;



Table 4: Continued.

| ICD code | Primary site                                                                     | Sex | Year |      |      |      |      | Mean of yearly values<br>2018–2022 |
|----------|----------------------------------------------------------------------------------|-----|------|------|------|------|------|------------------------------------|
|          |                                                                                  |     | 2018 | 2019 | 2020 | 2021 | 2022 |                                    |
| C78.7    | Secondary malignant neoplasm of liver and intrahepatic bile ducts                | M   | 0    | 0    | 1    | 0    | 0    | 0.2                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C78.8    | Secondary malignant neoplasm of other and unspecified digestive organs           | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C79      | Secondary malignant neoplasm of other and unspecified sites                      | M   | 0    | 2    | 3    | 2    | 1    | 1.6                                |
|          |                                                                                  | F   | 1    | 1    | 3    | 2    | 1    | 1.6                                |
| C79.0    | Secondary malignant neoplasm of kidney and renal pelvis                          | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C79.1    | Secondary malignant neoplasm of bladder and other and unspecified urinary organs | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C79.2    | Secondary malignant neoplasm of skin                                             | M   | 0    | 0    | 1    | 1    | 0    | 0.4                                |
|          |                                                                                  | F   | 1    | 0    | 2    | 1    | 1    | 1.0                                |
| C79.3    | Secondary malignant neoplasm of brain and cerebral meninges                      | M   | 0    | 1    | 1    | 1    | 0    | 0.6                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C79.4    | Secondary malignant neoplasm of other and unspecified parts of nervous system    | M   | 0    | 0    | 1    | 0    | 0    | 0.2                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C79.5    | Secondary malignant neoplasm of bone and bone marrow                             | M   | 0    | 1    | 0    | 0    | 0    | 0.2                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C79.6    | Secondary malignant neoplasm of ovary                                            | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C79.7    | Secondary malignant neoplasm of adrenal gland                                    | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| C79.8    | Secondary malignant neoplasm of other specified sites                            | M   | 0    | 0    | 0    | 0    | 1    | 0.2                                |
|          |                                                                                  | F   | 0    | 1    | 1    | 1    | 0    | 0.6                                |
| C80      | Malignant neoplasm, without specification of site                                | M   | 4    | 6    | 6    | 7    | 4    | 5.4                                |
|          |                                                                                  | F   | 2    | 3    | 5    | 6    | 4    | 4.0                                |
| D03      | Melanoma in situ                                                                 | M   | 149  | 179  | 182  | 165  | 266  | 188.2                              |
|          |                                                                                  | F   | 170  | 169  | 152  | 193  | 247  | 186.2                              |
| D03.0    | Melanoma in situ of lip                                                          | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| D03.1    | Melanoma in situ of eyelid, including canthus                                    | M   | 0    | 0    | 0    | 1    | 1    | 0.4                                |
|          |                                                                                  | F   | 1    | 1    | 4    | 2    | 3    | 2.2                                |
| D03.2    | Melanoma in situ of ear and external auricular canal                             | M   | 2    | 2    | 1    | 4    | 1    | 2.0                                |
|          |                                                                                  | F   | 1    | 0    | 3    | 0    | 3    | 1.4                                |
| D03.3    | Melanoma in situ of other and unspecified parts of face                          | M   | 16   | 17   | 21   | 17   | 24   | 19.0                               |
|          |                                                                                  | F   | 35   | 29   | 21   | 24   | 39   | 29.6                               |
| D03.4    | Melanoma in situ of scalp and neck                                               | M   | 6    | 14   | 10   | 13   | 23   | 13.2                               |
|          |                                                                                  | F   | 9    | 9    | 5    | 8    | 4    | 7.0                                |
| D03.5    | Melanoma in situ of trunk                                                        | M   | 93   | 111  | 112  | 100  | 154  | 114.0                              |
|          |                                                                                  | F   | 66   | 76   | 59   | 84   | 105  | 78.0                               |
| D03.6    | Melanoma in situ of upper limb, including shoulder                               | M   | 22   | 24   | 24   | 24   | 47   | 28.2                               |
|          |                                                                                  | F   | 28   | 26   | 28   | 40   | 51   | 34.6                               |
| D03.7    | Melanoma in situ of lower limb, including hip                                    | M   | 9    | 9    | 14   | 4    | 16   | 10.4                               |
|          |                                                                                  | F   | 30   | 27   | 32   | 35   | 42   | 33.2                               |
| D03.8    | Melanoma in situ of other sites                                                  | M   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
|          |                                                                                  | F   | 0    | 0    | 0    | 0    | 0    | 0.0                                |
| D03.9    | Melanoma in situ, unspecified                                                    | M   | 1    | 2    | 0    | 2    | 0    | 1.0                                |
|          |                                                                                  | F   | 0    | 1    | 0    | 0    | 0    | 0.2                                |

Table 5: Number and proportion of primary invasive skin melanoma (C43, C51, C60, C63) per patient, Slovenia 2018–2022.

| Year              | 2018               |       | 2019               |       | 2020               |       | 2021               |       | 2022               |       | 2018–2022          |       |
|-------------------|--------------------|-------|--------------------|-------|--------------------|-------|--------------------|-------|--------------------|-------|--------------------|-------|
| Number of tumours | Number of patients | %     | Number of patients | %     | Number of patients | %     | Number of patients | %     | Number of patients | %     | Number of patients | %     |
| 1                 | 543                | 88.7  | 583                | 91.0  | 592                | 92.2  | 573                | 91.1  | 810                | 92.6  | 3101               | 91.2  |
| 2                 | 57                 | 9.3   | 49                 | 7.6   | 43                 | 6.7   | 46                 | 7.3   | 56                 | 6.4   | 251                | 7.4   |
| 3                 | 11                 | 1.8   | 5                  | 0.8   | 5                  | 0.8   | 6                  | 1.0   | 5                  | 0.6   | 32                 | 0.9   |
| 4                 | 1                  | 0.2   | 2                  | 0.3   | 0                  | 0.0   | 3                  | 0.5   | 3                  | 0.3   | 9                  | 0.3   |
| 5                 | 0                  | 0.0   | 1                  | 0.2   | 1                  | 0.2   | 0                  | 0.0   | 1                  | 0.1   | 3                  | 0.1   |
| More than 5       | 0                  | 0.0   | 1                  | 0.2   | 1                  | 0.2   | 1                  | 0.2   | 0                  | 0.0   | 3                  | 0.1   |
| All               | 612                | 100.0 | 641                | 100.0 | 642                | 100.0 | 629                | 100.0 | 875                | 100.0 | 3399               | 100.0 |

Table 6a: Number and proportion of primary invasive skin melanoma (C43, C51, C60, C63) by UICC stage, Slovenia 2018–2022.

| UICC STAGE    | Number of new cases | Year  |       |       |       |       |           |
|---------------|---------------------|-------|-------|-------|-------|-------|-----------|
|               |                     | 2018  | 2019  | 2020  | 2021  | 2022  | 2018–2022 |
| All           | Number              | 612   | 641   | 642   | 629   | 875   | 3399      |
|               | %*                  | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0     |
| IA            | Number              | 297   | 309   | 337   | 311   | 499   | 1753      |
|               | %*                  | 48.5  | 48.2  | 52.5  | 49.4  | 57.0  | 51.6      |
| IB            | Number              | 83    | 67    | 73    | 86    | 106   | 415       |
|               | %*                  | 13.6  | 10.5  | 11.4  | 13.7  | 12.1  | 12.2      |
| All stage I   | Number              | 380   | 376   | 410   | 397   | 605   | 2168      |
|               | %*                  | 62.1  | 58.7  | 63.9  | 63.1  | 69.1  | 63.8      |
| IIA           | Number              | 39    | 67    | 54    | 40    | 62    | 262       |
|               | %*                  | 6.4   | 10.5  | 8.4   | 6.4   | 7.1   | 7.7       |
| IIB           | Number              | 40    | 45    | 38    | 26    | 50    | 199       |
|               | %*                  | 6.5   | 7.0   | 5.9   | 4.1   | 5.7   | 5.9       |
| IIC           | Number              | 44    | 39    | 42    | 31    | 54    | 210       |
|               | %*                  | 7.2   | 6.1   | 6.5   | 4.9   | 6.2   | 6.2       |
| All stage II  | Number              | 123   | 151   | 134   | 97    | 166   | 671       |
|               | %*                  | 20.1  | 23.6  | 20.9  | 15.4  | 19.0  | 19.7      |
| IIIA          | Number              | 9     | 12    | 9     | 10    | 9     | 49        |
|               | %*                  | 1.5   | 1.9   | 1.4   | 1.6   | 1.0   | 1.4       |
| IIIB          | Number              | 23    | 20    | 19    | 21    | 23    | 106       |
|               | %*                  | 3.8   | 3.1   | 3.0   | 3.3   | 2.6   | 3.1       |
| IIIC          | Number              | 48    | 53    | 44    | 62    | 44    | 251       |
|               | %*                  | 7.8   | 8.3   | 6.9   | 9.9   | 5.0   | 7.4       |
| IIID          | Number              | 6     | 9     | 6     | 12    | 4     | 37        |
|               | %*                  | 1.0   | 1.4   | 0.9   | 1.9   | 0.0   | 1.1       |
| All stage III | Number              | 86    | 94    | 78    | 105   | 80    | 443       |
|               | %*                  | 14.1  | 14.7  | 12.1  | 16.7  | 9.1   | 13.0      |
| IV            | Number              | 21    | 17    | 13    | 25    | 19    | 95        |
|               | %*                  | 3.4   | 2.7   | 2.0   | 4.0   | 2.2   | 2.8       |
| Unknown       | Number              | 2     | 3     | 7     | 5     | 5     | 22        |
|               | %*                  | 0.0   | 0.0   | 1.1   | 0.8   | 0.6   | 0.6       |

\* Percentages are not calculated for less than 5 cases.

Table 6b:

Sites of distant metastases of primary invasive skin melanoma (C43, C51, C60, C63), Slovenia 2018–2022.

| Year      | M classification    | Anatomical site of metastasis                             | Number of new cases / metastases |
|-----------|---------------------|-----------------------------------------------------------|----------------------------------|
| 2018      | Number of new cases | All                                                       | 610                              |
|           | M0                  | Number of new cases without metastasis                    | 589                              |
|           | M1                  | Number of new cases with distant metastases               | 21                               |
|           | M1a                 | Skin, subcutaneous tissue, lymph nodes                    | 26                               |
|           | M1b                 | Lung                                                      | 8                                |
|           | M1c                 | Visceral organs and all other defined sites excluding CNS | 11                               |
|           | M1d                 | CNS                                                       | 6                                |
|           |                     | All                                                       | 51                               |
| 2019      | Number of new cases | All                                                       | 641                              |
|           | M0                  | Number of new cases without metastasis                    | 624                              |
|           | M1                  | Number of new cases with distant metastases               | 17                               |
|           | M1a                 | Skin, subcutaneous tissue, lymph nodes                    | 15                               |
|           | M1b                 | Lung                                                      | 8                                |
|           | M1c                 | Visceral organs and all other defined sites excluding CNS | 13                               |
|           | M1d                 | CNS                                                       | 2                                |
|           |                     | All                                                       | 38                               |
| 2020      | Number of new cases | All                                                       | 642                              |
|           | M0                  | Number of new cases without metastasis                    | 629                              |
|           | M1                  | Number of new cases with distant metastases               | 13                               |
|           | M1a                 | Skin, subcutaneous tissue, lymph nodes                    | 10                               |
|           | M1b                 | Lung                                                      | 5                                |
|           | M1c                 | Visceral organs and all other defined sites excluding CNS | 10                               |
|           | M1d                 | CNS                                                       | 4                                |
|           |                     | All                                                       | 29                               |
| 2021      | Number of new cases | All                                                       | 629                              |
|           | M0                  | Number of new cases without metastasis                    | 604                              |
|           | M1                  | Number of new cases with distant metastases               | 25                               |
|           | M1a                 | Skin, subcutaneous tissue, lymph nodes                    | 28                               |
|           | M1b                 | Lung                                                      | 17                               |
|           | M1c                 | Visceral organs and all other defined sites excluding CNS | 17                               |
|           | M1d                 | CNS                                                       | 1                                |
|           |                     | All                                                       | 63                               |
| 2022      | Number of new cases | All                                                       | 875                              |
|           | M0                  | Number of new cases without metastasis                    | 856                              |
|           | M1                  | Number of new cases with distant metastases               | 19                               |
|           | M1a                 | Skin, subcutaneous tissue, lymph nodes                    | 15                               |
|           | M1b                 | Lung                                                      | 10                               |
|           | M1c                 | Visceral organs and all other defined sites excluding CNS | 13                               |
|           | M1d                 | CNS                                                       | 5                                |
|           |                     | All                                                       | 43                               |
| 2018–2022 | Number of new cases | All                                                       | 3397                             |
|           | M0                  | Number of new cases without metastasis                    | 3302                             |
|           | M1                  | Number of new cases with distant metastases               | 95                               |
|           | M1a                 | Skin, subcutaneous tissue, lymph nodes                    | 94                               |
|           | M1b                 | Lung                                                      | 48                               |
|           | M1c                 | Visceral organs and all other defined sites excluding CNS | 64                               |
|           | M1d                 | CNS                                                       | 18                               |
|           |                     | All                                                       | 224                              |

Table 7a: Number and proportion of primary invasive skin melanoma (C43, C51, C60, C63) according to Breslow thickness, Slovenia 2018–2022.

| Breslow thickness (mm) |               | Number of new cases | Year  |       |       |       |       |           |
|------------------------|---------------|---------------------|-------|-------|-------|-------|-------|-----------|
|                        |               |                     | 2018  | 2019  | 2020  | 2021  | 2022  | 2018–2022 |
| All                    |               | Number              | 612   | 641   | 642   | 629   | 875   | 3399      |
|                        |               | %                   | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0     |
| Specified              | All specified | Number              | 592   | 619   | 621   | 604   | 857   | 3293      |
|                        |               | %                   | 96.7  | 96.6  | 96.7  | 96.0  | 97.9  | 96.9      |
|                        |               | Mean                | 2.5   | 2.5   | 2.2   | 2.4   | 1.8   | 2.2       |
|                        |               | Median              | 1.0   | 1.0   | 0.9   | 1.0   | 0.8   | 0.9       |
|                        | ≤ 0.8         | Number              | 271   | 278   | 282   | 263   | 449   | 1543      |
|                        |               | %*                  | 44.3  | 43.4  | 43.9  | 41.8  | 51.3  | 45.4      |
|                        | > 0.8 - ≤ 1.0 | Number              | 33    | 34    | 56    | 51    | 54    | 228       |
|                        |               | %*                  | 5.4   | 5.3   | 8.7   | 8.1   | 6.2   | 6.7       |
|                        | > 1.0 - ≤ 2.0 | Number              | 111   | 102   | 107   | 118   | 146   | 584       |
|                        |               | %*                  | 18.1  | 15.9  | 16.7  | 18.8  | 16.7  | 17.2      |
|                        | > 2.0 - ≤ 4.0 | Number              | 77    | 111   | 89    | 73    | 99    | 449       |
|                        |               | %*                  | 12.6  | 17.3  | 13.9  | 11.6  | 11.3  | 13.2      |
|                        | > 4           | Number              | 100   | 94    | 87    | 99    | 109   | 489       |
|                        |               | %*                  | 16.3  | 14.7  | 13.6  | 15.7  | 12.5  | 14.4      |
| Unknown                |               | Number              | 20    | 22    | 21    | 25    | 18    | 106       |
|                        |               | %*                  | 3.3   | 3.4   | 3.3   | 4.0   | 2.1   | 3.1       |

\* Percentages are not calculated for less than 5 cases.

Table 7b: Number and proportion of primary invasive skin melanoma (C43, C51, C60, C63) with confirmed ulceration according to Breslow thicknesses, Slovenia 2018–2022.

| Breslow thickness (mm) | Number of new cases | Year  |       |       |       |       |           |
|------------------------|---------------------|-------|-------|-------|-------|-------|-----------|
|                        |                     | 2018  | 2019  | 2020  | 2021  | 2022  | 2018–2022 |
| All                    | Number              | 147   | 146   | 141   | 143   | 167   | 744       |
|                        | %*                  | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0     |
| ≤ 0.8                  | Number              | 11    | 10    | 6     | 6     | 8     | 41        |
|                        | %*                  | 7.5   | 6.8   | 4.3   | 4.2   | 4.8   | 5.5       |
| > 0.8 - ≤ 1.0          | Number              | 2     | 2     | 5     | 5     | 4     | 18        |
|                        | %*                  | -     | -     | 3.5   | 3.5   | -     | 2.4       |
| > 1.0 - ≤ 2.0          | Number              | 19    | 22    | 22    | 20    | 28    | 111       |
|                        | %*                  | 12.9  | 15.1  | 15.6  | 14.0  | 16.8  | 14.9      |
| > 2.0 - ≤ 4.0          | Number              | 38    | 48    | 42    | 35    | 45    | 208       |
|                        | %*                  | 25.9  | 32.9  | 29.8  | 24.5  | 26.9  | 28.0      |
| > 4                    | Number              | 77    | 64    | 66    | 77    | 81    | 365       |
|                        | %*                  | 52.4  | 43.8  | 46.8  | 53.8  | 48.5  | 49.1      |
| Unknown                | Number              | 0     | 0     | 0     | 0     | 1     | 1         |
|                        | %*                  | -     | -     | -     | -     | -     | -         |

\* Percentages are not calculated for less than 5 cases.

Table 7c: Number and proportion of Breslow thickness distribution in primary invasive skin melanoma (C43, C51, C60, C63) by sex and age, Slovenia 2018–2022.

| Year | Breslow thickness | Sex | Age      |       |        |   |        |      |        |      |        |      |
|------|-------------------|-----|----------|-------|--------|---|--------|------|--------|------|--------|------|
|      |                   |     | All ages |       | 0–19   |   | 20–49  |      | 50–74  |      | 75+    |      |
|      |                   |     | Number   | %     | Number | % | Number | %    | Number | %    | Number | %    |
| 2018 | All               | M+F | 612      | 100.0 | 0      | - | 140    | 22.9 | 295    | 48.2 | 177    | 28.9 |
|      |                   | M   | 323      | 100.0 | 0      | - | 49     | 15.2 | 169    | 52.3 | 105    | 32.5 |
|      |                   | F   | 289      | 100.0 | 0      | - | 91     | 31.5 | 126    | 43.6 | 72     | 24.9 |
|      | ≤ 0.8             | M   | 133      | 100.0 | 0      | - | 23     | 17.3 | 72     | 54.1 | 38     | 28.6 |
|      |                   | F   | 138      | 100.0 | 0      | - | 55     | 39.9 | 60     | 43.5 | 23     | 16.7 |
|      | > 0.8 - ≤ 1.0     | M   | 17       | 58.8  | 0      | - | 4      | -    | 10     | 58.8 | 3      | -    |
|      |                   | F   | 16       | 81.3  | 0      | - | 6      | 37.5 | 7      | 43.8 | 3      | -    |
|      | > 1.0 - ≤ 2.0     | M   | 55       | 100.0 | 0      | - | 8      | 14.5 | 34     | 61.8 | 13     | 23.6 |
|      |                   | F   | 56       | 100.0 | 0      | - | 22     | 39.3 | 23     | 41.1 | 11     | 19.6 |
|      | > 2.0 - ≤ 4.0     | M   | 48       | 91.7  | 0      | - | 4      | -    | 28     | 58.3 | 16     | 33.3 |
|      |                   | F   | 29       | 86.2  | 0      | - | 4      | -    | 18     | 62.1 | 7      | 24.1 |
|      | > 4               | M   | 57       | 100.0 | 0      | - | 8      | 14.0 | 19     | 33.3 | 30     | 52.6 |
|      |                   | F   | 43       | 93.0  | 0      | - | 3      | -    | 15     | 34.9 | 25     | 58.1 |
|      | Unknown           | M   | 13       | 84.6  | 0      | - | 2      | -    | 6      | 46.2 | 5      | 38.5 |
|      |                   | F   | 7        | 0.0   | 0      | - | 1      | -    | 3      | -    | 3      | -    |
| 2019 | All               | M+F | 641      | 99.7  | 2      | - | 141    | 22.0 | 339    | 52.9 | 159    | 24.8 |
|      |                   | M   | 320      | 100.0 | 0      | - | 57     | 17.8 | 181    | 56.6 | 82     | 25.6 |
|      |                   | F   | 321      | 99.4  | 2      | - | 84     | 26.2 | 158    | 49.2 | 77     | 24.0 |
|      | ≤ 0.8             | M   | 127      | 100.0 | 0      | - | 25     | 19.7 | 71     | 55.9 | 31     | 24.4 |
|      |                   | F   | 151      | 100.0 | 0      | - | 54     | 35.8 | 72     | 47.7 | 25     | 16.6 |
|      | > 0.8 - ≤ 1.0     | M   | 17       | 64.7  | 0      | - | 3      | -    | 11     | 64.7 | 3      | -    |
|      |                   | F   | 17       | 58.8  | 0      | - | 4      | -    | 10     | 58.8 | 3      | -    |
|      | > 1.0 - ≤ 2.0     | M   | 52       | 100.0 | 0      | - | 13     | 25.0 | 31     | 59.6 | 8      | 15.4 |
|      |                   | F   | 50       | 96.0  | 2      | - | 13     | 26.0 | 27     | 54.0 | 8      | 16.0 |
|      | > 2.0 - ≤ 4.0     | M   | 53       | 100.0 | 0      | - | 8      | 15.1 | 30     | 56.6 | 15     | 28.3 |
|      |                   | F   | 58       | 100.0 | 0      | - | 9      | 15.5 | 30     | 51.7 | 19     | 32.8 |
|      | > 4               | M   | 57       | 100.0 | 0      | - | 6      | 10.5 | 29     | 50.9 | 22     | 38.6 |
|      |                   | F   | 37       | 94.6  | 0      | - | 2      | -    | 15     | 40.5 | 20     | 54.1 |
|      | Unknown           | M   | 14       | 64.3  | 0      | - | 2      | -    | 9      | 64.3 | 3      | -    |
|      |                   | F   | 8        | 0.0   | 0      | - | 2      | -    | 4      | -    | 2      | -    |
| 2020 | All               | M+F | 642      | 99.4  | 4      | - | 133    | 20.7 | 324    | 50.5 | 181    | 28.2 |
|      |                   | M   | 330      | 99.4  | 2      | - | 54     | 16.4 | 189    | 57.3 | 85     | 25.8 |
|      |                   | F   | 312      | 99.4  | 2      | - | 79     | 25.3 | 135    | 43.3 | 96     | 30.8 |
|      | ≤ 0.8             | M   | 130      | 99.2  | 1      | - | 25     | 19.2 | 79     | 60.8 | 25     | 19.2 |
|      |                   | F   | 152      | 100.0 | 0      | - | 50     | 32.9 | 72     | 47.4 | 30     | 19.7 |
|      | > 0.8 - ≤ 1.0     | M   | 31       | 96.8  | 1      | - | 13     | 41.9 | 12     | 38.7 | 5      | 16.1 |
|      |                   | F   | 25       | 100.0 | 0      | - | 6      | 24.0 | 10     | 40.0 | 9      | 36.0 |
|      | > 1.0 - ≤ 2.0     | M   | 51       | 100.0 | 0      | - | 7      | 13.7 | 32     | 62.7 | 12     | 23.5 |
|      |                   | F   | 56       | 96.4  | 2      | - | 12     | 21.4 | 30     | 53.6 | 12     | 21.4 |
|      | > 2.0 - ≤ 4.0     | M   | 52       | 94.2  | 0      | - | 3      | -    | 33     | 63.5 | 16     | 30.8 |
|      |                   | F   | 37       | 100.0 | 0      | - | 6      | 16.2 | 14     | 37.8 | 17     | 45.9 |
|      | > 4               | M   | 58       | 93.1  | 0      | - | 4      | -    | 29     | 50.0 | 25     | 43.1 |
|      |                   | F   | 29       | 89.7  | 0      | - | 3      | -    | 5      | 17.2 | 21     | 72.4 |
|      | Unknown           | M   | 8        | 0.0   | 0      | - | 2      | -    | 4      | -    | 2      | -    |
|      |                   | F   | 13       | 53.8  | 0      | - | 2      | -    | 4      | -    | 7      | 53.8 |

Continued. —>

Table 7c: Continued.

| Year        | Breslow thickness | Sex | Age      |       |        |     |        |      |        |      |        |       |
|-------------|-------------------|-----|----------|-------|--------|-----|--------|------|--------|------|--------|-------|
|             |                   |     | All ages |       | 0–19   |     | 20–49  |      | 50–74  |      | 75+    |       |
|             |                   |     | Number   | %     | Number | %   | Number | %    | Number | %    | Number | %     |
| 2021        | All               | M+F | 629      | 99.4  | 4      | -   | 131    | 20.8 | 330    | 52.5 | 164    | 26.1  |
|             |                   | M   | 322      | 99.4  | 2      | -   | 59     | 18.3 | 172    | 53.4 | 89     | 27.6  |
|             |                   | F   | 307      | 99.3  | 2      | -   | 72     | 23.5 | 158    | 51.5 | 75     | 24.4  |
|             | ≤ 0.8             | M   | 117      | 100.0 | 0      | -   | 33     | 28.2 | 58     | 49.6 | 26     | 22.2  |
|             |                   | F   | 146      | 100.0 | 0      | -   | 43     | 29.5 | 78     | 53.4 | 25     | 17.1  |
|             | > 0.8 - ≤ 1.0     | M   | 22       | 86.4  | 0      | -   | 8      | 36.4 | 11     | 50.0 | 3      | -     |
|             |                   | F   | 29       | 89.7  | 0      | -   | 11     | 37.9 | 15     | 51.7 | 3      | -     |
|             | > 1.0 - ≤ 2.0     | M   | 64       | 96.9  | 2      | -   | 10     | 15.6 | 38     | 59.4 | 14     | 21.9  |
|             |                   | F   | 54       | 98.1  | 1      | -   | 10     | 18.5 | 32     | 59.3 | 11     | 20.4  |
|             | > 2.0 - ≤ 4.0     | M   | 42       | 100.0 | 0      | -   | 5      | 11.9 | 18     | 42.9 | 19     | 45.2  |
|             |                   | F   | 31       | 87.1  | 0      | -   | 4      | -    | 14     | 45.2 | 13     | 41.9  |
|             | > 4               | M   | 61       | 95.1  | 0      | -   | 3      | -    | 34     | 55.7 | 24     | 39.3  |
|             |                   | F   | 38       | 89.5  | 1      | -   | 3      | -    | 14     | 36.8 | 20     | 52.6  |
|             | Unknown           | M   | 16       | 81.3  | 0      | -   | 0      | -    | 13     | 81.3 | 3      | -     |
|             |                   | F   | 9        | 55.6  | 0      | -   | 1      | -    | 5      | 55.6 | 3      | -     |
| 2022        | All               | M+F | 875      | 99.5  | 4      | -   | 197    | 22.5 | 455    | 52.0 | 219    | 25.0  |
|             |                   | M   | 464      | 99.6  | 2      | -   | 85     | 18.3 | 254    | 54.7 | 123    | 26.5  |
|             |                   | F   | 411      | 99.5  | 2      | -   | 112    | 27.3 | 201    | 48.9 | 96     | 23.4  |
|             | ≤ 0.8             | M   | 229      | 99.6  | 1      | -   | 49     | 21.4 | 132    | 57.6 | 47     | 20.5  |
|             |                   | F   | 220      | 99.1  | 2      | -   | 76     | 34.5 | 114    | 51.8 | 28     | 12.7  |
|             | > 0.8 - ≤ 1.0     | M   | 30       | 100.0 | 0      | -   | 9      | 30.0 | 10     | 33.3 | 11     | 36.7  |
|             |                   | F   | 24       | 100.0 | 0      | -   | 6      | 25.0 | 13     | 54.2 | 5      | 20.8  |
|             | > 1.0 - ≤ 2.0     | M   | 85       | 98.8  | 1      | -   | 15     | 17.6 | 55     | 64.7 | 14     | 16.5  |
|             |                   | F   | 61       | 100.0 | 0      | -   | 16     | 26.2 | 36     | 59.0 | 9      | 14.8  |
|             | > 2.0 - ≤ 4.0     | M   | 53       | 100.0 | 0      | -   | 8      | 15.1 | 28     | 52.8 | 17     | 32.1  |
|             |                   | F   | 46       | 100.0 | 0      | -   | 7      | 15.2 | 22     | 47.8 | 17     | 37.0  |
|             | > 4               | M   | 59       | 94.9  | 0      | -   | 3      | -    | 25     | 42.4 | 31     | 52.5  |
|             |                   | F   | 50       | 100.0 | 0      | -   | 7      | 14.0 | 16     | 32.0 | 27     | 54.0  |
|             | Unknown           | M   | 8        | 0.0   | 0      | -   | 1      | -    | 4      | -    | 3      | -     |
|             |                   | F   | 10       | 100.0 | 0      | -   | 0      | -    | 0      | -    | 10     | 100.0 |
| 2018 – 2022 | All               | M+F | 3399     | 100.0 | 14     | 0.4 | 742    | 21.8 | 1743   | 51.3 | 900    | 26.5  |
|             |                   | M   | 1759     | 100.0 | 6      | 0.3 | 304    | 17.3 | 965    | 54.9 | 484    | 27.5  |
|             |                   | F   | 1640     | 100.0 | 8      | 0.5 | 438    | 26.7 | 778    | 47.4 | 416    | 25.4  |
|             | ≤ 0.8             | M   | 736      | 99.7  | 2      | -   | 155    | 21.1 | 412    | 56.0 | 167    | 22.7  |
|             |                   | F   | 807      | 99.8  | 2      | -   | 278    | 34.4 | 396    | 49.1 | 131    | 16.2  |
|             | > 0.8 - ≤ 1.0     | M   | 117      | 99.1  | 1      | -   | 37     | 31.6 | 54     | 46.2 | 25     | 21.4  |
|             |                   | F   | 111      | 100.0 | 0      | -   | 33     | 29.7 | 55     | 49.5 | 23     | 20.7  |
|             | > 1.0 - ≤ 2.0     | M   | 307      | 99.0  | 3      | -   | 53     | 17.3 | 190    | 61.9 | 61     | 19.9  |
|             |                   | F   | 277      | 100.0 | 5      | 1.8 | 73     | 26.4 | 148    | 53.4 | 51     | 18.4  |
|             | > 2.0 - ≤ 4.0     | M   | 248      | 100.0 | 0      | -   | 28     | 11.3 | 137    | 55.2 | 83     | 33.5  |
|             |                   | F   | 201      | 100.0 | 0      | -   | 30     | 14.9 | 98     | 48.8 | 73     | 36.3  |
|             | > 4               | M   | 292      | 100.0 | 0      | -   | 24     | 8.2  | 136    | 46.6 | 132    | 45.2  |
|             |                   | F   | 197      | 99.5  | 1      | -   | 18     | 9.1  | 65     | 33.0 | 113    | 57.4  |
|             | Unknown           | M   | 59       | 100.0 | 0      | -   | 7      | 11.9 | 36     | 61.0 | 16     | 27.1  |
|             |                   | F   | 47       | 100.0 | 0      | -   | 6      | 12.8 | 16     | 34.0 | 25     | 53.2  |

\* Percentages are not calculated for less than 5 cases.

Table 8: Number and proportion of skin melanoma (C43, C51, C60, C63, C77–C80, D03) by histological type, Slovenia 2018–2022.

| Year         |                                              | 2018   |       | 2019   |       | 2020   |       | 2021   |       | 2022   |       | 2018–2022 |       |
|--------------|----------------------------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
| ICD-0-3 code | Histological type                            | Number | %*    | Number | %*    | Number | %*    | Number | %*    | Number | %*    | Number    | %*    |
| 8720         | Malignant melanoma, NOS**                    | 368    | 39.1  | 421    | 42.1  | 448    | 44.9  | 487    | 48.4  | 587    | 41.9  | 2311      | 43.2  |
| 8721         | Nodular melanoma                             | 93     | 9.9   | 88     | 8.8   | 79     | 7.9   | 105    | 10.4  | 137    | 9.8   | 502       | 9.4   |
| 8722         | Balloon cell melanoma                        | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| 8723         | Malignant melanoma, regressing               | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| 8730         | Amelanotic melanoma                          | 2      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2         | -     |
| 8740         | Malignant melanoma in junctional lesion      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| 8741         | Malignant melanoma in precancerous melanosis | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| 8742         | Lentigo maligna                              | 83     | 8.8   | 63     | 6.3   | 54     | 5.4   | 49     | 4.9   | 60     | 4.3   | 309       | 5.8   |
| 8743         | Superficial spreading melanoma**             | 377    | 40.1  | 402    | 40.2  | 388    | 38.9  | 341    | 33.9  | 588    | 42.0  | 2096      | 39.2  |
| 8744         | Acral lentiginous melanoma, malignant        | 8      | 0.9   | 9      | 0.9   | 11     | 1.1   | 10     | 1.0   | 7      | 0.5   | 45        | 0.8   |
| 8745         | Desmoplastic melanoma, malignant             | 3      | -     | 3      | -     | 6      | 0.6   | 2      | -     | 8      | 0.6   | 22        | 0.4   |
| 8761         | Malignant melanoma in giant pigmented lesion | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| 8770         | Mixed epithelioid and spindle cell melanoma  | 3      | -     | 4      | -     | 1      | -     | 5      | 0.5   | 6      | 0.4   | 19        | 0.4   |
| 8771         | Epithelioid cell melanoma                    | 3      | -     | 8      | 0.8   | 9      | 0.9   | 6      | 0.6   | 5      | 0.4   | 31        | 0.6   |
| 8772         | Spindle cell melanoma, NOS                   | 0      | -     | 3      | -     | 1      | -     | 1      | -     | 3      | -     | 8         | 0.1   |
| 8780         | Blue lesion, malignant                       | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| 8720 – 8780  | All                                          | 940    | 100.0 | 1001   | 100.0 | 997    | 100.0 | 1006   | 100.0 | 1401   | 100.0 | 5345      | 100.0 |

\* Percentages are not calculated for less than 5 cases.

\*\* The histological types were recoded in 2023, which is why the numbers differ from previous reports.

# Survival

Table 9a: One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by ICD classification and sex, Slovenia 2018–2022.

| Survival type                   | ICD code           | Primary site                                | Sex | Number | 1-year survival (95% CI) |           | 3-year survival (95% CI) |           | 5-year survival (95% CI) |           | Median of survival (months) |
|---------------------------------|--------------------|---------------------------------------------|-----|--------|--------------------------|-----------|--------------------------|-----------|--------------------------|-----------|-----------------------------|
| Time to first progress or death | C43, C51, C60, C63 | Primary invasive skin melanoma              | M+F | 3381   | 91.0                     | 90.0–91.9 | 80.7                     | 79.3–82.1 | 73.8                     | 71.9–75.8 | /                           |
|                                 |                    |                                             | M   | 1752   | 89.6                     | 88.2–91.1 | 78.1                     | 76.0–80.3 | 70.7                     | 67.9–73.7 | /                           |
|                                 |                    |                                             | F   | 1629   | 92.4                     | 91.2–93.7 | 83.4                     | 81.5–85.4 | 77.1                     | 74.5–79.8 | /                           |
|                                 | D03                | Melanoma in situ                            | M+F | 1838   | 99.1                     | 98.6–99.5 | 95.5                     | 94.5–96.6 | 92.2                     | 90.4–93.9 | /                           |
|                                 |                    |                                             | M   | 923    | 98.7                     | 98.0–99.4 | 94.1                     | 92.4–95.9 | 90.0                     | 87.2–92.8 | /                           |
|                                 |                    |                                             | F   | 915    | 99.5                     | 99.0–99.9 | 97.0                     | 95.7–98.3 | 94.3                     | 92.3–96.4 | /                           |
|                                 | C77–C80            | Melanoma of secondary or unspecified origin | M+F | 73     | 24.7                     | 16.5–36.8 | 18.0                     | 10.8–29.9 | 12.0                     | 5.6–25.7  | 5.3                         |
|                                 |                    |                                             | M   | 40     | 20.0                     | 10.8–37.2 | 16.7                     | 8.1–34.1  | 8.3                      | 1.8–39.6  | 4.9                         |
|                                 |                    |                                             | F   | 33     | 30.3                     | 18.1–50.8 | 18.9                     | 9.0–39.9  | 14.2                     | 5.6–36.2  | 8.1                         |
| Observed survival               | C43, C51, C60, C63 | Primary invasive skin melanoma              | M+F | 3381   | 95.1                     | 94.3–95.8 | 85.1                     | 83.8–86.5 | 77.9                     | 76.0–79.8 | /                           |
|                                 |                    |                                             | M   | 1752   | 94.2                     | 93.1–95.3 | 83.0                     | 81.1–85.0 | 74.4                     | 71.5–77.3 | /                           |
|                                 |                    |                                             | F   | 1629   | 96.0                     | 95.1–97.0 | 87.4                     | 85.7–89.2 | 81.6                     | 79.2–84.2 | /                           |
|                                 | D03                | Melanoma in situ                            | M+F | 1838   | 99.1                     | 98.6–99.5 | 95.5                     | 94.5–96.6 | 92.2                     | 90.4–93.9 | /                           |
|                                 |                    |                                             | M   | 923    | 98.7                     | 98.0–99.4 | 94.1                     | 92.4–95.9 | 90.0                     | 87.2–92.8 | /                           |
|                                 |                    |                                             | F   | 915    | 99.5                     | 99.0–99.9 | 97.0                     | 95.7–98.3 | 94.3                     | 92.3–96.4 | /                           |
|                                 | C77–C80            | Melanoma of secondary or unspecified origin | M+F | 73     | 45.2                     | 35.1–58.2 | 31.6                     | 22.4–44.6 | 21.3                     | 11.9–38.0 | 9.8                         |
|                                 |                    |                                             | M   | 40     | 35.0                     | 22.9–53.4 | 29.6                     | 18.3–47.9 | 19.7                     | 7.8–50.2  | 6.8                         |
|                                 |                    |                                             | F   | 33     | 57.6                     | 43.0–77.2 | 34.1                     | 20.9–55.7 | 21.9                     | 9.8–49.2  | 17.4                        |




Figure 8: Kaplan-Meier survival curve to first progress or death for patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by ICD classification and sex, Slovenia 2018–2022.




Figure 9: Kaplan-Meier observed survival curve for patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by ICD classification and sex, Slovenia 2018–2022.



Table 9b: One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by histological type, Slovenia, 2018–2022.

| Survival type                   | ICD-O-3 code                                                    | Histological type              | Number | 1-year survival (95% CI) |            | 3-year survival (95% CI) |           | 5-year survival (95% CI) |           | Median of survival (months) |
|---------------------------------|-----------------------------------------------------------------|--------------------------------|--------|--------------------------|------------|--------------------------|-----------|--------------------------|-----------|-----------------------------|
| Time to first progress or death | 8720–8780                                                       | All                            | 3454   | 89.6                     | 88.6–90.6  | 79.4                     | 77.9–80.8 | 72.5                     | 70.6–74.5 | /                           |
|                                 | 8720                                                            | Malignant melanoma, NOS        | 651    | 77.3                     | 74.1–80.6  | 67.2                     | 63.5–71.1 | 58.4                     | 53.0–64.3 | /                           |
|                                 | 8721                                                            | Nodular melanoma               | 497    | 79.1                     | 75.6–82.7  | 59.5                     | 54.9–64.4 | 50.5                     | 45.2–56.4 | /                           |
|                                 | 8742                                                            | Lentigo maligna                | 88     | 93.2                     | 88.1–98.6  | 77.5                     | 69.0–87.0 | 68.3                     | 57.6–81.0 | /                           |
|                                 | 8743                                                            | Superficial spreading melanoma | 2091   | 95.8                     | 95.0–96.7  | 88.4                     | 86.9–89.9 | 82.4                     | 80.2–84.6 | /                           |
|                                 | 8722, 8723, 8730, 8740, 8741, 8744, 8745, 8761, 8770–8772, 8780 | Other histological types       | 127    | 88.2                     | 82.8–94.0  | 73.1                     | 65.2–81.8 | 69.4                     | 60.7–79.3 | /                           |
| Observed survival               | 8720–8780                                                       | All                            | 3454   | 94.0                     | 93.2–94.8  | 84.0                     | 82.7–85.4 | 76.7                     | 74.8–78.6 | /                           |
|                                 | 8720                                                            | Malignant melanoma, NOS        | 651    | 84.8                     | 82.1–87.6  | 72.4                     | 68.9–76.1 | 61.5                     | 56.2–67.4 | /                           |
|                                 | 8721                                                            | Nodular melanoma               | 497    | 89.5                     | 86.9–92.3  | 68.3                     | 63.9–73.0 | 59.2                     | 53.8–65.2 | /                           |
|                                 | 8742                                                            | Lentigo maligna                | 88     | 98.9                     | 96.7–100.0 | 82.6                     | 74.7–91.4 | 75.6                     | 65.4–87.3 | /                           |
|                                 | 8743                                                            | Superficial spreading melanoma | 2091   | 97.8                     | 97.1–98.4  | 91.5                     | 90.2–92.9 | 85.3                     | 83.2–87.4 | /                           |
|                                 | 8722, 8723, 8730, 8740, 8741, 8744, 8745, 8761, 8770–8772, 8780 | Other histological types       | 127    | 93.7                     | 89.6–98.0  | 83.9                     | 77.2–91.1 | 80.1                     | 72.0–89.0 | /                           |




Figure 10: Kaplan-Meier survival curve to first progress or death for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by histological type, Slovenia, 2018–2022.




Figure 11: Kaplan-Meier observed survival curve for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by histological type, Slovenia, 2018–2022,

Table 9c: One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by age group, Slovenia 2018–2022.

| Survival type                         | Age group | Number | 1-year survival<br>(95% CI) |             | 3-year survival<br>(95% CI) |             | 5-year survival<br>(95% CI) |             | Median of survival<br>(months) |
|---------------------------------------|-----------|--------|-----------------------------|-------------|-----------------------------|-------------|-----------------------------|-------------|--------------------------------|
| Time to first<br>progress<br>or death | All ages  | 3454   | 89.6                        | 88.6–90.6   | 79.4                        | 77.9–80.8   | 72.5                        | 70.6–74.5   | /                              |
|                                       | 0–19      | 14     | 100.0                       | 100.0–100.0 | 100.0                       | 100.0–100.0 | 100.0                       | 100.0–100.0 | /                              |
|                                       | 20–49     | 750    | 96.0                        | 94.6–97.4   | 91.6                        | 89.5–93.8   | 89.8                        | 87.2–92.6   | /                              |
|                                       | 50–74     | 1785   | 91.7                        | 90.4–92.9   | 83.8                        | 82.0–85.7   | 78.0                        | 75.6–80.5   | /                              |
|                                       | 75+       | 905    | 80.0                        | 77.4–82.6   | 60.2                        | 56.8–63.8   | 47.8                        | 43.6–52.5   | 58.2                           |
| Observed<br>survival                  | All ages  | 3454   | 94.0                        | 93.2–94.8   | 84.0                        | 82.7–85.4   | 76.7                        | 74.8–78.6   | /                              |
|                                       | 0–19      | 14     | 100.0                       | 100.0–100.0 | 100.0                       | 100.0–100.0 | 100.0                       | 100.0–100.0 | /                              |
|                                       | 20–49     | 750    | 98.5                        | 97.7–99.4   | 95.0                        | 93.3–96.8   | 91.9                        | 89.3–94.6   | /                              |
|                                       | 50–74     | 1785   | 95.9                        | 94.9–96.8   | 88.6                        | 87.0–90.2   | 83.0                        | 80.7–85.4   | /                              |
|                                       | 75+       | 905    | 86.5                        | 84.3–88.8   | 65.6                        | 62.3–69.1   | 52.0                        | 47.7–56.8   | /                              |




Figure 12: Kaplan-Meier survival curve to first progress or death for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by age group, Slovenia 2018–2022.




Figure 13: Kaplan-Meier observed survival curve for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by age group, Slovenia 2018–2022.

Table 9d: One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by UICC stage (simplified classification), Slovenia 2018–2022.

| Survival type                   | UICC stadij | Number | 1-year survival (95% CI) |           | 3-year survival (95% CI) |           | 5-year survival (95% CI) |           | Median of survival (months) |
|---------------------------------|-------------|--------|--------------------------|-----------|--------------------------|-----------|--------------------------|-----------|-----------------------------|
| Time to first progress or death | All stages  | 5292   | 92.9                     | 92.2–93.6 | 85.0                     | 83.9–86.0 | 79.3                     | 77.9–80.7 | /                           |
|                                 | 0 (In situ) | 1838   | 99.1                     | 98.6–99.5 | 95.5                     | 94.5–96.6 | 92.2                     | 90.4–93.9 | /                           |
|                                 | I           | 2164   | 98.8                     | 98.3–99.3 | 94.7                     | 93.7–95.8 | 90.4                     | 88.6–92.3 | /                           |
|                                 | II          | 664    | 85.7                     | 83.1–88.4 | 65.9                     | 62.1–69.9 | 55.1                     | 50.4–60.1 | /                           |
|                                 | III         | 442    | 74.0                     | 70.0–78.2 | 50.5                     | 45.8–55.8 | 39.0                     | 33.1–46.0 | 36.8                        |
|                                 | IV          | 91     | 31.9                     | 23.6–43.0 | 17.6                     | 10.9–28.3 | 11.1                     | 5.5–22.6  | 6.5                         |
|                                 | Unknown*    | 93     | 33.3                     | 25.0–44.4 | 23.9                     | 16.4–35.0 | 17.9                     | 10.8–29.6 | 7.4                         |
| Observed survival               | All stages  | 5292   | 95.8                     | 95.2–96.3 | 88.0                     | 87.0–89.0 | 82.0                     | 80.6–83.4 | /                           |
|                                 | 0 (In situ) | 1838   | 99.1                     | 98.6–99.5 | 95.5                     | 94.5–96.6 | 92.2                     | 90.4–93.9 | /                           |
|                                 | I           | 2164   | 99.2                     | 98.8–99.6 | 95.2                     | 94.2–96.3 | 90.8                     | 89.0–92.7 | /                           |
|                                 | II          | 664    | 92.9                     | 91.0–94.9 | 75.9                     | 72.5–79.6 | 64.2                     | 59.5–69.3 | /                           |
|                                 | III         | 442    | 88.7                     | 85.8–91.7 | 64.4                     | 59.6–69.4 | 51.6                     | 45.5–58.5 | 66.7                        |
|                                 | IV          | 91     | 48.4                     | 39.1–59.8 | 25.5                     | 17.6–36.9 | 19.9                     | 12.5–31.6 | 11.2                        |
|                                 | Unknown*    | 93     | 51.6                     | 42.4–62.8 | 40.9                     | 31.9–52.5 | 30.8                     | 20.9–45.4 | 15.6                        |

\*Includes unknown and unidentified stages.




Figure 14: Kaplan-Meier survival curve to first progress or death for patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by UICC stage, Slovenia 2018–2022.




Figure 15: Kaplan-Meier observed survival curve for patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by UICC stage, Slovenia 2018–2022.

Table 9e: One-, three- and five-year survival to first progress or death and observed survival with median of survival with 95% confidence interval (CI) of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by Breslow thickness, Slovenia, 2018–2022.

| Survival type                   | Breslow thickness | Number | 1-year survival<br>(95% CI) |            | 3-year survival<br>(95% CI) |           | 5-year survival<br>(95% CI) |           | Median of survival<br>(months) |
|---------------------------------|-------------------|--------|-----------------------------|------------|-----------------------------|-----------|-----------------------------|-----------|--------------------------------|
| Time to first progress or death | All               | 3454   | 89.6                        | 88.6–90.6  | 79.4                        | 77.9–80.8 | 72.5                        | 70.6–74.5 | /                              |
|                                 | ≤ 0,8             | 1670   | 98.8                        | 98.3–99.3  | 95.6                        | 94.5–96.7 | 90.9                        | 88.8–93.1 | /                              |
|                                 | > 0,8–≤ 1,0       | 97     | 96.9                        | 93.5–100.0 | 90.2                        | 83.8–97.1 | 88.3                        | 81.1–96.1 | /                              |
|                                 | > 1,0–≤ 2,0       | 695    | 89.4                        | 87.1–91.7  | 76.7                        | 73.4–80.2 | 70.7                        | 66.6–75.0 | /                              |
|                                 | > 2,0–≤ 4,0       | 457    | 86.9                        | 83.8–90.0  | 68.2                        | 63.7–73.0 | 56.3                        | 50.5–62.6 | /                              |
|                                 | > 4               | 360    | 71.7                        | 67.2–76.5  | 47.9                        | 42.7–53.7 | 37.5                        | 31.7–44.3 | 34.0                           |
| Observed survival               | Unknown           | 175    | 42.3                        | 35.6–50.3  | 27.0                        | 20.9–34.9 | 14.7                        | 6.2–34.9  | 9.5                            |
|                                 | All               | 3454   | 94.0                        | 93.2–94.8  | 84.0                        | 82.7–85.4 | 76.7                        | 74.8–78.6 | /                              |
|                                 | ≤ 0,8             | 1670   | 99.0                        | 98.5–99.5  | 95.8                        | 94.7–96.9 | 91.1                        | 88.9–93.2 | /                              |
|                                 | > 0,8–≤ 1,0       | 97     | 99.0                        | 97.0–100.0 | 90.9                        | 84.6–97.7 | 89.0                        | 81.9–96.7 | /                              |
|                                 | > 1,0–≤ 2,0       | 695    | 94.8                        | 93.2–96.5  | 81.4                        | 78.3–84.7 | 75.5                        | 71.5–79.7 | /                              |
|                                 | > 2,0–≤ 4,0       | 457    | 93.0                        | 90.7–95.4  | 78.1                        | 74.0–82.3 | 65.8                        | 60.3–71.9 | /                              |
|                                 | > 4               | 360    | 86.7                        | 83.2–90.3  | 62.5                        | 57.3–68.1 | 49.5                        | 42.9–57.0 | 59.7                           |
|                                 | Unknown           | 175    | 58.3                        | 51.4–66.1  | 41.4                        | 34.4–49.8 | 28.4                        | 19.6–41.1 | 17.9                           |




Figure 16: Kaplan-Meier survival curve to first progress or death for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by Breslow thickness, Slovenia, 2018–2022.




Figure 17: Kaplan-Meier observed survival curve for patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by Breslow thickness, Slovenia, 2018–2022.

# Diagnostics

Table 10: Health care institution that performed excisional biopsy (all lesions are included) to diagnose primary skin melanoma (C43, C51, C60, C63, D03), Slovenia 2018–2022.

| Year                                                                           | 2018       |             | 2019       |             | 2020       |             | 2021       |             | 2022       |             | 2018–2022   |             |
|--------------------------------------------------------------------------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|-------------|-------------|
| Healthcare institution                                                         | Number     | %*          | Number     | %*          | Number     | %*          | Number     | %*          | Number     | %*          | Number      | %*          |
| <b>Hospitals</b>                                                               | <b>776</b> | <b>76.6</b> | <b>711</b> | <b>67.5</b> | <b>685</b> | <b>66.2</b> | <b>662</b> | <b>62.7</b> | <b>768</b> | <b>52.0</b> | <b>3602</b> | <b>63.9</b> |
| Hospital Topolšica                                                             | 0          | -           | 0          | -           | 0          | -           | 0          | -           | 1          | -           | 1           | -           |
| Institute of Oncology Ljubljana                                                | 43         | 4.2         | 31         | 2.9         | 47         | 4.5         | 36         | 3.4         | 36         | 2.4         | 193         | 3.4         |
| General Hospital Brežice                                                       | 5          | -           | 5          | -           | 3          | -           | 14         | -           | 13         | -           | 40          | 0.7         |
| General Hospital Celje                                                         | 113        | 11.2        | 90         | 8.5         | 92         | 8.9         | 61         | 5.8         | 58         | 3.9         | 414         | 7.3         |
| General Hospital Dr. Franc Derganc Nova Gorica                                 | 25         | 2.5         | 20         | 1.9         | 16         | 1.5         | 16         | 1.5         | 12         | -           | 89          | 1.6         |
| General Hospital Dr. Jožeta Potrča Ptuj                                        | 8          | -           | 7          | -           | 16         | 1.5         | 20         | 1.9         | 36         | 2.4         | 87          | 1.5         |
| General Hospital Izola                                                         | 51         | 5.0         | 39         | 3.7         | 35         | 3.4         | 27         | 2.6         | 23         | 1.6         | 175         | 3.1         |
| General Hospital Jesenice                                                      | 62         | 6.1         | 52         | 4.9         | 40         | 3.9         | 35         | 3.3         | 43         | 2.9         | 232         | 4.1         |
| General Hospital Murska Sobota                                                 | 32         | 3.2         | 28         | 2.7         | 17         | 1.6         | 30         | 2.8         | 38         | 2.6         | 145         | 2.6         |
| General Hospital Novo mesto                                                    | 32         | 3.2         | 38         | 3.6         | 36         | 3.5         | 29         | 2.7         | 33         | 2.2         | 168         | 3.0         |
| General Hospital Slovenj Gradec                                                | 31         | 3.1         | 18         | 1.7         | 19         | 1.8         | 24         | 2.3         | 26         | 1.8         | 118         | 2.1         |
| General Hospital Trbovlje                                                      | 4          | -           | 5          | -           | 5          | -           | 3          | -           | 0          | -           | 17          | 0.3         |
| University Medical Centre Ljubljana                                            | 228        | 22.5        | 246        | 23.4        | 243        | 23.5        | 212        | 20.1        | 282        | 19.1        | 1211        | 21.5        |
| University Medical Centre Maribor                                              | 142        | 14.0        | 132        | 12.5        | 116        | 11.2        | 155        | 14.7        | 167        | 11.3        | 712         | 12.6        |
| <b>Private clinics</b>                                                         | <b>199</b> | <b>19.6</b> | <b>282</b> | <b>26.8</b> | <b>292</b> | <b>28.2</b> | <b>358</b> | <b>33.9</b> | <b>628</b> | <b>42.5</b> | <b>1759</b> | <b>31.2</b> |
| Agencija Avanta družba za komuniciranje d.o.o.                                 | 2          | -           | 0          | -           | 0          | -           | 0          | -           | 0          | -           | 2           | -           |
| Ageno d.o.o.                                                                   | 0          | -           | 0          | -           | 0          | -           | 0          | -           | 1          | -           | 1           | -           |
| AKD d.o.o.                                                                     | 12         | -           | 16         | 1.5         | 15         | 1.4         | 6          | -           | 20         | 1.4         | 69          | 1.2         |
| Ambulanta Genus d.o.o.                                                         | 0          | -           | 0          | -           | 0          | -           | 0          | -           | 1          | -           | 1           | -           |
| Aristotel d.o.o.                                                               | 1          | -           | 0          | -           | 1          | -           | 0          | -           | 1          | -           | 3           | -           |
| ARSDERMA d.o.o.                                                                | 18         | 1.8         | 9          | -           | 6          | -           | 10         | -           | 19         | 1.3         | 62          | 1.1         |
| asist.mag. Marko Bitenc - zasebni zdravnik                                     | 0          | -           | 1          | -           | 1          | -           | 0          | -           | 0          | -           | 2           | -           |
| BB dermatologija d.o.o.                                                        | 0          | -           | 0          | -           | 0          | -           | 6          | -           | 6          | -           | 12          | -           |
| Bival zdravje, zdravstvo, storitve in trgovina, d.o.o                          | 0          | -           | 0          | -           | 0          | -           | 0          | -           | 1          | -           | 1           | -           |
| Cardial d.o.o.                                                                 | 0          | -           | 0          | -           | 0          | -           | 0          | -           | 1          | -           | 1           | -           |
| Derma center Maribor                                                           | 0          | -           | 0          | -           | 2          | -           | 2          | -           | 2          | -           | 6           | -           |
| Dermacenter center za estetiko in lasersko odstranjevanje žil, znamenj in dlak | 3          | -           | 0          | -           | 2          | -           | 3          | -           | 8          | -           | 16          | 0.3         |
| Dermadent, d.o.o.                                                              | 0          | -           | 0          | -           | 0          | -           | 7          | -           | 9          | -           | 16          | 0.3         |
| Dermatologija Bartenjev d.o.o.                                                 | 50         | 4.9         | 65         | 6.2         | 19         | 1.8         | 49         | 4.6         | 81         | 5.5         | 264         | 4.7         |
| Dermatologija Jasmina Demšar s.p.                                              | 3          | -           | 8          | -           | 5          | -           | 2          | -           | 2          | -           | 20          | 0.4         |
| Dermatologija mag. Metka Adamič dr.med. s.p.                                   | 6          | -           | 0          | -           | 0          | -           | 2          | -           | 1          | -           | 9           | -           |
| Dermatologija Maja Kalač Pandurovič, zdravstvene in druge storitve, d.o.o.     | 1          | -           | 8          | -           | 11         | -           | 4          | -           | 2          | -           | 26          | 0.5         |
| Dermatologija Rogl Fabjan d.o.o.                                               | 3          | -           | 2          | -           | 46         | 4.4         | 55         | 5.2         | 32         | 2.2         | 138         | 2.4         |
| Dermatologija.si d.o.o.                                                        | 0          | -           | 0          | -           | 0          | -           | 1          | -           | 4          | -           | 5           | -           |
| Dermatološki center Derm - Blanka Zagoričnik Opara                             | 0          | -           | 1          | -           | 0          | -           | 0          | -           | 0          | -           | 1           | -           |
| Dermatovenerologija Natalija Evdakova Bodiroža                                 | 1          | -           | 12         | -           | 7          | -           | 4          | -           | 2          | -           | 26          | 0.5         |
| Dermis d.o.o.                                                                  | 0          | -           | 0          | -           | 2          | -           | 0          | -           | 1          | -           | 3           | -           |
| Dermostetika Izola                                                             | 0          | -           | 0          | -           | 0          | -           | 1          | -           | 0          | -           | 1           | -           |
| Diagnostični center Bled                                                       | 1          | -           | 7          | -           | 2          | -           | 1          | -           | 1          | -           | 12          | -           |
| Endomed d.o.o.                                                                 | 0          | -           | 1          | -           | 0          | -           | 0          | -           | 0          | -           | 1           | -           |
| Ergomed medicinski center, d. o. o.                                            | 0          | -           | 0          | -           | 1          | -           | 6          | -           | 3          | -           | 10          | -           |
| Estetika Fabjan                                                                | 11         | -           | 12         | -           | 26         | 2.5         | 56         | 5.3         | 198        | 13.4        | 303         | 5.4         |
| Estetika Med-Art d.o.o.                                                        | 0          | -           | 1          | -           | 1          | -           | 0          | -           | 2          | -           | 4           | -           |
| Estetika Milošević, plastična, rekonstrukcijska in estetska kirurgija d.o.o.   | 0          | -           | 0          | -           | 0          | -           | 1          | -           | 4          | -           | 5           | -           |

Continued. —>

Table 10: Continued.

| Year                                                                                                              | 2018   |       | 2019   |       | 2020   |       | 2021   |       | 2022   |       | 2018–2022 |       |
|-------------------------------------------------------------------------------------------------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
| Healthcare institution                                                                                            | Number | %*    | Number | %*    | Number | %*    | Number | %*    | Number | %*    | Number    | %*    |
| Inštitut za dermatologijo                                                                                         | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1         | -     |
| Janežič Tomaž, dr.med.                                                                                            | 10     | -     | 15     | 1.4   | 17     | 1.6   | 12     | -     | 17     | 1.2   | 71        | 1.3   |
| Juventina clinic d.o.o.                                                                                           | 0      | -     | 2      | -     | 1      | -     | 2      | -     | 5      | -     | 10        | -     |
| Kirurgija Arnež, d.o.o.                                                                                           | 6      | -     | 6      | -     | 11     | -     | 10     | -     | 21     | 1.4   | 54        | 1.0   |
| Kirurški center Toš d.o.o.                                                                                        | 3      | -     | 4      | -     | 11     | -     | 24     | 2.3   | 16     | 1.1   | 58        | 1.0   |
| Klinika Božikov d.o.o.                                                                                            | 1      | -     | 0      | -     | 1      | -     | 6      | -     | 3      | -     | 11        | -     |
| Klinika Doktor 24 d.o.o.                                                                                          | 7      | -     | 3      | -     | 5      | -     | 6      | -     | 10     | -     | 31        | 0.6   |
| Klinika Omnia, specialistične medicinske dejavnosti, d.o.o.                                                       | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1      | -     | 2         | -     |
| Koprivec, družinska medicina, d.o.o.                                                                              | 2      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2         | -     |
| Lantana, d.o.o.                                                                                                   | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1      | -     | 2         | -     |
| Medartis (bivši DTMC)                                                                                             | 3      | -     | 1      | -     | 2      | -     | 4      | -     | 5      | -     | 15        | 0.3   |
| MTC fontana d.o.o.                                                                                                | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
| Olivier's d.o.o.                                                                                                  | 5      | -     | 3      | -     | 0      | -     | 0      | -     | 0      | -     | 8         | -     |
| p. e. Medicina Volovec                                                                                            | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1         | -     |
| Plastična kirurgija Zorman                                                                                        | 1      | -     | 1      | -     | 3      | -     | 0      | -     | 4      | -     | 9         | -     |
| Poliklinika Nobilis d.o.o.                                                                                        | 0      | -     | 5      | -     | 3      | -     | 6      | -     | 15     | 1.0   | 29        | 0.5   |
| Proderma d.o.o.                                                                                                   | 1      | -     | 1      | -     | 5      | -     | 0      | -     | 1      | -     | 8         | -     |
| Profiderma d.o.o.                                                                                                 | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
| Remeda, medicinski center Domžale, d.o.o.                                                                         | 0      | -     | 2      | -     | 0      | -     | 2      | -     | 0      | -     | 4         | -     |
| Sanatorij Rožna dolina                                                                                            | 1      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 2         | -     |
| Simed, zdravstveni center                                                                                         | 22     | 2.2   | 53     | 5.0   | 45     | 4.3   | 40     | 3.8   | 82     | 5.6   | 242       | 4.3   |
| Simmed                                                                                                            | 0      | -     | 1      | -     | 2      | -     | 0      | -     | 0      | -     | 3         | -     |
| Venolek d.o.o.                                                                                                    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -     |
| Vok Marko - dermatovenerološka ordinacija                                                                         | 0      | -     | 4      | -     | 0      | -     | 0      | -     | 0      | -     | 4         | -     |
| Zasebna ambulanta družinske medicine - Franc Novak, dr. med., spec. splošne medicine, ordinacija splošne medicine | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
| Zdrav splet d.o.o.                                                                                                | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1      | -     | 2         | -     |
| Zdravilišče Rogaška - zdravstvo d.o.o.                                                                            | 8      | -     | 21     | 2.0   | 28     | 2.7   | 22     | 2.1   | 35     | 2.4   | 114       | 2.0   |
| Zdravje d.o.o.                                                                                                    | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
| Zdravstvene storitve, Lina Virnik Kovač s.p.                                                                      | 0      | -     | 0      | -     | 0      | -     | 2      | -     | 7      | -     | 9         | -     |
| private institution unknown                                                                                       | 16     | 1.6   | 16     | 1.5   | 8      | -     | 1      | -     | 1      | -     | 42        | 0.7   |
| Community health centres                                                                                          | 36     | 3.6   | 55     | 5.2   | 54     | 5.2   | 33     | 3.1   | 75     | 5.1   | 253       | 4.5   |
| ZD Ajdovščina                                                                                                     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2      | -     | 2         | -     |
| ZD Celje                                                                                                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -     |
| ZD Ivančna Gorica                                                                                                 | 0      | -     | 1      | -     | 2      | -     | 0      | -     | 4      | -     | 7         | -     |
| ZD Ljubljana - Center                                                                                             | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
| ZD Nova Gorica                                                                                                    | 0      | -     | 1      | -     | 1      | -     | 0      | -     | 0      | -     | 2         | -     |
| ZD Postojna                                                                                                       | 13     | -     | 13     | -     | 16     | 1.5   | 7      | -     | 10     | -     | 59        | 1.0   |
| ZD Sevnica                                                                                                        | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
| ZD Škofja Loka                                                                                                    | 4      | -     | 4      | -     | 2      | -     | 0      | -     | 0      | -     | 10        | -     |
| ZD Trbovlje                                                                                                       | 11     | -     | 16     | 1.5   | 8      | -     | 14     | -     | 15     | 1.0   | 64        | 1.1   |
| Železniški zdravstveni dom Ljubljana                                                                              | 8      | -     | 19     | 1.8   | 24     | 2.3   | 12     | -     | 43     | 2.9   | 106       | 1.9   |
| Other                                                                                                             | 2      | 0.2   | 5      | 0.5   | 4      | 0.4   | 3      | 0.3   | 6      | 0.4   | 20        | 0.4   |
| Healthcare institution unknown                                                                                    | 1      | -     | 3      | -     | 3      | -     | 1      | -     | 4      | -     | 12        | -     |
| Institution outside of Slovenia                                                                                   | 1      | -     | 2      | -     | 1      | -     | 2      | -     | 2      | -     | 8         | -     |
| All                                                                                                               | 1013   | 100.0 | 1053   | 100.0 | 1035   | 100.0 | 1056   | 100.0 | 1477   | 100.0 | 5634      | 100.0 |

\* Proportions are not calculated for less than 15 cases.

Table 11: Histopathology laboratory that assessed the excisional biopsy specimens (all lesions are included) to diagnose primary skin melanoma (C43, C51, C60, C63, D03), Slovenia 2018–2022.

| Year                                           | 2018   |       | 2019   |       | 2020   |       | 2021   |       | 2022   |       | 2018–2022 |       |
|------------------------------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
| Histopathology lab                             | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Institute of Oncology Ljubljana                | 47     | 4.6   | 37     | 3.5   | 58     | 5.6   | 38     | 3.6   | 48     | 3.2   | 228       | 4.0   |
| General Hospital Celje                         | 103    | 10.2  | 83     | 7.9   | 73     | 7.1   | 48     | 4.5   | 56     | 3.8   | 363       | 6.4   |
| General Hospital Dr. Franc Derganc Nova Gorica | 24     | 2.4   | 18     | 1.7   | 13     | 1.3   | 14     | 1.3   | 9      | 0.6   | 78        | 1.4   |
| General Hospital Izola                         | 50     | 4.9   | 38     | 3.6   | 33     | 3.2   | 23     | 2.2   | 21     | 1.4   | 165       | 2.9   |
| General Hospital Jesenice                      | 56     | 5.5   | 49     | 4.7   | 35     | 3.4   | 25     | 2.4   | 35     | 2.4   | 200       | 3.5   |
| General Hospital Murska Sobota                 | 1      | 0.1   | 2      | 0.2   | 12     | 1.2   | 14     | 1.3   | 24     | 1.6   | 53        | 0.9   |
| General Hospital Novo mesto                    | 38     | 3.8   | 34     | 3.2   | 35     | 3.4   | 32     | 3.0   | 27     | 1.8   | 166       | 2.9   |
| General Hospital Slovenj Gradec                | 25     | 2.5   | 18     | 1.7   | 19     | 1.8   | 32     | 3.0   | 35     | 2.4   | 129       | 2.3   |
| University of Ljubljana, Faculty of Medicine   | 468    | 46.2  | 595    | 56.5  | 547    | 52.9  | 622    | 58.9  | 855    | 57.9  | 3087      | 54.8  |
| University Medical Centre Ljubljana            | 19     | 1.9   | 23     | 2.2   | 33     | 3.2   | 29     | 2.7   | 39     | 2.6   | 143       | 2.5   |
| University Medical Centre Maribor              | 138    | 13.6  | 124    | 11.8  | 124    | 12.0  | 101    | 9.6   | 117    | 7.9   | 604       | 10.7  |
| University Clinic Golnik                       | 0      | 0.0   | 1      | 0.1   | 1      | 0.1   | 0      | 0.0   | 0      | 0.0   | 2         | 0.0   |
| Diagnostični center Bled                       | 28     | 2.8   | 19     | 1.8   | 37     | 3.6   | 67     | 6.3   | 25     | 1.7   | 176       | 3.1   |
| Institution outside of Slovenia                | 9      | 0.9   | 5      | 0.5   | 4      | 0.4   | 10     | 0.9   | 184    | 12.5  | 212       | 3.8   |
| Health institution unknown                     | 7      | 0.7   | 7      | 0.7   | 11     | 1.1   | 1      | 0.1   | 2      | 0.1   | 28        | 0.5   |
| All                                            | 1013   | 100.0 | 1053   | 100.0 | 1035   | 100.0 | 1056   | 100.0 | 1477   | 100.0 | 5634      | 100.0 |

Table 12: Type of biopsy for pathology report (all lesions are included) for primary skin melanoma (C43, C51, C60, C63, D03), Slovenia 2018–2022.

| Year        | Melanoma lesions          | Type of biopsy         |                   |                   |              |       |
|-------------|---------------------------|------------------------|-------------------|-------------------|--------------|-------|
|             |                           | Number of all biopsies | Excisional biopsy | Incisional biopsy | Punch biopsy | Other |
| 2018        | All melanoma lesions      | 1064                   | 1013              | 22                | 25           | 4     |
|             | Main melanoma lesions     | 947                    | 902               | 20                | 22           | 3     |
|             | Non-main melanoma lesions | 117                    | 111               | 2                 | 3            | 1     |
| 2019        | All melanoma lesions      | 1089                   | 1053              | 6                 | 23           | 7     |
|             | Main melanoma lesions     | 997                    | 965               | 6                 | 20           | 6     |
|             | Non-main melanoma lesions | 92                     | 88                | 0                 | 3            | 1     |
| 2020        | All melanoma lesions      | 1088                   | 1035              | 10                | 33           | 10    |
|             | Main melanoma lesions     | 1000                   | 955               | 8                 | 27           | 10    |
|             | Non-main melanoma lesions | 88                     | 80                | 2                 | 6            | 0     |
| 2021        | All melanoma lesions      | 1109                   | 1056              | 5                 | 42           | 6     |
|             | Main melanoma lesions     | 1010                   | 964               | 5                 | 36           | 5     |
|             | Non-main melanoma lesions | 99                     | 92                | 0                 | 6            | 1     |
| 2022        | All melanoma lesions      | 1533                   | 1477              | 0                 | 49           | 7     |
|             | Main melanoma lesions     | 1423                   | 1369              | 0                 | 47           | 7     |
|             | Non-main melanoma lesions | 110                    | 108               | 0                 | 2            | 0     |
| 2018 – 2022 | All melanoma lesions      | 5883                   | 5634              | 43                | 172          | 34    |
|             | Main melanoma lesions     | 5377                   | 5155              | 39                | 152          | 31    |
|             | Non-main melanoma lesions | 506                    | 479               | 4                 | 20           | 3     |

Table 13: Diagnostic histopathology of excisional biopsy specimens (all lesion excisions are included) in primary invasive skin melanoma (C43, C51, C60, C63), Slovenia 2018–2022.

| Year                           | 2018   |       | 2019   |       | 2020   |       | 2021   |       | 2022   |       | 2018–2022 |       |
|--------------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
| Histopathological diagnosis    | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Radial growth                  |        |       |        |       |        |       |        |       |        |       |           |       |
| No                             | 126    | 20.0  | 109    | 16.6  | 94     | 14.5  | 99     | 15.2  | 148    | 16.6  | 576       | 16.5  |
| Superficial spreading melanoma | 409    | 64.9  | 446    | 67.8  | 412    | 63.7  | 446    | 68.3  | 622    | 69.7  | 2335      | 67.1  |
| Lentigo malignant              | 33     | 5.2   | 15     | 2.3   | 15     | 2.3   | 19     | 2.9   | 18     | 2.0   | 100       | 2.9   |
| Acral lentiginous              | 6      | 1.0   | 9      | 1.4   | 12     | 1.9   | 9      | 1.4   | 7      | 0.8   | 43        | 1.2   |
| Unspecified type               | 22     | 3.5   | 38     | 5.8   | 78     | 12.1  | 56     | 8.6   | 74     | 8.3   | 268       | 7.7   |
| Cannot be assessed             | 5      | 0.8   | 6      | 0.9   | 4      | 0.6   | 4      | 0.6   | 8      | 0.9   | 27        | 0.8   |
| Unknown                        | 29     | 4.6   | 35     | 5.3   | 32     | 4.9   | 20     | 3.1   | 16     | 1.8   | 132       | 3.8   |
| All                            | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Vertical growth                |        |       |        |       |        |       |        |       |        |       |           |       |
| No                             | 111    | 17.6  | 138    | 21.0  | 160    | 24.7  | 154    | 23.6  | 234    | 26.2  | 797       | 22.9  |
| Epithelioid cell type          | 316    | 50.2  | 354    | 53.8  | 308    | 47.6  | 349    | 53.4  | 384    | 43.0  | 1711      | 49.2  |
| Spindle cell type              | 35     | 5.6   | 27     | 4.1   | 28     | 4.3   | 21     | 3.2   | 42     | 4.7   | 153       | 4.4   |
| Mixed cell type                | 117    | 18.6  | 92     | 14.0  | 97     | 15.0  | 100    | 15.3  | 129    | 14.4  | 535       | 15.4  |
| Cannot be assessed             | 1      | 0.2   | 1      | 0.2   | 2      | 0.3   | 3      | 0.5   | 2      | 0.2   | 9         | 0.3   |
| Present, type unknown          | 28     | 4.4   | 18     | 2.7   | 23     | 3.6   | 8      | 1.2   | 35     | 3.9   | 112       | 3.2   |
| Unknown                        | 22     | 3.5   | 28     | 4.3   | 29     | 4.5   | 18     | 2.8   | 67     | 7.5   | 164       | 4.7   |
| All                            | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Ulceration                     |        |       |        |       |        |       |        |       |        |       |           |       |
| No                             | 472    | 74.9  | 504    | 76.6  | 488    | 75.4  | 498    | 76.3  | 720    | 80.6  | 2682      | 77.0  |
| Present                        | 147    | 23.3  | 146    | 22.2  | 141    | 21.8  | 143    | 21.9  | 167    | 18.7  | 744       | 21.4  |
| Cannot be assessed             | 0      | 0.0   | 2      | 0.3   | 3      | 0.5   | 4      | 0.6   | 1      | 0.1   | 10        | 0.3   |
| Unknown                        | 11     | 1.7   | 6      | 0.9   | 15     | 2.3   | 8      | 1.2   | 5      | 0.6   | 45        | 1.3   |
| All                            | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Pigmentation                   |        |       |        |       |        |       |        |       |        |       |           |       |
| Absent                         | 49     | 7.8   | 45     | 6.8   | 35     | 5.4   | 38     | 5.8   | 56     | 6.3   | 223       | 6.4   |
| Mild to moderate               | 477    | 75.7  | 504    | 76.6  | 531    | 82.1  | 487    | 74.6  | 623    | 69.8  | 2622      | 75.3  |
| Strong                         | 57     | 9.0   | 79     | 12.0  | 40     | 6.2   | 90     | 13.8  | 84     | 9.4   | 350       | 10.1  |
| Unknown                        | 47     | 7.5   | 30     | 4.6   | 41     | 6.3   | 38     | 5.8   | 130    | 14.6  | 286       | 8.2   |
| All                            | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Lymphocytic infiltration       |        |       |        |       |        |       |        |       |        |       |           |       |
| Absent                         | 92     | 14.6  | 74     | 11.2  | 59     | 9.1   | 70     | 10.7  | 97     | 10.9  | 392       | 11.3  |
| Mild                           | 356    | 56.5  | 383    | 58.2  | 416    | 64.3  | 378    | 57.9  | 461    | 51.6  | 1994      | 57.3  |
| Substantial                    | 158    | 25.1  | 151    | 22.9  | 132    | 20.4  | 176    | 27.0  | 221    | 24.7  | 838       | 24.1  |
| Present, amount unknown        | 2      | 0.3   | 20     | 3.0   | 11     | 1.7   | 10     | 1.5   | 96     | 10.8  | 139       | 4.0   |
| Cannot be assessed             | 0      | 0.0   | 2      | 0.3   | 1      | 0.2   | 3      | 0.5   | 2      | 0.2   | 8         | 0.2   |
| Unknown                        | 22     | 3.5   | 28     | 4.3   | 28     | 4.3   | 16     | 2.5   | 16     | 1.8   | 110       | 3.2   |
| All                            | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Regression                     |        |       |        |       |        |       |        |       |        |       |           |       |
| No                             | 460    | 73.0  | 483    | 73.4  | 479    | 74.0  | 453    | 69.4  | 628    | 70.3  | 2503      | 71.9  |
| Present                        | 138    | 21.9  | 152    | 23.1  | 141    | 21.8  | 177    | 27.1  | 248    | 27.8  | 856       | 24.6  |
| Present, thinner than Breslow  | 0      | 0.0   | 0      | 0.0   | 0      | 0.0   | 0      | 0.0   | 0      | 0.0   | 0         | 0.0   |
| Unknown                        | 32     | 5.1   | 23     | 3.5   | 27     | 4.2   | 23     | 3.5   | 17     | 1.9   | 122       | 3.5   |
| All                            | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |

Continued. —>



Table 13: Continued.

| Year                                 | 2018   |       | 2019   |       | 2020   |       | 2021   |       | 2022   |       | 2018–2022 |       |
|--------------------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
| Histopathological diagnosis          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Associated melanocytic lesion        |        |       |        |       |        |       |        |       |        |       |           |       |
| No                                   | 378    | 60.0  | 405    | 61.6  | 412    | 63.7  | 391    | 59.9  | 547    | 61.3  | 2133      | 61.3  |
| Dysplastic                           | 76     | 12.1  | 47     | 7.1   | 67     | 10.4  | 67     | 10.3  | 56     | 6.3   | 313       | 9.0   |
| Typical                              | 96     | 15.2  | 76     | 11.6  | 89     | 13.8  | 89     | 13.6  | 115    | 12.9  | 465       | 13.4  |
| Congenital                           | 21     | 3.3   | 14     | 2.1   | 13     | 2.0   | 22     | 3.4   | 19     | 2.1   | 89        | 2.6   |
| Other                                | 15     | 2.4   | 69     | 10.5  | 35     | 5.4   | 61     | 9.3   | 69     | 7.7   | 249       | 7.2   |
| Unknown                              | 44     | 7.0   | 47     | 7.1   | 31     | 4.8   | 23     | 3.5   | 87     | 9.7   | 232       | 6.7   |
| All                                  | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Microsatellites                      |        |       |        |       |        |       |        |       |        |       |           |       |
| No                                   | 571    | 90.6  | 616    | 93.6  | 600    | 92.7  | 603    | 92.3  | 860    | 96.3  | 3250      | 93.4  |
| Present                              | 26     | 4.1   | 23     | 3.5   | 22     | 3.4   | 29     | 4.4   | 21     | 2.4   | 121       | 3.5   |
| Cannot be assessed                   | 0      | 0.0   | 1      | 0.2   | 1      | 0.2   | 2      | 0.3   | 2      | 0.2   | 6         | 0.2   |
| Unknown                              | 33     | 5.2   | 18     | 2.7   | 24     | 3.7   | 19     | 2.9   | 10     | 1.1   | 104       | 3.0   |
| All                                  | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Lymphovascular invasion              |        |       |        |       |        |       |        |       |        |       |           |       |
| No                                   | 585    | 92.9  | 590    | 89.7  | 601    | 92.9  | 600    | 91.9  | 774    | 86.7  | 3150      | 90.5  |
| Yes                                  | 25     | 4.0   | 38     | 5.8   | 20     | 3.1   | 33     | 5.1   | 24     | 2.7   | 140       | 4.0   |
| Cannot be assessed                   | 0      | 0.0   | 11     | 1.7   | 4      | 0.6   | 7      | 1.1   | 4      | 0.4   | 26        | 0.7   |
| Unknown                              | 20     | 3.2   | 19     | 2.9   | 22     | 3.4   | 13     | 2.0   | 91     | 10.2  | 165       | 4.7   |
| All                                  | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Perineural invasion                  |        |       |        |       |        |       |        |       |        |       |           |       |
| No                                   | 350    | 55.6  | 415    | 63.1  | 561    | 86.7  | 604    | 92.5  | 824    | 92.3  | 2754      | 79.1  |
| Yes                                  | 15     | 2.4   | 31     | 4.7   | 28     | 4.3   | 16     | 2.5   | 23     | 2.6   | 113       | 3.2   |
| Unknown                              | 265    | 42.1  | 212    | 32.2  | 58     | 9.0   | 33     | 5.1   | 46     | 5.2   | 614       | 17.6  |
| All                                  | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Lateral surgical margin              |        |       |        |       |        |       |        |       |        |       |           |       |
| Not involved                         | 610    | 96.8  | 640    | 97.3  | 631    | 97.5  | 633    | 96.9  | 880    | 98.5  | 3394      | 97.5  |
| Margin involved                      | 16     | 2.5   | 12     | 1.8   | 11     | 1.7   | 15     | 2.3   | 11     | 1.2   | 65        | 1.9   |
| Cannot be assessed                   | 0      | 0.0   | 2      | 0.3   | 0      | 0.0   | 1      | 0.2   | 0      | 0.0   | 3         | 0.1   |
| Unknown                              | 4      | 0.6   | 4      | 0.6   | 5      | 0.8   | 4      | 0.6   | 2      | 0.2   | 19        | 0.5   |
| All                                  | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Deep surgical margin                 |        |       |        |       |        |       |        |       |        |       |           |       |
| Not involved                         | 619    | 98.3  | 642    | 97.6  | 630    | 97.4  | 634    | 97.1  | 883    | 98.9  | 3408      | 97.9  |
| Margin involved                      | 5      | 0.8   | 8      | 1.2   | 10     | 1.5   | 14     | 2.1   | 8      | 0.9   | 45        | 1.3   |
| Cannot be assessed                   | 0      | 0.0   | 1      | 0.2   | 0      | 0.0   | 1      | 0.2   | 0      | 0.0   | 2         | 0.1   |
| Unknown                              | 6      | 1.0   | 7      | 1.1   | 7      | 1.1   | 4      | 0.6   | 2      | 0.2   | 26        | 0.7   |
| All                                  | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |
| Skin outside the tumour              |        |       |        |       |        |       |        |       |        |       |           |       |
| Unremarkable                         | 253    | 40.2  | 264    | 40.1  | 475    | 73.4  | 492    | 75.3  | 593    | 66.4  | 2077      | 59.7  |
| Melanocytic lesion                   | 19     | 3.0   | 16     | 2.4   | 46     | 7.1   | 4      | 0.6   | 10     | 1.1   | 95        | 2.7   |
| Malignant skin tumour (non-melanoma) | 1      | 0.2   | 0      | 0.0   | 3      | 0.5   | 0      | 0.0   | 2      | 0.2   | 6         | 0.2   |
| Other                                | 103    | 16.3  | 124    | 18.8  | 108    | 16.7  | 120    | 18.4  | 262    | 29.3  | 717       | 20.6  |
| Unknown                              | 254    | 40.3  | 254    | 38.6  | 15     | 2.3   | 37     | 5.7   | 26     | 2.9   | 586       | 16.8  |
| All                                  | 630    | 100.0 | 658    | 100.0 | 647    | 100.0 | 653    | 100.0 | 893    | 100.0 | 3481      | 100.0 |

Table 14: Diagnostic histopathology of surgically removed regional lymph nodes in the primary treatment of invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Year                                                                         | 2018                       |                 |     |                | 2019                       |                 |     |                | 2020                       |                 |     |                | 2021                       |                 |     |                | 2022                       |                 |     |                | 2018–2022                  |                 |      |                |
|------------------------------------------------------------------------------|----------------------------|-----------------|-----|----------------|----------------------------|-----------------|-----|----------------|----------------------------|-----------------|-----|----------------|----------------------------|-----------------|-----|----------------|----------------------------|-----------------|-----|----------------|----------------------------|-----------------|------|----------------|
| Diagnostic histopathology of surgically removed regional lymph nodes         | Sentinel lymph node biopsy | Lymphadenectomy | All | Proportion (%) | Sentinel lymph node biopsy | Lymphadenectomy | All | Proportion (%) | Sentinel lymph node biopsy | Lymphadenectomy | All | Proportion (%) | Sentinel lymph node biopsy | Lymphadenectomy | All | Proportion (%) | Sentinel lymph node biopsy | Lymphadenectomy | All | Proportion (%) | Sentinel lymph node biopsy | Lymphadenectomy | All  | Proportion (%) |
| Presence of extracapsular growth                                             |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |      |                |
| No                                                                           | 35                         | 13              | 48  | 16.8           | 41                         | 18              | 59  | 20.1           | 45                         | 19              | 64  | 20.1           | 37                         | 4               | 41  | 14.1           | 54                         | 23              | 77  | 26.3           | 212                        | 77              | 289  | 19.5           |
| Yes                                                                          | 8                          | 13              | 21  | 7.3            | 5                          | 8               | 13  | 4.4            | 1                          | 11              | 12  | 3.8            | 2                          | 8               | 10  | 3.4            | 3                          | 6               | 9   | 3.1            | 19                         | 46              | 65   | 4.4            |
| Unknown                                                                      | 8                          | 15              | 23  | 8.0            | 4                          | 11              | 15  | 5.1            | 5                          | 11              | 16  | 5.0            | 6                          | 9               | 15  | 5.2            | 3                          | 5               | 8   | 2.7            | 26                         | 51              | 77   | 5.2            |
| No positive lymph nodes                                                      | 168                        | 26              | 194 | 67.8           | 183                        | 23              | 206 | 70.3           | 209                        | 17              | 226 | 71.1           | 212                        | 12              | 224 | 77.2           | 192                        | 7               | 199 | 67.9           | 964                        | 85              | 1049 | 70.9           |
| All                                                                          | 219                        | 67              | 286 | 100.0          | 233                        | 60              | 293 | 100.0          | 260                        | 58              | 318 | 100.0          | 257                        | 33              | 290 | 100.0          | 252                        | 41              | 293 | 100.0          | 1221                       | 259             | 1480 | 100.0          |
| Fusion status of positive lymph nodes                                        |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |      |                |
| No                                                                           | 47                         | 25              | 72  | 25.2           | 12                         | 24              | 36  | 12.3           | 48                         | 28              | 76  | 23.9           | 45                         | 8               | 53  | 18.3           | 59                         | 26              | 85  | 29.0           | 211                        | 111             | 322  | 21.8           |
| Yes                                                                          | 0                          | 16              | 16  | 5.6            | 0                          | 11              | 11  | 3.8            | 3                          | 11              | 14  | 4.4            | 0                          | 13              | 13  | 4.5            | 0                          | 7               | 7   | 2.4            | 3                          | 58              | 61   | 4.1            |
| Unknown                                                                      | 4                          | 0               | 4   | 1.4            | 38                         | 2               | 40  | 13.7           | 0                          | 2               | 2   | 0.6            | 0                          | 0               | 0   | 0.0            | 1                          | 1               | 2   | 0.7            | 43                         | 5               | 48   | 3.2            |
| No positive lymph nodes                                                      | 168                        | 26              | 194 | 67.8           | 183                        | 23              | 206 | 70.3           | 209                        | 17              | 226 | 71.1           | 212                        | 12              | 224 | 77.2           | 192                        | 7               | 199 | 67.9           | 964                        | 85              | 1049 | 70.9           |
| All                                                                          | 219                        | 67              | 286 | 100.0          | 233                        | 60              | 293 | 100.0          | 260                        | 58              | 318 | 100.0          | 257                        | 33              | 290 | 100.0          | 252                        | 41              | 293 | 100.0          | 1221                       | 259             | 1480 | 100.0          |
| Tumour in fat or connective tissue outside of lymph nodes or vascular system |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |     |                |                            |                 |      |                |
| No                                                                           | 43                         | 32              | 75  | 26.2           | 35                         | 24              | 59  | 20.1           | 41                         | 20              | 61  | 19.2           | 31                         | 4               | 35  | 12.1           | 49                         | 18              | 67  | 22.9           | 199                        | 98              | 297  | 20.1           |
| Yes                                                                          | 1                          | 5               | 6   | 2.1            | 4                          | 4               | 8   | 2.7            | 2                          | 14              | 16  | 5.0            | 2                          | 9               | 11  | 3.8            | 5                          | 9               | 14  | 4.8            | 14                         | 41              | 55   | 3.7            |
| Unknown                                                                      | 7                          | 4               | 11  | 3.8            | 11                         | 9               | 20  | 6.8            | 8                          | 7               | 15  | 4.7            | 12                         | 8               | 20  | 6.9            | 6                          | 7               | 13  | 4.4            | 44                         | 35              | 79   | 5.3            |
| No positive lymph nodes                                                      | 168                        | 26              | 194 | 67.8           | 183                        | 23              | 206 | 70.3           | 209                        | 17              | 226 | 71.1           | 212                        | 12              | 224 | 77.2           | 192                        | 7               | 199 | 67.9           | 964                        | 85              | 1049 | 70.9           |
| All                                                                          | 219                        | 67              | 286 | 100.0          | 233                        | 60              | 293 | 100.0          | 260                        | 58              | 318 | 100.0          | 257                        | 33              | 290 | 100.0          | 252                        | 41              | 293 | 100.0          | 1221                       | 259             | 1480 | 100.0          |

Table 15: Number of imaging tests in baseline staging of skin melanoma (C43, C51, C60, C63, C77–C80, D03) by UICC stage, Slovenia 2018–2022.

| Year | Imaging tests                     | Number of melanomas | I   | II  | III | IV | Unknown | In situ |
|------|-----------------------------------|---------------------|-----|-----|-----|----|---------|---------|
| 2018 | No imaging test done              | 613                 | 269 | 16  | 7   | 1  | 2       | 318     |
|      | One of imaging tests was done     | 163                 | 84  | 56  | 15  | 5  | 2       | 1       |
|      | 2 imaging tests were done         | 127                 | 26  | 45  | 43  | 8  | 5       | 0       |
|      | 3 imaging tests were done         | 33                  | 1   | 5   | 20  | 6  | 1       | 0       |
|      | 4 or more imaging tests were done | 4                   | 0   | 1   | 1   | 1  | 1       | 0       |
|      | Diagnosed at autopsy              | 0                   | 0   | 0   | 0   | 0  | 0       | 0       |
|      | All                               | 940                 | 380 | 123 | 86  | 21 | 11      | 319     |
| 2019 | No imaging test done              | 663                 | 277 | 33  | 3   | 1  | 2       | 347     |
|      | One of imaging tests was done     | 152                 | 69  | 62  | 16  | 1  | 3       | 1       |
|      | 2 imaging tests were done         | 139                 | 29  | 55  | 42  | 10 | 3       | 0       |
|      | 3 imaging tests were done         | 41                  | 1   | 1   | 31  | 3  | 5       | 0       |
|      | 4 or more imaging tests were done | 6                   | 0   | 0   | 2   | 2  | 2       | 0       |
|      | Diagnosed at autopsy              | 0                   | 0   | 0   | 0   | 0  | 0       | 0       |
|      | All                               | 1001                | 376 | 151 | 94  | 17 | 15      | 348     |
| 2020 | No imaging test done              | 657                 | 293 | 22  | 4   | 1  | 4       | 333     |
|      | One of imaging tests was done     | 164                 | 86  | 58  | 13  | 1  | 5       | 1       |
|      | 2 imaging tests were done         | 120                 | 31  | 48  | 29  | 5  | 7       | 0       |
|      | 3 imaging tests were done         | 47                  | 0   | 4   | 29  | 4  | 10      | 0       |
|      | 4 or more imaging tests were done | 9                   | 0   | 2   | 3   | 2  | 2       | 0       |
|      | Diagnosed at autopsy              | 0                   | 0   | 0   | 0   | 0  | 0       | 0       |
|      | All                               | 997                 | 410 | 134 | 78  | 13 | 28      | 334     |

Continued. —>

Table 15: Continued.

| Year              | Imaging tests                     | Number of melanomas | I    | II  | III | IV | Unknown | In situ |
|-------------------|-----------------------------------|---------------------|------|-----|-----|----|---------|---------|
| 2021              | No imaging test done              | 629                 | 258  | 13  | 2   | 0  | 1       | 355     |
|                   | One of imaging tests was done     | 163                 | 101  | 46  | 9   | 3  | 2       | 2       |
|                   | 2 imaging tests were done         | 120                 | 35   | 33  | 40  | 6  | 5       | 1       |
|                   | 3 imaging tests were done         | 76                  | 3    | 4   | 46  | 11 | 12      | 0       |
|                   | 4 or more imaging tests were done | 14                  | 0    | 1   | 8   | 3  | 2       | 0       |
|                   | Diagnosed at autopsy              | 4                   | 0    | 0   | 0   | 2  | 2       | 0       |
|                   | All                               | 1006                | 397  | 97  | 105 | 25 | 24      | 358     |
| 2022              | No imaging test done              | 982                 | 446  | 26  | 3   | 0  | 2       | 505     |
|                   | One of imaging tests was done     | 223                 | 127  | 79  | 11  | 3  | 0       | 3       |
|                   | 2 imaging tests were done         | 129                 | 28   | 51  | 36  | 5  | 4       | 5       |
|                   | 3 imaging tests were done         | 56                  | 4    | 10  | 28  | 6  | 8       | 0       |
|                   | 4 or more imaging tests were done | 11                  | 0    | 0   | 2   | 5  | 4       | 0       |
|                   | Diagnosed at autopsy              | 0                   | 0    | 0   | 0   | 0  | 0       | 0       |
|                   | All                               | 1401                | 605  | 166 | 80  | 19 | 18      | 513     |
| 2018<br>–<br>2022 | No imaging test done              | 3544                | 1543 | 110 | 19  | 3  | 11      | 1858    |
|                   | One of imaging tests was done     | 865                 | 467  | 301 | 64  | 13 | 12      | 8       |
|                   | 2 imaging tests were done         | 635                 | 149  | 232 | 190 | 34 | 24      | 6       |
|                   | 3 imaging tests were done         | 253                 | 9    | 24  | 154 | 30 | 36      | 0       |
|                   | 4 or more imaging tests were done | 44                  | 0    | 4   | 16  | 13 | 11      | 0       |
|                   | Diagnosed at autopsy              | 4                   | 0    | 0   | 0   | 2  | 2       | 0       |
|                   | All                               | 5345                | 2168 | 671 | 443 | 95 | 96      | 1872    |

Table 16: The presence of BRAF, NRAS and c-KIT mutation in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Molecular properties of tumours | Year |      |      |      |      |           |
|---------------------------------|------|------|------|------|------|-----------|
|                                 | 2018 | 2019 | 2020 | 2021 | 2022 | 2018–2022 |
| BRAF positive: V600E            | 12   | 21   | 40   | 82   | 82   | 237       |
| BRAF positive: V600K            | 2    | 5    | 7    | 14   | 6    | 34        |
| BRAF positive: other            | 28   | 35   | 6    | 4    | 2    | 75        |
| BRAF negative                   | 40   | 48   | 55   | 53   | 86   | 282       |
| BRAF unknown                    | 93   | 121  | 54   | 5    | 13   | 286       |
| NRAS positive                   | 8    | 8    | 8    | 16   | 18   | 58        |
| NRAS negative                   | 24   | 36   | 25   | 28   | 66   | 179       |
| NRAS unknown                    | 143  | 186  | 129  | 114  | 105  | 677       |
| c-KIT positive                  | 0    | 1    | 0    | 1    | 3    | 5         |
| c-KIT negative                  | 28   | 41   | 30   | 24   | 65   | 188       |
| c-KIT unknown                   | 147  | 188  | 132  | 133  | 121  | 721       |
| Testing unsuccessful            | 0    | 0    | 0    | 1    | 3    | 4         |

Table 17: Level of serum LDH in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Level of serum LDH (µkat/L) | Year |      |      |      |      |           |
|-----------------------------|------|------|------|------|------|-----------|
|                             | 2018 | 2019 | 2020 | 2021 | 2022 | 2018–2022 |
| LDH determined              | 90   | 107  | 95   | 141  | 121  | 554       |
| Elevated*                   | 23   | 26   | 15   | 14   | 19   | 97        |
| Not elevated**              | 67   | 81   | 80   | 127  | 102  | 457       |
| LDH: average                | 4.4  | 4.9  | 4.2  | 4.8  | 4.1  | 4.5       |
| LDH: median                 | 3.1  | 3.0  | 3.0  | 3.0  | 3.0  | 3.0       |
| LDH: minimum                | 2.0  | 1.7  | 0.0  | 1.2  | 1.5  | 0.0       |
| LDH: maximum                | 42.8 | 74.4 | 61.8 | 79.3 | 79.3 | 79.3      |

\* over 4,13 M; over 4,12 F

\*\* below 4,13 M; below 4,12 F

# Treatment

Table 18a: Number and proportion of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by type of first treatment, Slovenia 2018–2022.

| Type of first treatment                    | 2018   |       | 2019   |       | 2020   |       | 2021   |       | 2022   |       | 2018–2022 |       |
|--------------------------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                            | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| No treatment                               | 6      | 1.0   | 9      | 1.4   | 9      | 1.4   | 6      | 0.9   | 4      | 0.5   | 34        | 1.0   |
| Surgery and systemic therapy               | 26     | 4.2   | 39     | 6.0   | 35     | 5.3   | 54     | 8.3   | 59     | 6.6   | 213       | 6.1   |
| Surgery and radiotherapy                   | 26     | 4.2   | 23     | 3.5   | 25     | 3.8   | 11     | 1.7   | 21     | 2.4   | 106       | 3.1   |
| Surgery, radiotherapy and systemic therapy | 4      | 0.6   | 19     | 2.9   | 9      | 1.4   | 14     | 2.2   | 4      | 0.5   | 50        | 1.4   |
| Radiotherapy and systemic therapy          | 3      | 0.5   | 2      | 0.3   | 1      | 0.2   | 1      | 0.2   | 0      | 0.0   | 7         | 0.2   |
| Surgery (exclusively)                      | 551    | 88.7  | 558    | 85.5  | 579    | 87.3  | 547    | 84.4  | 795    | 89.5  | 3030      | 87.2  |
| Systemic therapy (exclusively)             | 5      | 0.8   | 3      | 0.5   | 3      | 0.5   | 10     | 1.5   | 4      | 0.5   | 25        | 0.7   |
| Radiotherapy (exclusively)                 | 0      | 0.0   | 0      | 0.0   | 2      | 0.3   | 1      | 0.2   | 1      | 0.1   | 4         | 0.1   |
| Diagnosed at autopsy                       | 0      | 0.0   | 0      | 0.0   | 0      | 0.0   | 4      | 0.6   | 0      | 0.0   | 4         | 0.1   |
| All                                        | 621    | 100.0 | 653    | 100.0 | 663    | 100.0 | 648    | 100.0 | 888    | 100.0 | 3473      | 100.0 |

Table 18b: Number of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by UICC stage and type of first treatment, Slovenia 2018–2022.

| Type of first treatment                    | UICC stage |      |     |     |     |     |      |      |      |      |    |         |
|--------------------------------------------|------------|------|-----|-----|-----|-----|------|------|------|------|----|---------|
|                                            | All stages | IA   | IB  | IIA | IIB | IIC | IIIA | IIIB | IIIC | IIID | IV | Unknown |
| No treatment                               | 34         | 0    | 0   | 0   | 0   | 0   | 0    | 1    | 2    | 0    | 9  | 22      |
| Surgery and systemic therapy               | 213        | 0    | 1   | 1   | 6   | 4   | 29   | 41   | 80   | 4    | 40 | 7       |
| Surgery and radiotherapy                   | 106        | 7    | 2   | 4   | 6   | 7   | 2    | 6    | 38   | 13   | 9  | 12      |
| Surgery, radiotherapy and systemic therapy | 50         | 0    | 0   | 0   | 0   | 1   | 0    | 2    | 29   | 10   | 4  | 4       |
| Radiotherapy and systemic therapy          | 7          | 0    | 0   | 0   | 0   | 0   | 0    | 0    | 0    | 0    | 3  | 4       |
| Surgery (exclusively)                      | 3030       | 1746 | 412 | 257 | 187 | 198 | 18   | 56   | 102  | 10   | 19 | 25      |
| Systemic therapy (exclusively)             | 25         | 0    | 0   | 0   | 0   | 0   | 0    | 0    | 0    | 0    | 8  | 17      |
| Radiotherapy (exclusively)                 | 4          | 0    | 0   | 0   | 0   | 0   | 0    | 0    | 0    | 0    | 1  | 3       |
| Diagnosed at autopsy                       | 4          | 0    | 0   | 0   | 0   | 0   | 0    | 0    | 0    | 0    | 2  | 2       |
| All                                        | 3473       | 1753 | 415 | 262 | 199 | 210 | 49   | 106  | 251  | 37   | 95 | 96      |

Table 18c: Number and proportion of patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by age group and type of first treatment, Slovenia 2018–2022.

| Type of first treatment                    | Age      |       |        |       |        |       |        |       |        |       |
|--------------------------------------------|----------|-------|--------|-------|--------|-------|--------|-------|--------|-------|
|                                            | All ages |       | 0–19   |       | 20–49  |       | 50–74  |       | 75+    |       |
|                                            | Number   | %     | Number | %     | Number | %     | Number | %     | Number | %     |
| No treatment                               | 34       | 1.0   | 0      | 0.0   | 4      | 0.5   | 13     | 0.7   | 17     | 1.8   |
| Surgery and systemic therapy               | 213      | 6.1   | 1      | 7.1   | 52     | 6.9   | 145    | 8.1   | 15     | 1.6   |
| Surgery and radiotherapy                   | 106      | 3.1   | 0      | 0.0   | 4      | 0.5   | 42     | 2.3   | 60     | 6.5   |
| Surgery, radiotherapy and systemic therapy | 50       | 1.4   | 0      | 0.0   | 11     | 1.5   | 37     | 2.1   | 2      | 0.2   |
| Radiotherapy and systemic therapy          | 7        | 0.2   | 0      | 0.0   | 2      | 0.3   | 5      | 0.3   | 0      | 0.0   |
| Surgery (exclusively)                      | 3030     | 87.2  | 13     | 92.9  | 676    | 90.1  | 1519   | 85.0  | 822    | 89.3  |
| Systemic therapy (exclusively)             | 25       | 0.7   | 0      | 0.0   | 1      | 0.1   | 22     | 1.2   | 2      | 0.2   |
| Radiotherapy (exclusively)                 | 4        | 0.1   | 0      | 0.0   | 0      | 0.0   | 2      | 0.1   | 2      | 0.2   |
| Diagnosed at autopsy                       | 4        | 0.1   | 0      | 0.0   | 0      | 0.0   | 3      | 0.2   | 1      | 0.1   |
| All                                        | 3473     | 100.0 | 14     | 100.0 | 750    | 100.0 | 1788   | 100.0 | 921    | 100.0 |

Table 19a: Surgical treatment of regional lymph nodes for invasive skin melanoma (C43, C51, C60, C63, C77–C80) by treatment indication, Slovenia 2018–2022.

| Year      | ICD code           | Surgical treatment         | Treatment indication |                   |                         |
|-----------|--------------------|----------------------------|----------------------|-------------------|-------------------------|
|           |                    |                            | Number of treatments | Primary treatment | Treatment of recurrence |
| 2018      | C43, C51, C60, C63 | All treatments             | 309                  | 292               | 17                      |
|           |                    | Sentinel lymph node biopsy | 234                  | 233               | 1                       |
|           |                    | Lymphadenectomy            | 75                   | 59                | 16                      |
|           | C77–C80            | All treatments             | 2                    | 2                 | 0                       |
|           |                    | Sentinel lymph node biopsy | 1                    | 1                 | 0                       |
|           |                    | Lymphadenectomy            | 1                    | 1                 | 0                       |
|           | All treatments     |                            | 311                  | 294               | 17                      |
| 2019      | C43, C51, C60, C63 | All treatments             | 340                  | 318               | 22                      |
|           |                    | Sentinel lymph node biopsy | 263                  | 261               | 2                       |
|           |                    | Lymphadenectomy            | 77                   | 57                | 20                      |
|           | C77–C80            | All treatments             | 4                    | 1                 | 3                       |
|           |                    | Sentinel lymph node biopsy | 0                    | 0                 | 0                       |
|           |                    | Lymphadenectomy            | 4                    | 1                 | 3                       |
|           | All treatments     |                            | 344                  | 319               | 25                      |
| 2020      | C43, C51, C60, C63 | All treatments             | 298                  | 286               | 12                      |
|           |                    | Sentinel lymph node biopsy | 257                  | 256               | 1                       |
|           |                    | Lymphadenectomy            | 41                   | 30                | 11                      |
|           | C77–C80            | All treatments             | 4                    | 4                 | 0                       |
|           |                    | Sentinel lymph node biopsy | 1                    | 1                 | 0                       |
|           |                    | Lymphadenectomy            | 3                    | 3                 | 0                       |
|           | All treatments     |                            | 302                  | 290               | 12                      |
| 2021      | C43, C51, C60, C63 | All treatments             | 305                  | 294               | 11                      |
|           |                    | Sentinel lymph node biopsy | 255                  | 254               | 1                       |
|           |                    | Lymphadenectomy            | 50                   | 40                | 10                      |
|           | C77–C80            | All treatments             | 3                    | 2                 | 1                       |
|           |                    | Sentinel lymph node biopsy | 1                    | 1                 | 0                       |
|           |                    | Lymphadenectomy            | 2                    | 1                 | 1                       |
|           | All treatments     |                            | 308                  | 296               | 12                      |
| 2022      | C43, C51, C60, C63 | All treatments             | 319                  | 312               | 7                       |
|           |                    | Sentinel lymph node biopsy | 293                  | 293               | 0                       |
|           |                    | Lymphadenectomy            | 26                   | 19                | 7                       |
|           | C77–C80            | All treatments             | 4                    | 4                 | 0                       |
|           |                    | Sentinel lymph node biopsy | 0                    | 0                 | 0                       |
|           |                    | Lymphadenectomy            | 4                    | 4                 | 0                       |
|           | All treatments     |                            | 323                  | 316               | 7                       |
| 2018–2022 | C43, C51, C60, C63 | All treatments             | 1571                 | 1502              | 69                      |
|           |                    | Sentinel lymph node biopsy | 1302                 | 1297              | 5                       |
|           |                    | Lymphadenectomy            | 269                  | 205               | 64                      |
|           | C77–C80            | All treatments             | 17                   | 13                | 4                       |
|           |                    | Sentinel lymph node biopsy | 3                    | 3                 | 0                       |
|           |                    | Lymphadenectomy            | 14                   | 10                | 4                       |
|           | All treatments     |                            | 1588                 | 1515              | 73                      |

Table 19b: Number of patients with non-sentinel lymph node involvement after primary treatment with lymph node dissection in primary invasive skin melanoma (C43, C51, C60, C63), Slovenia 2018–2022.

| Year        | Surgery                                                                            | Number of examined lymph nodes | Number of resected lymph nodes at lymphadenectomy |    |        |           |     | Proportion (%) |
|-------------|------------------------------------------------------------------------------------|--------------------------------|---------------------------------------------------|----|--------|-----------|-----|----------------|
|             |                                                                                    |                                | 0                                                 | 1  | 2 to 5 | 6 or more | All |                |
| 2018        | Neck dissection (with or without superficial parotidectomy)                        | < 15                           | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 15                           | 4                                                 | 4  | 2      | 1         | 11  | 5.4            |
|             | Axillary dissections                                                               | < 10                           | 0                                                 | 0  | 1      | 0         | 1   | 0.5            |
|             |                                                                                    | ≥ 10                           | 10                                                | 9  | 5      | 3         | 27  | 13.2           |
|             | Inguinal dissection (with or without dissection of iliac or obturator lymph nodes) | < 5                            | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 5                            | 9                                                 | 4  | 7      | 0         | 20  | 9.8            |
| All         |                                                                                    |                                | 23                                                | 17 | 15     | 4         | 59  | 28.8           |
| 2019        | Neck dissection (with or without superficial parotidectomy)                        | < 15                           | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 15                           | 3                                                 | 5  | 7      | 0         | 15  | 7.3            |
|             | Axillary dissections                                                               | < 10                           | 0                                                 | 0  | 1      | 0         | 1   | 0.5            |
|             |                                                                                    | ≥ 10                           | 12                                                | 9  | 6      | 3         | 30  | 14.6           |
|             | Inguinal dissection (with or without dissection of iliac or obturator lymph nodes) | < 5                            | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 5                            | 2                                                 | 5  | 2      | 2         | 11  | 5.4            |
| All         |                                                                                    |                                | 17                                                | 19 | 16     | 5         | 57  | 27.8           |
| 2020        | Neck dissection (with or without superficial parotidectomy)                        | < 15                           | 1                                                 | 0  | 0      | 0         | 1   | 0.5            |
|             |                                                                                    | ≥ 15                           | 2                                                 | 0  | 1      | 1         | 4   | 2.0            |
|             | Axillary dissections                                                               | < 10                           | 0                                                 | 3  | 0      | 0         | 3   | 1.5            |
|             |                                                                                    | ≥ 10                           | 7                                                 | 4  | 1      | 3         | 15  | 7.3            |
|             | Inguinal dissection (with or without dissection of iliac or obturator lymph nodes) | < 5                            | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 5                            | 2                                                 | 1  | 3      | 1         | 7   | 3.4            |
| All         |                                                                                    |                                | 12                                                | 8  | 5      | 5         | 30  | 14.6           |
| 2021        | Neck dissection (with or without superficial parotidectomy)                        | < 15                           | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 15                           | 2                                                 | 2  | 6      | 1         | 11  | 5.4            |
|             | Axillary dissections                                                               | < 10                           | 0                                                 | 1  | 0      | 0         | 1   | 0.5            |
|             |                                                                                    | ≥ 10                           | 4                                                 | 5  | 10     | 3         | 22  | 10.7           |
|             | Inguinal dissection (with or without dissection of iliac or obturator lymph nodes) | < 5                            | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 5                            | 1                                                 | 1  | 2      | 2         | 6   | 2.9            |
| All         |                                                                                    |                                | 7                                                 | 9  | 18     | 6         | 40  | 19.5           |
| 2022        | Neck dissection (with or without superficial parotidectomy)                        | < 15                           | 0                                                 | 1  | 0      | 0         | 1   | 0.5            |
|             |                                                                                    | ≥ 15                           | 0                                                 | 0  | 1      | 0         | 1   | 0.5            |
|             | Axillary dissections                                                               | < 10                           | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 10                           | 0                                                 | 2  | 4      | 4         | 10  | 4.9            |
|             | Inguinal dissection (with or without dissection of iliac or obturator lymph nodes) | < 5                            | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 5                            | 0                                                 | 6  | 1      | 0         | 7   | 3.4            |
| All         |                                                                                    |                                | 0                                                 | 9  | 6      | 4         | 19  | 9.3            |
| 2018 – 2022 | Neck dissection (with or without superficial parotidectomy)                        | < 15                           | 1                                                 | 1  | 0      | 0         | 2   | 0.0            |
|             |                                                                                    | ≥ 15                           | 11                                                | 11 | 17     | 3         | 42  | 42.0           |
|             | Axillary dissections                                                               | < 10                           | 0                                                 | 4  | 2      | 0         | 6   | 6.0            |
|             |                                                                                    | ≥ 10                           | 33                                                | 29 | 26     | 16        | 104 | 104.0          |
|             | Inguinal dissection (with or without dissection of iliac or obturator lymph nodes) | < 5                            | 0                                                 | 0  | 0      | 0         | 0   | 0.0            |
|             |                                                                                    | ≥ 5                            | 14                                                | 17 | 15     | 5         | 51  | 51.0           |
| All         |                                                                                    |                                | 59                                                | 62 | 60     | 24        | 205 | 100.0          |

Table 19c: Amount and proportion of positive sentinel lymph nodes by Breslow thickness in patients with primary invasive skin melanoma (C43, C51, C60, C63) the course of first treatment, Slovenia 2018–2022.

| Year              | Sentinel lymph node biopsy (SNB) | Breslow thickness (mm) |       |               |               |      |         |      |
|-------------------|----------------------------------|------------------------|-------|---------------|---------------|------|---------|------|
|                   |                                  | < 0.8                  | ≤ 1.0 | > 1.0 - ≤ 2.0 | > 2.0 - ≤ 4.0 | > 4  | Unknown | All  |
| 2018              | Number of SNBs                   | 10                     | 16    | 88            | 56            | 54   | 1       | 225  |
|                   | Number of checked nodes          | 98                     | 70    | 352           | 386           | 349  | 4       | 1259 |
|                   | Number of positive nodes         | 1                      | 3     | 8             | 20            | 16   | 1       | 49   |
|                   | Proportion of positive nodes (%) | 10.0                   | 18.8  | 9.1           | 35.7          | 29.6 | 100.0   | 21.8 |
| 2019              | Number of SNBs                   | 11                     | 22    | 89            | 82            | 48   | 1       | 253  |
|                   | Number of checked nodes          | 17                     | 51    | 301           | 459           | 334  | 62      | 1224 |
|                   | Number of positive nodes         | 1                      | 1     | 10            | 23            | 13   | 1       | 49   |
|                   | Proportion of positive nodes (%) | 9.1                    | 4.5   | 11.2          | 28.0          | 27.1 | 100.0   | 19.4 |
| 2020              | Number of SNBs                   | 13                     | 32    | 96            | 60            | 50   | 3       | 254  |
|                   | Number of checked nodes          | 38                     | 65    | 280           | 354           | 172  | 4       | 913  |
|                   | Number of positive nodes         | 0                      | 0     | 12            | 20            | 12   | 1       | 45   |
|                   | Proportion of positive nodes (%) | 0.0                    | 0.0   | 12.5          | 33.3          | 24.0 | 33.3    | 17.7 |
| 2021              | Number of SNBs                   | 11                     | 40    | 101           | 57            | 41   | 3       | 253  |
|                   | Number of checked nodes          | 21                     | 89    | 273           | 221           | 335  | 16      | 955  |
|                   | Number of positive nodes         | 1                      | 1     | 12            | 20            | 27   | 0       | 61   |
|                   | Proportion of positive nodes (%) | 9.1                    | 2.5   | 11.9          | 35.1          | 65.9 | 0.0     | 24.1 |
| 2022              | Number of SNBs                   | 24                     | 30    | 114           | 73            | 43   | 1       | 285  |
|                   | Number of checked nodes          | 47                     | 61    | 275           | 180           | 122  | 5       | 690  |
|                   | Number of positive nodes         | 0                      | 2     | 11            | 22            | 12   | 0       | 47   |
|                   | Proportion of positive nodes (%) | 0.0                    | 6.7   | 9.6           | 30.1          | 27.9 | 0.0     | 16.5 |
| 2018<br>–<br>2022 | Number of SNBs                   | 69                     | 140   | 488           | 328           | 236  | 9       | 1270 |
|                   | Number of checked nodes          | 221                    | 336   | 1481          | 1600          | 1312 | 91      | 5041 |
|                   | Number of positive nodes         | 3                      | 7     | 53            | 105           | 80   | 3       | 251  |
|                   | Proportion of positive nodes (%) | 4.3                    | 5.0   | 10.9          | 32.0          | 33.9 | 33.3    | 19.8 |

Table 20: Radiotherapeutic treatment for invasive skin melanoma (C43, C51, C60, C63, C77–C80) by type of radiotherapy and treatment indication, Slovenia 2018–2022.

| Year              | ICD code           | Radiotherapy (RT) type | Treatment indication |                   |                         |
|-------------------|--------------------|------------------------|----------------------|-------------------|-------------------------|
|                   |                    |                        | Number of treatments | Primary treatment | Treatment of recurrence |
| 2018              | C43, C51, C60, C63 | All treatments         | 92                   | 35                | 57                      |
|                   |                    | Primary RT             | 4                    | 4                 | 0                       |
|                   |                    | Postoperative RT       | 45                   | 29                | 16                      |
|                   |                    | Palliative RT          | 43                   | 2                 | 41                      |
|                   | C77–C80            | All treatments         | 2                    | 1                 | 1                       |
|                   |                    | Primary RT             | 0                    | 0                 | 0                       |
|                   |                    | Postoperative RT       | 1                    | 1                 | 0                       |
|                   |                    | Palliative RT          | 1                    | 0                 | 1                       |
|                   | All treatments     |                        | 94                   | 36                | 58                      |
| 2019              | C43, C51, C60, C63 | All treatments         | 106                  | 47                | 59                      |
|                   |                    | Primary RT             | 0                    | 0                 | 0                       |
|                   |                    | Postoperative RT       | 62                   | 45                | 17                      |
|                   |                    | Palliative RT          | 44                   | 2                 | 42                      |
|                   | C77–C80            | All treatments         | 7                    | 3                 | 4                       |
|                   |                    | Primary RT             | 1                    | 1                 | 0                       |
|                   |                    | Postoperative RT       | 1                    | 1                 | 0                       |
|                   |                    | Palliative RT          | 5                    | 1                 | 4                       |
|                   | All treatments     |                        | 113                  | 50                | 63                      |
| 2020              | C43, C51, C60, C63 | All treatments         | 75                   | 31                | 44                      |
|                   |                    | Primary RT             | 1                    | 1                 | 0                       |
|                   |                    | Postoperative RT       | 35                   | 27                | 8                       |
|                   |                    | Palliative RT          | 39                   | 3                 | 36                      |
|                   | C77–C80            | All treatments         | 10                   | 8                 | 2                       |
|                   |                    | Primary RT             | 1                    | 1                 | 0                       |
|                   |                    | Postoperative RT       | 4                    | 4                 | 0                       |
|                   |                    | Palliative RT          | 5                    | 3                 | 2                       |
|                   | All treatments     |                        | 85                   | 39                | 46                      |
| 2021              | C43, C51, C60, C63 | All treatments         | 52                   | 26                | 26                      |
|                   |                    | Primary RT             | 0                    | 0                 | 0                       |
|                   |                    | Postoperative RT       | 33                   | 24                | 9                       |
|                   |                    | Palliative RT          | 19                   | 2                 | 17                      |
|                   | C77–C80            | All treatments         | 11                   | 4                 | 7                       |
|                   |                    | Primary RT             | 0                    | 0                 | 0                       |
|                   |                    | Postoperative RT       | 3                    | 2                 | 1                       |
|                   |                    | Palliative RT          | 8                    | 2                 | 6                       |
|                   | All treatments     |                        | 63                   | 30                | 33                      |
| 2022              | C43, C51, C60, C63 | All treatments         | 52                   | 29                | 23                      |
|                   |                    | Primary RT             | 2                    | 2                 | 0                       |
|                   |                    | Postoperative RT       | 26                   | 19                | 7                       |
|                   |                    | Palliative RT          | 24                   | 8                 | 16                      |
|                   | C77–C80            | All treatments         | 7                    | 6                 | 1                       |
|                   |                    | Primary RT             | 1                    | 1                 | 0                       |
|                   |                    | Postoperative RT       | 5                    | 4                 | 1                       |
|                   |                    | Palliative RT          | 1                    | 1                 | 0                       |
|                   | All treatments     |                        | 59                   | 35                | 24                      |
| 2018<br>–<br>2022 | C43, C51, C60, C63 | All treatments         | 377                  | 168               | 209                     |
|                   |                    | Primary RT             | 7                    | 7                 | 0                       |
|                   |                    | Postoperative RT       | 201                  | 144               | 57                      |
|                   |                    | Palliative RT          | 169                  | 17                | 152                     |
|                   | C77–C80            | All treatments         | 37                   | 22                | 15                      |
|                   |                    | Primary RT             | 3                    | 3                 | 0                       |
|                   |                    | Postoperative RT       | 14                   | 12                | 2                       |
|                   |                    | Palliative RT          | 20                   | 7                 | 13                      |
|                   | All treatments     |                        | 414                  | 190               | 224                     |



Table 21a: Number of systemic treatments by regimen, therapeutic subgroups and administered drugs according to place in therapy in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Year | Regimen                        | Systemic therapy |          |            |             |                  | Therapeutic subgroup            | Systemic therapy |          |            |             |                  | Drug                        | Systemic therapy |          |            |             |                  |
|------|--------------------------------|------------------|----------|------------|-------------|------------------|---------------------------------|------------------|----------|------------|-------------|------------------|-----------------------------|------------------|----------|------------|-------------|------------------|
|      |                                | Neoadjuvant      | Adjuvant | First line | Second line | Subsequent lines |                                 | Neoadjuvant      | Adjuvant | First line | Second line | Subsequent lines |                             | Neoadjuvant      | Adjuvant | First line | Second line | Subsequent lines |
| 2018 | Anti PD-1                      | 0                | 25       | 32         | 5           | 4                | Anti PD-1                       | 0                | 25       | 32         | 5           | 4                | Nivolumab<br>Pembrolizumab  | 0<br>0           | 16<br>9  | 3<br>29    | 0<br>5      | 1<br>3           |
|      | BRAF in MEK inhibitors         | 0                | 5        | 21         | 4           | 4                | BRAF inhibitors                 | 0                | 5        | 21         | 4           | 4                | Dabrafenib<br>Vemurafenib   | 0<br>0           | 5<br>0   | 20<br>1    | 4<br>0      | 1<br>3           |
|      |                                |                  |          |            |             |                  | MEK inhibitors                  | 0                | 5        | 21         | 4           | 4                | Cobimetinib<br>Trametinib   | 0<br>0           | 0<br>5   | 1<br>20    | 0<br>4      | 3<br>1           |
|      | Combination immunotherapy      | 0                | 0        | 2          | 7           | 1                | Anti CTLA-4                     | 0                | 0        | 2          | 7           | 1                | Ipilimumab                  | 0                | 0        | 2          | 7           | 1                |
|      |                                |                  |          |            |             |                  | Anti PD-1                       | 0                | 0        | 2          | 7           | 1                | Nivolumab                   | 0                | 0        | 2          | 7           | 1                |
|      | Combination chemotherapy       | 0                | 0        | 1          | 3           | 6                | Nitrosourea analogues           | 0                | 0        | 0          | 0           | 2                | Lomustine                   | 0                | 0        | 0          | 0           | 2                |
|      |                                |                  |          |            |             |                  | Platinum analogues              | 0                | 0        | 1          | 3           | 6                | Cisplatin<br>Carboplatin    | 0<br>0           | 0<br>0   | 0<br>1     | 0<br>3      | 2<br>4           |
|      |                                |                  |          |            |             |                  | Taxanes                         | 0                | 0        | 1          | 3           | 4                | Paclitaxel                  | 0                | 0        | 1          | 3           | 4                |
|      |                                |                  |          |            |             |                  | Vinca alkaloids                 | 0                | 0        | 0          | 0           | 2                | Vinblastine                 | 0                | 0        | 0          | 0           | 2                |
|      | Monochemotherapy               | 0                | 0        | 2          | 9           | 1                | Alkylating agents               | 0                | 0        | 2          | 9           | 1                | Dakarbazine<br>Temozolomide | 0<br>0           | 0<br>0   | 2<br>0     | 8<br>1      | 1<br>1           |
|      | All                            | 0                | 30       | 58         | 28          | 16               | All                             | 0                | 35       | 82         | 42          | 29               | All                         | 0                | 35       | 82         | 41          | 29               |
| 2019 | Anti PD-1                      | 0                | 38       | 20         | 7           | 1                | Anti PD-1                       | 0                | 38       | 20         | 7           | 1                | Nivolumab<br>Pembrolizumab  | 0<br>0           | 22<br>16 | 3<br>18    | 5<br>2      | 0<br>1           |
|      | BRAF in MEK inhibitors         | 0                | 25       | 19         | 6           | 3                | BRAF inhibitors                 | 0                | 25       | 19         | 6           | 3                | Dabrafenib<br>Vemurafenib   | 0<br>0           | 25<br>0  | 16<br>3    | 5<br>2      | 2<br>1           |
|      |                                |                  |          |            |             |                  | MEK inhibitors                  | 0                | 25       | 19         | 6           | 3                | Cobimetinib<br>Trametinib   | 0<br>0           | 0<br>25  | 3<br>16    | 2<br>5      | 1<br>2           |
|      | BRAF inhibitors                | 0                | 0        | 0          | 0           | 1                | BRAF inhibitors                 | 0                | 0        | 0          | 0           | 1                | Dabrafenib                  | 0                | 0        | 0          | 0           | 1                |
|      | Other combination of therapies | 0                | 0        | 0          | 0           | 1                | Anti PD-1                       | 0                | 0        | 0          | 0           | 1                | Pembrolizumab               | 0                | 0        | 0          | 0           | 1                |
|      |                                |                  |          |            |             |                  | Other protein kinase inhibitors | 0                | 0        | 0          | 0           | 1                | Lenvatinib                  | 0                | 0        | 0          | 0           | 1                |
|      | Combination immunotherapy      | 1                | 0        | 8          | 7           | 2                | Anti CTLA-4                     | 1                | 0        | 8          | 7           | 2                | Ipilimumab                  | 1                | 0        | 8          | 7           | 2                |
|      |                                |                  |          |            |             |                  | Anti PD-1                       | 1                | 0        | 8          | 7           | 2                | Nivolumab                   | 1                | 0        | 8          | 7           | 2                |
|      | Combination chemotherapy       | 0                | 0        | 1          | 0           | 5                | Platinum analogues              | 0                | 0        | 1          | 0           | 5                | Carboplatin                 | 0                | 0        | 1          | 0           | 5                |
|      |                                |                  |          |            |             |                  | Taxanes                         | 0                | 0        | 1          | 0           | 5                | Paclitaxel                  | 0                | 0        | 1          | 0           | 5                |
|      | Monochemotherapy               | 0                | 0        | 5          | 8           | 3                | Alkylating agents               | 0                | 0        | 5          | 8           | 3                | Dakarbazine<br>Temozolomide | 0<br>0           | 0<br>0   | 4<br>1     | 8<br>0      | 3<br>0           |
|      | All                            | 1                | 63       | 53         | 28          | 16               | All                             | 2                | 88       | 81         | 41          | 27               | All                         | 2                | 88       | 81         | 43          | 27               |
| 2020 | Anti PD-1                      | 0                | 34       | 18         | 1           | 0                | Anti PD-1                       | 0                | 34       | 18         | 1           | 0                | Nivolumab<br>Pembrolizumab  | 0<br>0           | 11<br>23 | 2<br>16    | 0<br>1      | 0<br>0           |
|      | BRAF in MEK inhibitors         | 0                | 9        | 8          | 4           | 0                | BRAF inhibitors                 | 0                | 9        | 8          | 4           | 0                | Dabrafenib<br>Vemurafenib   | 0<br>0           | 9<br>0   | 6<br>2     | 4<br>0      | 0<br>0           |
|      |                                |                  |          |            |             |                  | MEK inhibitors                  | 0                | 9        | 8          | 4           | 0                | Cobimetinib<br>Trametinib   | 0<br>0           | 0<br>9   | 2<br>6     | 0<br>4      | 0<br>0           |
|      | Combination immunotherapy      | 0                | 0        | 6          | 4           | 0                | Anti CTLA-4                     | 0                | 0        | 6          | 4           | 0                | Ipilimumab                  | 0                | 0        | 6          | 4           | 0                |
|      |                                |                  |          |            |             |                  | Anti PD-1                       | 0                | 0        | 6          | 4           | 0                | Nivolumab                   | 0                | 0        | 6          | 4           | 0                |
|      | Combination chemotherapy       | 0                | 0        | 0          | 2           | 1                | Platinum analogues              | 0                | 0        | 0          | 2           | 1                | Carboplatin                 | 0                | 0        | 0          | 2           | 1                |
|      |                                |                  |          |            |             |                  | Taxanes                         | 0                | 0        | 0          | 2           | 1                | Paclitaxel                  | 0                | 0        | 0          | 2           | 1                |
|      | Monochemotherapy               | 0                | 0        | 5          | 3           | 2                | Alkylating agents               | 0                | 0        | 5          | 3           | 2                | Dakarbazine<br>Temozolomide | 0<br>0           | 0<br>0   | 5<br>1     | 3<br>0      | 2<br>0           |
|      | All                            | 0                | 43       | 37         | 14          | 3                | All                             | 0                | 52       | 51         | 24          | 4                | All                         | 0                | 52       | 51         | 24          | 4                |

Continued. —>

Table 21a: Continued.

| Year                            | Regimen                        | Systemic therapy |          |            |             |                  | Therapeutic subgroup            | Systemic therapy |          |            |             |                  | Drug                          | Systemic therapy |              |             |             |                  |
|---------------------------------|--------------------------------|------------------|----------|------------|-------------|------------------|---------------------------------|------------------|----------|------------|-------------|------------------|-------------------------------|------------------|--------------|-------------|-------------|------------------|
|                                 |                                | Neoadjuvant      | Adjuvant | First line | Second line | Subsequent lines |                                 | Neoadjuvant      | Adjuvant | First line | Second line | Subsequent lines |                               | Neoadjuvant      | Adjuvant     | First line  | Second line | Subsequent lines |
| 2021                            | Anti PD-1                      | 2                | 47       | 24         | 2           | 2                | Anti PD-1                       | 2                | 47       | 24         | 2           | 2                | Nivolumab<br>Pembrolizumab    | 0<br>2           | 9<br>38      | 1<br>23     | 1<br>1      | 1<br>1           |
|                                 | BRAF in MEK inhibitors         | 2                | 15       | 10         | 5           | 3                | BRAF inhibitors                 | 2                | 15       | 10         | 5           | 3                | Dabrafenib<br>Vemurafenib     | 2<br>0           | 15<br>0      | 10<br>0     | 5<br>0      | 2<br>1           |
|                                 |                                |                  |          |            |             |                  | MEK inhibitors                  | 2                | 15       | 10         | 5           | 3                | Cobimetinib<br>Trametinib     | 0<br>2           | 0<br>15      | 0<br>10     | 0<br>5      | 1<br>2           |
|                                 | Other combination of therapies | 1                | 0        | 1          | 0           | 0                | Anti CTLA-4                     | 0                | 0        | 1          | 0           | 0                | Ipilimumab                    | 0                | 0            | 1           | 0           | 0                |
|                                 |                                |                  |          |            |             |                  | Anti PD-1                       | 1                | 0        | 1          | 0           | 0                | Nivolumab<br>Pembrolizumab    | 0<br>1           | 0<br>0       | 1<br>0      | 0<br>0      | 0<br>0           |
|                                 |                                |                  |          |            |             |                  | BRAF inhibitors                 | 1                | 0        | 1          | 0           | 0                | Dabrafenib                    | 1                | 0            | 1           | 0           | 0                |
|                                 |                                |                  |          |            |             |                  | MEK inhibitors                  | 1                | 0        | 1          | 0           | 0                | Trametinib                    | 1                | 0            | 1           | 0           | 0                |
|                                 | Combination immunotherapy      | 0                | 0        | 5          | 5           | 2                | Anti CTLA-4                     | 0                | 0        | 5          | 5           | 2                | Ipilimumab                    | 0                | 0            | 5           | 5           | 2                |
|                                 |                                |                  |          |            |             |                  | Anti PD-1                       | 0                | 0        | 5          | 5           | 2                | Nivolumab                     | 0                | 0            | 5           | 5           | 2                |
|                                 | Combination chemotherapy       | 0                | 0        | 0          | 0           | 1                | Platinum analogues              | 0                | 0        | 0          | 0           | 1                | Carboplatin                   | 0                | 0            | 0           | 0           | 1                |
|                                 |                                |                  |          |            |             |                  | Taxanes                         | 0                | 0        | 0          | 0           | 1                | Paclitaxel                    | 0                | 0            | 0           | 0           | 1                |
|                                 | Monochemotherapy               | 0                | 0        | 0          | 4           | 0                | Alkylating agents               | 0                | 0        | 0          | 4           | 0                | Dakarbazinee                  | 0                | 0            | 0           | 4           | 0                |
|                                 | All                            | 5                | 62       | 40         | 16          | 8                | All                             | 9                | 77       | 58         | 26          | 14               | All                           | 9                | 77           | 58          | 26          | 14               |
| 2022                            | Anti PD-1                      | 2                | 51       | 21         | 1           | 1                | Anti PD-1                       | 2                | 51       | 21         | 1           | 1                | Nivolumab<br>Pembrolizumab    | 0<br>2           | 2<br>49      | 1<br>20     | 1<br>0      | 1<br>0           |
|                                 | BRAF in MEK inhibitors         | 0                | 7        | 4          | 3           | 0                | BRAF inhibitors                 | 0                | 7        | 4          | 3           | 0                | Dabrafenib<br>Vemurafenib     | 0<br>0           | 7<br>0       | 4<br>1      | 3<br>0      | 0<br>0           |
|                                 |                                |                  |          |            |             |                  | MEK inhibitors                  | 0                | 7        | 4          | 3           | 0                | Cobimetinib<br>Trametinib     | 0<br>0           | 0<br>7       | 1<br>4      | 0<br>3      | 0<br>0           |
|                                 | Combination immunotherapy      | 0                | 0        | 5          | 1           | 2                | Anti CTLA-4                     | 0                | 0        | 5          | 1           | 2                | Ipilimumab                    | 0                | 0            | 5           | 1           | 2                |
|                                 |                                |                  |          |            |             |                  | Anti PD-1                       | 0                | 0        | 5          | 1           | 2                | Nivolumab                     | 0                | 0            | 5           | 1           | 2                |
|                                 | Monochemotherapy               | 0                | 0        | 0          | 2           | 0                | Alkylating agents               | 0                | 0        | 0          | 2           | 0                | Dakarbazinee                  | 0                | 0            | 0           | 2           | 0                |
|                                 | All                            | 2                | 58       | 30         | 7           | 3                | All                             | 2                | 65       | 39         | 11          | 5                | All                           | 2                | 65           | 41          | 11          | 5                |
| Mean of yearly values 2018–2022 | Anti PD-1                      | 0,8              | 39,0     | 23,0       | 3,2         | 1,6              | Anti PD-1                       | 0,8              | 39,0     | 23,0       | 3,2         | 1,6              | Nivolumab<br>Pembrolizumab    | 0,0<br>0,8       | 12,0<br>27,0 | 2,0<br>21,2 | 1,4<br>1,8  | 0,6<br>1,0       |
|                                 | BRAF in MEK inhibitors         | 0,4              | 12,2     | 12,4       | 4,4         | 2,0              | BRAF inhibitors                 | 0,4              | 12,2     | 12,4       | 4,4         | 2,0              | Dabrafenib<br>Vemurafenib     | 0,4<br>0,0       | 12,2<br>0,0  | 11,2<br>1,4 | 4,2<br>0,4  | 1,0<br>1,0       |
|                                 |                                |                  |          |            |             |                  | MEK inhibitors                  | 0,4              | 12,2     | 12,4       | 4,4         | 2,0              | Cobimetinib<br>Trametinib     | 0,0<br>0,4       | 0,0<br>12,2  | 1,4<br>11,2 | 0,4<br>4,2  | 1,0<br>1,0       |
|                                 | BRAF inhibitors                | 0,0              | 0,0      | 0,0        | 0,0         | 1,0              | BRAF inhibitors                 | 0,0              | 0,0      | 0,0        | 0,0         | 1,0              | Dabrafenib                    | 0,0              | 0,0          | 0,0         | 0,0         | 1,0              |
|                                 | Other combination of therapies | 0,5              | 0,0      | 0,5        | 0,0         | 0,5              | Anti CTLA-4                     | 0,0              | 0,0      | 1,0        | 0,0         | 0,0              | Ipilimumab                    | 0,0              | 0,0          | 1,0         | 0,0         | 0,0              |
|                                 |                                |                  |          |            |             |                  | Anti PD-1                       | 0,5              | 0,0      | 0,5        | 0,0         | 0,5              | Nivolumab<br>Pembrolizumab    | 0,0<br>0,5       | 0,0<br>0,0   | 1,0<br>0,0  | 0,0<br>0,0  | 0,0<br>0,5       |
|                                 |                                |                  |          |            |             |                  | BRAF inhibitors                 | 1,0              | 0,0      | 1,0        | 0,0         | 0,0              | Dabrafenib                    | 1,0              | 0,0          | 1,0         | 0,0         | 0,0              |
|                                 |                                |                  |          |            |             |                  | Other protein kinase inhibitors | 0,0              | 0,0      | 0,0        | 0,0         | 1,0              | Lenvatinib                    | 0,0              | 0,0          | 0,0         | 0,0         | 1,0              |
|                                 | Combination immunotherapy      | 0,2              | 0,0      | 5,2        | 4,8         | 1,4              | MEK inhibitors                  | 1,0              | 0,0      | 1,0        | 0,0         | 0,0              | Trametinib                    | 1,0              | 0,0          | 1,0         | 0,0         | 0,0              |
|                                 |                                |                  |          |            |             |                  | Anti CTLA-4                     | 0,2              | 0,0      | 5,2        | 4,8         | 1,4              | Ipilimumab                    | 0,2              | 0,0          | 5,2         | 4,8         | 1,4              |
|                                 | Combination chemotherapy       | 0,0              | 0,0      | 0,5        | 1,3         | 3,3              | Anti PD-1                       | 0,2              | 0,0      | 5,2        | 4,8         | 1,4              | Nivolumab                     | 0,2              | 0,0          | 5,2         | 4,8         | 1,4              |
|                                 |                                |                  |          |            |             |                  | Nitrosourea analogues           | 0,0              | 0,0      | 0,0        | 0,0         | 2,0              | Lomustine                     | 0,0              | 0,0          | 0,0         | 0,0         | 2,0              |
|                                 |                                |                  |          |            |             |                  | Platinum analogues              | 0,0              | 0,0      | 0,5        | 1,3         | 3,3              | Cisplatin<br>Carboplatin      | 0,0<br>0,0       | 0,0<br>0,0   | 0,0<br>0,5  | 0,0<br>1,3  | 2,0<br>2,8       |
|                                 |                                |                  |          |            |             |                  | Taxanes                         | 0,0              | 0,0      | 0,5        | 1,3         | 2,8              | Paclitaxel                    | 0,0              | 0,0          | 0,5         | 1,3         | 2,8              |
|                                 |                                |                  |          |            |             |                  | Vinca alcaloids                 | 0,0              | 0,0      | 0,0        | 0,0         | 2,0              | Vinblastinee                  | 0,0              | 0,0          | 0,0         | 0,0         | 2,0              |
|                                 | Monochemotherapy               | 0,0              | 0,0      | 2,4        | 5,2         | 1,2              | Alkylating agents               | 0,0              | 0,0      | 2,4        | 5,2         | 1,2              | Dakarbazinee<br>Temozolomidee | 0,0<br>0,0       | 0,0<br>0,0   | 2,2<br>0,5  | 5,0<br>0,5  | 1,2<br>0,5       |
|                                 | All                            | 1,9              | 51,2     | 44,0       | 18,9        | 11,0             | All                             | 4,5              | 63,4     | 65,1       | 29,3        | 22,1             | All                           | 4,5              | 63,4         | 66,5        | 30,0        | 24,1             |

Table 21b: Number of systemic treatments by regimen, therapeutic subgroups and administered drugs by treatment indication in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Year | Place in therapy | Regimen                   | Treatment indication |                         | Therapeutic subgroup              | Treatment indication |                         | Drug                          | Treatment indication |                         |
|------|------------------|---------------------------|----------------------|-------------------------|-----------------------------------|----------------------|-------------------------|-------------------------------|----------------------|-------------------------|
|      |                  |                           | Primary treatment    | Treatment of recurrence |                                   | Primary treatment    | Treatment of recurrence |                               | Primary treatment    | Treatment of recurrence |
| 2018 | Neoadjuvant      | /                         | /                    | /                       | /                                 | /                    | /                       | /                             | /                    | /                       |
|      | Adjuvant         | Anti PD-1                 | 17                   | 8                       | Anti PD-1                         | 17                   | 8                       | Nivolumab<br>Pembrolizumab    | 14<br>3              | 2<br>6                  |
|      |                  | BRAF in MEK inhibitors    | 3                    | 2                       | BRAF inhibitors<br>MEK inhibitors | 3<br>3               | 2<br>2                  | Dabrafenib<br>Trametinib      | 3<br>3               | 2<br>2                  |
|      | First line       | Anti PD-1                 | 10                   | 22                      | Anti PD-1                         | 10                   | 22                      | Nivolumab<br>Pembrolizumab    | 1<br>9               | 2<br>20                 |
|      |                  | BRAF in MEK inhibitors    | 7                    | 14                      | BRAF inhibitors                   | 7                    | 14                      | Dabrafenib<br>Vemurafenib     | 7<br>0               | 13<br>1                 |
|      |                  |                           |                      |                         | MEK inhibitors                    | 7                    | 14                      | Cobimetinib<br>Trametinib     | 0<br>7               | 1<br>13                 |
|      |                  | Combination immunotherapy | 0                    | 2                       | Anti CTLA-4                       | 0                    | 2                       | Ipilimumab                    | 0                    | 2                       |
|      |                  |                           |                      |                         | Anti PD-1                         | 0                    | 2                       | Nivolumab                     | 0                    | 2                       |
|      |                  | Combination chemotherapy  | 1                    | 0                       | Platinum analogues                | 1                    | 0                       | Carboplatin                   | 1                    | 0                       |
|      |                  |                           |                      |                         | Taxanes                           | 1                    | 0                       | Paclitaxel                    | 1                    | 0                       |
|      |                  | Monochemotherapy          | 0                    | 2                       | Alkylating agents                 | 0                    | 2                       | Dakarbazinee                  | 0                    | 2                       |
|      | Second line      | Anti PD-1                 | 0                    | 5                       | Anti PD-1                         | 0                    | 5                       | Pembrolizumab                 | 0                    | 5                       |
|      |                  | BRAF in MEK inhibitors    | 0                    | 4                       | BRAF inhibitors                   | 0                    | 4                       | Dabrafenib                    | 0                    | 4                       |
|      |                  |                           |                      |                         | MEK inhibitors                    | 0                    | 4                       | Trametinib                    | 0                    | 4                       |
|      |                  | Combination immunotherapy | 0                    | 7                       | Anti CTLA-4                       | 0                    | 7                       | Ipilimumab                    | 0                    | 7                       |
|      |                  |                           |                      |                         | Anti PD-1                         | 0                    | 7                       | Nivolumab                     | 0                    | 7                       |
|      |                  | Combination chemotherapy  | 0                    | 3                       | Platinum analogues                | 0                    | 3                       | Carboplatin                   | 0                    | 3                       |
|      |                  |                           |                      |                         | Taxanes                           | 0                    | 3                       | Paclitaxel                    | 0                    | 3                       |
|      |                  | Monochemotherapy          | 0                    | 9                       | Alkylating agents                 | 0                    | 9                       | Dakarbazinee                  | 0                    | 8                       |
|      |                  |                           |                      |                         |                                   |                      |                         | Temozolomidee                 | 0                    | 1                       |
|      | Subsequent lines | Anti PD-1                 | 0                    | 4                       | Anti PD-1                         | 0                    | 4                       | Nivolumab                     | 0                    | 1                       |
|      |                  |                           |                      |                         |                                   |                      |                         | Pembrolizumab                 | 0                    | 3                       |
|      |                  | BRAF in MEK inhibitors    | 0                    | 4                       | BRAF inhibitors                   | 0                    | 4                       | Dabrafenib<br>Vemurafenib     | 0<br>0               | 1<br>3                  |
|      |                  |                           |                      |                         | MEK inhibitors                    | 0                    | 4                       | Cobimetinib<br>Trametinib     | 0<br>0               | 3<br>1                  |
|      |                  | Combination immunotherapy | 0                    | 1                       | Anti CTLA-4                       | 0                    | 1                       | Ipilimumab                    | 0                    | 1                       |
|      |                  |                           |                      |                         | Anti PD-1                         | 0                    | 1                       | Nivolumab                     | 0                    | 1                       |
|      |                  | Combination chemotherapy  | 0                    | 6                       | Nitrosourea analogues             | 0                    | 2                       | Lomustine                     | 0                    | 2                       |
|      |                  |                           |                      |                         | Platinum analogues                | 0                    | 6                       | Cisplatin<br>Carboplatin      | 0<br>0               | 2<br>4                  |
|      |                  |                           |                      |                         | Taxanes                           | 0                    | 4                       | Paclitaxel                    | 0                    | 4                       |
|      |                  |                           |                      |                         | Vinca alcaloids                   | 0                    | 2                       | Vinblastinee                  | 0                    | 2                       |
|      |                  | Monochemotherapy          | 0                    | 1                       | Alkylating agents                 | 0                    | 1                       | Dakarbazinee<br>Temozolomidee | 0<br>0               | 1<br>1                  |
|      |                  |                           |                      |                         |                                   |                      |                         |                               |                      |                         |
|      | All              | All                       | 38                   | 94                      | All                               | 49                   | 139                     | All                           | 49                   | 140                     |
| 2019 | Neoadjuvant      | Combination immunotherapy | 0                    | 1                       | Anti CTLA-4                       | 0                    | 1                       | Ipilimumab                    | 0                    | 1                       |
|      |                  |                           |                      |                         | Anti PD-1                         | 0                    | 1                       | Nivolumab                     | 0                    | 1                       |
|      | Adjuvant         | Anti PD-1                 | 26                   | 12                      | Anti PD-1                         | 26                   | 12                      | Nivolumab<br>Pembrolizumab    | 16<br>10             | 6<br>6                  |
|      |                  | BRAF in MEK inhibitors    | 23                   | 2                       | BRAF inhibitors                   | 23                   | 2                       | Dabrafenib                    | 23                   | 2                       |
|      |                  |                           |                      |                         | MEK inhibitors                    | 23                   | 2                       | Trametinib                    | 23                   | 2                       |

Continued. —>

Table 21b: Continued.

| Year | Place in therapy | Regimen                        | Treatment indication |                         | Therapeutic subgroup            | Treatment indication |                         | Drug                          | Treatment indication |                         |
|------|------------------|--------------------------------|----------------------|-------------------------|---------------------------------|----------------------|-------------------------|-------------------------------|----------------------|-------------------------|
|      |                  |                                | Primary treatment    | Treatment of recurrence |                                 | Primary treatment    | Treatment of recurrence |                               | Primary treatment    | Treatment of recurrence |
| 2019 | First line       | Anti PD-1                      | 5                    | 15                      | Anti PD-1                       | 5                    | 15                      | Nivolumab<br>Pembrolizumab    | 0<br>5               | 3<br>13                 |
|      |                  | BRAF in MEK inhibitors         | 7                    | 12                      | BRAF inhibitors                 | 7                    | 12                      | Dabrafenib<br>Vemurafenib     | 5<br>2               | 11<br>1                 |
|      |                  |                                |                      |                         | MEK inhibitors                  | 7                    | 12                      | Cobimetinib<br>Trametinib     | 2<br>5               | 1<br>11                 |
|      |                  | Combination immunotherapy      | 1                    | 7                       | Anti CTLA-4                     | 1                    | 7                       | Ipilimumab                    | 1                    | 7                       |
|      |                  |                                |                      |                         | Anti PD-1                       | 1                    | 7                       | Nivolumab                     | 1                    | 7                       |
|      |                  | Combination chemotherapy       | 1                    | 0                       | Platinum analogues              | 1                    | 0                       | Carboplatin                   | 1                    | 0                       |
|      |                  |                                |                      |                         | Taxanes                         | 1                    | 0                       | Paclitaxel                    | 1                    | 0                       |
|      | Second line      | Monochemotherapy               | 1                    | 4                       | Alkylating agents               | 1                    | 4                       | Dakarbazinee<br>Temozolomidee | 1<br>0               | 3<br>1                  |
|      |                  | Anti PD-1                      | 0                    | 7                       | Anti PD-1                       | 0                    | 7                       | Nivolumab<br>Pembrolizumab    | 0<br>0               | 5<br>2                  |
|      |                  | BRAF in MEK inhibitors         | 0                    | 6                       | BRAF inhibitors                 | 0                    | 6                       | Dabrafenib<br>Vemurafenib     | 0<br>0               | 5<br>2                  |
|      |                  |                                |                      |                         | MEK inhibitors                  | 0                    | 6                       | Cobimetinib<br>Trametinib     | 0<br>0               | 2<br>5                  |
|      |                  | Combination immunotherapy      | 0                    | 7                       | Anti CTLA-4<br>Anti PD-1        | 0<br>0               | 7<br>7                  | Ipilimumab<br>Nivolumab       | 0<br>0               | 7<br>7                  |
|      |                  | Monochemotherapy               | 0                    | 8                       | Alkylating agents               | 0                    | 8                       | Dakarbazinee                  | 0                    | 8                       |
|      | Subsequent lines | Anti PD-1                      | 0                    | 1                       | Anti PD-1                       | 0                    | 1                       | Pembrolizumab                 | 0                    | 1                       |
|      |                  | BRAF in MEK inhibitors         | 0                    | 3                       | BRAF inhibitors                 | 0                    | 3                       | Dabrafenib<br>Vemurafenib     | 0<br>0               | 2<br>1                  |
|      |                  |                                |                      |                         | MEK inhibitors                  | 0                    | 3                       | Cobimetinib<br>Trametinib     | 0<br>0               | 1<br>2                  |
|      |                  | BRAF inhibitors                | 0                    | 1                       | BRAF inhibitors                 | 0                    | 1                       | Dabrafenib                    | 0                    | 1                       |
|      |                  | Other combination of therapies | 0                    | 1                       | Anti PD-1                       | 0                    | 1                       | Pembrolizumab                 | 0                    | 1                       |
|      |                  |                                |                      |                         | Other protein kinase inhibitors | 0                    | 1                       | Lenvatinib                    | 0                    | 1                       |
|      |                  | Combination immunotherapy      | 0                    | 2                       | Anti CTLA-4<br>Anti PD-1        | 0<br>0               | 2<br>2                  | Ipilimumab<br>Nivolumab       | 0<br>0               | 2<br>2                  |
|      |                  | Combination chemotherapy       | 0                    | 5                       | Platinum analogues              | 0                    | 5                       | Carboplatin                   | 0                    | 5                       |
|      |                  |                                |                      |                         | Taxanes                         | 0                    | 5                       | Paclitaxel                    | 0                    | 5                       |
|      |                  | Monochemotherapy               | 0                    | 3                       | Alkylating agents               | 0                    | 3                       | Dakarbazinee<br>Temozolomidee | 0<br>0               | 3<br>1                  |
|      | All              | All                            | 64                   | 96                      | All                             | 96                   | 141                     | All                           | 96                   | 144                     |
| 2020 | Neoadjuvant      | /                              | /                    | /                       | /                               | /                    | /                       | /                             | /                    | /                       |
|      | Adjuvant         | Anti PD-1                      | 30                   | 4                       | Anti PD-1                       | 30                   | 4                       | Nivolumab<br>Pembrolizumab    | 8<br>22              | 3<br>1                  |
|      |                  | BRAF in MEK inhibitors         | 9                    | 0                       | BRAF inhibitors                 | 9                    | 0                       | Dabrafenib                    | 9                    | 0                       |
|      |                  |                                |                      |                         | MEK inhibitors                  | 9                    | 0                       | Trametinib                    | 9                    | 0                       |
|      | First line       | Anti PD-1                      | 4                    | 14                      | Anti PD-1                       | 4                    | 14                      | Nivolumab<br>Pembrolizumab    | 0<br>4               | 2<br>12                 |
|      |                  | BRAF in MEK inhibitors         | 4                    | 4                       | BRAF inhibitors                 | 4                    | 4                       | Dabrafenib<br>Vemurafenib     | 3<br>1               | 3<br>1                  |
|      |                  |                                |                      |                         | MEK inhibitors                  | 4                    | 4                       | Cobimetinib<br>Trametinib     | 1<br>3               | 1<br>3                  |
|      |                  | Combination immunotherapy      | 2                    | 4                       | Anti CTLA-4                     | 2                    | 4                       | Ipilimumab                    | 2                    | 4                       |
|      |                  |                                |                      |                         | Anti PD-1                       | 2                    | 4                       | Nivolumab                     | 2                    | 4                       |
|      |                  | Monochemotherapy               | 0                    | 5                       | Alkylating agents               | 0                    | 5                       | Dakarbazinee                  | 0                    | 5                       |

Continued. —&gt;

Table 21b: Continued.

| Year | Place in therapy | Regimen                        | Treatment indication |                         | Therapeutic subgroup | Treatment indication |                         | Drug                       | Treatment indication |                         |
|------|------------------|--------------------------------|----------------------|-------------------------|----------------------|----------------------|-------------------------|----------------------------|----------------------|-------------------------|
|      |                  |                                | Primary treatment    | Treatment of recurrence |                      | Primary treatment    | Treatment of recurrence |                            | Primary treatment    | Treatment of recurrence |
| 2020 | Second line      | Anti PD-1                      | 0                    | 1                       | Anti PD-1            | 0                    | 1                       | Pembrolizumab              | 0                    | 1                       |
|      |                  | BRAF in MEK inhibitors         | 0                    | 4                       | BRAF inhibitors      | 0                    | 4                       | Dabrafenib                 | 0                    | 4                       |
|      |                  |                                |                      |                         | MEK inhibitors       | 0                    | 4                       | Trametinib                 | 0                    | 4                       |
|      |                  | Combination immunotherapy      | 0                    | 4                       | Anti CTLA-4          | 0                    | 4                       | Ipilimumab                 | 0                    | 4                       |
|      |                  |                                |                      |                         | Anti PD-1            | 0                    | 4                       | Nivolumab                  | 0                    | 4                       |
|      |                  | Combination chemotherapy       | 0                    | 2                       | Platinum analogues   | 0                    | 2                       | Carboplatin                | 0                    | 2                       |
|      | Taxanes          |                                |                      |                         | 0                    | 2                    | Paclitaxel              | 0                          | 2                    |                         |
|      | Subsequent lines | Monochemotherapy               | 0                    | 3                       | Alkylating agents    | 0                    | 3                       | Dakarbazinee               | 0                    | 3                       |
|      |                  | Combination chemotherapy       | 0                    | 1                       | Platinum analogues   | 0                    | 1                       | Carboplatin                | 0                    | 1                       |
|      |                  |                                |                      |                         | Taxanes              | 0                    | 1                       | Paclitaxel                 | 0                    | 1                       |
|      |                  | Monochemotherapy               | 0                    | 2                       | Alkylating agents    | 0                    | 2                       | Dakarbazinee               | 0                    | 2                       |
|      | All              |                                | 49                   | 48                      | All                  | 64                   | 67                      | All                        | 64                   | 67                      |
| 2021 | Neoadjuvant      | Anti PD-1                      | 1                    | 1                       | Anti PD-1            | 1                    | 1                       | Pembrolizumab              | 1                    | 1                       |
|      |                  | BRAF in MEK inhibitors         | 1                    | 1                       | BRAF inhibitors      | 1                    | 1                       | Dabrafenib                 | 1                    | 1                       |
|      |                  |                                |                      |                         | MEK inhibitors       | 1                    | 1                       | Trametinib                 | 1                    | 1                       |
|      |                  | Other combination of therapies | 0                    | 1                       | Anti PD-1            | 0                    | 1                       | Pembrolizumab              | 0                    | 1                       |
|      |                  |                                |                      |                         | BRAF inhibitors      | 0                    | 1                       | Dabrafenib                 | 0                    | 1                       |
|      |                  |                                |                      |                         | MEK inhibitors       | 0                    | 1                       | Trametinib                 | 0                    | 1                       |
|      | Adjuvant         | Anti PD-1                      | 43                   | 4                       | Anti PD-1            | 43                   | 4                       | Nivolumab<br>Pembrolizumab | 9<br>34              | 0<br>4                  |
|      |                  | BRAF in MEK inhibitors         | 14                   | 1                       | BRAF inhibitors      | 14                   | 1                       | Dabrafenib                 | 14                   | 1                       |
|      |                  |                                |                      |                         | MEK inhibitors       | 14                   | 1                       | Trametinib                 | 14                   | 1                       |
|      | First line       | Anti PD-1                      | 15                   | 9                       | Anti PD-1            | 15                   | 9                       | Nivolumab<br>Pembrolizumab | 0<br>15              | 1<br>8                  |
|      |                  | BRAF in MEK inhibitors         | 6                    | 4                       | BRAF inhibitors      | 6                    | 4                       | Dabrafenib                 | 6                    | 4                       |
|      |                  |                                |                      |                         | MEK inhibitors       | 6                    | 4                       | Trametinib                 | 6                    | 4                       |
|      |                  | Other combination of therapies | 1                    | 0                       | Anti CTLA-4          | 1                    | 0                       | Ipilimumab                 | 1                    | 0                       |
|      |                  |                                |                      |                         | Anti PD-1            | 1                    | 0                       | Nivolumab                  | 1                    | 0                       |
|      |                  |                                |                      |                         | BRAF inhibitors      | 1                    | 0                       | Dabrafenib                 | 1                    | 0                       |
|      |                  |                                |                      |                         | MEK inhibitors       | 1                    | 0                       | Trametinib                 | 1                    | 0                       |
|      |                  | Combination immunotherapy      | 4                    | 1                       | Anti CTLA-4          | 4                    | 1                       | Ipilimumab                 | 4                    | 1                       |
|      |                  |                                |                      |                         | Anti PD-1            | 4                    | 1                       | Nivolumab                  | 4                    | 1                       |
|      | Second line      | Anti PD-1                      | 0                    | 2                       | Anti PD-1            | 0                    | 2                       | Nivolumab<br>Pembrolizumab | 0<br>0               | 1<br>1                  |
|      |                  | BRAF in MEK inhibitors         | 0                    | 5                       | BRAF inhibitors      | 0                    | 5                       | Dabrafenib                 | 0                    | 5                       |
|      |                  |                                |                      |                         | MEK inhibitors       | 0                    | 5                       | Trametinib                 | 0                    | 5                       |
|      |                  | Combination immunotherapy      | 0                    | 5                       | Anti CTLA-4          | 0                    | 5                       | Ipilimumab                 | 0                    | 5                       |
|      |                  |                                |                      |                         | Anti PD-1            | 0                    | 5                       | Nivolumab                  | 0                    | 5                       |
|      |                  | Monochemotherapy               | 0                    | 4                       | Alkylating agents    | 0                    | 4                       | Dakarbazinee               | 0                    | 4                       |
|      | Subsequent lines | Anti PD-1                      | 0                    | 2                       | Anti PD-1            | 0                    | 2                       | Nivolumab<br>Pembrolizumab | 0<br>0               | 1<br>1                  |
|      |                  | BRAF in MEK inhibitors         | 0                    | 3                       | BRAF inhibitors      | 0                    | 3                       | Dabrafenib<br>Vemurafenib  | 0<br>0               | 2<br>1                  |
|      |                  |                                |                      |                         | MEK inhibitors       | 0                    | 3                       | Cobimetinib<br>Trametinib  | 0<br>0               | 1<br>2                  |
|      |                  | Combination immunotherapy      | 0                    | 2                       | Anti CTLA-4          | 0                    | 2                       | Ipilimumab                 | 0                    | 2                       |
|      |                  |                                |                      |                         | Anti PD-1            | 0                    | 2                       | Nivolumab                  | 0                    | 2                       |
|      |                  | Combination chemotherapy       | 0                    | 1                       | Platinum analogues   | 0                    | 1                       | Carboplatin                | 0                    | 1                       |
|      |                  |                                |                      |                         | Taxanes              | 0                    | 1                       | Paclitaxel                 | 0                    | 1                       |
|      |                  | All                            |                      | 83                      | 43                   | All                  | 110                     | 65                         | All                  | 110                     |

Continued. —&gt;

Table 21b: Continued.

| Year                           | Place in therapy                | Regimen                        | Treatment indication   |                         | Therapeutic subgroup | Treatment indication |                         | Drug                          | Treatment indication |                         |     |
|--------------------------------|---------------------------------|--------------------------------|------------------------|-------------------------|----------------------|----------------------|-------------------------|-------------------------------|----------------------|-------------------------|-----|
|                                |                                 |                                | Primary treatment      | Treatment of recurrence |                      | Primary treatment    | Treatment of recurrence |                               | Primary treatment    | Treatment of recurrence |     |
| 2022                           | Neoadjuvant                     | Anti PD-1                      | 0                      | 2                       | Anti PD-1            | 0                    | 2                       | Pembrolizumab                 | 0                    | 2                       |     |
|                                | Adjuvant                        | Anti PD-1                      | 46                     | 5                       | Anti PD-1            | 46                   | 5                       | Nivolumab<br>Pembrolizumab    | 2<br>44              | 0<br>5                  |     |
|                                |                                 | BRAF in MEK inhibitors         | 6                      | 1                       | BRAF inhibitors      | 6                    | 1                       | Dabrafenib                    | 6                    | 1                       |     |
|                                |                                 |                                |                        |                         | MEK inhibitors       | 6                    | 1                       | Trametinib                    | 6                    | 1                       |     |
|                                | First line                      | Anti PD-1                      | 11                     | 10                      | Anti PD-1            | 11                   | 10                      | Nivolumab<br>Pembrolizumab    | 0<br>11              | 1<br>9                  |     |
|                                |                                 | BRAF in MEK inhibitors         | 1                      | 3                       | BRAF inhibitors      | 1                    | 3                       | Dabrafenib<br>Vemurafenib     | 1<br>0               | 3<br>1                  |     |
|                                |                                 |                                |                        |                         | MEK inhibitors       | 1                    | 3                       | Cobimetinib<br>Trametinib     | 0<br>1               | 1<br>3                  |     |
|                                |                                 | Combination immunotherapy      | 3                      | 2                       | Anti CTLA-4          | 3                    | 2                       | Ipilimumab                    | 3                    | 2                       |     |
|                                |                                 |                                |                        |                         | Anti PD-1            | 3                    | 2                       | Nivolumab                     | 3                    | 2                       |     |
|                                |                                 | Second line                    | Anti PD-1              | 0                       | 1                    | Anti PD-1            | 0                       | 1                             | Nivolumab            | 0                       | 1   |
|                                | BRAF in MEK inhibitors          |                                | 0                      | 3                       | BRAF inhibitors      | 0                    | 3                       | Dabrafenib                    | 0                    | 3                       |     |
|                                |                                 |                                |                        |                         | MEK inhibitors       | 0                    | 3                       | Trametinib                    | 0                    | 3                       |     |
|                                | Combination immunotherapy       |                                | 0                      | 1                       | Anti CTLA-4          | 0                    | 1                       | Ipilimumab                    | 0                    | 1                       |     |
|                                |                                 |                                |                        |                         | Anti PD-1            | 0                    | 1                       | Nivolumab                     | 0                    | 1                       |     |
|                                | Monochemotherapy                |                                | 0                      | 2                       | Alkylating agents    | 0                    | 2                       | Dakarbazinee                  | 0                    | 2                       |     |
|                                | Subsequent lines                | Anti PD-1                      | 0                      | 1                       | Anti PD-1            | 0                    | 1                       | Nivolumab                     | 0                    | 1                       |     |
|                                |                                 | Combination immunotherapy      | 0                      | 2                       | Anti CTLA-4          | 0                    | 2                       | Ipilimumab                    | 0                    | 2                       |     |
|                                |                                 |                                |                        |                         | Anti PD-1            | 0                    | 2                       | Nivolumab                     | 0                    | 2                       |     |
|                                | All                             | All                            | 67                     | 33                      | All                  | 77                   | 45                      | All                           | 77                   | 47                      |     |
|                                | Mean of yearly values 2018–2022 | Neoadjuvant                    | Anti PD-1              | 0,5                     | 1,5                  | Anti PD-1            | 0,5                     | 1,5                           | Pembrolizumab        | 0,5                     | 1,5 |
|                                |                                 |                                | BRAF in MEK inhibitors | 1,0                     | 1,0                  | BRAF inhibitors      | 1,0                     | 1,0                           | Dabrafenib           | 1,0                     | 1,0 |
| MEK inhibitors                 |                                 |                                |                        |                         |                      | 1,0                  | 1,0                     | Trametinib                    | 1,0                  | 1,0                     |     |
| Other combination of therapies |                                 |                                | 0,0                    | 1,0                     | Anti PD-1            | 0,0                  | 1,0                     | Pembrolizumab                 | 0,0                  | 1,0                     |     |
|                                |                                 |                                |                        |                         | BRAF inhibitors      | 0,0                  | 1,0                     | Dabrafenib                    | 0,0                  | 1,0                     |     |
| MEK inhibitors                 |                                 |                                | 13,0                   | 6,5                     | Trametinib           | 8,0                  | 3,5                     |                               |                      |                         |     |
| Adjuvant                       |                                 | Combination immunotherapy      | 0,0                    | 1,0                     | Anti CTLA-4          | 0,0                  | 1,0                     | Ipilimumab                    | 0,0                  | 1,0                     |     |
|                                |                                 |                                |                        |                         | Anti PD-1            | 0,0                  | 1,0                     | Nivolumab                     | 0,0                  | 1,0                     |     |
|                                |                                 | Anti PD-1                      | 32,4                   | 6,6                     | Anti PD-1            | 32,4                 | 6,6                     | Nivolumab<br>Pembrolizumab    | 9,8<br>22,6          | 2,2<br>4,4              |     |
|                                |                                 | BRAF in MEK inhibitors         | 11,0                   | 1,2                     | BRAF inhibitors      | 11,0                 | 1,2                     | Dabrafenib                    | 11,0                 | 1,2                     |     |
|                                |                                 |                                |                        |                         | MEK inhibitors       | 11,0                 | 1,2                     | Trametinib                    | 11,0                 | 1,2                     |     |
| First line                     |                                 | Anti PD-1                      | 9,0                    | 14,0                    | Anti PD-1            | 9,0                  | 14,0                    | Nivolumab<br>Pembrolizumab    | 0,2<br>8,8           | 1,8<br>12,4             |     |
|                                |                                 | BRAF in MEK inhibitors         | 5,0                    | 7,4                     | BRAF inhibitors      | 5,0                  | 7,4                     | Dabrafenib<br>Vemurafenib     | 4,4<br>1,8           | 6,8<br>1,6              |     |
|                                |                                 |                                |                        |                         | MEK inhibitors       | 5,0                  | 7,4                     | Cobimetinib<br>Trametinib     | 0,8<br>4,4           | 1,0<br>6,8              |     |
|                                |                                 | Other combination of therapies | 1,0                    | 0,0                     | Anti CTLA-4          | 1,0                  | 0,0                     | Ipilimumab                    | 1,0                  | 0,0                     |     |
|                                |                                 |                                |                        |                         | Anti PD-1            | 1,0                  | 0,0                     | Nivolumab                     | 1,0                  | 0,0                     |     |
|                                |                                 |                                |                        |                         | BRAF inhibitors      | 1,0                  | 0,0                     | Dabrafenib                    | 1,0                  | 0,0                     |     |
|                                |                                 |                                |                        |                         | MEK inhibitors       | 1,0                  | 0,0                     | Trametinib                    | 1,0                  | 0,0                     |     |
|                                |                                 | Combination immunotherapy      | 2,0                    | 3,2                     | Anti CTLA-4          | 2,0                  | 3,2                     | Ipilimumab                    | 2,0                  | 3,2                     |     |
|                                |                                 |                                |                        |                         | Anti PD-1            | 2,0                  | 3,2                     | Nivolumab                     | 2,0                  | 3,2                     |     |
|                                |                                 | Combination chemotherapy       | 1,0                    | 0,0                     | Platinum analogues   | 1,0                  | 0,0                     | Carboplatin                   | 1,0                  | 0,0                     |     |
|                                |                                 |                                |                        |                         | Taxanes              | 1,0                  | 0,0                     | Paclitaxel                    | 1,0                  | 0,0                     |     |
|                                |                                 | Monochemotherapy               | 0,3                    | 3,7                     | Alkylating agents    | 0,3                  | 3,7                     | Dakarbazinee<br>Temozolomidee | 0,3<br>0,0           | 3,3<br>1,0              |     |

Continued. —&gt;

Table 21b: Continued.

| Year                            | Place in therapy | Regimen                        | Treatment indication |                         | Therapeutic subgroup            | Treatment indication |                         | Drug                          | Treatment indication |                         |
|---------------------------------|------------------|--------------------------------|----------------------|-------------------------|---------------------------------|----------------------|-------------------------|-------------------------------|----------------------|-------------------------|
|                                 |                  |                                | Primary treatment    | Treatment of recurrence |                                 | Primary treatment    | Treatment of recurrence |                               | Primary treatment    | Treatment of recurrence |
| Mean of yearly values 2018–2022 | Second line      | Anti PD-1                      | 0,0                  | 3,2                     | Anti PD-1                       | 0,0                  | 3,2                     | Nivolumab<br>Pembrolizumab    | 0,0<br>0,0           | 2,3<br>2,3              |
|                                 |                  | BRAF in MEK inhibitors         | 0,0                  | 4,4                     | BRAF inhibitors                 | 0,0                  | 4,4                     | Dabrafenib<br>Vemurafenib     | 0,0<br>0,0           | 4,2<br>1,5              |
|                                 |                  |                                |                      |                         | MEK inhibitors                  | 0,0                  | 4,4                     | Cobimetinib<br>Trametinib     | 0,0<br>0,0           | 1,5<br>4,2              |
|                                 |                  | Combination immunotherapy      | 0,0                  | 4,8                     | Anti CTLA-4                     | 0,0                  | 4,8                     | Ipilimumab                    | 0,0                  | 4,8                     |
|                                 |                  |                                |                      |                         | Anti PD-1                       | 0,0                  | 4,8                     | Nivolumab                     | 0,0                  | 4,8                     |
|                                 |                  | Combination chemotherapy       | 0,0                  | 2,5                     | Platinum analogues              | 0,0                  | 2,5                     | Carboplatin                   | 0,0                  | 2,5                     |
|                                 |                  |                                |                      |                         | Taxanes                         | 0,0                  | 2,5                     | Paclitaxel                    | 0,0                  | 2,5                     |
|                                 |                  | Monochemotherapy               | 0,0                  | 5,2                     | Alkylating agents               | 0,0                  | 5,2                     | Dakarbazinee<br>Temozolomidee | 0,0<br>0,0           | 5,0<br>1,0              |
|                                 | Subsequent lines | Anti PD-1                      | 0,0                  | 2,0                     | Anti PD-1                       | 0,0                  | 2,0                     | Nivolumab<br>Pembrolizumab    | 0,0<br>0,0           | 1,0<br>1,7              |
|                                 |                  | BRAF in MEK inhibitors         | 0,0                  | 3,3                     | BRAF inhibitors                 | 0,0                  | 3,3                     | Dabrafenib<br>Vemurafenib     | 0,0<br>0,0           | 1,7<br>1,7              |
|                                 |                  |                                |                      |                         | MEK inhibitors                  | 0,0                  | 3,3                     | Cobimetinib<br>Trametinib     | 0,0<br>0,0           | 1,7<br>1,7              |
|                                 |                  | BRAF inhibitors                | 0,0                  | 1,0                     | BRAF inhibitors                 | 0,0                  | 1,0                     | Dabrafenib                    | 0,0                  | 1,0                     |
|                                 |                  | Other combination of therapies | 0,0                  | 1,0                     | Anti PD-1                       | 0,0                  | 1,0                     | Pembrolizumab                 | 0,0                  | 1,0                     |
|                                 |                  |                                |                      |                         | Other protein kinase inhibitors | 0,0                  | 1,0                     | Lenvatinib                    | 0,0                  | 1,0                     |
|                                 |                  | Combination immunotherapy      | 0,0                  | 1,8                     | Anti CTLA-4                     | 0,0                  | 1,8                     | Ipilimumab                    | 0,0                  | 1,8                     |
|                                 |                  |                                |                      |                         | Anti PD-1                       | 0,0                  | 1,8                     | Nivolumab                     | 0,0                  | 1,8                     |
|                                 |                  | Combination chemotherapy       | 0,0                  | 3,3                     | Nitrosourea analogues           | 0,0                  | 2,0                     | Lomustine                     | 0,0                  | 2,0                     |
|                                 |                  |                                |                      |                         | Platinum analogues              | 0,0                  | 3,3                     | Cisplatin<br>Carboplatin      | 0,0<br>0,0           | 2,0<br>2,8              |
|                                 |                  |                                |                      |                         | Taxanes                         | 0,0                  | 2,8                     | Paclitaxel                    | 0,0                  | 2,8                     |
|                                 |                  |                                |                      |                         | Vinca alcaloids                 | 0,0                  | 2,0                     | Vinblastinee                  | 0,0                  | 2,0                     |
|                                 |                  | Monochemotherapy               | 0,0                  | 2,0                     | Alkylating agents               | 0,0                  | 2,0                     | Dakarbazinee<br>Temozolomidee | 0,0<br>0,0           | 2,0<br>1,0              |
|                                 |                  | All                            | 63,2                 | 75,0                    | All                             | 99,2                 | 120,8                   | All                           | 95,6                 | 128,1                   |

Table 21c: Number of systemic treatments by treatment type, medication group and administered medication by UICC stage at diagnosis in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Stage                 | Place in therapy | Regimen                   | Year                      |      |      |      |      | Therapeutic subgroup | Year                            |             |      |      |      | Drug | Year      |                                 |            |      |      |      |      |                                 |
|-----------------------|------------------|---------------------------|---------------------------|------|------|------|------|----------------------|---------------------------------|-------------|------|------|------|------|-----------|---------------------------------|------------|------|------|------|------|---------------------------------|
|                       |                  |                           | 2018                      | 2019 | 2020 | 2021 | 2022 |                      | Mean of yearly values 2018–2022 | 2018        | 2019 | 2020 | 2021 |      | 2022      | Mean of yearly values 2018–2022 | 2018       | 2019 | 2020 | 2021 | 2022 | Mean of yearly values 2018–2022 |
| IA                    | Neoadjuvant      | Anti PD-1                 | 0                         | 0    | 0    | 1    | 0    | 0,2                  | Anti PD-1                       | 0           | 0    | 0    | 1    | 0    | 0,2       | Pembrolizumab                   | 0          | 0    | 0    | 1    | 0    | 0,2                             |
|                       |                  | BRAF in MEK inhibitors    | 0                         | 0    | 0    | 1    | 0    | 0,2                  | BRAF inhibitors                 | 0           | 0    | 0    | 1    | 0    | 0,2       | Dabrafenib                      | 0          | 0    | 0    | 1    | 0    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      | MEK inhibitors                  | 0           | 0    | 0    | 1    | 0    | 0,2       | Trametinib                      | 0          | 0    | 0    | 1    | 0    | 0,2                             |
|                       | Adjuvant         | Anti PD-1                 | 1                         | 1    | 0    | 0    | 0    | 0,4                  | Anti PD-1                       | 1           | 1    | 0    | 0    | 0    | 0,4       | Pembrolizumab                   | 1          | 1    | 0    | 0    | 0    | 0,4                             |
|                       | First line       | Anti PD-1                 | 1                         | 0    | 1    | 0    | 0    | 0,4                  | Anti PD-1                       | 1           | 0    | 1    | 0    | 0    | 0,4       | Pembrolizumab                   | 1          | 0    | 1    | 0    | 0    | 0,4                             |
|                       |                  | BRAF in MEK inhibitors    | 2                         | 2    | 0    | 0    | 0    | 0,8                  | BRAF inhibitors                 | 2           | 2    | 0    | 0    | 0    | 0,8       | Dabrafenib                      | 1          | 2    | 0    | 0    | 0    | 0,6                             |
|                       |                  |                           |                           |      |      |      |      |                      | Vemurafenib                     | 1           | 0    | 0    | 0    | 0    | 0,2       | Cobimetinib                     | 1          | 0    | 0    | 0    | 0    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      | Trametinib                      | 1           | 2    | 0    | 0    | 0    | 0,6       | Trametinib                      | 1          | 2    | 0    | 0    | 0    | 0,6                             |
|                       |                  | Combination immunotherapy | 0                         | 1    | 0    | 0    | 0    | 0,2                  | Anti CTLA-4                     | 0           | 1    | 0    | 0    | 0    | 0,2       | Ipilimumab                      | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       | Anti PD-1        |                           |                           |      |      |      |      |                      | 0                               | 1           | 0    | 0    | 0    | 0,2  | Nivolumab | 0                               | 1          | 0    | 0    | 0    | 0,2  |                                 |
|                       | Second line      | Anti PD-1                 | 0                         | 2    | 0    | 0    | 0    | 0,4                  | Anti PD-1                       | 0           | 2    | 0    | 0    | 0    | 0,4       | Nivolumab                       | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  | Monochemotherapy          | 1                         | 0    | 0    | 0    | 0    | 0,2                  | Alkylating agents               | 1           | 0    | 0    | 0    | 0    | 0,2       | Pembrolizumab                   | 0          | 1    | 0    | 0    | 0    | 0,2                             |
| Subsequent lines (3+) | /                | /                         | /                         | /    | /    | /    | /    | /                    | /                               | /           | /    | /    | /    | /    | /         | /                               | /          | /    | /    | /    | /    |                                 |
| All                   | All              | 5                         | 6                         | 1    | 2    | 0    | 2,8  | All                  | 7                               | 9           | 1    | 3    | 0    | 4,0  | All       | 7                               | 9          | 1    | 3    | 0    | 4,0  |                                 |
| IB                    | Neoadjuvant      | Anti PD-1                 | 0                         | 0    | 0    | 0    | 1    | 0,2                  | Anti PD-1                       | 0           | 0    | 0    | 0    | 1    | 0,2       | Pembrolizumab                   | 0          | 0    | 0    | 0    | 1    | 0,2                             |
|                       | Adjuvant         | Anti PD-1                 | 0                         | 2    | 0    | 0    | 1    | 0,6                  | Anti PD-1                       | 0           | 2    | 0    | 0    | 1    | 0,6       | Nivolumab                       | 0          | 2    | 0    | 0    | 0    | 0,4                             |
|                       |                  | BRAF in MEK inhibitors    | 1                         | 0    | 0    | 0    | 0    | 0,2                  | BRAF inhibitors                 | 1           | 0    | 0    | 0    | 0    | 0,2       | Pembrolizumab                   | 0          | 0    | 0    | 0    | 1    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      | MEK inhibitors                  | 1           | 0    | 0    | 0    | 0    | 0,2       | Dabrafenib                      | 1          | 0    | 0    | 0    | 0,2  |                                 |
|                       | First line       | Anti PD-1                 | 1                         | 2    | 0    | 0    | 0    | 0,6                  | Anti PD-1                       | 1           | 2    | 0    | 0    | 0    | 0,6       | Trametinib                      | 1          | 0    | 0    | 0    | 0    | 0,2                             |
|                       |                  | BRAF in MEK inhibitors    | 0                         | 1    | 0    | 0    | 0    | 0,2                  | BRAF inhibitors                 | 0           | 1    | 0    | 0    | 0    | 0,2       | Nivolumab                       | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      | MEK inhibitors                  | 0           | 1    | 0    | 0    | 0    | 0,2       | Pembrolizumab                   | 1          | 2    | 0    | 0    | 0    | 0,6                             |
|                       | Second line      | BRAF in MEK inhibitors    | 0                         | 1    | 0    | 0    | 0    | 0,2                  | BRAF inhibitors                 | 0           | 1    | 0    | 0    | 0    | 0,2       | Dabrafenib                      | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  | Combination immunotherapy | 0                         | 1    | 0    | 0    | 0    | 0,2                  | MEK inhibitors                  | 0           | 1    | 0    | 0    | 0    | 0,2       | Trametinib                      | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      | Anti CTLA-4                     | 0           | 1    | 0    | 0    | 0    | 0,2       | Ipilimumab                      | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  | Monochemotherapy          | 0                         | 1    | 0    | 0    | 0    | 0,2                  | Anti PD-1                       | 0           | 1    | 0    | 0    | 0    | 0,2       | Nivolumab                       | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  | Subsequent lines (3+)     | /                         | /    | /    | /    | /    | /                    | /                               | /           | /    | /    | /    | /    | /         | /                               | /          | /    | /    | /    | /    | /                               |
|                       | All              | All                       | 2                         | 8    | 0    | 0    | 2    | 2,4                  | All                             | 3           | 11   | 0    | 0    | 2    | 3,2       | All                             | 3          | 12   | 0    | 0    | 2    | 3,4                             |
|                       | IIA              | Neoadjuvant               | Combination immunotherapy | 0    | 1    | 0    | 0    | 0                    | 0,2                             | Anti CTLA-4 | 0    | 1    | 0    | 0    | 0         | 0,2                             | Ipilimumab | 0    | 1    | 0    | 0    | 0                               |
| Adjuvant              |                  | Anti PD-1                 | 3                         | 2    | 0    | 1    | 1    | 1,4                  | Anti PD-1                       | 0           | 1    | 0    | 0    | 0    | 0,2       | Nivolumab                       | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
| First line            |                  | Anti PD-1                 | 1                         | 1    | 2    | 0    | 0    | 0,8                  | Anti PD-1                       | 1           | 1    | 2    | 0    | 0    | 0,8       | Nivolumab                       | 1          | 2    | 0    | 0    | 0    | 0,6                             |
|                       |                  | BRAF in MEK inhibitors    | 3                         | 0    | 1    | 0    | 0    | 0,8                  | BRAF inhibitors                 | 3           | 0    | 1    | 0    | 0    | 0,8       | Pembrolizumab                   | 2          | 0    | 0    | 1    | 1    | 0,8                             |
|                       |                  |                           |                           |      |      |      |      |                      | MEK inhibitors                  | 3           | 0    | 1    | 0    | 0    | 0,8       | Dabrafenib                      | 3          | 0    | 0    | 0    | 0    | 0,6                             |
|                       |                  |                           |                           |      |      |      |      |                      | Vemurafenib                     | 0           | 0    | 1    | 0    | 0    | 0,2       | Cobimetinib                     | 0          | 0    | 1    | 0    | 0    | 0,2                             |
|                       |                  | Combination immunotherapy | 0                         | 1    | 0    | 0    | 1    | 0,4                  | Anti CTLA-4                     | 0           | 1    | 0    | 0    | 1    | 0,4       | Trametinib                      | 3          | 0    | 0    | 0    | 0    | 0,6                             |
| Second line           |                  | Anti PD-1                 | 0                         | 0    | 1    | 0    | 0    | 0,2                  | Anti PD-1                       | 0           | 1    | 0    | 0    | 1    | 0,4       | Ipilimumab                      | 0          | 1    | 0    | 0    | 1    | 0,4                             |
|                       |                  | BRAF in MEK inhibitors    | 1                         | 1    | 0    | 0    | 0    | 0,4                  | BRAF inhibitors                 | 0           | 1    | 0    | 0    | 0    | 0,2       | Nivolumab                       | 0          | 1    | 0    | 0    | 1    | 0,4                             |
|                       |                  | Combination immunotherapy | 2                         | 0    | 0    | 0    | 0    | 0,4                  | MEK inhibitors                  | 1           | 1    | 0    | 0    | 0    | 0,4       | Pembrolizumab                   | 0          | 0    | 1    | 0    | 0    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      | Anti CTLA-4                     | 2           | 0    | 0    | 0    | 0    | 0,4       | Dabrafenib                      | 1          | 1    | 0    | 0    | 0    | 0,4                             |
|                       |                  | Monochemotherapy          | 0                         | 2    | 0    | 0    | 0    | 0,4                  | Anti PD-1                       | 2           | 0    | 0    | 0    | 0    | 0,4       | Trametinib                      | 1          | 1    | 0    | 0    | 0    | 0,4                             |
| Subsequent lines (3+) |                  | Druga kombinacija terapij | 0                         | 1    | 0    | 0    | 0    | 0,2                  | Alkylating agents               | 0           | 2    | 0    | 0    | 0    | 0,4       | Ipilimumab                      | 2          | 0    | 0    | 0    | 0    | 0,4                             |
|                       |                  |                           |                           |      |      |      |      |                      | Anti PD-1                       | 0           | 1    | 0    | 0    | 0    | 0,2       | Nivolumab                       | 2          | 0    | 0    | 0    | 0    | 0,4                             |
| All                   |                  | All                       | 10                        | 9    | 4    | 1    | 2    | 5,2                  | All                             | 0           | 1    | 0    | 0    | 0    | 0,2       | Pembrolizumab                   | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      | Drugi zaviralci protein kinaz   | 0           | 1    | 0    | 0    | 0    | 0,2       | Lenvatinib                      | 0          | 1    | 0    | 0    | 0    | 0,2                             |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |
|                       |                  |                           |                           |      |      |      |      |                      |                                 |             |      |      |      |      |           |                                 |            |      |      |      |      |                                 |

Continued. —>



Table 21c: Continued.

| Stage                     | Place in therapy      | Regimen                   | Year                      |      |      |      |                   | Therapeutic subgroup | Year                              |                 |        |        |        | Drug        | Year       |                                 |               |        |        |        |            |                                 |     |
|---------------------------|-----------------------|---------------------------|---------------------------|------|------|------|-------------------|----------------------|-----------------------------------|-----------------|--------|--------|--------|-------------|------------|---------------------------------|---------------|--------|--------|--------|------------|---------------------------------|-----|
|                           |                       |                           | 2018                      | 2019 | 2020 | 2021 | 2022              |                      | Mean of yearly values 2018–2022   | 2018            | 2019   | 2020   | 2021   |             | 2022       | Mean of yearly values 2018–2022 | 2018          | 2019   | 2020   | 2021   | 2022       | Mean of yearly values 2018–2022 |     |
| IIB                       | Neoadjuvant           | /                         | /                         | /    | /    | /    | /                 | /                    | /                                 | /               | /      | /      | /      | /           | /          | /                               | /             | /      | /      | /      |            |                                 |     |
|                           | Adjuvant              | Anti PD-1                 | 0                         | 2    | 2    | 0    | 6                 | 2,0                  | Anti PD-1                         | 0               | 2      | 2      | 0      | 6           | 2,0        | Nivolumab<br>Pembrolizumab      | 0<br>0        | 0<br>2 | 0<br>1 | 0<br>0 | 0<br>6     | 0,2<br>1,8                      |     |
|                           |                       | BRAF in MEK inhibitors    | 0                         | 1    | 0    | 0    | 0                 | 0,2                  | BRAF inhibitors<br>MEK inhibitors | 0<br>0          | 1<br>1 | 0<br>0 | 0<br>0 | 0<br>0      | 0,2<br>0,2 | Dabrafenib<br>Trametinib        | 0<br>0        | 1<br>1 | 0<br>0 | 0<br>0 | 0<br>0     | 0,2<br>0,2                      |     |
|                           | First line            | Anti PD-1                 | 2                         | 4    | 2    | 0    | 2                 | 2,0                  | Anti PD-1                         | 2               | 4      | 2      | 0      | 2           | 2,0        | Nivolumab<br>Pembrolizumab      | 0<br>2        | 1<br>3 | 0<br>2 | 0<br>0 | 0<br>2     | 0,2<br>1,8                      |     |
|                           |                       | BRAF in MEK inhibitors    | 2                         | 1    | 0    | 0    | 1                 | 0,8                  | BRAF inhibitors                   | 2               | 1      | 0      | 0      | 1           | 0,8        | Dabrafenib<br>Vemurafenib       | 2<br>0        | 1<br>0 | 0<br>0 | 0<br>0 | 1<br>1     | 0,8<br>0,2                      |     |
|                           |                       |                           |                           |      |      |      |                   |                      | MEK inhibitors                    | 2               | 1      | 0      | 0      | 1           | 0,8        | Cobimetinib<br>Trametinib       | 0<br>2        | 0<br>1 | 0<br>0 | 0<br>1 | 0,2<br>0,8 |                                 |     |
|                           |                       | Combination immunotherapy | 1                         | 0    | 1    | 0    | 0                 | 0,4                  | Anti CTLA-4                       | 1               | 0      | 1      | 0      | 0           | 0,4        | Ipilimumab                      | 1             | 0      | 1      | 0      | 0          | 0,4                             |     |
|                           |                       |                           |                           |      |      |      |                   |                      | Anti PD-1                         | 1               | 0      | 1      | 0      | 0           | 0,4        | Nivolumab                       | 1             | 0      | 1      | 0      | 0          | 0,4                             |     |
|                           | Second line           | Anti PD-1                 | 1                         | 1    | 0    | 0    | 0                 | 0,4                  | Anti PD-1                         | 1               | 1      | 0      | 0      | 0           | 0,4        | Nivolumab<br>Pembrolizumab      | 0<br>1        | 1<br>0 | 0<br>0 | 0<br>0 | 0<br>0     | 0,2<br>0,2                      |     |
|                           |                       | BRAF in MEK inhibitors    | 0                         | 1    | 0    | 0    | 0                 | 0,2                  | BRAF inhibitors                   | 0               | 1      | 0      | 0      | 0           | 0,2        | Dabrafenib<br>Vemurafenib       | 0<br>0        | 1<br>1 | 0<br>0 | 0<br>0 | 0<br>0     | 0,2<br>0,2                      |     |
|                           |                       |                           |                           |      |      |      |                   |                      | MEK inhibitors                    | 0               | 1      | 0      | 0      | 0           | 0,2        | Cobimetinib<br>Trametinib       | 0<br>0        | 1<br>1 | 0<br>0 | 0<br>0 | 0,2<br>0,2 |                                 |     |
|                           |                       | Monochemotherapy          | 1                         | 0    | 1    | 0    | 0                 | 0,4                  | Alkylating agents                 | 1               | 0      | 1      | 0      | 0           | 0,4        | Dakarbazine                     | 1             | 0      | 1      | 0      | 0          | 0,4                             |     |
|                           |                       |                           |                           |      |      |      |                   |                      | BRAF inhibitors                   | 1               | 0      | 0      | 0      | 0           | 0,2        | Vemurafenib                     | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
|                           | Subsequent lines (3+) | BRAF in MEK inhibitors    | 1                         | 0    | 0    | 0    | 0                 | 0,2                  | MEK inhibitors                    | 1               | 0      | 0      | 0      | 0           | 0,2        | Cobimetinib                     | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
|                           |                       |                           |                           |      |      |      |                   |                      | All                               | All             | 8      | 10     | 6      | 0           | 9          | 6,6                             | All           | 11     | 13     | 7      | 0          | 10                              | 8,2 |
|                           | IIC                   | Neoadjuvant               | Anti PD-1                 | 0    | 0    | 0    | 0                 | 1                    | 0,2                               | Anti PD-1       | 0      | 0      | 0      | 0           | 1          | 0,2                             | Pembrolizumab | 0      | 0      | 0      | 0          | 1                               | 0,2 |
|                           |                       |                           | Druga kombinacija terapij | 0    | 0    | 0    | 1                 | 0                    | 0,2                               | Anti PD-1       | 0      | 0      | 0      | 1           | 0          | 0,2                             | Pembrolizumab | 0      | 0      | 0      | 1          | 0                               | 0,2 |
|                           |                       |                           |                           |      |      |      |                   |                      |                                   | BRAF inhibitors | 0      | 0      | 0      | 1           | 0          | 0,2                             | Dabrafenib    | 0      | 0      | 0      | 1          | 0                               | 0,2 |
| MEK inhibitors            |                       |                           |                           |      |      |      |                   |                      |                                   | 0               | 0      | 0      | 1      | 0           | 0,2        | Trametinib                      | 0             | 0      | 0      | 1      | 0          | 0,2                             |     |
| Adjuvant                  |                       | Anti PD-1                 | 4                         | 1    | 0    | 0    | 6                 | 2,2                  | Anti PD-1                         | 4               | 1      | 0      | 0      | 6           | 2,2        | Nivolumab<br>Pembrolizumab      | 1<br>3        | 0<br>1 | 0<br>0 | 0<br>0 | 0<br>6     | 0,2<br>2,0                      |     |
|                           |                       | BRAF in MEK inhibitors    | 1                         | 0    | 0    | 0    | 0                 | 0,2                  | BRAF inhibitors                   | 1               | 0      | 0      | 0      | 0           | 0,2        | Dabrafenib                      | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
|                           |                       |                           |                           |      |      |      |                   |                      | MEK inhibitors                    | 1               | 0      | 0      | 0      | 0           | 0,2        | Trametinib                      | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
| First line                |                       | Anti PD-1                 | 1                         | 2    | 2    | 4    | 2                 | 2,2                  | Anti PD-1                         | 1               | 2      | 2      | 4      | 2           | 2,2        | Nivolumab<br>Pembrolizumab      | 0<br>1        | 0<br>2 | 0<br>2 | 0<br>3 | 1<br>1     | 0,4<br>1,8                      |     |
|                           |                       | BRAF in MEK inhibitors    | 1                         | 1    | 0    | 0    | 0                 | 0,4                  | BRAF inhibitors                   | 1               | 1      | 0      | 0      | 0           | 0,4        | Dabrafenib                      | 1             | 1      | 0      | 0      | 0          | 0,4                             |     |
|                           |                       |                           |                           |      |      |      |                   |                      | MEK inhibitors                    | 1               | 1      | 0      | 0      | 0           | 0,4        | Trametinib                      | 1             | 1      | 0      | 0      | 0          | 0,4                             |     |
|                           |                       | Monochemotherapy          | 1                         | 1    | 0    | 0    | 0                 | 0,4                  | Alkylating agents                 | 1               | 1      | 0      | 0      | 0           | 0,4        | Dakarbazine                     | 1             | 1      | 0      | 0      | 0          | 0,4                             |     |
| Second line               |                       | Anti PD-1                 | 0                         | 1    | 0    | 0    | 0                 | 0,2                  | Anti PD-1                         | 0               | 1      | 0      | 0      | 0           | 0,2        | Nivolumab                       | 0             | 1      | 0      | 0      | 0          | 0,2                             |     |
|                           |                       | Combination immunotherapy | 1                         | 0    | 0    | 0    | 0                 | 0,2                  | Anti CTLA-4                       | 1               | 0      | 0      | 0      | 0           | 0,2        | Ipilimumab                      | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
|                           |                       |                           |                           |      |      |      |                   |                      | Anti PD-1                         | 1               | 0      | 0      | 0      | 0           | 0,2        | Nivolumab                       | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
|                           |                       | Monochemotherapy          | 1                         | 0    | 0    | 0    | 0                 | 0,2                  | Alkylating agents                 | 1               | 0      | 0      | 0      | 0           | 0,2        | Dakarbazine                     | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
| Subsequent lines (3+)     |                       | Anti PD-1                 | 1                         | 0    | 0    | 0    | 0                 | 0,2                  | Anti PD-1                         | 1               | 0      | 0      | 0      | 0           | 0,2        | Pembrolizumab                   | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
|                           |                       | BRAF in MEK inhibitors    | 1                         | 0    | 0    | 0    | 0                 | 0,2                  | BRAF inhibitors                   | 1               | 0      | 0      | 0      | 0           | 0,2        | Vemurafenib                     | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
|                           |                       |                           |                           |      |      |      |                   |                      | MEK inhibitors                    | 1               | 0      | 0      | 0      | 0           | 0,2        | Cobimetinib                     | 1             | 0      | 0      | 0      | 0          | 0,2                             |     |
|                           |                       | Combination chemotherapy  | 1                         | 0    | 0    | 0    | 0                 | 0,2                  | Platinum analogues<br>Taxanes     | 1<br>1          | 0<br>0 | 0<br>0 | 0<br>0 | 0<br>0      | 0,2<br>0,2 | Carboplatin<br>Paclitaxel       | 1<br>1        | 0<br>0 | 0<br>0 | 0<br>0 | 0<br>0     | 0,2<br>0,2                      |     |
| All                       |                       | All                       | 13                        | 6    | 2    | 5    | 9                 | 7,0                  | All                               | 17              | 7      | 2      | 7      | 9           | 8,4        | All                             | 17            | 7      | 2      | 7      | 9          | 8,4                             |     |
| IIIA                      | Neoadjuvant           | /                         | /                         | /    | /    | /    | /                 | /                    | /                                 | /               | /      | /      | /      | /           | /          | /                               | /             | /      | /      | /      |            |                                 |     |
|                           | Adjuvant              | Anti PD-1                 | 2                         | 4    | 5    | 4    | 8                 | 4,6                  | Anti PD-1                         | 2               | 4      | 5      | 4      | 8           | 4,6        | Nivolumab<br>Pembrolizumab      | 1<br>1        | 0<br>4 | 0<br>5 | 0<br>4 | 0<br>7     | 0,4<br>4,2                      |     |
|                           |                       | BRAF in MEK inhibitors    | 0                         | 6    | 0    | 1    | 1                 | 1,6                  | BRAF inhibitors                   | 0               | 6      | 0      | 1      | 1           | 1,6        | Dabrafenib                      | 0             | 6      | 0      | 1      | 1          | 1,6                             |     |
|                           | MEK inhibitors        |                           |                           |      |      |      |                   |                      | 0                                 | 6               | 0      | 1      | 1      | 1,6         | Trametinib | 0                               | 6             | 0      | 1      | 1      | 1,6        |                                 |     |
|                           | First line            | Anti PD-1                 | 2                         | 0    | 0    | 1    | 0                 | 0,6                  | Anti PD-1                         | 2               | 0      | 0      | 1      | 0           | 0,6        | Pembrolizumab                   | 2             | 0      | 0      | 1      | 0          | 0,6                             |     |
|                           |                       | BRAF in MEK inhibitors    | 0                         | 0    | 1    | 0    | 0                 | 0,2                  | BRAF inhibitors                   | 0               | 0      | 1      | 0      | 0           | 0,2        | Dabrafenib                      | 0             | 0      | 1      | 0      | 0          | 0,2                             |     |
|                           |                       |                           |                           |      |      |      |                   |                      | MEK inhibitors                    | 0               | 0      | 1      | 0      | 0           | 0,2        | Trametinib                      | 0             | 0      | 1      | 0      | 0          | 0,2                             |     |
| Combination immunotherapy |                       | 0                         | 1                         | 0    | 0    | 0    | 0,2               | Anti CTLA-4          | 0                                 | 1               | 0      | 0      | 0      | 0,2         | Ipilimumab | 0                               | 1             | 0      | 0      | 0      | 0,2        |                                 |     |
|                           |                       |                           |                           |      |      |      |                   | Anti PD-1            | 0                                 | 1               | 0      | 0      | 0      | 0,2         | Nivolumab  | 0                               | 1             | 0      | 0      | 0      | 0,2        |                                 |     |
| Monochemotherapy          | 0                     | 0                         | 1                         | 0    | 0    | 0,2  | Alkylating agents | 0                    | 0                                 | 1               | 0      | 0      | 0,2    | Dakarbazine | 0          | 0                               | 1             | 0      | 0      | 0,2    |            |                                 |     |

Continued. —&gt;

Table 21c: Continued.

| Stage                     | Place in therapy      | Regimen                   | Year                   |      |      |      |      | Therapeutic subgroup | Year                              |                                   |        |        |        | Drug       | Year                      |                                 |                            |        |         |        |            |                                 |                         |
|---------------------------|-----------------------|---------------------------|------------------------|------|------|------|------|----------------------|-----------------------------------|-----------------------------------|--------|--------|--------|------------|---------------------------|---------------------------------|----------------------------|--------|---------|--------|------------|---------------------------------|-------------------------|
|                           |                       |                           | 2018                   | 2019 | 2020 | 2021 | 2022 |                      | Mean of yearly values 2018–2022   | 2018                              | 2019   | 2020   | 2021   |            | 2022                      | Mean of yearly values 2018–2022 | 2018                       | 2019   | 2020    | 2021   | 2022       | Mean of yearly values 2018–2022 |                         |
| IIIA                      | Second line           | BRAF in MEK inhibitors    | 1                      | 0    | 0    | 0    | 0    | 0,2                  | BRAF inhibitors<br>MEK inhibitors | 1                                 | 0      | 0      | 0      | 0          | 0,2                       | Dabrafenib<br>Trametinib        | 1                          | 0      | 0       | 0      | 0          | 0,2                             |                         |
|                           | Subsequent lines (3+) | /                         | /                      | /    | /    | /    | /    | /                    | /                                 | /                                 | /      | /      | /      | /          | /                         | /                               | /                          | /      | /       | /      | /          |                                 |                         |
|                           | All                   | All                       | 5                      | 11   | 7    | 6    | 9    | 7,6                  | All                               | 6                                 | 18     | 8      | 7      | 10         | 9,8                       | All                             | 6                          | 18     | 8       | 7      | 10         | 9,8                             |                         |
| IIIB                      | Neoadjuvant           | /                         | /                      | /    | /    | /    | /    | /                    | /                                 | /                                 | /      | /      | /      | /          | /                         | /                               | /                          | /      | /       | /      | /          |                                 |                         |
|                           | Adjuvant              | Anti PD-1                 | 3                      | 5    | 6    | 9    | 12   | 7,0                  | Anti PD-1                         | 3                                 | 5      | 6      | 9      | 12         | 7,0                       | Nivolumab<br>Pembrolizumab      | 3<br>0                     | 4<br>1 | 1<br>5  | 2<br>7 | 0<br>12    | 2,0<br>5,0                      |                         |
|                           |                       | BRAF in MEK inhibitors    | 1                      | 7    | 1    | 1    | 3    | 2,6                  | BRAF inhibitors<br>MEK inhibitors | 1                                 | 7      | 1      | 1      | 3          | 2,6                       | Dabrafenib<br>Trametinib        | 1<br>1                     | 7<br>1 | 1<br>1  | 1<br>3 | 3<br>2,6   | 2,6                             |                         |
|                           | First line            | Anti PD-1                 | 3                      | 1    | 0    | 1    | 0    | 1,0                  | Anti PD-1                         | 3                                 | 1      | 0      | 1      | 0          | 1,0                       | Nivolumab<br>Pembrolizumab      | 1<br>2                     | 0<br>1 | 0<br>0  | 0<br>1 | 0<br>0     | 0,2<br>0,8                      |                         |
|                           |                       | BRAF in MEK inhibitors    | 2                      | 2    | 0    | 0    | 1    | 1,0                  | BRAF inhibitors                   | 2                                 | 2      | 0      | 0      | 1          | 1,0                       | Dabrafenib<br>Vemurafenib       | 2<br>0                     | 1<br>1 | 0<br>0  | 0<br>0 | 1<br>0     | 0,8<br>0,2                      |                         |
|                           |                       |                           |                        |      |      |      |      |                      | MEK inhibitors                    | 2                                 | 2      | 0      | 0      | 1          | 1,0                       | Cobimetinib<br>Trametinib       | 0<br>2                     | 1<br>1 | 0<br>0  | 0<br>1 | 0<br>0,8   |                                 |                         |
|                           |                       |                           |                        |      |      |      |      |                      | Monochemotherapy                  | 1                                 | 0      | 2      | 0      | 0          | 0,6                       | Alkylating agents               | 1                          | 0      | 2       | 0      | 0          | 0,6                             | Dakarbazine             |
|                           | Second line           | Anti PD-1                 | 1                      | 0    | 0    | 0    | 1    | 0,4                  | Anti PD-1                         | 1                                 | 0      | 0      | 0      | 1          | 0,4                       | Nivolumab<br>Pembrolizumab      | 0<br>1                     | 0<br>0 | 0<br>0  | 0<br>0 | 1<br>0     | 0,2<br>0,2                      |                         |
|                           |                       | BRAF in MEK inhibitors    | 0                      | 0    | 0    | 1    | 0    | 0,2                  | BRAF inhibitors<br>MEK inhibitors | 0                                 | 0      | 0      | 1      | 0          | 0,2                       | Dabrafenib<br>Trametinib        | 0<br>0                     | 0<br>0 | 0<br>1  | 0<br>0 | 1<br>0     | 0,2<br>0,2                      |                         |
|                           |                       | Combination immunotherapy | 0                      | 1    | 1    | 0    | 0    | 0,4                  | Anti CTLA-4                       | 0                                 | 1      | 1      | 0      | 0          | 0,4                       | Ipilimumab                      | 0                          | 1      | 1       | 0      | 0          | 0,4                             |                         |
|                           |                       |                           |                        |      |      |      |      |                      | Anti PD-1                         | 0                                 | 1      | 1      | 0      | 0          | 0,4                       | Nivolumab                       | 0                          | 1      | 1       | 0      | 0          | 0,4                             |                         |
|                           |                       | Combination chemotherapy  | 0                      | 0    | 1    | 0    | 0    | 0,2                  | Platinum analogues                | 0                                 | 0      | 1      | 0      | 0          | 0,2                       | Carboplatin                     | 0                          | 0      | 1       | 0      | 0          | 0,2                             |                         |
|                           |                       |                           |                        |      |      |      |      |                      | Taxanes                           | 0                                 | 0      | 1      | 0      | 0          | 0,2                       | Paclitaxel                      | 0                          | 0      | 1       | 0      | 0          | 0,2                             |                         |
|                           | Subsequent lines (3+) | BRAF inhibitors           | 0                      | 1    | 0    | 0    | 0    | 0,2                  | BRAF inhibitors                   | 0                                 | 1      | 0      | 0      | 0          | 0,2                       | Dabrafenib                      | 0                          | 1      | 0       | 0      | 0          | 0,2                             |                         |
|                           |                       | Combination chemotherapy  | 0                      | 1    | 0    | 0    | 0    | 0,2                  | Platinum analogues                | 0                                 | 1      | 0      | 0      | 0          | 0,2                       | Carboplatin                     | 0                          | 1      | 0       | 0      | 0          | 0,2                             |                         |
|                           |                       | Monochemotherapy          | 0                      | 1    | 0    | 0    | 0    | 0,2                  | Taxanes                           | 0                                 | 1      | 0      | 0      | 0          | 0,2                       | Paclitaxel                      | 0                          | 1      | 0       | 0      | 0          | 0,2                             |                         |
|                           | All                   | All                       | 11                     | 19   | 11   | 12   | 17   | 14,0                 | All                               | 14                                | 30     | 14     | 14     | 21         | 18,6                      | All                             | 14                         | 30     | 14      | 14     | 21         | 18,6                            |                         |
|                           | IIIC                  | Neoadjuvant               | Anti PD-1              | 0    | 0    | 0    | 1    | 0                    | 0,2                               | Anti PD-1                         | 0      | 0      | 0      | 1          | 0                         | 0,2                             | Pembrolizumab              | 0      | 0       | 0      | 1          | 0                               | 0,2                     |
|                           |                       |                           | BRAF in MEK inhibitors | 0    | 0    | 0    | 1    | 0                    | 0,2                               | BRAF inhibitors<br>MEK inhibitors | 0      | 0      | 0      | 1          | 0                         | 0,2                             | Dabrafenib<br>Trametinib   | 0<br>0 | 0<br>0  | 0<br>1 | 0<br>0     | 0<br>2,6                        | 2,6                     |
|                           |                       | Adjuvant                  | Anti PD-1              | 11   | 19   | 13   | 29   | 15                   | 17,4                              | Anti PD-1                         | 11     | 19     | 13     | 29         | 15                        | 17,4                            | Nivolumab<br>Pembrolizumab | 9<br>2 | 13<br>6 | 4<br>9 | 5<br>24    | 0<br>15                         | 6,2<br>11,2             |
|                           |                       |                           | BRAF in MEK inhibitors | 2    | 9    | 6    | 8    | 1                    | 5,2                               | BRAF inhibitors<br>MEK inhibitors | 2<br>2 | 9<br>9 | 6<br>6 | 8<br>1     | 5,2<br>5,2                | Dabrafenib<br>Trametinib        | 2<br>2                     | 9<br>9 | 6<br>6  | 8<br>1 | 1<br>5,2   | 5,2                             |                         |
|                           |                       | First line                | Anti PD-1              | 8    | 5    | 6    | 3    | 4                    | 5,2                               | Anti PD-1                         | 8      | 5      | 6      | 3          | 4                         | 5,2                             | Nivolumab<br>Pembrolizumab | 1<br>7 | 1<br>4  | 2<br>4 | 0<br>3     | 0<br>4                          | 0,8<br>4,4              |
|                           |                       |                           | BRAF in MEK inhibitors | 3    | 3    | 3    | 2    | 1                    | 2,4                               | BRAF inhibitors                   | 3      | 3      | 3      | 2          | 1                         | 2,4                             | Dabrafenib                 | 3      | 3       | 3      | 2          | 1                               | 2,4                     |
|                           |                       |                           |                        |      |      |      |      |                      |                                   | MEK inhibitors                    | 3      | 3      | 3      | 2          | 1                         | 2,4                             | Trametinib                 | 3      | 3       | 3      | 2          | 1                               | 2,4                     |
|                           |                       |                           |                        |      |      |      |      |                      |                                   | Combination immunotherapy         | 1      | 1      | 1      | 1          | 1                         | 1,0                             | Anti CTLA-4<br>Anti PD-1   | 1<br>1 | 1<br>1  | 1<br>1 | 1<br>1     | 1,0<br>1,0                      | Ipilimumab<br>Nivolumab |
|                           |                       | Monochemotherapy          | 0                      | 2    | 2    | 0    | 0    | 0,8                  | Alkylating agents                 | 0                                 | 2      | 2      | 0      | 0          | 0,8                       | Dakarbazine<br>Temozolomide     | 0<br>0                     | 1<br>1 | 2<br>0  | 0<br>0 | 0<br>0     | 0,6<br>0,2                      |                         |
|                           |                       | Second line               | Anti PD-1              | 0    | 1    | 0    | 1    | 0                    | 0,4                               | Anti PD-1                         | 0      | 1      | 0      | 1          | 0                         | 0,4                             | Nivolumab<br>Pembrolizumab | 0<br>0 | 0<br>1  | 0<br>0 | 1<br>0     | 0<br>0                          | 0,2<br>0,2              |
|                           |                       |                           | BRAF in MEK inhibitors | 1    | 2    | 2    | 1    | 1                    | 1,4                               | BRAF inhibitors                   | 1      | 2      | 2      | 1          | 1                         | 1,4                             | Dabrafenib<br>Vemurafenib  | 1<br>0 | 1<br>1  | 2<br>0 | 1<br>0     | 1<br>0                          | 1,2<br>0,2              |
|                           |                       |                           |                        |      |      |      |      |                      |                                   | MEK inhibitors                    | 1      | 2      | 2      | 1          | 1                         | 1,4                             | Cobimetinib<br>Trametinib  | 0<br>1 | 1<br>1  | 0<br>2 | 0<br>1     | 0<br>1                          | 0,2<br>1,2              |
| Combination immunotherapy |                       |                           | 2                      | 2    | 1    | 1    | 1    | 1,4                  | Anti CTLA-4<br>Anti PD-1          | 2<br>2                            | 2<br>2 | 1<br>1 | 1<br>1 | 1,4<br>1,4 | Ipilimumab<br>Nivolumab   | 2<br>2                          | 2<br>2                     | 1<br>1 | 1<br>1  | 1<br>1 | 1,4<br>1,4 |                                 |                         |
| Combination chemotherapy  |                       |                           | 0                      | 0    | 1    | 0    | 0    | 0,2                  | Platinum analogues<br>Taxanes     | 0<br>0                            | 0<br>0 | 1<br>1 | 0<br>0 | 0,2<br>0,2 | Carboplatin<br>Paclitaxel | 0<br>0                          | 0<br>0                     | 1<br>1 | 0<br>0  | 0<br>0 | 0,2<br>0,2 |                                 |                         |
| Monochemotherapy          |                       |                           | 3                      | 3    | 0    | 0    | 0    | 1,2                  | Alkylating agents                 | 3                                 | 3      | 0      | 0      | 0          | 1,2                       | Dakarbazine                     | 3                          | 3      | 0       | 0      | 0          | 1,2                             |                         |

Continued. —&gt;

Table 21c: Continued.

| Stage | Place in therapy          | Regimen                   | Year      |      |      |      |      | Therapeutic subgroup | Year                            |           |      |      |      | Drug | Year        |                                 |                            |      |      |      |      |                                 |
|-------|---------------------------|---------------------------|-----------|------|------|------|------|----------------------|---------------------------------|-----------|------|------|------|------|-------------|---------------------------------|----------------------------|------|------|------|------|---------------------------------|
|       |                           |                           | 2018      | 2019 | 2020 | 2021 | 2022 |                      | Mean of yearly values 2018–2022 | 2018      | 2019 | 2020 | 2021 |      | 2022        | Mean of yearly values 2018–2022 | 2018                       | 2019 | 2020 | 2021 | 2022 | Mean of yearly values 2018–2022 |
| IIIC  | Subsequent lines (3+)     | Anti PD-1                 | 0         | 1    | 0    | 1    | 0    | 0,4                  | Anti PD-1                       | 0         | 1    | 0    | 1    | 0    | 0,4         | Pembrolizumab                   | 0                          | 1    | 0    | 1    | 0    | 0,4                             |
|       |                           | BRAF in MEK inhibitors    | 0         | 1    | 0    | 2    | 0    | 0,6                  | BRAF inhibitors                 | 0         | 1    | 0    | 2    | 0    | 0,6         | Dabrafenib<br>Vemurafenib       | 0                          | 1    | 0    | 1    | 0    | 0,4<br>0,2                      |
|       |                           |                           |           |      |      |      |      |                      | MEK inhibitors                  | 0         | 1    | 0    | 2    | 0    | 0,6         | Cobimetinib<br>Trametinib       | 0                          | 0    | 0    | 1    | 0    | 0,2<br>0,4                      |
|       |                           | Combination immunotherapy | 0         | 2    | 0    | 0    | 1    | 0,6                  | Anti CTLA-4                     | 0         | 2    | 0    | 0    | 1    | 0,6         | Ipilimumab                      | 0                          | 2    | 0    | 0    | 1    | 0,6                             |
|       |                           |                           |           |      |      |      |      |                      | Anti PD-1                       | 0         | 2    | 0    | 0    | 1    | 0,6         | Nivolumab                       | 0                          | 2    | 0    | 0    | 1    | 0,6                             |
|       |                           | Combination chemotherapy  | 0         | 2    | 0    | 0    | 0    | 0,4                  | Platinum analogues              | 0         | 2    | 0    | 0    | 0    | 0,4         | Carboplatin                     | 0                          | 2    | 0    | 0    | 0    | 0,4                             |
|       |                           |                           |           |      |      |      |      |                      | Taxanes                         | 0         | 2    | 0    | 0    | 0    | 0,4         | Paclitaxel                      | 0                          | 2    | 0    | 0    | 0    | 0,4                             |
|       | Monochemotherapy          | 0                         | 2         | 1    | 0    | 0    | 0,6  | Alkylating agents    | 0                               | 2         | 1    | 0    | 0    | 0,6  | Dakarbazine | 0                               | 2                          | 1    | 0    | 0    | 0,6  |                                 |
| All   | All                       | 31                        | 55        | 36   | 51   | 25   | 39,6 | All                  | 40                              | 77        | 50   | 67   | 31   | 53,0 | All         | 40                              | 77                         | 50   | 67   | 31   | 53,0 |                                 |
| IIID  | Neoadjuvant               | /                         | /         | /    | /    | /    | /    | /                    | /                               | /         | /    | /    | /    | /    | /           | /                               | /                          | /    | /    | /    | /    |                                 |
|       | Adjuvant                  | Anti PD-1                 | 1         | 1    | 3    | 1    | 1    | 1,4                  | Anti PD-1                       | 1         | 1    | 3    | 1    | 1    | 1,4         | Nivolumab<br>Pembrolizumab      | 1                          | 1    | 1    | 1    | 0    | 0,8<br>0,6                      |
|       |                           | BRAF in MEK inhibitors    | 0         | 2    | 1    | 4    | 1    | 1,6                  | BRAF inhibitors                 | 0         | 2    | 1    | 4    | 1    | 1,6         | Dabrafenib                      | 0                          | 2    | 1    | 4    | 1    | 1,6                             |
|       |                           |                           |           |      |      |      |      |                      | MEK inhibitors                  | 0         | 2    | 1    | 4    | 1    | 1,6         | Trametinib                      | 0                          | 2    | 1    | 4    | 1    | 1,6                             |
|       | First line                | Anti PD-1                 | 0         | 1    | 0    | 1    | 0    | 0,4                  | Anti PD-1                       | 0         | 1    | 0    | 1    | 0    | 0,4         | Pembrolizumab                   | 0                          | 1    | 0    | 1    | 0    | 0,4                             |
|       |                           | BRAF in MEK inhibitors    | 1         | 0    | 0    | 2    | 0    | 0,6                  | BRAF inhibitors                 | 1         | 0    | 0    | 2    | 0    | 0,6         | Dabrafenib                      | 1                          | 0    | 0    | 2    | 0    | 0,6                             |
|       |                           |                           |           |      |      |      |      |                      | MEK inhibitors                  | 1         | 0    | 0    | 2    | 0    | 0,6         | Trametinib                      | 1                          | 0    | 0    | 2    | 0    | 0,6                             |
|       |                           | Combination immunotherapy | 0         | 2    | 1    | 0    | 0    | 0,6                  | Anti CTLA-4                     | 0         | 2    | 1    | 0    | 0    | 0,6         | Ipilimumab                      | 0                          | 2    | 1    | 0    | 0    | 0,6                             |
|       |                           |                           |           |      |      |      |      |                      | Anti PD-1                       | 0         | 2    | 1    | 0    | 0    | 0,6         | Nivolumab                       | 0                          | 2    | 1    | 0    | 0    | 0,6                             |
|       | Second line               | Anti PD-1                 | 0         | 0    | 0    | 1    | 0    | 0,2                  | Anti PD-1                       | 0         | 0    | 0    | 1    | 0    | 0,2         | Pembrolizumab                   | 0                          | 0    | 0    | 1    | 0    | 0,2                             |
|       |                           | BRAF in MEK inhibitors    | 0         | 1    | 0    | 0    | 0    | 0,2                  | BRAF inhibitors                 | 0         | 1    | 0    | 0    | 0    | 0,2         | Dabrafenib                      | 0                          | 1    | 0    | 0    | 0    | 0,2                             |
|       |                           |                           |           |      |      |      |      |                      | MEK inhibitors                  | 0         | 1    | 0    | 0    | 0    | 0,2         | Trametinib                      | 0                          | 1    | 0    | 0    | 0    | 0,2                             |
|       |                           | Monochemotherapy          | 0         | 0    | 0    | 1    | 0    | 0,2                  | Alkylating agents               | 0         | 0    | 0    | 1    | 0    | 0,2         | Dakarbazine                     | 0                          | 0    | 0    | 1    | 0    | 0,2                             |
|       | Subsequent lines (3+)     | /                         | /         | /    | /    | /    | /    | /                    | /                               | /         | /    | /    | /    | /    | /           | /                               | /                          | /    | /    | /    | /    |                                 |
|       | All                       | All                       | 2         | 7    | 5    | 10   | 2    | 5,2                  | All                             | 3         | 12   | 7    | 16   | 3    | 8,2         | All                             | 3                          | 12   | 7    | 16   | 3    | 8,2                             |
| IV    | Neoadjuvant               | /                         | /         | /    | /    | /    | /    | /                    | /                               | /         | /    | /    | /    | /    | /           | /                               | /                          | /    | /    | /    | /    |                                 |
|       | Adjuvant                  | Anti PD-1                 | 0         | 0    | 0    | 0    | 1    | 0,2                  | Anti PD-1                       | 0         | 0    | 0    | 0    | 1    | 0,2         | Nivolumab                       | 0                          | 0    | 0    | 0    | 1    | 0,2                             |
|       | First line                | Anti PD-1                 | 9         | 2    | 3    | 10   | 10   | 6,8                  | Anti PD-1                       | 9         | 2    | 3    | 10   | 10   | 6,8         | Nivolumab<br>Pembrolizumab      | 1                          | 0    | 0    | 0    | 0    | 0,2<br>6,6                      |
|       |                           | BRAF in MEK inhibitors    | 7         | 8    | 2    | 2    | 1    | 4,0                  | BRAF inhibitors                 | 7         | 8    | 2    | 2    | 1    | 4,0         | Dabrafenib<br>Vemurafenib       | 7                          | 6    | 1    | 2    | 1    | 3,4<br>0,6                      |
|       |                           |                           |           |      |      |      |      |                      | MEK inhibitors                  | 7         | 8    | 2    | 2    | 1    | 4,0         | Cobimetinib<br>Trametinib       | 0                          | 2    | 1    | 0    | 0    | 0,6<br>3,4                      |
|       |                           |                           |           |      |      |      |      |                      | Combination immunotherapy       | 0         | 0    | 1    | 2    | 1    | 0,8         | Anti CTLA-4                     | 0                          | 0    | 1    | 2    | 1    | 0,8                             |
|       |                           | Combination chemotherapy  | 1         | 0    | 0    | 0    | 0    | 0,2                  | Anti PD-1                       | 0         | 0    | 1    | 2    | 1    | 0,8         | Nivolumab                       | 0                          | 0    | 1    | 2    | 1    | 0,8                             |
|       |                           |                           |           |      |      |      |      |                      | Platinum analogues              | 1         | 0    | 0    | 0    | 0    | 0,2         | Carboplatin                     | 1                          | 0    | 0    | 0    | 0    | 0,2                             |
|       |                           | Taxanes                   | 1         | 0    | 0    | 0    | 0    | 0,2                  | Paclitaxel                      | 1         | 0    | 0    | 0    | 0    | 0,2         |                                 |                            |      |      |      |      |                                 |
|       |                           | Second line               | Anti PD-1 | 3    | 1    | 0    | 0    | 0                    | 0,8                             | Anti PD-1 | 3    | 1    | 0    | 0    | 0           | 0,8                             | Nivolumab<br>Pembrolizumab | 0    | 1    | 0    | 0    | 0                               |
|       | BRAF in MEK inhibitors    |                           | 0         | 0    | 1    | 1    | 2    | 0,8                  | BRAF inhibitors                 | 0         | 0    | 1    | 1    | 2    | 0,8         | Dabrafenib                      | 0                          | 0    | 1    | 1    | 2    | 0,8                             |
|       |                           |                           |           |      |      |      |      |                      | MEK inhibitors                  | 0         | 0    | 1    | 1    | 2    | 0,8         | Trametinib                      | 0                          | 0    | 1    | 1    | 2    | 0,8                             |
|       | Combination immunotherapy |                           | 2         | 2    | 0    | 1    | 0    | 1,0                  | Anti CTLA-4                     | 2         | 2    | 0    | 1    | 0    | 1,0         | Ipilimumab                      | 2                          | 2    | 0    | 1    | 0    | 1,0                             |
|       |                           |                           |           |      |      |      |      |                      | Anti PD-1                       | 2         | 2    | 0    | 1    | 0    | 1,0         | Nivolumab                       | 2                          | 2    | 0    | 1    | 0    | 1,0                             |
|       | Combination chemotherapy  |                           | 2         | 0    | 0    | 0    | 0    | 0,4                  | Platinum analogues              | 2         | 0    | 0    | 0    | 0    | 0,4         | Carboplatin                     | 2                          | 0    | 0    | 0    | 0    | 0,4                             |
|       |                           |                           |           |      |      |      |      |                      | Taxanes                         | 2         | 0    | 0    | 0    | 0    | 0,4         | Paclitaxel                      | 2                          | 0    | 0    | 0    | 0    | 0,4                             |
|       | Monochemotherapy          | 3                         | 1         | 1    | 2    | 1    | 1,6  | Alkylating agents    | 3                               | 1         | 1    | 2    | 1    | 1,6  | Dakarbazine | 3                               | 1                          | 1    | 2    | 1    | 1,6  |                                 |

Continued. —&gt;

Table 21c: Continued.

| Stage  | Place in therapy          | Regimen                   | Year                   |      |      |      |      | Therapeutic subgroup | Year                              |                 |        |        |        | Drug       | Year                     |                                 |            |        |        |        |            |                                 |     |
|--------|---------------------------|---------------------------|------------------------|------|------|------|------|----------------------|-----------------------------------|-----------------|--------|--------|--------|------------|--------------------------|---------------------------------|------------|--------|--------|--------|------------|---------------------------------|-----|
|        |                           |                           | 2018                   | 2019 | 2020 | 2021 | 2022 |                      | Mean of yearly values 2018–2022   | 2018            | 2019   | 2020   | 2021   |            | 2022                     | Mean of yearly values 2018–2022 | 2018       | 2019   | 2020   | 2021   | 2022       | Mean of yearly values 2018–2022 |     |
| IV     | Subsequent lines (3+)     | Anti PD-1                 | 3                      | 0    | 0    | 1    | 1    | 1,0                  | Anti PD-1                         | 3               | 0      | 0      | 1      | 1          | 1,0                      | Nivolumab<br>Pembrolizumab      | 1<br>2     | 0<br>0 | 0<br>0 | 1<br>0 | 1<br>0     | 0,6<br>0,4                      |     |
|        |                           | BRAF in MEK inhibitors    | 2                      | 2    | 0    | 0    | 0    | 0,8                  | BRAF inhibitors                   | 2               | 2      | 0      | 0      | 0          | 0,8                      | Dabrafenib<br>Vemurafenib       | 1<br>1     | 1<br>1 | 0<br>0 | 0<br>0 | 0<br>0     | 0,4<br>0,4                      |     |
|        |                           |                           |                        |      |      |      |      |                      | MEK inhibitors                    | 2               | 2      | 0      | 0      | 0          | 0,8                      | Cobimetinib<br>Trametinib       | 1<br>1     | 1<br>1 | 0<br>0 | 0<br>0 | 0<br>0     | 0,4<br>0,4                      |     |
|        |                           | Combination immunotherapy | 1                      | 0    | 0    | 1    | 1    | 0,6                  | Anti CTLA-4                       | 1               | 0      | 0      | 1      | 1          | 0,6                      | Ipilimumab                      | 1          | 0      | 0      | 1      | 1          | 0,6                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Anti PD-1                         | 1               | 0      | 0      | 1      | 1          | 0,6                      | Nivolumab                       | 1          | 0      | 0      | 1      | 1          | 0,6                             |     |
|        |                           | Combination chemotherapy  | 4                      | 1    | 0    | 0    | 0    | 1,0                  | Nitrosourea analogues             | 1               | 0      | 0      | 0      | 0          | 0,2                      | Lomustin                        | 1          | 0      | 0      | 0      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Platinum analogues                | 4               | 1      | 0      | 0      | 0          | 1,0                      | Cisplatin<br>Carboplatin        | 1<br>3     | 0<br>1 | 0<br>0 | 0<br>0 | 0<br>0     | 0,2<br>0,8                      |     |
|        |                           |                           |                        |      |      |      |      |                      | Taxanes                           | 3               | 1      | 0      | 0      | 0          | 0,8                      | Paclitaxel                      | 3          | 1      | 0      | 0      | 0          | 0,8                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Vinca alkaloids                   | 1               | 0      | 0      | 0      | 0          | 0,2                      | Vinblastine                     | 1          | 0      | 0      | 0      | 0          | 0,2                             |     |
|        |                           | Monochemotherapy          | 1                      | 0    | 1    | 0    | 0    | 0,4                  | Alkylating agents                 | 1               | 0      | 1      | 0      | 0          | 0,4                      | Dakarbazine<br>Temozolomide     | 1<br>1     | 0<br>0 | 1<br>0 | 0<br>0 | 0<br>0     | 0,4<br>0,2                      |     |
| All    | All                       | 38                        | 17                     | 9    | 20   | 18   | 20,4 | All                  | 58                                | 30              | 13     | 27     | 23     | 30,2       | All                      | 58                              | 30         | 13     | 27     | 23     | 30,2       |                                 |     |
| Neznan | Neoadjuvant               | /                         | /                      | /    | /    | /    | /    | /                    | /                                 | /               | /      | /      | /      | /          | /                        | /                               | /          | /      | /      | /      | /          |                                 |     |
|        | Adjuvant                  | Anti PD-1                 | 0                      | 1    | 5    | 3    | 0    | 1,8                  | Anti PD-1                         | 0               | 1      | 5      | 3      | 0          | 1,8                      | Nivolumab<br>Pembrolizumab      | 0<br>0     | 0<br>1 | 4<br>1 | 1<br>2 | 0<br>0     | 1,0<br>0,8                      |     |
|        |                           | BRAF in MEK inhibitors    | 0                      | 0    | 1    | 1    | 1    | 0,6                  | BRAF inhibitors<br>MEK inhibitors | 0<br>0          | 0<br>0 | 1<br>1 | 1<br>1 | 0,6<br>0,6 | Dabrafenib<br>Trametinib | 0<br>0                          | 0<br>0     | 1<br>1 | 1<br>1 | 1<br>1 | 0,6<br>0,6 |                                 |     |
|        | First line                | Anti PD-1                 | 4                      | 2    | 2    | 4    | 3    | 3,0                  | Anti PD-1                         | 4               | 2      | 2      | 4      | 3          | 3,0                      | Pembrolizumab                   | 4          | 2      | 2      | 4      | 3          | 3,0                             |     |
|        |                           | BRAF in MEK inhibitors    | 0                      | 1    | 1    | 4    | 0    | 1,2                  | BRAF inhibitors                   | 0               | 1      | 1      | 4      | 0          | 1,2                      | Dabrafenib                      | 0          | 1      | 1      | 4      | 0          | 1,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | MEK inhibitors                    | 0               | 1      | 1      | 4      | 0          | 1,2                      | Trametinib                      | 0          | 1      | 1      | 4      | 0          | 1,2                             |     |
|        |                           | Druga kombinacija terapij | 0                      | 0    | 0    | 1    | 0    | 0,2                  | Anti CTLA-4                       | 0               | 0      | 0      | 1      | 0          | 0,2                      | Ipilimumab                      | 0          | 0      | 0      | 1      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Anti PD-1                         | 0               | 0      | 0      | 1      | 0          | 0,2                      | Nivolumab                       | 0          | 0      | 0      | 1      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | BRAF inhibitors                   | 0               | 0      | 0      | 1      | 0          | 0,2                      | Dabrafenib                      | 0          | 0      | 0      | 1      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | MEK inhibitors                    | 0               | 0      | 0      | 1      | 0          | 0,2                      | Trametinib                      | 0          | 0      | 0      | 1      | 0          | 0,2                             |     |
|        |                           | Combination immunotherapy | 0                      | 2    | 2    | 2    | 2    | 1,6                  | Anti CTLA-4                       | 0               | 2      | 2      | 2      | 2          | 1,6                      | Ipilimumab                      | 0          | 2      | 2      | 2      | 2          | 1,6                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Anti PD-1                         | 0               | 2      | 2      | 2      | 2          | 1,6                      | Nivolumab                       | 0          | 2      | 2      | 2      | 2          | 1,6                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Platinum analogues                | 0               | 1      | 0      | 0      | 0          | 0,2                      | Carboplatin                     | 0          | 1      | 0      | 0      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Taxanes                           | 0               | 1      | 0      | 0      | 0          | 0,2                      | Paclitaxel                      | 0          | 1      | 0      | 0      | 0          | 0,2                             |     |
|        |                           | Monochemotherapy          | 0                      | 2    | 0    | 0    | 0    | 0,4                  | Alkylating agents                 | 0               | 2      | 0      | 0      | 0          | 0,4                      | Dakarbazine                     | 0          | 2      | 0      | 0      | 0          | 0,4                             |     |
|        |                           | Second line               | Anti PD-1              | 0    | 1    | 0    | 0    | 0                    | 0,2                               | Anti PD-1       | 0      | 1      | 0      | 0          | 0                        | 0,2                             | Nivolumab  | 0      | 1      | 0      | 0          | 0                               | 0,2 |
|        |                           |                           | BRAF in MEK inhibitors | 1    | 0    | 1    | 2    | 0                    | 0,8                               | BRAF inhibitors | 1      | 0      | 1      | 2          | 0                        | 0,8                             | Dabrafenib | 1      | 0      | 1      | 2          | 0                               | 0,8 |
|        | MEK inhibitors            |                           |                        |      |      |      |      |                      |                                   | 1               | 0      | 1      | 2      | 0          | 0,8                      | Trametinib                      | 1          | 0      | 1      | 2      | 0          | 0,8                             |     |
|        | Combination immunotherapy |                           | 0                      | 1    | 2    | 3    | 0    | 1,2                  | Anti CTLA-4                       | 0               | 1      | 2      | 3      | 0          | 1,2                      | Ipilimumab                      | 0          | 1      | 2      | 3      | 0          | 1,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Anti PD-1                         | 0               | 1      | 2      | 3      | 0          | 1,2                      | Nivolumab                       | 0          | 1      | 2      | 3      | 0          | 1,2                             |     |
|        | Combination chemotherapy  |                           | 1                      | 0    | 0    | 0    | 0    | 0,2                  | Platinum analogues                | 1               | 0      | 0      | 0      | 0          | 0,2                      | Carboplatin                     | 1          | 0      | 0      | 0      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Taxanes                           | 1               | 0      | 0      | 0      | 0          | 0,2                      | Paclitaxel                      | 1          | 0      | 0      | 0      | 0          | 0,2                             |     |
|        | Monochemotherapy          |                           | 0                      | 1    | 1    | 1    | 1    | 0,8                  | Alkylating agents                 | 0               | 1      | 1      | 1      | 1          | 0,8                      | Dakarbazine                     | 0          | 1      | 1      | 1      | 1          | 0,8                             |     |
|        | Subsequent lines (3+)     | BRAF in MEK inhibitors    | 0                      | 0    | 0    | 1    | 0    | 0,2                  | BRAF inhibitors                   | 0               | 0      | 0      | 1      | 0          | 0,2                      | Dabrafenib                      | 0          | 0      | 0      | 1      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | MEK inhibitors                    | 0               | 0      | 0      | 1      | 0          | 0,2                      | Trametinib                      | 0          | 0      | 0      | 1      | 0          | 0,2                             |     |
|        |                           | Combination immunotherapy | 0                      | 0    | 0    | 1    | 0    | 0,2                  | Anti CTLA-4                       | 0               | 0      | 0      | 1      | 0          | 0,2                      | Ipilimumab                      | 0          | 0      | 0      | 1      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Anti PD-1                         | 0               | 0      | 0      | 1      | 0          | 0,2                      | Nivolumab                       | 0          | 0      | 0      | 1      | 0          | 0,2                             |     |
|        |                           | Combination chemotherapy  | 1                      | 1    | 1    | 1    | 0    | 0,8                  | Nitrosourea analogues             | 1               | 0      | 0      | 0      | 0          | 0,2                      | Lomustin                        | 1          | 0      | 0      | 0      | 0          | 0,2                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Platinum analogues                | 1               | 1      | 1      | 1      | 0          | 0,8                      | Cisplatin<br>Carboplatin        | 1<br>0     | 0<br>1 | 0<br>1 | 0<br>1 | 0<br>0     | 0,2<br>0,6                      |     |
|        |                           |                           |                        |      |      |      |      |                      | Taxanes                           | 0               | 1      | 1      | 1      | 0          | 0,6                      | Paclitaxel                      | 0          | 1      | 1      | 1      | 0          | 0,6                             |     |
|        |                           |                           |                        |      |      |      |      |                      | Vinca alkaloids                   | 1               | 0      | 0      | 0      | 0          | 0,2                      | Vinblastine                     | 1          | 0      | 0      | 0      | 0          | 0,2                             |     |
|        | All                       | All                       | 7                      | 13   | 16   | 24   | 7    | 13,4                 | All                               | 9               | 17     | 22     | 40     | 10         | 19,6                     | All                             | 9          | 17     | 22     | 40     | 10         | 19,6                            |     |

Table 21d: Number of systemic treatments by treatment type, medication group and administered medication by BRAF status in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Year | Place in therapy | Regimen                   | BRAF status |           |         | Therapeutic subgroup  | BRAF status |           |         | Drug          | BRAF status |           |         |
|------|------------------|---------------------------|-------------|-----------|---------|-----------------------|-------------|-----------|---------|---------------|-------------|-----------|---------|
|      |                  |                           | Pozitiven   | Negativen | Neznano |                       | Pozitiven   | Negativen | Neznano |               | Pozitiven   | Negativen | Neznano |
| 2018 | Neoadjuvant      | /                         | /           | /         | /       | /                     | /           | /         | /       | /             | /           | /         | /       |
|      | Adjuvant         | Anti PD-1                 | 7           | 11        | 7       | Anti PD-1             | 7           | 11        | 7       | Nivolumab     | 3           | 7         | 6       |
|      |                  | BRAF in MEK inhibitors    | 5           | 0         | 0       | BRAF inhibitors       | 5           | 0         | 0       | Pembrolizumab | 4           | 4         | 1       |
|      |                  |                           |             |           |         | MEK inhibitors        | 5           | 0         | 0       | Dabrafenib    | 5           | 0         | 0       |
|      | First line       | Anti PD-1                 | 7           | 22        | 3       | Anti PD-1             | 7           | 22        | 3       | Trametinib    | 5           | 0         | 0       |
|      |                  | BRAF in MEK inhibitors    | 21          | 0         | 0       | Nivolumab             | 21          | 0         | 0       | Nivolumab     | 2           | 1         | 0       |
|      |                  |                           |             |           |         | Pembrolizumab         |             |           |         | Pembrolizumab | 5           | 21        | 3       |
|      |                  |                           |             |           |         | Dabrafenib            |             |           |         | Dabrafenib    | 20          | 0         | 0       |
|      |                  | Combination immunotherapy | 0           | 1         | 1       | Vemurafenib           | 21          | 0         | 0       | Vemurafenib   | 1           | 0         | 0       |
|      |                  |                           |             |           |         | MEK inhibitors        |             |           |         | Cobimetinib   | 1           | 0         | 0       |
|      |                  | Combination chemotherapy  | 1           | 0         | 0       | Trametinib            | 21          | 0         | 0       | Trametinib    | 20          | 0         | 0       |
|      |                  |                           |             |           |         | Anti CTLA-4           |             |           |         | Ipilimumab    | 0           | 1         | 1       |
|      |                  | Monochemotherapy          | 1           | 0         | 1       | Anti PD-1             | 0           | 1         | 1       | Nivolumab     | 0           | 1         | 1       |
|      |                  |                           |             |           |         | Platinum analogues    |             |           |         | Carboplatin   | 1           | 0         | 0       |
|      | Second line      | Anti PD-1                 | 5           | 0         | 0       | Taxanes               | 1           | 0         | 0       | Paclitaxel    | 1           | 0         | 0       |
|      |                  | BRAF in MEK inhibitors    | 4           | 0         | 0       | Alkylating agents     | 1           | 0         | 1       | Dakarbazinee  | 1           | 0         | 1       |
|      |                  |                           |             |           |         | Anti PD-1             | 5           | 0         | 0       | Pembrolizumab | 5           | 0         | 0       |
|      |                  |                           |             |           |         | BRAF inhibitors       | 4           | 0         | 0       | Dabrafenib    | 4           | 0         | 0       |
|      |                  | Combination immunotherapy | 5           | 2         | 0       | MEK inhibitors        | 4           | 0         | 0       | Trametinib    | 4           | 0         | 0       |
|      |                  |                           |             |           |         | Anti CTLA-4           | 5           | 2         | 0       | Ipilimumab    | 5           | 2         | 0       |
|      |                  | Combination chemotherapy  | 2           | 1         | 0       | Anti PD-1             | 5           | 2         | 0       | Nivolumab     | 5           | 2         | 0       |
|      |                  |                           |             |           |         | Platinum analogues    | 2           | 1         | 0       | Carboplatin   | 2           | 1         | 0       |
|      |                  | Monochemotherapy          | 2           | 7         | 0       | Taxanes               | 2           | 1         | 0       | Paclitaxel    | 2           | 1         | 0       |
|      |                  |                           |             |           |         | Alkylating agents     | 2           | 7         | 0       | Dakarbazinee  | 1           | 7         | 0       |
|      | Subsequent lines | Anti PD-1                 | 3           | 1         | 0       | Alkylating agents     | 2           | 7         | 0       | Temozolomidee | 1           | 0         | 0       |
|      |                  | BRAF in MEK inhibitors    | 4           | 0         | 0       | Anti PD-1             | 3           | 1         | 0       | Nivolumab     | 1           | 0         | 0       |
|      |                  |                           |             |           |         | BRAF inhibitors       | 4           | 0         | 0       | Pembrolizumab | 2           | 1         | 0       |
|      |                  |                           |             |           |         | MEK inhibitors        | 4           | 0         | 0       | Dabrafenib    | 1           | 0         | 0       |
|      |                  | Combination immunotherapy | 0           | 1         | 0       | Vemurafenib           | 4           | 0         | 0       | Vemurafenib   | 3           | 0         | 0       |
|      |                  |                           |             |           |         | Cobimetinib           |             |           |         | Cobimetinib   | 3           | 0         | 0       |
|      |                  | Combination chemotherapy  | 0           | 6         | 0       | Trametinib            | 4           | 0         | 0       | Trametinib    | 1           | 0         | 0       |
|      |                  |                           |             |           |         | Anti CTLA-4           |             |           |         | Ipilimumab    | 0           | 1         | 0       |
|      |                  |                           |             |           |         | Anti PD-1             |             |           |         | Nivolumab     | 0           | 1         | 0       |
|      |                  |                           |             |           |         | Nitrosourea analogues |             |           |         | Lomustine     | 0           | 2         | 0       |
|      |                  |                           |             |           |         | Platinum analogues    |             |           |         | Cisplatin     | 0           | 2         | 0       |
|      | All              | All                       | 68          | 52        | 12      | Taxanes               | 0           | 4         | 0       | Carboplatin   | 0           | 4         | 0       |
|      |                  |                           |             |           |         | Vinca alkaloids       |             |           |         | Paclitaxel    | 0           | 4         | 0       |
|      |                  |                           |             |           |         | Alkylating agents     |             |           |         | Vinblastinee  | 0           | 2         | 0       |
|      |                  |                           |             |           |         | Alkylating agents     |             |           |         | Dakarbazinee  | 1           | 0         | 0       |
| 2019 | Neoadjuvant      | Combination immunotherapy | 1           | 0         | 0       | Alkylating agents     | 1           | 0         | 0       | Temozolomidee | 1           | 0         | 0       |
|      | Adjuvant         | Anti PD-1                 | 10          | 25        | 3       | Anti CTLA-4           | 1           | 0         | 0       | Ipilimumab    | 1           | 0         | 0       |
|      |                  | BRAF in MEK inhibitors    | 25          | 0         | 0       | Anti PD-1             | 1           | 0         | 0       | Nivolumab     | 1           | 0         | 0       |
|      |                  |                           |             |           |         | BRAF inhibitors       | 25          | 0         | 0       | Pembrolizumab | 5           | 15        | 2       |
|      | First line       | Anti PD-1                 | 5           | 11        | 4       | MEK inhibitors        | 25          | 0         | 0       | Dabrafenib    | 25          | 0         | 0       |
|      |                  |                           |             |           |         | Trametinib            | 25          | 0         | 0       | Trametinib    | 25          | 0         | 0       |
|      |                  | BRAF in MEK inhibitors    | 19          | 0         | 0       | Nivolumab             | 19          | 0         | 0       | Nivolumab     | 1           | 2         | 0       |
|      |                  |                           |             |           |         | Pembrolizumab         |             |           |         | Pembrolizumab | 4           | 10        | 4       |
|      |                  |                           |             |           |         | Dabrafenib            |             |           |         | Dabrafenib    | 16          | 0         | 0       |
|      |                  | Combination immunotherapy | 5           | 3         | 0       | Vemurafenib           | 19          | 0         | 0       | Vemurafenib   | 3           | 0         | 0       |
|      |                  |                           |             |           |         | MEK inhibitors        |             |           |         | Cobimetinib   | 3           | 0         | 0       |
|      |                  | Combination chemotherapy  | 0           | 1         | 0       | Trametinib            | 19          | 0         | 0       | Trametinib    | 16          | 0         | 0       |
|      |                  |                           |             |           |         | Anti CTLA-4           |             |           |         | Ipilimumab    | 5           | 3         | 0       |
|      | All              | All                       | 68          | 52        | 12      | Anti PD-1             | 0           | 1         | 0       | Nivolumab     | 5           | 3         | 0       |
|      |                  |                           |             |           |         | Platinum analogues    |             |           |         | Carboplatin   | 0           | 1         | 0       |
|      |                  |                           |             |           |         | Taxanes               |             |           |         | Paclitaxel    | 0           | 1         | 0       |
|      |                  |                           |             |           |         | Alkylating agents     |             |           |         | Dakarbazinee  | 0           | 4         | 0       |

Continued. —>

Table 21d: Continued.

| Year | Place in therapy | Regimen                        | BRAF status |           |         | Therapeutic subgroup            | BRAF status |           |         | Drug                       | BRAF status |           |         |
|------|------------------|--------------------------------|-------------|-----------|---------|---------------------------------|-------------|-----------|---------|----------------------------|-------------|-----------|---------|
|      |                  |                                | Positiven   | Negativen | Neznano |                                 | Positiven   | Negativen | Neznano |                            | Positiven   | Negativen | Neznano |
| 2019 | Second line      | Anti PD-1                      | 5           | 2         | 0       | Anti PD-1                       | 5           | 2         | 0       | Nivolumab<br>Pembrolizumab | 3<br>2      | 2<br>0    | 0<br>0  |
|      |                  | BRAF in MEK inhibitors         | 6           | 0         | 0       | BRAF inhibitors                 | 6           | 0         | 0       | Dabrafenib<br>Vemurafenib  | 5<br>2      | 0<br>0    | 0<br>0  |
|      |                  |                                |             |           |         | MEK inhibitors                  | 6           | 0         | 0       | Cobimetinib<br>Trametinib  | 2<br>5      | 0<br>0    | 0<br>0  |
|      |                  | Combination immunotherapy      | 7           | 0         | 0       | Anti CTLA-4<br>Anti PD-1        | 7<br>7      | 0<br>0    | 0       | Ipilimumab<br>Nivolumab    | 7<br>7      | 0<br>0    | 0<br>0  |
|      |                  | Monochemotherapy               | 1           | 7         | 0       | Alkylating agents               | 1           | 7         | 0       | Dakarbazinee               | 1           | 7         | 0       |
|      | Subsequent lines | Anti PD-1                      | 0           | 1         | 0       | Anti PD-1                       | 0           | 1         | 0       | Pembrolizumab              | 0           | 1         | 0       |
|      |                  | BRAF in MEK inhibitors         | 3           | 0         | 0       | BRAF inhibitors                 | 3           | 0         | 0       | Dabrafenib<br>Vemurafenib  | 2<br>1      | 0<br>0    | 0<br>0  |
|      |                  |                                |             |           |         | MEK inhibitors                  | 3           | 0         | 0       | Cobimetinib<br>Trametinib  | 1<br>2      | 0<br>0    | 0<br>0  |
|      |                  | BRAF inhibitors                | 1           | 0         | 0       | BRAF inhibitors                 | 1           | 0         | 0       | Dabrafenib                 | 1           | 0         | 0       |
|      |                  | Other combination of therapies | 0           | 1         | 0       | Anti PD-1                       | 0           | 1         | 0       | Pembrolizumab              | 0           | 1         | 0       |
|      |                  |                                |             |           |         | Other protein kinase inhibitors | 0           | 1         | 0       | Lenvatinib                 | 0           | 1         | 0       |
|      |                  | Combination immunotherapy      | 1           | 1         | 0       | Anti CTLA-4                     | 1           | 1         | 0       | Ipilimumab                 | 1           | 1         | 0       |
|      |                  |                                |             |           |         | Anti PD-1                       | 1           | 1         | 0       | Nivolumab                  | 1           | 1         | 0       |
|      |                  | Combination chemotherapy       | 3           | 2         | 0       | Platinum analogues              | 3           | 2         | 0       | Carboplatin                | 3           | 2         | 0       |
|      |                  |                                |             |           |         | Taxanes                         | 3           | 2         | 0       | Paclitaxel                 | 3           | 2         | 0       |
|      |                  | Monochemotherapy               | 3           | 0         | 0       | Alkylating agents               | 3           | 0         | 0       | Dakarbazinee               | 3           | 0         | 0       |
|      | All              | All                            | 95          | 59        | 7       | All                             | 165         | 67        | 7       | All                        | 167         | 68        | 7       |
| 2020 | Neoadjuvant      | /                              | /           | /         | /       | /                               | /           | /         | /       | /                          | /           | /         | /       |
|      | Adjuvant         | Anti PD-1                      | 6           | 23        | 5       | Anti PD-1                       | 6           | 23        | 5       | Nivolumab<br>Pembrolizumab | 0<br>6      | 9<br>14   | 2<br>3  |
|      |                  | BRAF in MEK inhibitors         | 9           | 0         | 0       | BRAF inhibitors                 | 9           | 0         | 0       | Dabrafenib                 | 9           | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors                  | 9           | 0         | 0       | Trametinib                 | 9           | 0         | 0       |
|      | First line       | Anti PD-1                      | 8           | 8         | 2       | Anti PD-1                       | 8           | 8         | 2       | Nivolumab<br>Pembrolizumab | 1<br>7      | 0<br>8    | 1<br>1  |
|      |                  | BRAF in MEK inhibitors         | 7           | 1         | 0       | BRAF inhibitors                 | 7           | 1         | 0       | Dabrafenib<br>Vemurafenib  | 6<br>1      | 0<br>1    | 0<br>0  |
|      |                  |                                |             |           |         | MEK inhibitors                  | 7           | 1         | 0       | Cobimetinib<br>Trametinib  | 1<br>6      | 1<br>0    | 0<br>0  |
|      |                  | Combination immunotherapy      | 3           | 3         | 0       | Anti CTLA-4                     | 3           | 3         | 0       | Ipilimumab                 | 3           | 3         | 0       |
|      |                  |                                |             |           |         | Anti PD-1                       | 3           | 3         | 0       | Nivolumab                  | 3           | 3         | 0       |
|      |                  | Monochemotherapy               | 0           | 5         | 0       | Alkylating agents               | 0           | 5         | 0       | Dakarbazinee               | 0           | 5         | 0       |
|      | Second line      | Anti PD-1                      | 0           | 1         | 0       | Anti PD-1                       | 0           | 1         | 0       | Pembrolizumab              | 0           | 1         | 0       |
|      |                  | BRAF in MEK inhibitors         | 4           | 0         | 0       | BRAF inhibitors                 | 4           | 0         | 0       | Dabrafenib                 | 4           | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors                  | 4           | 0         | 0       | Trametinib                 | 4           | 0         | 0       |
|      |                  | Combination immunotherapy      | 3           | 1         | 0       | Anti CTLA-4                     | 3           | 1         | 0       | Ipilimumab                 | 3           | 1         | 0       |
|      |                  |                                |             |           |         | Anti PD-1                       | 3           | 1         | 0       | Nivolumab                  | 3           | 1         | 0       |
|      |                  | Combination chemotherapy       | 0           | 2         | 0       | Platinum analogues              | 0           | 2         | 0       | Carboplatin                | 0           | 2         | 0       |
|      |                  |                                |             |           |         | Taxanes                         | 0           | 2         | 0       | Paclitaxel                 | 0           | 2         | 0       |
|      |                  | Monochemotherapy               | 0           | 3         | 0       | Alkylating agents               | 0           | 3         | 0       | Dakarbazinee               | 0           | 3         | 0       |
|      |                  | Combination chemotherapy       | 0           | 1         | 0       | Platinum analogues              | 0           | 1         | 0       | Carboplatin                | 0           | 1         | 0       |
|      |                  |                                |             |           |         | Taxanes                         | 0           | 1         | 0       | Paclitaxel                 | 0           | 1         | 0       |
|      |                  | Monochemotherapy               | 2           | 0         | 0       | Alkylating agents               | 2           | 0         | 0       | Dakarbazinee               | 2           | 0         | 0       |
|      | All              | All                            | 42          | 48        | 7       | All                             | 68          | 56        | 7       | All                        | 68          | 56        | 7       |
| 2021 | Neoadjuvant      | Anti PD-1                      | 1           | 1         | 0       | Anti PD-1                       | 1           | 1         | 0       | Pembrolizumab              | 1           | 1         | 0       |
|      |                  | BRAF in MEK inhibitors         | 2           | 0         | 0       | BRAF inhibitors                 | 2           | 0         | 0       | Dabrafenib                 | 2           | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors                  | 2           | 0         | 0       | Trametinib                 | 2           | 0         | 0       |
|      |                  | Other combination of therapies | 1           | 0         | 0       | Anti PD-1                       | 1           | 0         | 0       | Pembrolizumab              | 1           | 0         | 0       |
|      |                  |                                |             |           |         | BRAF inhibitors                 | 1           | 0         | 0       | Dabrafenib                 | 1           | 0         | 0       |

Continued. —&gt;

Table 21d: Continued.

| Year | Place in therapy | Regimen                        | BRAF status |           |         | Therapeutic subgroup | BRAF status |           |         | Drug                       | BRAF status |           |         |
|------|------------------|--------------------------------|-------------|-----------|---------|----------------------|-------------|-----------|---------|----------------------------|-------------|-----------|---------|
|      |                  |                                | Pozitiven   | Negativen | Neznano |                      | Pozitiven   | Negativen | Neznano |                            | Pozitiven   | Negativen | Neznano |
| 2021 | Adjuvant         | Anti PD-1                      | 28          | 16        | 3       | Anti PD-1            | 28          | 16        | 3       | Nivolumab<br>Pembrolizumab | 4<br>24     | 3<br>13   | 2<br>1  |
|      |                  | BRAF in MEK inhibitors         | 15          | 0         | 0       | BRAF inhibitors      | 15          | 0         | 0       | Dabrafenib                 | 15          | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors       | 15          | 0         | 0       | Trametinib                 | 15          | 0         | 0       |
|      | First line       | Anti PD-1                      | 11          | 12        | 1       | Anti PD-1            | 11          | 12        | 1       | Nivolumab<br>Pembrolizumab | 1<br>10     | 0<br>12   | 0<br>1  |
|      |                  | BRAF in MEK inhibitors         | 10          | 0         | 0       | BRAF inhibitors      | 10          | 0         | 0       | Dabrafenib                 | 10          | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors       | 10          | 0         | 0       | Trametinib                 | 10          | 0         | 0       |
|      |                  | Other combination of therapies | 1           | 0         | 0       | Anti CTLA-4          | 1           | 0         | 0       | Ipilimumab                 | 1           | 0         | 0       |
|      |                  |                                |             |           |         | Anti PD-1            | 1           | 0         | 0       | Nivolumab                  | 1           | 0         | 0       |
|      |                  |                                |             |           |         | BRAF inhibitors      | 1           | 0         | 0       | Dabrafenib                 | 1           | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors       | 1           | 0         | 0       | Trametinib                 | 1           | 0         | 0       |
|      |                  | Combination immunotherapy      | 5           | 0         | 0       | Anti CTLA-4          | 5           | 0         | 0       | Ipilimumab                 | 5           | 0         | 0       |
|      |                  |                                |             |           |         | Anti PD-1            | 5           | 0         | 0       | Nivolumab                  | 5           | 0         | 0       |
|      | Second line      | Anti PD-1                      | 2           | 0         | 0       | Anti PD-1            | 2           | 0         | 0       | Nivolumab<br>Pembrolizumab | 1<br>1      | 0<br>0    | 0<br>0  |
|      |                  | BRAF in MEK inhibitors         | 5           | 0         | 0       | BRAF inhibitors      | 5           | 0         | 0       | Dabrafenib                 | 5           | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors       | 5           | 0         | 0       | Trametinib                 | 5           | 0         | 0       |
|      |                  | Combination immunotherapy      | 4           | 1         | 0       | Anti CTLA-4          | 4           | 1         | 0       | Ipilimumab                 | 4           | 1         | 0       |
|      |                  |                                |             |           |         | Anti PD-1            | 4           | 1         | 0       | Nivolumab                  | 4           | 1         | 0       |
|      |                  | Monochemotherapy               | 1           | 3         | 0       | Alkylating agents    | 1           | 3         | 0       | Dakarbazine                | 1           | 3         | 0       |
|      | Subsequent lines | Anti PD-1                      | 1           | 1         | 0       | Anti PD-1            | 1           | 1         | 0       | Nivolumab<br>Pembrolizumab | 0<br>1      | 1<br>0    | 0<br>0  |
|      |                  | BRAF in MEK inhibitors         | 3           | 0         | 0       | BRAF inhibitors      | 3           | 0         | 0       | Dabrafenib<br>Vemurafenib  | 2<br>1      | 0<br>0    | 0<br>0  |
|      |                  |                                |             |           |         | MEK inhibitors       | 3           | 0         | 0       | Cobimetinib<br>Trametinib  | 1<br>2      | 0<br>0    | 0<br>0  |
|      |                  | Combination immunotherapy      | 1           | 1         | 0       | Anti CTLA-4          | 1           | 1         | 0       | Ipilimumab                 | 1           | 1         | 0       |
|      |                  |                                |             |           |         | Anti PD-1            | 1           | 1         | 0       | Nivolumab                  | 1           | 1         | 0       |
|      |                  | Combination chemotherapy       | 0           | 1         | 0       | Platinum analogues   | 0           | 1         | 0       | Carboplatin                | 0           | 1         | 0       |
|      |                  |                                |             |           |         | Taxanes              | 0           | 1         | 0       | Paclitaxel                 | 0           | 1         | 0       |
|      | All              | All                            | 91          | 36        | 4       | All                  | 141         | 39        | 4       | All                        | 141         | 39        | 4       |
| 2022 | Neoadjuvant      | Anti PD-1                      | 0           | 0         | 2       | Anti PD-1            | 0           | 0         | 2       | Pembrolizumab              | 0           | 0         | 2       |
|      | Adjuvant         | Anti PD-1                      | 19          | 23        | 6       | Anti PD-1            | 19          | 23        | 6       | Nivolumab<br>Pembrolizumab | 0<br>19     | 2<br>21   | 0<br>9  |
|      |                  | BRAF in MEK inhibitors         | 7           | 0         | 0       | BRAF inhibitors      | 7           | 0         | 0       | Dabrafenib                 | 7           | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors       | 7           | 0         | 0       | Trametinib                 | 7           | 0         | 0       |
|      | First line       | Anti PD-1                      | 9           | 11        | 1       | Anti PD-1            | 9           | 11        | 1       | Nivolumab<br>Pembrolizumab | 0<br>9      | 1<br>10   | 0<br>1  |
|      |                  | BRAF in MEK inhibitors         | 4           | 0         | 0       | BRAF inhibitors      | 4           | 0         | 0       | Dabrafenib<br>Vemurafenib  | 4<br>1      | 0<br>0    | 0<br>0  |
|      |                  |                                |             |           |         | MEK inhibitors       | 4           | 0         | 0       | Cobimetinib<br>Trametinib  | 1<br>4      | 0<br>0    | 0<br>0  |
|      |                  | Combination immunotherapy      | 3           | 2         | 0       | Anti CTLA-4          | 3           | 2         | 0       | Ipilimumab                 | 3           | 2         | 0       |
|      |                  |                                |             |           |         | Anti PD-1            | 3           | 2         | 0       | Nivolumab                  | 3           | 2         | 0       |
|      |                  | Anti PD-1                      | 1           | 0         | 0       | Anti PD-1            | 1           | 0         | 0       | Nivolumab                  | 1           | 0         | 0       |
|      | Second line      | BRAF in MEK inhibitors         | 3           | 0         | 0       | BRAF inhibitors      | 3           | 0         | 0       | Dabrafenib                 | 3           | 0         | 0       |
|      |                  |                                |             |           |         | MEK inhibitors       | 3           | 0         | 0       | Trametinib                 | 3           | 0         | 0       |
|      |                  | Combination immunotherapy      | 1           | 0         | 0       | Anti CTLA-4          | 1           | 0         | 0       | Ipilimumab                 | 1           | 0         | 0       |
|      |                  |                                |             |           |         | Anti PD-1            | 1           | 0         | 0       | Nivolumab                  | 1           | 0         | 0       |
|      |                  | Monochemotherapy               | 0           | 2         | 0       | Alkylating agents    | 0           | 2         | 0       | Dakarbazine                | 0           | 2         | 0       |
|      | Subsequent lines | Anti PD-1                      | 0           | 1         | 0       | Anti PD-1            | 0           | 1         | 0       | Nivolumab                  | 0           | 1         | 0       |
|      |                  | Combination immunotherapy      | 2           | 0         | 0       | Anti CTLA-4          | 2           | 0         | 0       | Ipilimumab                 | 2           | 0         | 0       |
|      |                  |                                |             |           |         | Anti PD-1            | 2           | 0         | 0       | Nivolumab                  | 2           | 0         | 0       |
|      | All              | All                            | 49          | 39        | 9       | All                  | 69          | 41        | 9       | All                        | 71          | 41        | 12      |

Continued. —&gt;

Table 21d: Continued.

| Year                            | Place in therapy | Regimen                        | BRAF status |           |         | Therapeutic subgroup            | BRAF status |           |         | Drug          | BRAF status |           |         |
|---------------------------------|------------------|--------------------------------|-------------|-----------|---------|---------------------------------|-------------|-----------|---------|---------------|-------------|-----------|---------|
|                                 |                  |                                | Positiven   | Negativen | Neznano |                                 | Positiven   | Negativen | Neznano |               | Positiven   | Negativen | Neznano |
| Mean of yearly values 2018–2022 | Neoadjuvant      | Anti PD-1                      | 0,5         | 0,5       | 1,0     | Anti PD-1                       | 0,5         | 0,5       | 1,0     | Pembrolizumab | 0,5         | 0,5       | 1,0     |
|                                 |                  | BRAF in MEK inhibitors         | 2,0         | 0,0       | 0,0     | BRAF inhibitors                 | 2,0         | 0,0       | 0,0     | Dabrafenib    | 2,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | MEK inhibitors                  | 2,0         | 0,0       | 0,0     | Trametinib    | 2,0         | 0,0       | 0,0     |
|                                 |                  | Other combination of therapies | 1,0         | 0,0       | 0,0     | Anti PD-1                       | 1,0         | 0,0       | 0,0     | Pembrolizumab | 1,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | BRAF inhibitors                 | 1,0         | 0,0       | 0,0     | Dabrafenib    | 1,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | MEK inhibitors                  | 1,0         | 0,0       | 0,0     | Trametinib    | 1,0         | 0,0       | 0,0     |
|                                 |                  | Combination immunotherapy      | 1,0         | 0,0       | 0,0     | Anti CTLA-4                     | 1,0         | 0,0       | 0,0     | Ipilimumab    | 1,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | Anti PD-1                       | 1,0         | 0,0       | 0,0     | Nivolumab     | 1,0         | 0,0       | 0,0     |
|                                 | Adjuvant         | Anti PD-1                      | 14,0        | 19,6      | 4,8     | Anti PD-1                       | 14,0        | 19,6      | 4,8     | Nivolumab     | 2,4         | 7,2       | 2,4     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Pembrolizumab | 11,6        | 12,4      | 3,0     |
|                                 |                  | BRAF in MEK inhibitors         | 12,2        | 0,0       | 0,0     | BRAF inhibitors                 | 12,2        | 0,0       | 0,0     | Dabrafenib    | 12,2        | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | MEK inhibitors                  | 12,2        | 0,0       | 0,0     | Trametinib    | 12,2        | 0,0       | 0,0     |
|                                 | First line       | Anti PD-1                      | 8,0         | 12,8      | 2,2     | Anti PD-1                       | 8,0         | 12,8      | 2,2     | Nivolumab     | 1,0         | 0,8       | 0,2     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Pembrolizumab | 7,0         | 12,2      | 2,0     |
|                                 |                  | BRAF in MEK inhibitors         | 12,2        | 0,2       | 0,0     | BRAF inhibitors                 | 12,2        | 0,2       | 0,0     | Dabrafenib    | 11,2        | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Vemurafenib   | 1,5         | 0,3       | 0,0     |
|                                 |                  |                                |             |           |         | MEK inhibitors                  | 12,2        | 0,2       | 0,0     | Cobimetinib   | 1,5         | 0,3       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Trametinib    | 11,2        | 0,0       | 0,0     |
|                                 |                  | Other combination of therapies | 1,0         | 0,0       | 0,0     | Anti CTLA-4                     | 1,0         | 0,0       | 0,0     | Ipilimumab    | 1,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | Anti PD-1                       | 1,0         | 0,0       | 0,0     | Nivolumab     | 1,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | BRAF inhibitors                 | 1,0         | 0,0       | 0,0     | Dabrafenib    | 1,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | MEK inhibitors                  | 1,0         | 0,0       | 0,0     | Trametinib    | 1,0         | 0,0       | 0,0     |
|                                 |                  | Combination immunotherapy      | 3,2         | 1,8       | 0,2     | Anti CTLA-4                     | 3,2         | 1,8       | 0,2     | Ipilimumab    | 3,2         | 1,8       | 0,2     |
|                                 |                  |                                |             |           |         | Anti PD-1                       | 3,2         | 1,8       | 0,2     | Nivolumab     | 3,2         | 1,8       | 0,2     |
|                                 |                  | Combination chemotherapy       | 0,5         | 0,5       | 0,0     | Platinum analogues              | 0,5         | 0,5       | 0,0     | Carboplatin   | 0,5         | 0,5       | 0,0     |
|                                 |                  |                                |             |           |         | Taxanes                         | 0,5         | 0,5       | 0,0     | Paclitaxel    | 0,5         | 0,5       | 0,0     |
|                                 |                  | Monochemotherapy               | 0,3         | 3,3       | 0,3     | Alkylating agents               | 0,3         | 3,3       | 0,3     | Dakarbazinee  | 0,3         | 3,0       | 0,3     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Temozolomidee | 0,0         | 1,0       | 0,0     |
|                                 | Second line      | Anti PD-1                      | 2,6         | 0,6       | 0,0     | Anti PD-1                       | 2,6         | 0,6       | 0,0     | Nivolumab     | 1,7         | 0,7       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Pembrolizumab | 2,0         | 0,3       | 0,0     |
|                                 |                  | BRAF in MEK inhibitors         | 4,4         | 0,0       | 0,0     | BRAF inhibitors                 | 4,4         | 0,0       | 0,0     | Dabrafenib    | 4,2         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Vemurafenib   | 2,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | MEK inhibitors                  | 4,4         | 0,0       | 0,0     | Cobimetinib   | 2,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Trametinib    | 4,2         | 0,0       | 0,0     |
|                                 |                  | Combination immunotherapy      | 4,0         | 0,8       | 0,0     | Anti CTLA-4                     | 4,0         | 0,8       | 0,0     | Ipilimumab    | 4,0         | 0,8       | 0,0     |
|                                 |                  |                                |             |           |         | Anti PD-1                       | 4,0         | 0,8       | 0,0     | Nivolumab     | 4,0         | 0,8       | 0,0     |
|                                 |                  | Combination chemotherapy       | 1,0         | 1,5       | 0,0     | Platinum analogues              | 1,0         | 1,5       | 0,0     | Carboplatin   | 1,0         | 1,5       | 0,0     |
|                                 |                  |                                |             |           |         | Taxanes                         | 1,0         | 1,5       | 0,0     | Paclitaxel    | 1,0         | 1,5       | 0,0     |
|                                 |                  | Monochemotherapy               | 0,8         | 4,4       | 0,0     | Alkylating agents               | 0,8         | 4,4       | 0,0     | Dakarbazinee  | 0,6         | 4,4       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Temozolomidee | 1,0         | 0,0       | 0,0     |
|                                 | Subsequent lines | Anti PD-1                      | 1,0         | 1,0       | 0,0     | Anti PD-1                       | 1,0         | 1,0       | 0,0     | Nivolumab     | 0,3         | 0,7       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Pembrolizumab | 1,0         | 0,7       | 0,0     |
|                                 |                  | BRAF in MEK inhibitors         | 3,3         | 0,0       | 0,0     | BRAF inhibitors                 | 3,3         | 0,0       | 0,0     | Dabrafenib    | 1,7         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Vemurafenib   | 1,7         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         | MEK inhibitors                  | 3,3         | 0,0       | 0,0     | Cobimetinib   | 1,7         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Trametinib    | 1,7         | 0,0       | 0,0     |
|                                 |                  | BRAF inhibitors                | 1,0         | 0,0       | 0,0     | BRAF inhibitors                 | 1,0         | 0,0       | 0,0     | Dabrafenib    | 1,0         | 0,0       | 0,0     |
|                                 |                  | Other combination of therapies | 0,0         | 1,0       | 0,0     | Anti PD-1                       | 0,0         | 1,0       | 0,0     | Pembrolizumab | 0,0         | 1,0       | 0,0     |
|                                 |                  |                                |             |           |         | Other protein kinase inhibitors | 0,0         | 1,0       | 0,0     | Lenvatinib    | 0,0         | 1,0       | 0,0     |
|                                 |                  | Combination immunotherapy      | 1,0         | 0,8       | 0,0     | Anti CTLA-4                     | 1,0         | 0,8       | 0,0     | Ipilimumab    | 1,0         | 0,8       | 0,0     |
|                                 |                  |                                |             |           |         | Anti PD-1                       | 1,0         | 0,8       | 0,0     | Nivolumab     | 1,0         | 0,8       | 0,0     |
|                                 |                  | Combination chemotherapy       | 0,8         | 2,5       | 0,0     | Nitrosourea analogues           | 0,0         | 2,0       | 0,0     | Lomustine     | 0,0         | 2,0       | 0,0     |
|                                 |                  |                                |             |           |         | Platinum analogues              | 0,8         | 2,5       | 0,0     | Cisplatin     | 0,8         | 2,0       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Carboplatin   | 0,8         | 2,0       | 0,0     |
|                                 |                  |                                |             |           |         | Taxanes                         | 6,7         | 2,0       | 2,0     | Paclitaxel    | 0,3         | 2,0       | 0,0     |
|                                 |                  |                                |             |           |         | Vinca alkaloids                 | 0,0         | 2,0       | 0,0     | Vinblastinee  | 0,0         | 2,0       | 0,0     |
|                                 |                  | Monochemotherapy               | 2,0         | 0,0       | 0,0     | Alkylating agents               | 2,0         | 0,0       | 0,0     | Dakarbazinee  | 2,0         | 0,0       | 0,0     |
|                                 |                  |                                |             |           |         |                                 |             |           |         | Temozolomidee | 1,0         | 0,0       | 0,0     |
| All                             | All              | All                            | 77,8        | 51,3      | 8,5     | All                             | 134,3       | 63,8      | 10,7    | All           | 136,5       | 67,0      | 9,3     |



Table 21e: Number of systemic treatments by treatment type, medication group and administered medication by age in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Year | Place in therapy | Regimen                   | Age group |       |       |     | Therapeutic subgroup  | Age group |       |       |     | Drug          | Age group |       |       |     |
|------|------------------|---------------------------|-----------|-------|-------|-----|-----------------------|-----------|-------|-------|-----|---------------|-----------|-------|-------|-----|
|      |                  |                           | 0–19      | 20–49 | 50–74 | 75+ |                       | 0–19      | 20–49 | 50–74 | 75+ |               | 0–19      | 20–49 | 50–74 | 75+ |
| 2018 | Neoadjuvant      | /                         | /         | /     | /     | /   | /                     | /         | /     | /     | /   | /             | /         | /     | /     | /   |
|      | Adjuvant         | Anti PD-1                 | 0         | 7     | 18    | 0   | Anti PD-1             | 0         | 7     | 18    | 0   | Nivolumab     | 0         | 2     | 14    | 0   |
|      |                  |                           |           |       |       |     |                       |           |       |       |     | Pembrolizumab | 0         | 5     | 4     | 0   |
|      |                  | BRAF in MEK inhibitors    | 0         | 2     | 3     | 0   | BRAF inhibitors       | 0         | 2     | 3     | 0   | Dabrafenib    | 0         | 2     | 3     | 0   |
|      | First line       |                           |           |       |       |     | MEK inhibitors        | 0         | 2     | 3     | 0   | Trametinib    | 0         | 2     | 3     | 0   |
|      |                  | Anti PD-1                 | 0         | 3     | 21    | 8   | Anti PD-1             | 0         | 3     | 21    | 8   | Nivolumab     | 0         | 0     | 2     | 1   |
|      |                  |                           |           |       |       |     |                       |           |       |       |     | Pembrolizumab | 0         | 3     | 19    | 7   |
|      |                  | BRAF in MEK inhibitors    | 0         | 9     | 12    | 0   | BRAF inhibitors       | 0         | 9     | 12    | 0   | Dabrafenib    | 0         | 8     | 12    | 0   |
|      |                  |                           |           |       |       |     | Vemurafenib           | 0         | 1     | 0     | 0   |               | 0         | 1     | 0     | 0   |
|      |                  |                           |           |       |       |     | MEK inhibitors        | 0         | 9     | 12    | 0   | Cobimetinib   | 0         | 1     | 0     | 0   |
|      |                  |                           |           |       |       |     | Trametinib            | 0         | 8     | 12    | 0   |               | 0         | 8     | 12    | 0   |
|      |                  | Combination immunotherapy | 0         | 1     | 1     | 0   | Anti CTLA-4           | 0         | 1     | 1     | 0   | Ipilimumab    | 0         | 1     | 1     | 0   |
|      |                  |                           |           |       |       |     | Anti PD-1             | 0         | 1     | 1     | 0   | Nivolumab     | 0         | 1     | 1     | 0   |
|      |                  | Combination chemotherapy  | 0         | 1     | 0     | 0   | Platinum analogues    | 0         | 1     | 0     | 0   | Carboplatin   | 0         | 1     | 0     | 0   |
|      | Second line      |                           |           |       |       |     | Taxanes               | 0         | 1     | 0     | 0   | Paclitaxel    | 0         | 1     | 0     | 0   |
|      |                  | Monochemotherapy          | 0         | 0     | 1     | 1   | Alkylating agents     | 0         | 0     | 1     | 1   | Dakarbazinee  | 0         | 0     | 1     | 1   |
|      |                  | Anti PD-1                 | 0         | 0     | 5     | 0   | Anti PD-1             | 0         | 0     | 5     | 0   | Pembrolizumab | 0         | 0     | 5     | 0   |
|      |                  | BRAF in MEK inhibitors    | 0         | 2     | 1     | 1   | BRAF inhibitors       | 0         | 2     | 1     | 1   | Dabrafenib    | 0         | 2     | 1     | 1   |
|      |                  |                           |           |       |       |     | MEK inhibitors        | 0         | 2     | 1     | 1   | Trametinib    | 0         | 2     | 1     | 1   |
|      |                  |                           |           |       |       |     | Anti CTLA-4           | 0         | 4     | 3     | 0   | Ipilimumab    | 0         | 4     | 3     | 0   |
|      |                  | Combination immunotherapy | 0         | 4     | 3     | 0   | Anti PD-1             | 0         | 4     | 3     | 0   | Nivolumab     | 0         | 4     | 3     | 0   |
|      |                  | Combination chemotherapy  | 0         | 2     | 1     | 0   | Platinum analogues    | 0         | 2     | 1     | 0   | Carboplatin   | 0         | 2     | 1     | 0   |
|      |                  |                           |           |       |       |     | Taxanes               | 0         | 2     | 1     | 0   | Paclitaxel    | 0         | 2     | 1     | 0   |
|      |                  | Monochemotherapy          | 0         | 3     | 6     | 0   | Alkylating agents     | 0         | 3     | 6     | 0   | Dakarbazinee  | 0         | 2     | 6     | 0   |
|      | Subsequent lines |                           |           |       |       |     | Temozolomidee         | 0         | 1     | 0     | 0   |               | 0         | 1     | 0     | 0   |
|      |                  | Anti PD-1                 | 0         | 2     | 2     | 0   | Anti PD-1             | 0         | 2     | 2     | 0   | Nivolumab     | 0         | 0     | 1     | 0   |
|      |                  |                           |           |       |       |     |                       |           |       |       |     | Pembrolizumab | 0         | 2     | 1     | 0   |
|      |                  | BRAF in MEK inhibitors    | 0         | 1     | 3     | 0   | Dabrafenib            | 0         | 1     | 3     | 0   | Dabrafenib    | 0         | 0     | 1     | 0   |
|      |                  |                           |           |       |       |     | Vemurafenib           | 0         | 1     | 3     | 0   |               | 0         | 1     | 2     | 0   |
|      |                  |                           |           |       |       |     | MEK inhibitors        | 0         | 1     | 3     | 0   | Cobimetinib   | 0         | 1     | 2     | 0   |
|      |                  |                           |           |       |       |     | Trametinib            | 0         | 0     | 1     | 0   |               | 0         | 0     | 1     | 0   |
|      |                  | Combination immunotherapy | 0         | 0     | 1     | 0   | Anti CTLA-4           | 0         | 0     | 1     | 0   | Ipilimumab    | 0         | 0     | 1     | 0   |
|      |                  |                           |           |       |       |     | Anti PD-1             | 0         | 0     | 1     | 0   | Nivolumab     | 0         | 0     | 1     | 0   |
|      |                  | Combination chemotherapy  | 0         | 2     | 4     | 0   | Nitrosourea analogues | 0         | 1     | 1     | 0   | Lomustine     | 0         | 1     | 1     | 0   |
|      |                  |                           |           |       |       |     | Platinum analogues    | 0         | 2     | 4     | 0   | Cisplatin     | 0         | 1     | 1     | 0   |
|      |                  |                           |           |       |       |     | Taxanes               | 0         | 1     | 3     | 0   | Carboplatin   | 0         | 1     | 3     | 0   |
|      |                  |                           |           |       |       |     | Vinca alcaloids       | 0         | 1     | 1     | 0   | Paclitaxel    | 0         | 1     | 3     | 0   |
|      |                  |                           |           |       |       |     | Alkylating agents     | 0         | 1     | 0     | 0   | Vinblastinee  | 0         | 1     | 1     | 0   |
|      |                  | Monochemotherapy          | 0         | 1     | 0     | 0   |                       |           |       |       |     | Dakarbazinee  | 0         | 1     | 0     | 0   |
|      |                  |                           |           |       |       |     |                       |           |       |       |     | Temozolomidee | 0         | 1     | 0     | 0   |
|      | All              | All                       | 0         | 40    | 82    | 10  | All                   | 0         | 65    | 112   | 11  | All           | 0         | 66    | 112   | 11  |
| 2019 | Neoadjuvant      | Combination immunotherapy | 0         | 0     | 1     | 0   | Anti CTLA-4           | 0         | 0     | 1     | 0   | Ipilimumab    | 0         | 0     | 1     | 0   |
|      |                  |                           |           |       |       |     | Anti PD-1             | 0         | 0     | 1     | 0   | Nivolumab     | 0         | 0     | 1     | 0   |
|      | Adjuvant         | Anti PD-1                 | 0         | 12    | 25    | 1   | Anti PD-1             | 0         | 12    | 25    | 1   | Nivolumab     | 0         | 7     | 14    | 1   |
|      |                  |                           |           |       |       |     |                       |           |       |       |     | Pembrolizumab | 0         | 5     | 11    | 0   |
|      |                  | BRAF in MEK inhibitors    | 0         | 12    | 13    | 0   | BRAF inhibitors       | 0         | 12    | 13    | 0   | Dabrafenib    | 0         | 12    | 13    | 0   |
|      | First line       |                           |           |       |       |     | MEK inhibitors        | 0         | 12    | 13    | 0   | Trametinib    | 0         | 12    | 13    | 0   |
|      |                  | Anti PD-1                 | 0         | 2     | 12    | 6   | Anti PD-1             | 0         | 2     | 12    | 6   | Nivolumab     | 0         | 0     | 3     | 0   |
|      |                  |                           |           |       |       |     |                       |           |       |       |     | Pembrolizumab | 0         | 2     | 10    | 6   |
|      |                  | BRAF in MEK inhibitors    | 0         | 4     | 12    | 3   | Dabrafenib            | 0         | 4     | 12    | 3   | Dabrafenib    | 0         | 3     | 11    | 2   |
|      |                  |                           |           |       |       |     | Vemurafenib           | 0         | 1     | 1     | 1   |               | 0         | 1     | 1     | 1   |
|      |                  |                           |           |       |       |     | MEK inhibitors        | 0         | 4     | 12    | 3   | Cobimetinib   | 0         | 1     | 1     | 1   |
|      |                  |                           |           |       |       |     | Trametinib            | 0         | 3     | 11    | 2   |               | 0         | 3     | 11    | 2   |
|      |                  | Combination immunotherapy | 0         | 4     | 4     | 0   | Anti CTLA-4           | 0         | 4     | 4     | 0   | Ipilimumab    | 0         | 4     | 4     | 0   |
|      |                  |                           |           |       |       |     | Anti PD-1             | 0         | 4     | 4     | 0   | Nivolumab     | 0         | 4     | 4     | 0   |
|      |                  | Combination chemotherapy  | 0         | 1     | 0     | 0   | Platinum analogues    | 0         | 1     | 0     | 0   | Carboplatin   | 0         | 1     | 0     | 0   |
|      |                  |                           |           |       |       |     | Taxanes               | 0         | 1     | 0     | 0   | Paclitaxel    | 0         | 1     | 0     | 0   |
|      |                  | Monochemotherapy          | 0         | 0     | 5     | 0   | Alkylating agents     | 0         | 0     | 5     | 0   | Dakarbazinee  | 0         | 0     | 4     | 0   |
|      |                  |                           |           |       |       |     |                       |           |       |       |     | Temozolomidee | 0         | 0     | 1     | 0   |

Continued. —>

Table 21e: Continued.

| Year | Place in therapy | Regimen                        | Age group |       |       |     | Therapeutic subgroup            | Age group |       |       |     | Drug          | Age group |       |       |     |
|------|------------------|--------------------------------|-----------|-------|-------|-----|---------------------------------|-----------|-------|-------|-----|---------------|-----------|-------|-------|-----|
|      |                  |                                | 0–19      | 20–49 | 50–74 | 75+ |                                 | 0–19      | 20–49 | 50–74 | 75+ |               | 0–19      | 20–49 | 50–74 | 75+ |
| 2019 | Second line      | Anti PD-1                      | 0         | 3     | 4     | 0   | Anti PD-1                       | 0         | 3     | 4     | 0   | Nivolumab     | 0         | 2     | 3     | 0   |
|      |                  |                                |           |       |       |     |                                 |           |       |       |     | Pembrolizumab | 0         | 1     | 1     | 0   |
|      |                  | BRAF in MEK inhibitors         | 0         | 3     | 3     | 0   | BRAF inhibitors                 | 0         | 3     | 3     | 0   | Dabrafenib    | 0         | 3     | 2     | 0   |
|      |                  |                                |           |       |       |     | Vemurafenib                     | 0         | 0     | 2     | 0   |               |           |       |       |     |
|      |                  |                                |           |       |       |     | MEK inhibitors                  | 0         | 3     | 3     | 0   | Cobimetinib   | 0         | 0     | 2     | 0   |
|      | Subsequent lines | Combination immunotherapy      | 0         | 1     | 5     | 1   | Anti CTLA-4                     | 0         | 1     | 5     | 1   | Ipilimumab    | 0         | 1     | 5     | 1   |
|      |                  | Monochemotherapy               | 0         | 4     | 4     | 0   | Anti PD-1                       | 0         | 1     | 5     | 1   | Nivolumab     | 0         | 1     | 5     | 1   |
|      |                  |                                |           |       |       |     | Alkylating agents               | 0         | 4     | 4     | 0   | Dakarbazinee  | 0         | 4     | 4     | 0   |
|      |                  | Anti PD-1                      | 0         | 1     | 0     | 0   | Anti PD-1                       | 0         | 1     | 0     | 0   | Pembrolizumab | 0         | 1     | 0     | 0   |
|      |                  | BRAF in MEK inhibitors         | 0         | 0     | 3     | 0   | BRAF inhibitors                 | 0         | 0     | 3     | 0   | Dabrafenib    | 0         | 0     | 2     | 0   |
|      |                  |                                |           |       |       |     | Vemurafenib                     | 0         | 0     | 1     | 0   |               |           |       |       |     |
|      |                  |                                |           |       |       |     | MEK inhibitors                  | 0         | 0     | 3     | 0   | Cobimetinib   | 0         | 0     | 1     | 0   |
|      |                  | BRAF inhibitors                | 0         | 1     | 0     | 0   | BRAF inhibitors                 | 0         | 1     | 0     | 0   | Dabrafenib    | 0         | 1     | 0     | 0   |
|      |                  | Other combination of therapies | 0         | 1     | 0     | 0   | Anti PD-1                       | 0         | 1     | 0     | 0   | Pembrolizumab | 0         | 1     | 0     | 0   |
|      |                  |                                |           |       |       |     | Other protein kinase inhibitors | 0         | 1     | 0     | 0   | Lenvatinib    | 0         | 1     | 0     | 0   |
|      |                  | Combination immunotherapy      | 0         | 2     | 0     | 0   | Anti CTLA-4                     | 0         | 2     | 0     | 0   | Ipilimumab    | 0         | 2     | 0     | 0   |
|      |                  | Combination chemotherapy       | 0         | 4     | 1     | 0   | Anti PD-1                       | 0         | 2     | 0     | 0   | Nivolumab     | 0         | 2     | 0     | 0   |
|      |                  |                                |           |       |       |     | Platinum analogues              | 0         | 4     | 1     | 0   | Carboplatin   | 0         | 4     | 1     | 0   |
|      |                  | Monochemotherapy               | 0         | 2     | 1     | 0   | Taxanes                         | 0         | 4     | 1     | 0   | Paclitaxel    | 0         | 4     | 1     | 0   |
|      |                  |                                |           |       |       |     | Alkylating agents               | 0         | 2     | 1     | 0   | Dakarbazinee  | 0         | 2     | 1     | 0   |
|      | All              | All                            | 0         | 57    | 93    | 11  | All                             | 0         | 89    | 135   | 15  | All           | 0         | 89    | 138   | 15  |
| 2020 | Neoadjuvant      | /                              | /         | /     | /     | /   | /                               | /         | /     | /     | /   | /             | /         | /     | /     | /   |
|      | Adjuvant         | Anti PD-1                      | 0         | 6     | 24    | 4   | Anti PD-1                       | 0         | 6     | 24    | 4   | Nivolumab     | 0         | 1     | 10    | 0   |
|      |                  |                                |           |       |       |     |                                 |           |       |       |     | Pembrolizumab | 0         | 5     | 14    | 4   |
|      |                  | BRAF in MEK inhibitors         | 0         | 4     | 4     | 1   | BRAF inhibitors                 | 0         | 4     | 4     | 1   | Dabrafenib    | 0         | 4     | 4     | 1   |
|      | First line       |                                |           |       |       |     | MEK inhibitors                  | 0         | 4     | 4     | 1   | Trametinib    | 0         | 4     | 4     | 1   |
|      |                  | Anti PD-1                      | 0         | 0     | 10    | 8   | Anti PD-1                       | 0         | 0     | 10    | 8   | Nivolumab     | 0         | 0     | 1     | 1   |
|      |                  |                                |           |       |       |     |                                 |           |       |       |     | Pembrolizumab | 0         | 0     | 9     | 7   |
|      |                  | BRAF in MEK inhibitors         | 0         | 2     | 6     | 0   | BRAF inhibitors                 | 0         | 2     | 6     | 0   | Dabrafenib    | 0         | 2     | 4     | 0   |
|      |                  |                                |           |       |       |     | Vemurafenib                     | 0         | 0     | 2     | 0   |               |           |       |       |     |
|      |                  |                                |           |       |       |     | MEK inhibitors                  | 0         | 2     | 6     | 0   | Cobimetinib   | 0         | 0     | 2     | 0   |
|      |                  | Combination immunotherapy      | 0         | 2     | 4     | 0   | Anti CTLA-4                     | 0         | 2     | 4     | 0   | Ipilimumab    | 0         | 2     | 4     | 0   |
|      |                  | Monochemotherapy               | 0         | 1     | 4     | 0   | Anti PD-1                       | 0         | 2     | 4     | 0   | Nivolumab     | 0         | 2     | 4     | 0   |
|      |                  |                                |           |       |       |     | Alkylating agents               | 0         | 1     | 4     | 0   | Dakarbazinee  | 0         | 1     | 4     | 0   |
|      | Second line      | Anti PD-1                      | 0         | 0     | 1     | 0   | Anti PD-1                       | 0         | 0     | 1     | 0   | Pembrolizumab | 0         | 0     | 1     | 0   |
|      |                  | BRAF in MEK inhibitors         | 0         | 0     | 4     | 0   | BRAF inhibitors                 | 0         | 0     | 4     | 0   | Dabrafenib    | 0         | 0     | 4     | 0   |
|      |                  |                                |           |       |       |     | MEK inhibitors                  | 0         | 0     | 4     | 0   | Trametinib    | 0         | 0     | 4     | 0   |
|      |                  |                                |           |       |       |     | Anti CTLA-4                     | 0         | 0     | 4     | 0   | Ipilimumab    | 0         | 0     | 4     | 0   |
|      |                  | Combination immunotherapy      | 0         | 0     | 4     | 0   | Anti PD-1                       | 0         | 0     | 4     | 0   | Nivolumab     | 0         | 0     | 4     | 0   |
|      |                  | Combination chemotherapy       | 0         | 0     | 2     | 0   | Platinum analogues              | 0         | 0     | 2     | 0   | Carboplatin   | 0         | 0     | 2     | 0   |
|      |                  |                                |           |       |       |     | Taxanes                         | 0         | 0     | 2     | 0   | Paclitaxel    | 0         | 0     | 2     | 0   |
|      |                  | Monochemotherapy               | 0         | 0     | 3     | 0   | Alkylating agents               | 0         | 0     | 3     | 0   | Dakarbazinee  | 0         | 0     | 3     | 0   |
|      | Subsequent lines | Combination chemotherapy       | 0         | 0     | 1     | 0   | Platinum analogues              | 0         | 0     | 1     | 0   | Carboplatin   | 0         | 0     | 1     | 0   |
|      |                  |                                |           |       |       |     | Taxanes                         | 0         | 0     | 1     | 0   | Paclitaxel    | 0         | 0     | 1     | 0   |
|      |                  | Monochemotherapy               | 0         | 0     | 2     | 0   | Alkylating agents               | 0         | 0     | 2     | 0   | Dakarbazinee  | 0         | 0     | 2     | 0   |
|      | All              | All                            | 0         | 15    | 69    | 13  | All                             | 0         | 23    | 94    | 14  | All           | 0         | 23    | 94    | 14  |

Continued. —&gt;

Table 21e: Continued.

| Year                      | Place in therapy       | Regimen                        | Age group              |       |       |     | Therapeutic subgroup           | Age group       |        |        |            | Drug                       | Age group                  |        |         |         |               |
|---------------------------|------------------------|--------------------------------|------------------------|-------|-------|-----|--------------------------------|-----------------|--------|--------|------------|----------------------------|----------------------------|--------|---------|---------|---------------|
|                           |                        |                                | 0–19                   | 20–49 | 50–74 | 75+ |                                | 0–19            | 20–49  | 50–74  | 75+        |                            | 0–19                       | 20–49  | 50–74   | 75+     |               |
| 2021                      | Neoadjuvant            | Anti PD-1                      | 0                      | 0     | 2     | 0   | Anti PD-1                      | 0               | 0      | 2      | 0          | Pembrolizumab              | 0                          | 0      | 2       | 0       |               |
|                           |                        | BRAF in MEK inhibitors         | 0                      | 0     | 2     | 0   | BRAF inhibitors                | 0               | 0      | 2      | 0          | Dabrafenib                 | 0                          | 0      | 2       | 0       |               |
|                           |                        |                                |                        |       |       |     | MEK inhibitors                 | 0               | 0      | 2      | 0          | Trametinib                 | 0                          | 0      | 2       | 0       |               |
|                           |                        |                                |                        |       |       |     | Other combination of therapies | 0               | 1      | 0      | 0          | Anti PD-1                  | 0                          | 1      | 0       | 0       | Pembrolizumab |
|                           |                        | BRAF inhibitors                | 0                      | 1     | 0     | 0   | Dabrafenib                     |                 |        |        |            | 0                          | 1                          | 0      | 0       |         |               |
|                           |                        | MEK inhibitors                 | 0                      | 1     | 0     | 0   | Trametinib                     |                 |        |        |            | 0                          | 1                          | 0      | 0       |         |               |
|                           | Adjuvant               | Anti PD-1                      | 0                      | 5     | 39    | 3   | Anti PD-1                      | 0               | 5      | 39     | 3          | Nivolumab<br>Pembrolizumab | 0<br>0                     | 0<br>5 | 9<br>30 | 0<br>3  |               |
|                           |                        | BRAF in MEK inhibitors         | 0                      | 4     | 11    | 0   | BRAF inhibitors                | 0               | 4      | 11     | 0          | Dabrafenib                 | 0                          | 4      | 11      | 0       |               |
|                           | MEK inhibitors         |                                |                        |       |       |     | 0                              | 4               | 11     | 0      | Trametinib | 0                          | 4                          | 11     | 0       |         |               |
|                           | First line             | Anti PD-1                      | 0                      | 0     | 20    | 4   | Anti PD-1                      | 0               | 0      | 20     | 4          | Nivolumab<br>Pembrolizumab | 0<br>0                     | 0<br>0 | 1<br>19 | 0<br>4  |               |
|                           |                        | BRAF in MEK inhibitors         | 0                      | 1     | 8     | 1   | BRAF inhibitors                | 0               | 1      | 8      | 1          | Dabrafenib                 | 0                          | 1      | 8       | 1       |               |
|                           |                        |                                |                        |       |       |     | MEK inhibitors                 | 0               | 1      | 8      | 1          | Trametinib                 | 0                          | 1      | 8       | 1       |               |
|                           |                        | Other combination of therapies | 0                      | 0     | 1     | 0   | Anti CTLA-4                    | 0               | 0      | 1      | 0          | Ipilimumab                 | 0                          | 0      | 1       | 0       |               |
|                           |                        |                                |                        |       |       |     | Anti PD-1                      | 0               | 0      | 1      | 0          | Nivolumab                  | 0                          | 0      | 1       | 0       |               |
|                           |                        |                                |                        |       |       |     | BRAF inhibitors                | 0               | 0      | 1      | 0          | Dabrafenib                 | 0                          | 0      | 1       | 0       |               |
|                           |                        |                                |                        |       |       |     | MEK inhibitors                 | 0               | 0      | 1      | 0          | Trametinib                 | 0                          | 0      | 1       | 0       |               |
|                           |                        | Combination immunotherapy      | 0                      | 0     | 5     | 0   | Anti CTLA-4                    | 0               | 0      | 5      | 0          | Ipilimumab                 | 0                          | 0      | 5       | 0       |               |
|                           |                        |                                |                        |       |       |     | Anti PD-1                      | 0               | 0      | 5      | 0          | Nivolumab                  | 0                          | 0      | 5       | 0       |               |
|                           |                        | Second line                    | Anti PD-1              | 0     | 0     | 1   | 1                              | Anti PD-1       | 0      | 0      | 1          | 1                          | Nivolumab<br>Pembrolizumab | 0<br>0 | 0<br>0  | 0<br>1  | 1<br>0        |
|                           | BRAF in MEK inhibitors |                                | 0                      | 0     | 5     | 0   | BRAF inhibitors                | 0               | 0      | 5      | 0          | Dabrafenib                 | 0                          | 0      | 5       | 0       |               |
|                           |                        |                                |                        |       |       |     | MEK inhibitors                 | 0               | 0      | 5      | 0          | Trametinib                 | 0                          | 0      | 5       | 0       |               |
|                           |                        |                                |                        |       |       |     | Combination immunotherapy      | 0               | 1      | 4      | 0          | Anti CTLA-4                | 0                          | 1      | 4       | 0       | Ipilimumab    |
|                           | Monochemotherapy       |                                | 0                      | 0     | 4     | 0   | Alkylating agents              | 0               | 0      | 4      | 0          | Dakarbazinee               | 0                          | 0      | 4       | 0       |               |
|                           | Subsequent lines       | Anti PD-1                      | 0                      | 0     | 1     | 1   | Anti PD-1                      | 0               | 0      | 1      | 1          | Nivolumab<br>Pembrolizumab | 0<br>0                     | 0<br>0 | 1<br>0  | 0<br>1  |               |
|                           |                        | BRAF in MEK inhibitors         | 0                      | 0     | 2     | 1   | BRAF inhibitors                | 0               | 0      | 2      | 1          | Dabrafenib                 | 0                          | 0      | 1       | 1       |               |
|                           |                        |                                |                        |       |       |     | MEK inhibitors                 | 0               | 0      | 2      | 1          | Vemurafenib                | 0                          | 0      | 1       | 0       |               |
|                           |                        |                                |                        |       |       |     | Cobimetinib<br>Trametinib      | 0<br>0          | 0<br>0 | 1<br>1 | 0<br>1     |                            |                            |        |         |         |               |
|                           |                        | Combination immunotherapy      | 0                      | 0     | 2     | 0   | Anti CTLA-4                    | 0               | 0      | 2      | 0          | Ipilimumab                 | 0                          | 0      | 2       | 0       |               |
|                           |                        |                                |                        |       |       |     | Anti PD-1                      | 0               | 0      | 2      | 0          | Nivolumab                  | 0                          | 0      | 2       | 0       |               |
|                           |                        |                                |                        |       |       |     | Combination chemotherapy       | 0               | 0      | 1      | 0          | Platinum analogues         | 0                          | 0      | 1       | 0       | Carboplatin   |
|                           |                        |                                |                        |       |       |     | Taxanes                        | 0               | 0      | 1      | 0          | Paclitaxel                 | 0                          | 0      | 1       | 0       |               |
|                           |                        | All                            | All                    | 0     | 12    | 108 | 11                             | All             | 0      | 20     | 151        | 13                         | All                        | 0      | 20      | 151     | 13            |
|                           | 2022                   | Neoadjuvant                    | Anti PD-1              | 0     | 0     | 1   | 1                              | Anti PD-1       | 0      | 0      | 1          | 1                          | Pembrolizumab              | 0      | 0       | 1       | 1             |
|                           |                        | Adjuvant                       | Anti PD-1              | 1     | 13    | 36  | 1                              | Anti PD-1       | 1      | 13     | 36         | 1                          | Nivolumab<br>Pembrolizumab | 0<br>1 | 0<br>13 | 2<br>34 | 0<br>1        |
|                           |                        |                                | BRAF in MEK inhibitors | 0     | 3     | 4   | 0                              | BRAF inhibitors | 0      | 3      | 4          | 0                          | Dabrafenib                 | 0      | 3       | 4       | 0             |
|                           |                        |                                |                        |       |       |     |                                | MEK inhibitors  | 0      | 3      | 4          | 0                          | Trametinib                 | 0      | 3       | 4       | 0             |
| First line                |                        | Anti PD-1                      | 0                      | 3     | 12    | 6   | Anti PD-1                      | 0               | 3      | 12     | 6          | Nivolumab<br>Pembrolizumab | 0<br>0                     | 0<br>3 | 1<br>11 | 0<br>6  |               |
|                           |                        | BRAF in MEK inhibitors         | 0                      | 0     | 3     | 1   | BRAF inhibitors                | 0               | 0      | 3      | 1          | Dabrafenib                 | 0                          | 0      | 3       | 1       |               |
|                           |                        |                                |                        |       |       |     | MEK inhibitors                 | 0               | 0      | 3      | 1          | Vemurafenib                | 0                          | 0      | 1       | 0       |               |
|                           |                        |                                |                        |       |       |     | Cobimetinib<br>Trametinib      | 0<br>0          | 0<br>0 | 1<br>3 | 0<br>1     |                            |                            |        |         |         |               |
|                           |                        | Combination immunotherapy      | 0                      | 1     | 4     | 0   | Anti CTLA-4                    | 0               | 1      | 4      | 0          | Ipilimumab                 | 0                          | 1      | 4       | 0       |               |
|                           |                        |                                |                        |       |       |     | Anti PD-1                      | 0               | 1      | 4      | 0          | Nivolumab                  | 0                          | 1      | 4       | 0       |               |
|                           |                        | Second line                    | Anti PD-1              | 0     | 0     | 1   | 0                              | Anti PD-1       | 0      | 0      | 1          | 0                          | Nivolumab                  | 0      | 0       | 1       | 0             |
| BRAF in MEK inhibitors    |                        |                                | 0                      | 3     | 0     | 0   | BRAF inhibitors                | 0               | 3      | 0      | 0          | Dabrafenib                 | 0                          | 3      | 0       | 0       |               |
|                           |                        |                                |                        |       |       |     | MEK inhibitors                 | 0               | 3      | 0      | 0          | Trametinib                 | 0                          | 3      | 0       | 0       |               |
| Combination immunotherapy |                        |                                | 0                      | 0     | 1     | 0   | Anti CTLA-4                    | 0               | 0      | 1      | 0          | Ipilimumab                 | 0                          | 0      | 1       | 0       |               |
|                           |                        |                                |                        |       |       |     | Anti PD-1                      | 0               | 0      | 1      | 0          | Nivolumab                  | 0                          | 0      | 1       | 0       |               |
| Monochemotherapy          |                        |                                | 0                      | 0     | 2     | 0   | Alkylating agents              | 0               | 0      | 2      | 0          | Dakarbazinee               | 0                          | 0      | 2       | 0       |               |
| Subsequent lines          |                        | Anti PD-1                      | 0                      | 0     | 1     | 0   | Anti PD-1                      | 0               | 0      | 1      | 0          | Nivolumab                  | 0                          | 0      | 1       | 0       |               |
|                           |                        | Combination immunotherapy      | 0                      | 2     | 0     | 0   | Anti CTLA-4                    | 0               | 2      | 0      | 0          | Ipilimumab                 | 0                          | 2      | 0       | 0       |               |
|                           |                        |                                |                        |       |       |     | Anti PD-1                      | 0               | 2      | 0      | 0          | Nivolumab                  | 0                          | 2      | 0       | 0       |               |
| All                       | All                    | 1                              | 25                     | 65    | 9     | All | 1                              | 34              | 77     | 10     | All        | 1                          | 34                         | 79     | 10      |         |               |

Continued. —&gt;

Table 21e: Continued.

| Year                            | Place in therapy | Regimen                        | Age group |       |       |     | Therapeutic subgroup            | Age group |       |       |     | Drug          | Age group |       |       |     |
|---------------------------------|------------------|--------------------------------|-----------|-------|-------|-----|---------------------------------|-----------|-------|-------|-----|---------------|-----------|-------|-------|-----|
|                                 |                  |                                | 0–19      | 20–49 | 50–74 | 75+ |                                 | 0–19      | 20–49 | 50–74 | 75+ |               | 0–19      | 20–49 | 50–74 | 75+ |
| Mean of yearly values 2018–2022 | Neoadjuvant      | Anti PD-1                      | 0,0       | 0,0   | 1,5   | 0,5 | Anti PD-1                       | 0,0       | 0,0   | 1,5   | 0,5 | Pembrolizumab | 0,0       | 0,0   | 1,5   | 0,5 |
|                                 |                  | BRAF in MEK inhibitors         | 0,0       | 0,0   | 2,0   | 0,0 | BRAF inhibitors                 | 0,0       | 0,0   | 2,0   | 0,0 | Dabrafenib    | 0,0       | 0,0   | 2,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | MEK inhibitors                  | 0,0       | 0,0   | 2,0   | 0,0 | Trametinib    | 0,0       | 0,0   | 2,0   | 0,0 |
|                                 |                  | Other combination of therapies | 0,0       | 1,0   | 0,0   | 0,0 | Anti PD-1                       | 0,0       | 1,0   | 0,0   | 0,0 | Pembrolizumab | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | BRAF inhibitors                 | 0,0       | 1,0   | 0,0   | 0,0 | Dabrafenib    | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | MEK inhibitors                  | 0,0       | 1,0   | 0,0   | 0,0 | Trametinib    | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 | Adjuvant         | Combination immunotherapy      | 0,0       | 0,0   | 1,0   | 0,0 | Anti CTLA-4                     | 0,0       | 0,0   | 1,0   | 0,0 | Ipilimumab    | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Anti PD-1                       | 0,0       | 0,0   | 1,0   | 0,0 | Nivolumab     | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  | Anti PD-1                      | 0,2       | 8,6   | 28,4  | 1,8 | Anti PD-1                       | 0,2       | 8,6   | 28,4  | 1,8 | Nivolumab     | 0,0       | 2,0   | 9,8   | 0,2 |
|                                 |                  |                                |           |       |       |     | BRAF inhibitors                 | 0,0       | 5,0   | 7,0   | 0,2 | Pembrolizumab | 0,2       | 6,6   | 18,6  | 1,6 |
|                                 |                  |                                |           |       |       |     | MEK inhibitors                  | 0,0       | 5,0   | 7,0   | 0,2 | Dabrafenib    | 0,0       | 5,0   | 7,0   | 0,2 |
|                                 | First line       | BRAF in MEK inhibitors         | 0,0       | 5,0   | 7,0   | 0,2 | MEK inhibitors                  | 0,0       | 5,0   | 7,0   | 0,2 | Trametinib    | 0,0       | 5,0   | 7,0   | 0,2 |
|                                 |                  |                                |           |       |       |     | Anti PD-1                       | 0,0       | 1,6   | 15,0  | 6,4 | Nivolumab     | 0,0       | 0,0   | 1,6   | 0,4 |
|                                 |                  | BRAF in MEK inhibitors         | 0,0       | 3,2   | 8,2   | 1,0 | Anti PD-1                       | 0,0       | 1,6   | 15,0  | 6,4 | Pembrolizumab | 0,0       | 1,6   | 13,6  | 6,0 |
|                                 |                  |                                |           |       |       |     | BRAF inhibitors                 | 0,0       | 3,2   | 8,2   | 1,0 | Dabrafenib    | 0,0       | 2,8   | 7,6   | 0,8 |
|                                 |                  |                                |           |       |       |     | MEK inhibitors                  | 0,0       | 3,2   | 8,2   | 1,0 | Vemurafenib   | 0,0       | 0,5   | 1,0   | 0,3 |
|                                 |                  | Other combination of therapies | 0,0       | 0,0   | 1,0   | 0,0 | Cobimetinib                     | 0,0       | 0,6   | 2,4   | 0,4 | Trametinib    | 0,0       | 0,6   | 2,4   | 0,4 |
|                                 |                  |                                |           |       |       |     | Trametinib                      | 0,0       | 2,8   | 7,6   | 0,8 | Ipilimumab    | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Anti CTLA-4                     | 0,0       | 0,0   | 1,0   | 0,0 | Nivolumab     | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Anti PD-1                       | 0,0       | 0,0   | 1,0   | 0,0 | Dabrafenib    | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  | Combination immunotherapy      | 0,0       | 1,6   | 3,6   | 0,0 | BRAF inhibitors                 | 0,0       | 0,0   | 1,0   | 0,0 | Trametinib    | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | MEK inhibitors                  | 0,0       | 0,0   | 1,0   | 0,0 | Ipilimumab    | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  | Combination chemotherapy       | 0,0       | 1,0   | 0,0   | 0,0 | Anti CTLA-4                     | 0,0       | 1,6   | 3,6   | 0,0 | Nivolumab     | 0,0       | 1,6   | 3,6   | 0,0 |
|                                 |                  |                                |           |       |       |     | Anti PD-1                       | 0,0       | 1,6   | 3,6   | 0,0 | Carboplatin   | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 |                  | Monochemotherapy               | 0,0       | 0,3   | 3,3   | 0,3 | Platinum analogues              | 0,0       | 1,0   | 0,0   | 0,0 | Paclitaxel    | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Taxanes                         | 0,0       | 1,0   | 0,0   | 0,0 | Dakarbazinee  | 0,0       | 0,3   | 3,0   | 0,3 |
|                                 | Second line      | BRAF in MEK inhibitors         | 0,0       | 1,6   | 2,6   | 0,2 | Alkylating agents               | 0,0       | 0,3   | 3,3   | 0,3 | Temozolomidee | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Anti PD-1                       | 0,0       | 0,6   | 2,4   | 0,2 | Nivolumab     | 0,0       | 0,7   | 1,3   | 0,3 |
|                                 |                  | BRAF in MEK inhibitors         | 0,0       | 1,6   | 2,6   | 0,2 | Anti PD-1                       | 0,0       | 0,6   | 2,4   | 0,2 | Pembrolizumab | 0,0       | 0,3   | 2,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | BRAF inhibitors                 | 0,0       | 1,6   | 2,6   | 0,2 | Dabrafenib    | 0,0       | 1,6   | 2,4   | 0,2 |
|                                 |                  |                                |           |       |       |     | MEK inhibitors                  | 0,0       | 1,6   | 2,6   | 0,2 | Vemurafenib   | 0,0       | 0,0   | 2,0   | 0,0 |
|                                 |                  | Combination immunotherapy      | 0,0       | 1,2   | 3,4   | 0,2 | Cobimetinib                     | 0,0       | 0,0   | 2,0   | 0,0 | Trametinib    | 0,0       | 0,0   | 2,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Ipilimumab                      | 0,0       | 1,2   | 3,4   | 0,2 | Nivolumab     | 0,0       | 1,2   | 3,4   | 0,2 |
|                                 |                  | Combination chemotherapy       | 0,0       | 1,0   | 1,5   | 0,0 | Anti PD-1                       | 0,0       | 1,2   | 3,4   | 0,2 | Carboplatin   | 0,0       | 1,0   | 1,5   | 0,0 |
|                                 |                  |                                |           |       |       |     | Platinum analogues              | 0,0       | 1,0   | 1,5   | 0,0 | Paclitaxel    | 0,0       | 1,0   | 1,5   | 0,0 |
|                                 |                  | Monochemotherapy               | 0,0       | 1,4   | 3,8   | 0,0 | Taxanes                         | 0,0       | 1,0   | 1,5   | 0,0 | Dakarbazinee  | 0,0       | 1,2   | 3,8   | 0,0 |
|                                 |                  |                                |           |       |       |     | Alkylating agents               | 0,0       | 1,4   | 3,8   | 0,0 | Temozolomidee | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 | Subsequent lines | BRAF in MEK inhibitors         | 0,0       | 0,3   | 2,7   | 0,3 | Anti PD-1                       | 0,0       | 0,8   | 1,0   | 0,3 | Nivolumab     | 0,0       | 0,0   | 1,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Anti PD-1                       | 0,0       | 0,8   | 1,0   | 0,3 | Pembrolizumab | 0,0       | 1,0   | 0,3   | 0,3 |
|                                 |                  | BRAF in MEK inhibitors         | 0,0       | 0,3   | 2,7   | 0,3 | BRAF inhibitors                 | 0,0       | 0,3   | 2,7   | 0,3 | Dabrafenib    | 0,0       | 0,0   | 1,3   | 0,3 |
|                                 |                  |                                |           |       |       |     | MEK inhibitors                  | 0,0       | 0,3   | 2,7   | 0,3 | Vemurafenib   | 0,0       | 0,3   | 1,3   | 0,0 |
|                                 |                  |                                |           |       |       |     | Cobimetinib                     | 0,0       | 0,3   | 2,7   | 0,3 | Trametinib    | 0,0       | 0,3   | 1,3   | 0,0 |
|                                 |                  | BRAF inhibitors                | 0,0       | 1,0   | 0,0   | 0,0 | Trametinib                      | 0,0       | 0,0   | 1,3   | 0,3 | Dabrafenib    | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | BRAF inhibitors                 | 0,0       | 1,0   | 0,0   | 0,0 | Pembrolizumab | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 |                  | Other combination of therapies | 0,0       | 1,0   | 0,0   | 0,0 | Anti PD-1                       | 0,0       | 1,0   | 0,0   | 0,0 | Lenvatinib    | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Other protein kinase inhibitors | 0,0       | 1,0   | 0,0   | 0,0 | Ipilimumab    | 0,0       | 1,0   | 0,8   | 0,0 |
|                                 |                  | Combination immunotherapy      | 0,0       | 1,0   | 0,8   | 0,0 | Anti CTLA-4                     | 0,0       | 1,0   | 0,8   | 0,0 | Nivolumab     | 0,0       | 1,0   | 0,8   | 0,0 |
|                                 |                  |                                |           |       |       |     | Anti PD-1                       | 0,0       | 1,0   | 0,8   | 0,0 | Lomustine     | 0,0       | 1,0   | 1,0   | 0,0 |
|                                 |                  | Combination chemotherapy       | 0,0       | 1,5   | 1,8   | 0,0 | Nitrosourea analogues           | 0,0       | 1,0   | 1,0   | 0,0 | Cisplatin     | 0,0       | 1,0   | 1,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Platinum analogues              | 0,0       | 1,5   | 1,8   | 0,0 | Carboplatin   | 0,0       | 1,3   | 1,5   | 0,0 |
|                                 |                  |                                |           |       |       |     | Taxanes                         | 0,0       | 1,3   | 1,5   | 0,0 | Paclitaxel    | 0,0       | 0,8   | 1,8   | 0,3 |
|                                 |                  |                                |           |       |       |     | Vinca alcaloids                 | 0,0       | 1,0   | 1,0   | 0,0 | Vinblastinee  | 0,0       | 1,0   | 1,0   | 0,0 |
|                                 |                  | Monochemotherapy               | 0,0       | 1,0   | 1,0   | 0,0 | Alkylating agents               | 0,0       | 1,0   | 1,0   | 0,0 | Dakarbazinee  | 0,0       | 1,0   | 1,0   | 0,0 |
|                                 |                  |                                |           |       |       |     | Alkylating agents               | 0,0       | 1,0   | 1,0   | 0,0 | Temozolomidee | 0,0       | 1,0   | 0,0   | 0,0 |
|                                 | All              | All                            | 0,0       | 1,4   | 3,8   | 0,5 | All                             | 0,0       | 1,3   | 3,0   | 0,3 | All           | 0,0       | 1,0   | 2,4   | 0,2 |

# Assessment of Response to Treatment

Table 22a: Review of performing assessment of response to systemic treatment in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), Slovenia 2018–2022.

| Response assessment | Year   |      |        |      |        |      |        |      |        |      |           |       |
|---------------------|--------|------|--------|------|--------|------|--------|------|--------|------|-----------|-------|
|                     | 2018   |      | 2019   |      | 2020   |      | 2021   |      | 2022   |      | 2018–2022 |       |
|                     | Number | %    | Number | %    | Number | %    | Number | %    | Number | %    | Number    | %     |
| All                 | 134    | 20.8 | 164    | 25.5 | 99     | 15.4 | 138    | 21.5 | 108    | 16.8 | 643       | 100.0 |
| Done                | 66     | 19.9 | 72     | 21.8 | 58     | 17.5 | 83     | 25.1 | 52     | 15.7 | 331       | 100.0 |
| Not done            | 68     | 21.8 | 92     | 29.5 | 41     | 13.1 | 55     | 17.6 | 56     | 17.9 | 312       | 100.0 |

Table 22b: Assessment of response to treatment in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by systemic treatment regimen, Slovenia 2018–2022.

| Place in therapy      | Number of lines | Regimen                        | Number of treatments (type) | Systemic treatment not completed | Complete response (CR) | Treatment of progressive disease (PD) | Partial response (PR) | Stable disease (SD) | Unknown |
|-----------------------|-----------------|--------------------------------|-----------------------------|----------------------------------|------------------------|---------------------------------------|-----------------------|---------------------|---------|
| Neoadjuvant           | 8               | Anti PD-1                      | 4                           | 0                                | 0                      | 1                                     | 0                     | 0                   | 3       |
|                       |                 | BRAF and MEK inhibitors        | 2                           | 0                                | 1                      | 0                                     | 0                     | 0                   | 1       |
|                       |                 | Other combination of therapies | 1                           | 0                                | 0                      | 0                                     | 0                     | 0                   | 1       |
|                       |                 | Combination immunotherapy      | 1                           | 0                                | 0                      | 0                                     | 0                     | 0                   | 1       |
| Adjuvant              | 258             | Anti PD-1                      | 196                         | 15                               | 30                     | 12                                    | 8                     | 22                  | 109     |
|                       |                 | BRAF and MEK inhibitors        | 62                          | 2                                | 12                     | 2                                     | 2                     | 8                   | 36      |
| First line            | 217             | Anti PD-1                      | 114                         | 6                                | 15                     | 24                                    | 17                    | 15                  | 37      |
|                       |                 | BRAF and MEK inhibitors        | 61                          | 1                                | 2                      | 10                                    | 11                    | 7                   | 30      |
|                       |                 | Other combination of therapies | 1                           | 0                                | 0                      | 0                                     | 1                     | 0                   | 0       |
|                       |                 | Combination immunotherapy      | 26                          | 1                                | 4                      | 5                                     | 3                     | 1                   | 12      |
|                       |                 | Combination chemotherapy       | 2                           | 0                                | 0                      | 0                                     | 0                     | 0                   | 2       |
|                       |                 | Monochemotherapy               | 13                          | 0                                | 0                      | 3                                     | 0                     | 0                   | 10      |
| Second line           | 92              | Anti PD-1                      | 16                          | 2                                | 1                      | 1                                     | 1                     | 4                   | 7       |
|                       |                 | BRAF and MEK inhibitors        | 22                          | 2                                | 0                      | 3                                     | 4                     | 3                   | 10      |
|                       |                 | Combination immunotherapy      | 24                          | 0                                | 2                      | 9                                     | 0                     | 2                   | 11      |
|                       |                 | Combination chemotherapy       | 5                           | 0                                | 0                      | 3                                     | 0                     | 0                   | 2       |
|                       |                 | Monochemotherapy               | 25                          | 1                                | 0                      | 10                                    | 3                     | 0                   | 11      |
| Subsequent lines (3+) | 46              | Anti PD-1                      | 8                           | 1                                | 0                      | 5                                     | 0                     | 0                   | 2       |
|                       |                 | BRAF and MEK inhibitors        | 10                          | 0                                | 0                      | 2                                     | 2                     | 0                   | 6       |
|                       |                 | BRAF inhibitors                | 1                           | 0                                | 0                      | 1                                     | 0                     | 0                   | 0       |
|                       |                 | Combination chemotherapy       | 1                           | 1                                | 0                      | 0                                     | 0                     | 0                   | 0       |
|                       |                 | Combination immunotherapy      | 7                           | 0                                | 0                      | 1                                     | 1                     | 1                   | 4       |
|                       |                 | BRAF inhibitors                | 13                          | 0                                | 0                      | 1                                     | 3                     | 0                   | 9       |
|                       |                 | Monochemotherapy               | 6                           | 0                                | 0                      | 0                                     | 0                     | 1                   | 5       |

# Adverse events

Table 23: Adverse events\* of systemic treatment in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80), by treatment type, Slovenia 2018–2022.

| Line                           | No. of lines | Type of treatment              | No. of treatments (type) | None      | Blood and lymphatic system | Cardiac | Ear and labyrinth | Endocrine | Eye | Gastrointestinal | General | Hepatobiliary | Infections | Injury | Musculoskeletal and connective tissue | Nervous system | Psychiatric | Respirator and thoracic | Pneumonitis | Skin and subcutaneous tissue | Metabolism and nutrition | Renal and urinary | Vascular | Unknown | All |
|--------------------------------|--------------|--------------------------------|--------------------------|-----------|----------------------------|---------|-------------------|-----------|-----|------------------|---------|---------------|------------|--------|---------------------------------------|----------------|-------------|-------------------------|-------------|------------------------------|--------------------------|-------------------|----------|---------|-----|
| Neoadjuvant                    | 8            | Anti PD-1                      | 4                        | 1         | 0                          | 0       | 0                 | 2         | 0   | 0                | 1       | 1             | 0          | 2      | 0                                     | 0              | 0           | 0                       | 0           | 0                            | 0                        | 0                 | 0        | 0       | 7   |
|                                |              | BRAF and MEK inhibitors        | 2                        | 0         | 0                          | 0       | 0                 | 0         | 1   | 0                | 0       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 1                            | 0                        | 0                 | 0        | 0       | 2   |
|                                |              | Other combination of therapies | 1                        | 0         | 0                          | 0       | 0                 | 1         | 0   | 0                | 1       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 0                            | 0                        | 0                 | 0        | 0       | 2   |
|                                |              | Combination immunotherapy      | 1                        | 0         | 0                          | 0       | 0                 | 0         | 0   | 0                | 0       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 0                            | 1                        | 0                 | 0        | 0       | 1   |
|                                |              | All                            | 8                        | 1         | 0                          | 0       | 0                 | 3         | 1   | 0                | 2       | 1             | 0          | 2      | 0                                     | 0              | 0           | 0                       | 0           | 1                            | 1                        | 0                 | 0        | 0       | 12  |
| Adjuvant                       | 258          | Anti PD-1                      | 196                      | 64        | 0                          | 0       | 4                 | 35        | 1   | 35               | 53      | 10            | 3          | 11     | 15                                    | 13             | 3           | 4                       | 4           | 45                           | 5                        | 0                 | 4        | 0       | 309 |
|                                |              | BRAF and MEK inhibitors        | 62                       | 9         | 2                          | 3       | 2                 | 1         | 1   | 13               | 38      | 9             | 0          | 3      | 0                                     | 6              | 3           | 1                       | 1           | 16                           | 0                        | 0                 | 2        | 0       | 110 |
|                                |              | All                            | 258                      | 73        | 2                          | 3       | 6                 | 36        | 2   | 48               | 91      | 19            | 3          | 14     | 15                                    | 19             | 6           | 5                       | 5           | 61                           | 5                        | 0                 | 6        | 0       | 419 |
| First line                     | 217          | Anti PD-1                      | 114                      | 36        | 4                          | 1       | 1                 | 13        | 0   | 21               | 20      | 4             | 1          | 7      | 8                                     | 4              | 2           | 2                       | 5           | 35                           | 1                        | 1                 | 0        | 6       | 172 |
|                                |              | BRAF and MEK inhibitors        | 61                       | 29        | 3                          | 0       | 2                 | 0         | 1   | 10               | 22      | 1             | 0          | 3      | 2                                     | 0              | 0           | 0                       | 0           | 6                            | 2                        | 1                 | 0        | 0       | 82  |
|                                |              | Other combination of therapies | 1                        | 0         | 0                          | 0       | 0                 | 1         | 0   | 1                | 0       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 0                            | 0                        | 0                 | 0        | 0       | 2   |
|                                |              | Combination immunotherapy      | 26                       | 3         | 1                          | 1       | 2                 | 3         | 1   | 10               | 6       | 3             | 0          | 6      | 0                                     | 2              | 0           | 1                       | 5           | 12                           | 1                        | 3                 | 1        | 0       | 61  |
|                                |              | Combination chemotherapy       | 2                        | 2         | 0                          | 0       | 0                 | 0         | 0   | 0                | 0       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 0                            | 0                        | 0                 | 0        | 0       | 2   |
|                                |              | Monochemotherapy               | 13                       | 7         | 0                          | 0       | 0                 | 0         | 0   | 0                | 4       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 1                            | 0                        | 0                 | 0        | 1       | 13  |
|                                |              | All                            | 217                      | 77        | 8                          | 2       | 5                 | 17        | 2   | 42               | 52      | 8             | 1          | 16     | 10                                    | 6              | 2           | 3                       | 10          | 54                           | 4                        | 5                 | 1        | 7       | 332 |
| Second line                    | 92           | Anti PD-1                      | 16                       | 8         | 0                          | 0       | 1                 | 0         | 1   | 2                | 1       | 0             | 0          | 0      | 2                                     | 1              | 0           | 0                       | 2           | 3                            | 0                        | 0                 | 0        | 0       | 21  |
|                                |              | BRAF and MEK inhibitors        | 22                       | 6         | 0                          | 0       | 0                 | 1         | 2   | 6                | 12      | 1             | 0          | 5      | 0                                     | 1              | 0           | 1                       | 0           | 5                            | 1                        | 0                 | 0        | 0       | 41  |
|                                |              | Combination immunotherapy      | 24                       | 10        | 0                          | 0       | 0                 | 2         | 0   | 6                | 4       | 2             | 0          | 1      | 0                                     | 1              | 1           | 0                       | 2           | 4                            | 0                        | 0                 | 0        | 0       | 33  |
|                                |              | Combination chemotherapy       | 5                        | 3         | 0                          | 0       | 0                 | 0         | 0   | 1                | 2       | 0             | 0          | 0      | 1                                     | 0              | 0           | 0                       | 0           | 0                            | 0                        | 0                 | 0        | 0       | 7   |
|                                |              | Monochemotherapy               | 25                       | 13        | 1                          | 0       | 0                 | 0         | 0   | 4                | 4       | 0             | 0          | 1      | 0                                     | 1              | 0           | 2                       | 0           | 2                            | 1                        | 0                 | 0        | 1       | 30  |
|                                |              | All                            | 92                       | 40        | 1                          | 0       | 1                 | 3         | 3   | 19               | 23      | 3             | 0          | 7      | 3                                     | 4              | 1           | 3                       | 4           | 14                           | 2                        | 0                 | 0        | 1       | 132 |
|                                |              | Subsequent lines (3+)          | 46                       | Anti PD-1 | 8                          | 4       | 0                 | 0         | 0   | 0                | 0       | 0             | 3          | 1      | 0                                     | 0              | 0           | 0                       | 0           | 0                            | 0                        | 0                 | 0        | 0       | 0   |
| BRAF and MEK inhibitors        | 10           |                                |                          | 5         | 1                          | 0       | 0                 | 0         | 1   | 1                | 1       | 1             | 0          | 0      | 0                                     | 2              | 0           | 1                       | 0           | 1                            | 0                        | 0                 | 0        | 0       | 14  |
| BRAF inhibitors                | 1            |                                |                          | 1         | 0                          | 0       | 0                 | 0         | 0   | 0                | 0       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 0                            | 0                        | 0                 | 0        | 0       | 1   |
| Other combination of therapies | 1            |                                |                          | 0         | 0                          | 0       | 0                 | 0         | 0   | 0                | 0       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 0                            | 0                        | 0                 | 0        | 1       | 1   |
| Combination immunotherapy      | 7            |                                |                          | 2         | 0                          | 1       | 0                 | 0         | 0   | 2                | 2       | 1             | 0          | 2      | 1                                     | 0              | 0           | 0                       | 0           | 1                            | 0                        | 0                 | 0        | 0       | 12  |
| Combination chemotherapy       | 13           |                                |                          | 5         | 1                          | 1       | 1                 | 0         | 0   | 3                | 6       | 0             | 0          | 0      | 1                                     | 0              | 0           | 1                       | 0           | 1                            | 0                        | 0                 | 1        | 0       | 21  |
| Monochemotherapy               | 6            |                                |                          | 5         | 0                          | 0       | 0                 | 0         | 0   | 1                | 0       | 0             | 0          | 0      | 0                                     | 0              | 0           | 0                       | 0           | 1                            | 0                        | 0                 | 0        | 0       | 7   |
| All                            | 46           |                                |                          | 22        | 2                          | 2       | 1                 | 0         | 1   | 7                | 12      | 3             | 0          | 2      | 2                                     | 2              | 0           | 2                       | 0           | 4                            | 0                        | 0                 | 1        | 2       | 65  |

\* According to CTCAE (Common Terminology Criteria for Adverse Events).

# Conclusion of Systemic Treatment

Table 24: Reasons for systemic treatment discontinuation in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by treatment type, Slovenia 2018–2022.

| Place in therapy      | No. of lines | Regimen                        | No. of treatments (type) | ST not yet completed | Yes, the patient received the complete planned ST | Discontinuation of ST because of recurrence | Discontinuation of ST because of adverse effects | Discontinuation of ST because complete response was reached | Discontinuation of ST because of patient decision | Discontinuation of ST because of patient death | Discontinuation of ST for other reasons |
|-----------------------|--------------|--------------------------------|--------------------------|----------------------|---------------------------------------------------|---------------------------------------------|--------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------|------------------------------------------------|-----------------------------------------|
| All                   | 621          | All                            | 621                      | 79                   | 168                                               | 178                                         | 107                                              | 2                                                           | 6                                                 | 36                                             | 45                                      |
| Neoadjuvant           | 8            | Anti PD-1                      | 4                        | 0                    | 3                                                 | 0                                           | 1                                                | 0                                                           | 0                                                 | 0                                              | 0                                       |
|                       |              | BRAF and MEK inhibitors        | 2                        | 0                    | 0                                                 | 0                                           | 0                                                | 0                                                           | 0                                                 | 1                                              | 1                                       |
|                       |              | Other combination of therapies | 1                        | 0                    | 0                                                 | 0                                           | 0                                                | 0                                                           | 0                                                 | 0                                              | 1                                       |
|                       |              | Combination immunotherapy      | 1                        | 0                    | 0                                                 | 0                                           | 1                                                | 0                                                           | 0                                                 | 0                                              | 0                                       |
|                       |              | All                            | 8                        | 0                    | 3                                                 | 0                                           | 2                                                | 0                                                           | 0                                                 | 1                                              | 2                                       |
| Adjuvant              | 256          | Anti PD-1                      | 195                      | 26                   | 100                                               | 18                                          | 40                                               | 1                                                           | 2                                                 | 1                                              | 7                                       |
|                       |              | BRAF and MEK inhibitors        | 61                       | 2                    | 37                                                | 3                                           | 16                                               | 0                                                           | 1                                                 | 0                                              | 2                                       |
|                       |              | All                            | 256                      | 28                   | 137                                               | 21                                          | 56                                               | 1                                                           | 3                                                 | 1                                              | 9                                       |
| First line            | 218          | Anti PD-1                      | 115                      | 25                   | 18                                                | 39                                          | 15                                               | 0                                                           | 2                                                 | 9                                              | 7                                       |
|                       |              | BRAF and MEK inhibitors        | 62                       | 5                    | 0                                                 | 38                                          | 6                                                | 0                                                           | 1                                                 | 6                                              | 6                                       |
|                       |              | Other combination of therapies | 1                        | 0                    | 0                                                 | 0                                           | 0                                                | 0                                                           | 0                                                 | 1                                              | 0                                       |
|                       |              | Combination immunotherapy      | 26                       | 3                    | 1                                                 | 8                                           | 10                                               | 1                                                           | 0                                                 | 2                                              | 1                                       |
|                       |              | Combination chemotherapy       | 2                        | 0                    | 0                                                 | 1                                           | 0                                                | 0                                                           | 0                                                 | 0                                              | 1                                       |
|                       |              | Monochemotherapy               | 12                       | 0                    | 1                                                 | 5                                           | 2                                                | 0                                                           | 0                                                 | 1                                              | 3                                       |
|                       |              | All                            | 218                      | 33                   | 20                                                | 91                                          | 33                                               | 1                                                           | 3                                                 | 19                                             | 18                                      |
| Second line           | 93           | Anti PD-1                      | 16                       | 4                    | 3                                                 | 2                                           | 3                                                | 0                                                           | 0                                                 | 3                                              | 1                                       |
|                       |              | BRAF and MEK inhibitors        | 22                       | 5                    | 0                                                 | 12                                          | 3                                                | 0                                                           | 0                                                 | 0                                              | 2                                       |
|                       |              | Combination immunotherapy      | 24                       | 3                    | 0                                                 | 9                                           | 5                                                | 0                                                           | 0                                                 | 5                                              | 2                                       |
|                       |              | Combination chemotherapy       | 5                        | 0                    | 0                                                 | 2                                           | 0                                                | 0                                                           | 0                                                 | 1                                              | 2                                       |
|                       |              | Monochemotherapy               | 26                       | 3                    | 0                                                 | 19                                          | 0                                                | 0                                                           | 0                                                 | 2                                              | 2                                       |
|                       |              | All                            | 93                       | 15                   | 3                                                 | 44                                          | 11                                               | 0                                                           | 0                                                 | 11                                             | 9                                       |
| Subsequent lines (3+) | 46           | Anti PD-1                      | 8                        | 1                    | 1                                                 | 4                                           | 1                                                | 0                                                           | 0                                                 | 0                                              | 1                                       |
|                       |              | BRAF and MEK inhibitors        | 10                       | 0                    | 1                                                 | 7                                           | 1                                                | 0                                                           | 0                                                 | 0                                              | 1                                       |
|                       |              | BRAF inhibitors                | 1                        | 0                    | 0                                                 | 1                                           | 0                                                | 0                                                           | 0                                                 | 0                                              | 0                                       |
|                       |              | Other combination of therapies | 1                        | 1                    | 0                                                 | 0                                           | 0                                                | 0                                                           | 0                                                 | 0                                              | 0                                       |
|                       |              | Combination immunotherapy      | 7                        | 0                    | 2                                                 | 3                                           | 0                                                | 0                                                           | 0                                                 | 1                                              | 1                                       |
|                       |              | Combination chemotherapy       | 13                       | 0                    | 1                                                 | 5                                           | 3                                                | 0                                                           | 0                                                 | 1                                              | 3                                       |
|                       |              | Monochemotherapy               | 6                        | 1                    | 0                                                 | 2                                           | 0                                                | 0                                                           | 0                                                 | 2                                              | 1                                       |
|                       |              | All                            | 46                       | 3                    | 5                                                 | 22                                          | 5                                                | 0                                                           | 0                                                 | 4                                              | 7                                       |

# Disease Reccurrence

Table 25: First recurrence of disease in patients with invasive skin melanoma (C43, C51, C60, C63, C77–C80) by primary disease site, recurrence type and time from start of primary systemic treatment and disease progression, Slovenia 2018–2022.

| Year         | ICD code                    | Primary site                                | All recurrences | Time to recurrence |               |                |                  |                   |                      | Type of recurrence |            |                         |          |          |
|--------------|-----------------------------|---------------------------------------------|-----------------|--------------------|---------------|----------------|------------------|-------------------|----------------------|--------------------|------------|-------------------------|----------|----------|
|              |                             |                                             |                 | Less than 1 month  | 1 to 6 months | 6 to 12 months | More than 1 year | More than 2 years | Time not calculated* | Local              | In transit | In transit and regional | Regional | Systemic |
| 2018         | C43, C51, C60, C63, C77–C80 | Invasive skin melanoma                      | 100             | 3                  | 6             | 6              | 5                | 5                 | 75                   | 12                 | 1          | 11                      | 16       | 60       |
|              | C43, C51, C60, C63          | Primary invasive skin melanoma              | 96              | 3                  | 4             | 6              | 5                | 5                 | 73                   | 12                 | 1          | 11                      | 16       | 56       |
|              | C77–C80                     | Melanoma of secondary or unspecified origin | 4               | 0                  | 2             | 0              | 0                | 0                 | 2                    | 0                  | 0          | 0                       | 0        | 4        |
| 2019         | C43, C51, C60, C63, C77–C80 | Invasive skin melanoma                      | 106             | 3                  | 14            | 3              | 11               | 3                 | 72                   | 10                 | 2          | 13                      | 20       | 61       |
|              | C43, C51, C60, C63          | Primary invasive skin melanoma              | 100             | 3                  | 11            | 3              | 11               | 3                 | 69                   | 10                 | 2          | 13                      | 19       | 56       |
|              | C77–C80                     | Melanoma of secondary or unspecified origin | 6               | 0                  | 3             | 0              | 0                | 0                 | 3                    | 0                  | 0          | 0                       | 1        | 5        |
| 2020         | C43, C51, C60, C63, C77–C80 | Invasive skin melanoma                      | 81              | 0                  | 9             | 4              | 5                | 3                 | 60                   | 9                  | 1          | 8                       | 17       | 46       |
|              | C43, C51, C60, C63          | Primary invasive skin melanoma              | 75              | 0                  | 7             | 4              | 5                | 2                 | 57                   | 9                  | 1          | 8                       | 17       | 40       |
|              | C77–C80                     | Melanoma of secondary or unspecified origin | 6               | 0                  | 2             | 0              | 0                | 1                 | 3                    | 0                  | 0          | 0                       | 0        | 6        |
| 2021         | C43, C51, C60, C63, C77–C80 | Invazivni kožni melanom                     | 78              | 8                  | 10            | 8              | 8                | 0                 | 44                   | 6                  | 2          | 10                      | 16       | 44       |
|              | C43, C51, C60, C63          | Primary invasive skin melanoma              | 67              | 5                  | 6             | 6              | 7                | 0                 | 43                   | 6                  | 2          | 10                      | 16       | 33       |
|              | C77–C80                     | Melanoma of secondary or unspecified origin | 11              | 3                  | 4             | 2              | 1                | 0                 | 1                    | 0                  | 0          | 0                       | 0        | 11       |
| 2022         | C43, C51, C60, C63, C77–C80 | Invasive skin melanoma                      | 64              | 1                  | 10            | 3              | 3                | –                 | 47                   | 12                 | 0          | 8                       | 10       | 34       |
|              | C43, C51, C60, C63          | Primary invasive skin melanoma              | 59              | 1                  | 10            | 2              | 2                | –                 | 44                   | 12                 | 0          | 8                       | 10       | 29       |
|              | C77–C80                     | Melanoma of secondary or unspecified origin | 5               | 0                  | 0             | 1              | 1                | –                 | 3                    | 0                  | 0          | 0                       | 0        | 5        |
| 2018 to 2022 | C43, C51, C60, C63, C77–C80 | Invasive skin melanoma                      | 429             | 15                 | 49            | 24             | 32               | 11                | 298                  | 49                 | 6          | 50                      | 79       | 245      |
|              | C43, C51, C60, C63          | Primary invasive skin melanoma              | 397             | 12                 | 38            | 21             | 30               | 10                | 286                  | 49                 | 6          | 50                      | 78       | 214      |
|              | C77–C80                     | Melanoma of secondary or unspecified origin | 32              | 3                  | 11            | 3              | 2                | 1                 | 12                   | 0                  | 0          | 0                       | 1        | 31       |

\* No systemic therapy before first recurrence.



# Compliance with Guidelines

Table 26: Adherence to clinical practice guidelines in diagnostics and primary treatment of patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by stage (excluding autopsy-only registered cases), Slovenia 2018–2022.

| Stage 0                                                                                    |                  |        |       |        |       |        |       |        |       |        |       |           |       |
|--------------------------------------------------------------------------------------------|------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                            |                  | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                         |                  | 319    |       | 348    |       | 334    |       | 358    |       | 513    |       | 1872      |       |
| Mean (age)                                                                                 |                  | 59.8   |       | 61.3   |       | 61.9   |       | 63.3   |       | 61.0   |       | 61.5      |       |
| Median (age)                                                                               |                  | 61     |       | 64     |       | 65     |       | 65     |       | 62     |       | 63        |       |
| Histological type (ICD-O-3 code)                                                           |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)***                                                          |                  | 267    | 83.7  | 303    | 87.1  | 296    | 88.6  | 321    | 89.7  | 467    | 91.0  | 1654      | 88.4  |
| Nodular melanoma (8721)                                                                    |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Lentigo maligna (8742)                                                                     |                  | 52     | 16.3  | 45     | 12.9  | 38     | 11.4  | 37     | 10.3  | 46     | 9.0   | 218       | 11.6  |
| Superficial spreading melanoma (8743)***                                                   |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Other histological types (8722, 8723, 8730, 8740, 8741, 8744, 8745, 8761, 8770-8772, 8780) |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| All (8720–8780)                                                                            |                  | 319    | 100.0 | 348    | 100.0 | 334    | 100.0 | 358    | 100.0 | 513    | 100.0 | 1872      | 100.0 |
| Diagnostic treatment                                                                       |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                         | No               | 301    | 94.4  | 345    | 99.1  | 333    | 99.7  | 355    | 99.2  | 505    | 98.4  | 1839      | 98.2  |
|                                                                                            | PET-CT           | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                            | CT               | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                            | MRI              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                            | US               | 1      | -     | 0      | -     | 0      | -     | 3      | -     | 7      | 0.4   | 11        | 0.6   |
|                                                                                            | X-ray            | 0      | -     | 1      | -     | 1      | -     | 1      | -     | 6      | 0.3   | 9         | 0.5   |
|                                                                                            | Unknown          | 17     | 5.3   | 2      | -     | 0      | -     | 0      | -     | 0      | -     | 19        | 1.0   |
| Surgical treatment                                                                         |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                                   | Yes              | 312    | 97.8  | 343    | 98.6  | 331    | 99.1  | 354    | 98.9  | 510    | 99.4  | 1850      | 98.8  |
|                                                                                            | No               | 7      | 2.2   | 5      | 1.4   | 3      | -     | 4      | -     | 3      | -     | 22        | 1.2   |
|                                                                                            | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                                       | < 2mm            | 111    | 35.6  | 151    | 44.0  | 157    | 47.4  | 142    | 40.1  | 215    | 42.2  | 776       | 41.9  |
|                                                                                            | 2 - 5mm          | 157    | 50.3  | 144    | 42.0  | 128    | 38.7  | 156    | 44.1  | 223    | 43.7  | 808       | 43.7  |
|                                                                                            | ≥ 5mm            | 16     | 5.1   | 13     | 3.8   | 7      | 2.1   | 13     | 3.7   | 18     | 3.5   | 67        | 3.6   |
|                                                                                            | Unknown          | 28     | 9.0   | 35     | 10.2  | 39     | 11.8  | 43     | 12.1  | 54     | 10.6  | 199       | 10.8  |
| Deep surgical margin                                                                       | < 2mm            | 1      | -     | 3      | -     | 12     | 3.6   | 11     | 3.1   | 7      | 1.4   | 34        | 1.8   |
|                                                                                            | 2 - 5mm          | 16     | 5.1   | 34     | 9.9   | 30     | 9.1   | 48     | 13.6  | 47     | 9.2   | 175       | 9.5   |
|                                                                                            | ≥ 5mm            | 17     | 5.4   | 23     | 6.7   | 13     | 3.9   | 30     | 8.5   | 28     | 5.5   | 111       | 6.0   |
|                                                                                            | Unknown          | 278    | 89.1  | 283    | 82.5  | 276    | 83.4  | 265    | 74.9  | 428    | 83.9  | 1530      | 82.7  |
| Re-excision if diagnostic excision margin < 5mm                                            | Yes              | 59     | 18.9  | 85     | 24.8  | 111    | 33.6  | 257    | 73.0  | 432    | 86.2  | 944       | 51.4  |
|                                                                                            | No               | 253    | 81.1  | 258    | 75.2  | 219    | 66.4  | 95     | 27.0  | 69     | 13.8  | 894       | 48.6  |
|                                                                                            | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Re-excision if diagnostic excision margin < 5mm and within 3 months after diagnosis        | Yes              | -      | -     | -      | -     | -      | -     | 245    | 95.3  | 404    | 93.5  | -         | -     |
|                                                                                            | No               | -      | -     | -      | -     | -      | -     | 12     | 4.7   | 28     | 6.5   | -         | -     |

Continued. —>

Table 26: Continued.

| Stage IA                                                                             |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|--------------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                      |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                   |                          | 297    |       | 309    |       | 337    |       | 311    |       | 499    |       | 1753      |       |
| Mean (age)                                                                           |                          | 60.2   |       | 59.5   |       | 59.5   |       | 59.3   |       | 59.6   |       | 59.6      |       |
| Median (age)                                                                         |                          | 62     |       | 62     |       | 59     |       | 59     |       | 60     |       | 60        |       |
| Histological type (ICD-O-3 code)                                                     |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                       |                          | 32     | 10.8  | 29     | 9.4   | 66     | 19.6  | 76     | 24.4  | 58     | 11.6  | 261       | 14.9  |
| Nodular melanoma (8721)                                                              |                          | 4      | 1.3   | 2      | 0.6   | 4      | 1.2   | 6      | 1.9   | 12     | 2.4   | 28        | 1.6   |
| Lentigo maligna (8742)                                                               |                          | 23     | 7.7   | 9      | 2.9   | 10     | 3.0   | 7      | 2.3   | 11     | 2.2   | 60        | 3.4   |
| Superficial spreading melanoma (8743)                                                |                          | 231    | 77.8  | 262    | 84.8  | 248    | 73.6  | 217    | 69.8  | 411    | 82.4  | 1369      | 78.1  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770-8772,8780)    |                          | 7      | 2.4   | 7      | 2.3   | 9      | 2.7   | 5      | 1.6   | 7      | 1.4   | 35        | 2.0   |
| All (8720–8780)                                                                      |                          | 297    | 100.0 | 309    | 100.0 | 337    | 100.0 | 311    | 100.0 | 499    | 100.0 | 1753      | 100.0 |
| Diagnostic treatment                                                                 |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                   | No                       | 134    | 45.1  | 268    | 86.7  | 281    | 83.4  | 255    | 82.0  | 432    | 86.6  | 1370      | 78.2  |
|                                                                                      | PET-CT                   | 2      | -     | 4      | -     | 1      | -     | 3      | -     | 2      | -     | 12        | 0.7   |
|                                                                                      | CT                       | 0      | -     | 0      | -     | 1      | -     | 2      | -     | 0      | -     | 3         | -     |
|                                                                                      | MRI                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                      | US                       | 16     | 5.4   | 13     | 4.2   | 19     | 5.6   | 14     | 4.5   | 19     | 3.8   | 81        | 4.6   |
|                                                                                      | X-ray                    | 26     | 8.8   | 35     | 11.3  | 50     | 14.8  | 48     | 15.4  | 61     | 12.2  | 220       | 12.5  |
|                                                                                      | Unknown                  | 129    | 43.4  | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 130       | 7.4   |
| Microscopic confirmation of regional metastases                                      | Metastases not confirmed | 0      | -     | 5      | 1.6   | 11     | 3.3   | 0      | -     | 0      | -     | 16        | 0.9   |
|                                                                                      | Cytologically confirmed  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                      | Histologically confirmed | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                      | No metastases            | 25     | 8.4   | 33     | 10.7  | 37     | 11.0  | 63     | 20.3  | 65     | 13.0  | 223       | 12.7  |
|                                                                                      | Unknown                  | 272    | 91.6  | 271    | 87.7  | 289    | 85.8  | 248    | 79.7  | 434    | 87.0  | 1514      | 86.4  |
| Surgical treatment                                                                   |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                             | Yes                      | 296    | 99.7  | 309    | 100.0 | 335    | 99.4  | 311    | 100.0 | 497    | 99.6  | 1748      | 99.7  |
|                                                                                      | No                       | 1      | -     | 0      | -     | 2      | -     | 0      | -     | 2      | -     | 5         | 0.3   |
|                                                                                      | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                                 | < 10mm                   | 283    | 95.6  | 304    | 98.4  | 314    | 93.7  | 303    | 97.4  | 483    | 97.2  | 1687      | 96.5  |
|                                                                                      | 10mm and more            | 2      | -     | 1      | -     | 5      | 1.5   | 0      | -     | 7      | 1.4   | 15        | 0.9   |
|                                                                                      | Unknown                  | 11     | 3.7   | 4      | -     | 16     | 4.8   | 8      | 2.6   | 7      | 1.4   | 46        | 2.6   |
| Deep surgical margin                                                                 | < 10mm                   | 215    | 72.6  | 261    | 84.5  | 310    | 92.5  | 285    | 91.6  | 395    | 79.5  | 1466      | 83.9  |
|                                                                                      | 10mm and more            | 12     | 4.1   | 6      | 1.9   | 5      | 1.5   | 8      | 2.6   | 13     | 2.6   | 44        | 2.5   |
|                                                                                      | Unknown                  | 69     | 23.3  | 42     | 13.6  | 20     | 6.0   | 18     | 5.8   | 89     | 17.9  | 238       | 13.6  |
| Re-excision if diagnostic excision margin < 10mm                                     | Yes                      | 95     | 32.1  | 127    | 41.1  | 171    | 51.0  | 269    | 87.1  | 448    | 91.6  | 1110      | 63.9  |
|                                                                                      | No                       | 201    | 67.9  | 182    | 58.9  | 164    | 49.0  | 40     | 12.9  | 41     | 8.4   | 628       | 36.1  |
|                                                                                      | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Re-excision if diagnostic excision margin < 10mm and within 3 months after diagnosis | Yes                      | -      | -     | -      | -     | -      | -     | 243    | 90.3  | 409    | 91.3  | -         | -     |
|                                                                                      | No                       | -      | -     | -      | -     | -      | -     | 26     | 9.7   | 39     | 8.7   | -         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IB                                                                          |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|-----------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                          | 83     |       | 67     |       | 73     |       | 86     |       | 106    |       | 415       |       |
| Mean (age)                                                                        |                          | 59.6   |       | 58.8   |       | 61.9   |       | 61.1   |       | 60.4   |       | 60.4      |       |
| Median (age)                                                                      |                          | 62     |       | 60     |       | 66     |       | 63.5   |       | 62     |       | 63        |       |
| Histological type (ICD-O-3 code)                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                          | 10     | 12.0  | 12     | 17.9  | 16     | 21.9  | 13     | 15.1  | 11     | 10.4  | 62        | 14.9  |
| Nodular melanoma (8721)                                                           |                          | 10     | 12.0  | 4      | 6.0   | 4      | 5.5   | 3      | 3.5   | 6      | 5.7   | 27        | 6.5   |
| Lentigo maligna (8742)                                                            |                          | 4      | 4.8   | 3      | 4.5   | 3      | 4.1   | 1      | 1.2   | 2      | 1.9   | 13        | 3.1   |
| Superficial spreading melanoma (8743)                                             |                          | 57     | 68.7  | 44     | 65.7  | 48     | 65.8  | 59     | 68.6  | 82     | 77.4  | 290       | 69.9  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770-8772,8780) |                          | 2      | 2.4   | 4      | 6.0   | 2      | 2.7   | 10     | 11.6  | 5      | 4.7   | 23        | 5.5   |
| All (8720–8780)                                                                   |                          | 83     | 100.0 | 67     | 100.0 | 73     | 100.0 | 86     | 100.0 | 106    | 100.0 | 415       | 100.0 |
| Diagnostic treatment                                                              |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                | No                       | 3      | -     | 8      | 11.9  | 11     | 15.1  | 3      | 3.5   | 14     | 13.2  | 39        | 9.4   |
|                                                                                   | PET-CT                   | 1      | -     | 5      | 7.5   | 0      | -     | 8      | 9.3   | 5      | 4.7   | 19        | 4.6   |
|                                                                                   | CT                       | 1      | -     | 1      | -     | 2      | -     | 2      | -     | 4      | -     | 10        | 2.4   |
|                                                                                   | MRI                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | US                       | 20     | 24.1  | 19     | 28.4  | 14     | 19.2  | 21     | 24.4  | 14     | 13.2  | 88        | 21.2  |
|                                                                                   | X-ray                    | 73     | 88.0  | 53     | 79.1  | 61     | 83.6  | 82     | 95.3  | 90     | 84.9  | 359       | 86.5  |
|                                                                                   | Unknown                  | 3      | -     | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 4         | -     |
| Microscopic confirmation of regional metastases                                   | Metastases not confirmed | 0      | -     | 5      | 7.5   | 16     | 21.9  | 0      | -     | 0      | -     | 21        | 5.1   |
|                                                                                   | Cytologically confirmed  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Histologically confirmed | 0      | -     | 1      | -     | 1      | -     | 0      | -     | 0      | -     | 2         | -     |
|                                                                                   | No metastases            | 68     | 81.9  | 55     | 82.1  | 48     | 65.8  | 75     | 87.2  | 80     | 75.5  | 326       | 78.6  |
|                                                                                   | Unknown                  | 15     | 18.1  | 6      | 9.0   | 8      | 11.0  | 11     | 12.8  | 26     | 24.5  | 66        | 15.9  |
| BRAF status determination                                                         | Negative                 | 1      | -     | 1      | -     | 0      | -     | 1      | -     | 9      | 8.5   | 12        | 2.9   |
|                                                                                   | Positive                 | 2      | -     | 2      | -     | 2      | -     | 4      | -     | 5      | 4.7   | 15        | 3.6   |
|                                                                                   | Unknown                  | 80     | 96.4  | 64     | 95.5  | 71     | 97.3  | 81     | 94.2  | 92     | 86.8  | 388       | 93.5  |
|                                                                                   | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Surgical treatment                                                                |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                          | Yes                      | 82     | 98.8  | 67     | 100.0 | 73     | 100.0 | 86     | 100.0 | 106    | 100.0 | 414       | 99.8  |
|                                                                                   | No                       | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                              | < 10mm                   | 78     | 95.1  | 62     | 92.5  | 68     | 93.2  | 82     | 95.3  | 102    | 96.2  | 392       | 94.7  |
|                                                                                   | 10–20mm                  | 2      | -     | 1      | -     | 1      | -     | 1      | -     | 0      | -     | 5         | 1.2   |
|                                                                                   | ≥ 20mm                   | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2      | -     | 2         | -     |
|                                                                                   | Unknown                  | 2      | -     | 4      | -     | 4      | -     | 3      | -     | 2      | -     | 15        | 3.6   |
| Deep surgical margin                                                              | < 10mm                   | 62     | 75.6  | 57     | 85.1  | 65     | 89.0  | 77     | 89.5  | 88     | 83.0  | 349       | 84.3  |
|                                                                                   | 10–20mm                  | 9      | 11.0  | 3      | -     | 5      | 6.8   | 5      | 5.8   | 7      | 6.6   | 29        | 7.0   |
|                                                                                   | ≥ 20mm                   | 0      | -     | 0      | -     | 3      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Unknown                  | 11     | 13.4  | 7      | 10.4  | 0      | -     | 4      | -     | 11     | 10.4  | 36        | 8.7   |
| Re-excision if diagnostic excision margin < 10mm                                  | Yes                      | 69     | 85.2  | 63     | 94.0  | 69     | 97.2  | 80     | 95.2  | 97     | 96.0  | 378       | 93.6  |
|                                                                                   | No                       | 12     | 14.8  | 4      | -     | 2      | -     | 4      | -     | 4      | -     | 26        | 6.4   |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Sentinel lymph node biopsy (SNB)                                                  | Yes                      | 68     | 81.9  | 59     | 88.1  | 65     | 89.0  | 74     | 86.0  | 86     | 81.1  | 352       | 84.8  |
|                                                                                   | No                       | 15     | 18.1  | 8      | 11.9  | 8      | 11.0  | 12     | 14.0  | 10     | 9.4   | 53        | 12.8  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 10     | 9.4   | 10        | 2.4   |
| Positive lymph nodes at SNB                                                       | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | No                       | 68     | 100.0 | 59     | 100.0 | 65     | 100.0 | 74     | 100.0 | 86     | 100.0 | 352       | 100.0 |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IB                                                                                                                              |                  |        |       |        |       |        |       |        |       |        |       |           |       |
|---------------------------------------------------------------------------------------------------------------------------------------|------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                                                                       |                  | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Surgical treatment                                                                                                                    |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diameter of the largest positive lymph node at SNB                                                                                    | < 0,3mm          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | 0,3 – 1,0mm      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | > 1,0mm          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| SNB completed within 3 months after diagnosis (authorization of pathological report of excision biopsy)                               | Yes              | -      | -     | -      | -     | -      | -     | 73     | 98.6  | 81     | 94.2  | -         | -     |
|                                                                                                                                       | No               | -      | -     | -      | -     | -      | -     | 1      | 1.4   | 5      | 5.8   | -         | -     |
| Lymphadenectomy                                                                                                                       | Yes              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | No               | 83     | 100.0 | 67     | 100.0 | 73     | 100.0 | 86     | 100.0 | 106    | 100.0 | 415       | 100.0 |
|                                                                                                                                       | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Lymphadenectomy completed within 4 months after diagnosis (authorization of pathological report or positive cytology or positive SNB) | Yes              | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -     |
|                                                                                                                                       | No               | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -     |
| Adjuvant systemic treatment                                                                                                           |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Adjuvant systemic treatment                                                                                                           | Yes              | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                                                                       | No               | 83     | 100.0 | 66     | 98.5  | 73     | 100.0 | 86     | 100.0 | 105    | 99.1  | 413       | 99.5  |
|                                                                                                                                       | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -     |
| Immunotherapy with interferon α2b                                                                                                     |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF inhibitors                                                                                                                       |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| MEK inhibitors                                                                                                                        |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF in MEK inhibitors                                                                                                                |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Ipilimumab                                                                                                                            |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Nivolumab                                                                                                                             |                  | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
| Pembrolizumab                                                                                                                         |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Began systemic treatment within 8 weeks after last surgery                                                                            | Yes              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | No               | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
| Stage IIA                                                                                                                             |                  |        |       |        |       |        |       |        |       |        |       |           |       |
|                                                                                                                                       |                  | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                                                                    |                  | 39     |       | 67     |       | 54     |       | 40     |       | 62     |       | 262       |       |
| Mean (age)                                                                                                                            |                  | 66.0   |       | 64.6   |       | 66.2   |       | 68.2   |       | 65.9   |       | 66.0      |       |
| Median (age)                                                                                                                          |                  | 66     |       | 67     |       | 71     |       | 69.5   |       | 65.5   |       | 68        |       |
| Histological type (ICD-O-3 code)                                                                                                      |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                                                                        |                  | 2      | 5.1   | 15     | 22.4  | 10     | 18.5  | 5      | 12.5  | 9      | 14.5  | 41        | 15.6  |
| Nodular melanoma (8721)                                                                                                               |                  | 8      | 20.5  | 12     | 17.9  | 12     | 22.2  | 13     | 32.5  | 20     | 32.3  | 65        | 24.8  |
| Lentigo maligna (8742)                                                                                                                |                  | 1      | 2.6   | 3      | 4.5   | 2      | 3.7   | 1      | 2.5   | 0      | 0.0   | 7         | 2.7   |
| Superficial spreading melanoma (8743)                                                                                                 |                  | 25     | 64.1  | 32     | 47.8  | 25     | 46.3  | 20     | 50.0  | 29     | 46.8  | 131       | 50.0  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770–8772,8780)                                                     |                  | 3      | 7.7   | 5      | 7.5   | 5      | 9.3   | 1      | 2.5   | 4      | 6.5   | 18        | 6.9   |
| All (8720–8780)                                                                                                                       |                  | 39     | 100.0 | 67     | 100.0 | 54     | 100.0 | 40     | 100.0 | 62     | 100.0 | 262       | 100.0 |
| Diagnostic treatment                                                                                                                  |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                                                                    | No               | 3      | -     | 11     | 16.4  | 6      | 11.1  | 5      | 12.5  | 7      | 11.3  | 32        | 12.2  |
|                                                                                                                                       | PET-CT           | 0      | -     | 0      | -     | 1      | -     | 3      | -     | 0      | -     | 4         | -     |
|                                                                                                                                       | CT               | 2      | -     | 0      | -     | 1      | -     | 1      | -     | 3      | -     | 7         | 2.7   |
|                                                                                                                                       | MRI              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2      | -     | 2         | -     |
|                                                                                                                                       | US               | 15     | 38.5  | 23     | 34.3  | 15     | 27.8  | 9      | 22.5  | 17     | 27.4  | 79        | 30.2  |
|                                                                                                                                       | X-ray            | 28     | 71.8  | 55     | 82.1  | 45     | 83.3  | 33     | 82.5  | 51     | 82.3  | 212       | 80.9  |
|                                                                                                                                       | Unknown          | 2      | -     | 1      | -     | 1      | -     | 0      | -     | 0      | -     | 4         | 1.5   |

Continued. —&gt;

Table 26: Continued.

| Stage IIA                                                                                                                             |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                                                                       |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Microscopic confirmation of regional metastases                                                                                       | Metastases not confirmed | 0      | -     | 3      | -     | 9      | 16.7  | 0      | -     | 0      | -     | 12        | 4.6   |
|                                                                                                                                       | Cytologically confirmed  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | Histologically confirmed | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | No metastases            | 26     | 66.7  | 49     | 73.1  | 33     | 61.1  | 33     | 82.5  | 43     | 69.4  | 184       | 70.2  |
|                                                                                                                                       | Unknown                  | 13     | 33.3  | 15     | 22.4  | 12     | 22.2  | 7      | 17.5  | 19     | 30.6  | 66        | 25.2  |
| BRAF status determination                                                                                                             | Negative                 | 4      | -     | 7      | 10.4  | 3      | -     | 2      | -     | 7      | 11.3  | 23        | 8.8   |
|                                                                                                                                       | Positive                 | 3      | -     | 2      | -     | 3      | -     | 2      | -     | 4      | -     | 14        | 5.3   |
|                                                                                                                                       | Unknown                  | 32     | 82.1  | 58     | 86.6  | 48     | 88.9  | 36     | 90.0  | 51     | 82.3  | 225       | 85.9  |
|                                                                                                                                       | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Surgical treatment                                                                                                                    |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                                                                              | Yes                      | 39     | 100.0 | 67     | 100.0 | 53     | 98.1  | 40     | 100.0 | 62     | 100.0 | 261       | 99.6  |
|                                                                                                                                       | No                       | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                                                                       | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                                                                                  | < 20mm                   | 38     | 97.4  | 62     | 92.5  | 49     | 92.5  | 37     | 92.5  | 58     | 93.5  | 244       | 93.5  |
|                                                                                                                                       | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -     |
|                                                                                                                                       | Unknown                  | 1      | -     | 5      | 7.5   | 4      | -     | 3      | -     | 3      | -     | 16        | 6.1   |
| Deep surgical margin                                                                                                                  | < 20mm                   | 33     | 84.6  | 59     | 88.1  | 50     | 94.3  | 38     | 95.0  | 52     | 83.9  | 232       | 88.9  |
|                                                                                                                                       | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | Unknown                  | 6      | 15.4  | 8      | 11.9  | 3      | -     | 2      | -     | 10     | 16.1  | 29        | 11.1  |
| Re-excision if diagnostic excision margin < 20mm                                                                                      | Yes                      | 30     | 76.9  | 58     | 86.6  | 48     | 90.6  | 35     | 89.7  | 56     | 100.0 | 227       | 89.4  |
|                                                                                                                                       | No                       | 9      | 23.1  | 9      | 13.4  | 5      | 9.4   | 4      | -     | 0      | -     | 27        | 10.6  |
|                                                                                                                                       | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Sentinel lymph node biopsy (SNB)                                                                                                      | Yes                      | 26     | 66.7  | 52     | 77.6  | 41     | 75.9  | 33     | 82.5  | 45     | 72.6  | 197       | 75.2  |
|                                                                                                                                       | No                       | 12     | 30.8  | 15     | 22.4  | 13     | 24.1  | 5      | 12.5  | 12     | 19.4  | 57        | 21.8  |
|                                                                                                                                       | Not carried out*         | 1      | -     | 0      | -     | 0      | -     | 2      | -     | 5      | 8.1   | 8         | 3.1   |
| Positive lymph nodes at SNB                                                                                                           | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | No                       | 26     | 100.0 | 52     | 100.0 | 41     | 100.0 | 33     | 100.0 | 45     | 100   | 197       | 100.0 |
|                                                                                                                                       | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Diameter of the largest positive lymph node at SNB                                                                                    | < 0,3mm                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | 0,3 – 1,0mm              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | > 1,0mm                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| SNB completed within 3 months after diagnosis (authorization of pathological report of excision biopsy)                               | Yes                      | -      | -     | -      | -     | -      | -     | 31     | 93.9  | 42     | 93.3  | -         | -     |
|                                                                                                                                       | No                       | -      | -     | -      | -     | -      | -     | 2      | -     | 3      | -     | -         | -     |
| Lymphadenectomy                                                                                                                       | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | No                       | 39     | 100.0 | 67     | 100.0 | 54     | 100.0 | 40     | 100.0 | 62     | 100.0 | 262       | 100.0 |
|                                                                                                                                       | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Lymphadenectomy completed within 4 months after diagnosis (authorization of pathological report or positive cytology or positive SNB) | Yes                      | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -     |
|                                                                                                                                       | No                       | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -     |
| Adjuvant systemic treatment                                                                                                           |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Adjuvant systemic treatment                                                                                                           | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | No                       | 39     | 100.0 | 67     | 100.0 | 54     | 100.0 | 40     | 100.0 | 60     | 96.8  | 260       | 99.2  |
|                                                                                                                                       | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2      | -     | 2         | -     |
| Immunotherapy with interferon α2b                                                                                                     |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF inhibitors                                                                                                                       |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| MEK inhibitors                                                                                                                        |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF in MEK inhibitors                                                                                                                |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Ipilimumab                                                                                                                            |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IIA                                                                         |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|-----------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Nivolumab                                                                         |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Pembrolizumab                                                                     |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Began systemic treatment within 8 weeks after last surgery                        | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | No                       | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Stage IIB                                                                         |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                          | 40     |       | 45     |       | 38     |       | 26     |       | 50     |       | 199       |       |
| Mean (age)                                                                        |                          | 69.7   |       | 67.3   |       | 69.6   |       | 70.7   |       | 71.5   |       | 69.7      |       |
| Median (age)                                                                      |                          | 71.5   |       | 70     |       | 68.5   |       | 75     |       | 73     |       | 72        |       |
| Histological type (ICD-O-3 code)                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                          | 4      | -     | 8      | 17.8  | 5      | 13.2  | 6      | 23.1  | 3      | -     | 26        | 13.1  |
| Nodular melanoma (8721)                                                           |                          | 18     | 45.0  | 17     | 37.8  | 10     | 26.3  | 14     | 53.8  | 29     | 58.0  | 88        | 44.2  |
| Lentigo maligna (8742)                                                            |                          | 0      | -     | 2      | -     | 0      | -     | 1      | -     | 1      | -     | 4         | -     |
| Superficial spreading melanoma (8743)                                             |                          | 16     | 40.0  | 13     | 28.9  | 20     | 52.6  | 4      | -     | 15     | 30.0  | 68        | 34.2  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770–8772,8780) |                          | 2      | -     | 5      | 11.1  | 3      | -     | 1      | -     | 2      | -     | 13        | 6.5   |
| All (8720–8780)                                                                   |                          | 40     | 100.0 | 45     | 100.0 | 38     | 100.0 | 26     | 100.0 | 50     | 100.0 | 199       | 100.0 |
| Diagnostic treatment                                                              |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                | No                       | 1      | -     | 10     | 22.2  | 5      | 13.2  | 3      | -     | 8      | 16.0  | 27        | 13.6  |
|                                                                                   | PET-CT                   | 4      | -     | 4      | -     | 6      | 15.8  | 7      | 26.9  | 5      | 10.0  | 26        | 13.1  |
|                                                                                   | CT                       | 2      | -     | 0      | -     | 5      | 13.2  | 3      | -     | 2      | -     | 12        | 6.0   |
|                                                                                   | MRI                      | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                   | US                       | 14     | 35.0  | 13     | 28.9  | 17     | 44.7  | 8      | 30.8  | 24     | 48.0  | 76        | 38.2  |
|                                                                                   | X-ray                    | 33     | 82.5  | 35     | 77.8  | 30     | 78.9  | 19     | 73.1  | 38     | 76.0  | 155       | 77.9  |
|                                                                                   | Unknown                  | 5      | 12.5  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 5         | 2.5   |
| Mikroskopska potrditev regionalnih zasevkov                                       | Metastases not confirmed | 0      | -     | 4      | -     | 6      | 15.8  | 0      | -     | 0      | -     | 10        | 5.0   |
|                                                                                   | Cytologically confirmed  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Histologically confirmed | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | No metastases            | 29     | 72.5  | 34     | 75.6  | 19     | 50.0  | 16     | 61.5  | 28     | 56.0  | 126       | 63.3  |
|                                                                                   | Unknown                  | 11     | 27.5  | 7      | 15.6  | 13     | 34.2  | 10     | 38.5  | 22     | 44.0  | 63        | 31.7  |
| BRAF status determination                                                         | Negative                 | 2      | -     | 7      | 15.6  | 6      | 15.8  | 1      | -     | 5      | 10.0  | 21        | 10.6  |
|                                                                                   | Positive                 | 2      | -     | 5      | 11.1  | 0      | -     | 2      | -     | 8      | 16.0  | 17        | 8.5   |
|                                                                                   | Unknown                  | 36     | 90.0  | 33     | 73.3  | 32     | 84.2  | 23     | 88.5  | 37     | 74.0  | 161       | 80.9  |
|                                                                                   | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Surgical treatment                                                                |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                          | Yes                      | 40     | 100.0 | 45     | 100.0 | 38     | 100.0 | 26     | 100.0 | 50     | 100.0 | 199       | 100   |
|                                                                                   | No                       | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                              | < 20mm                   | 36     | 90.0  | 40     | 88.9  | 36     | 94.7  | 25     | 96.2  | 48     | 96.0  | 185       | 93.0  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -     |
|                                                                                   | Unknown                  | 4      | -     | 5      | 11.1  | 2      | -     | 1      | -     | 1      | -     | 13        | 6.5   |
| Deep surgical margin                                                              | < 20mm                   | 33     | 82.5  | 38     | 84.4  | 35     | 92.1  | 25     | 96.2  | 41     | 82.0  | 172       | 86.4  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Unknown                  | 7      | 17.5  | 7      | 15.6  | 3      | 7.9   | 1      | -     | 9      | 18.0  | 27        | 13.6  |
| Re-excision if diagnostic excision margin < 20mm                                  | Yes                      | 32     | 80.0  | 38     | 84.4  | 31     | 81.6  | 18     | 72.0  | 37     | 92.5  | 156       | 83.0  |
|                                                                                   | No                       | 8      | 20.0  | 7      | 15.6  | 7      | 18.4  | 7      | 28.0  | 3      | -     | 32        | 17.0  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IIB                                                                                                                             |                  |        |       |        |       |        |       |        |       |        |       |           |       |
|---------------------------------------------------------------------------------------------------------------------------------------|------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                                                                       |                  | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Surgical treatment                                                                                                                    |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Sentinel lymph node biopsy (SNB)                                                                                                      | Yes              | 29     | 72.5  | 39     | 86.7  | 24     | 63.2  | 16     | 61.5  | 29     | 58.0  | 137       | 68.8  |
|                                                                                                                                       | No               | 10     | 25.0  | 6      | 13.3  | 13     | 34.2  | 9      | 34.6  | 12     | 24.0  | 50        | 25.1  |
|                                                                                                                                       | Not carried out* | 1      | -     | 0      | -     | 1      | -     | 1      | -     | 9      | 18.0  | 12        | 6.0   |
| Positive lymph nodes at SNB                                                                                                           | Yes              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | No               | 29     | 100.0 | 39     | 100.0 | 24     | 100.0 | 16     | 100.0 | 29     | 100.0 | 137       | 100.0 |
|                                                                                                                                       | Unknown          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Diameter of the largest positive lymph node at SNB                                                                                    | < 0,3mm          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | 0,3 – 1,0mm      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | > 1,0mm          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| SNB completed within 3 months after diagnosis (authorization of pathological report of excision biopsy)                               | Yes              | -      | -     | -      | -     | -      | -     | 15     | 93.8  | 26     | 89.7  | -         | -     |
|                                                                                                                                       | No               | -      | -     | -      | -     | -      | -     | 1      | -     | 3      | -     | -         | -     |
| Lymphadenectomy                                                                                                                       | Yes              | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                                                                       | No               | 40     | 100.0 | 45     | 100.0 | 37     | 97.4  | 26     | 100.0 | 50     | 100.0 | 198       | 99.5  |
|                                                                                                                                       | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Lymphadenectomy completed within 4 months after diagnosis (authorization of pathological report or positive cytology or positive SNB) | Yes              | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -     |
|                                                                                                                                       | No               | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -     |
| Adjuvant systemic treatment                                                                                                           |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Adjuvant systemic treatment                                                                                                           | Yes              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 6      | 12.0  | 6         | 3.0   |
|                                                                                                                                       | No               | 40     | 100.0 | 45     | 100.0 | 38     | 100.0 | 26     | 100.0 | 44     | 88.0  | 193       | 97.0  |
|                                                                                                                                       | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Immunotherapy with interferon α2b                                                                                                     |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF inhibitors                                                                                                                       |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| MEK inhibitors                                                                                                                        |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF in MEK inhibitors                                                                                                                |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Ipilimumab                                                                                                                            |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Nivolumab                                                                                                                             |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Pembrolizumab                                                                                                                         |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 6      | 100.0 | 6         | 100.0 |
| Began systemic treatment within 8 weeks after last surgery                                                                            | Yes              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 6      | 100.0 | 6         | 100.0 |
|                                                                                                                                       | No               | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IIC                                                                         |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|-----------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                          | 44     |       | 39     |       | 42     |       | 31     |       | 54     |       | 210       |       |
| Mean (age)                                                                        |                          | 73.3   |       | 75.4   |       | 75.8   |       | 76.1   |       | 76.1   |       | 75.3      |       |
| Median (age)                                                                      |                          | 78.5   |       | 77     |       | 81     |       | 81     |       | 77     |       | 78.5      |       |
| Histological type (ICD-O-3 code)                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                          | 11     | 25.0  | 6      | 15.4  | 8      | 19.0  | 6      | 19.4  | 5      | 9.3   | 36        | 17.1  |
| Nodular melanoma (8721)                                                           |                          | 19     | 43.2  | 22     | 56.4  | 23     | 54.8  | 18     | 58.1  | 30     | 55.6  | 112       | 53.3  |
| Lentigo maligna (8742)                                                            |                          | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
| Superficial spreading melanoma (8743)                                             |                          | 13     | 29.5  | 10     | 25.6  | 11     | 26.2  | 5      | 16.1  | 16     | 29.6  | 55        | 26.2  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770-8772,8780) |                          | 0      | -     | 1      | -     | 0      | -     | 2      | -     | 3      | -     | 6         | 2.9   |
| All (8720–8780)                                                                   |                          | 44     | 100.0 | 39     | 100.0 | 42     | 100.0 | 31     | 100.0 | 54     | 100.0 | 210       | 100.0 |
| Diagnostic treatment                                                              |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                | No                       | 4      | -     | 12     | 30.8  | 10     | 23.8  | 5      | 16.1  | 11     | 20.4  | 42        | 20.0  |
|                                                                                   | PET-CT                   | 11     | 25.0  | 4      | -     | 2      | -     | 3      | -     | 8      | 14.8  | 28        | 13.3  |
|                                                                                   | CT                       | 2      | -     | 0      | -     | 6      | 14.3  | 2      | -     | 4      | -     | 14        | 6.7   |
|                                                                                   | MRI                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2      | -     | 2         | -     |
|                                                                                   | US                       | 17     | 38.6  | 16     | 41.0  | 16     | 38.1  | 17     | 54.8  | 22     | 40.7  | 88        | 41.9  |
|                                                                                   | X-ray                    | 37     | 84.1  | 24     | 61.5  | 29     | 69.0  | 23     | 74.2  | 33     | 61.1  | 146       | 69.5  |
|                                                                                   | Unknown                  | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
| Microscopic confirmation of regional metastases                                   | Metastases not confirmed | 0      | -     | 5      | 12.8  | 4      | -     | 0      | -     | 0      | -     | 9         | 4.3   |
|                                                                                   | Cytologically confirmed  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Histologically confirmed | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | No metastases            | 26     | 59.1  | 15     | 38.5  | 21     | 50.0  | 9      | 29.0  | 21     | 38.9  | 92        | 43.8  |
|                                                                                   | Unknown                  | 18     | 40.9  | 19     | 48.7  | 17     | 40.5  | 22     | 71.0  | 33     | 61.1  | 109       | 51.9  |
| BRAF status determination                                                         | Negative                 | 4      | -     | 2      | -     | 3      | -     | 1      | -     | 11     | 20.4  | 21        | 10.0  |
|                                                                                   | Positive                 | 4      | -     | 2      | -     | 6      | 14.3  | 6      | 19.4  | 4      | -     | 22        | 10.5  |
|                                                                                   | Unknown                  | 36     | 81.8  | 35     | 89.7  | 33     | 78.6  | 24     | 77.4  | 39     | 72.2  | 167       | 79.5  |
|                                                                                   | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Surgical treatment                                                                |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                          | Yes                      | 44     | 100.0 | 38     | 97.4  | 42     | 100.0 | 31     | 100.0 | 54     | 100.0 | 209       | 99.5  |
|                                                                                   | No                       | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                              | < 20mm                   | 39     | 88.6  | 37     | 97.4  | 41     | 97.6  | 28     | 90.3  | 52     | 96.3  | 197       | 94.3  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Unknown                  | 5      | 11.4  | 1      | -     | 1      | -     | 3      | -     | 2      | -     | 12        | 5.7   |
| Deep surgical margin                                                              | < 20mm                   | 39     | 88.6  | 36     | 94.7  | 36     | 85.7  | 28     | 90.3  | 51     | 94.4  | 190       | 90.9  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Unknown                  | 5      | 11.4  | 2      | -     | 6      | 14.3  | 3      | -     | 3      | -     | 19        | 9.1   |
| Re-excision if diagnostic excision margin < 20mm                                  | Yes                      | 31     | 70.5  | 26     | 70.3  | 28     | 68.3  | 16     | 59.3  | 33     | 86.8  | 134       | 71.7  |
|                                                                                   | No                       | 13     | 29.5  | 11     | 29.7  | 13     | 31.7  | 11     | 40.7  | 5      | 13.2  | 53        | 28.3  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Sentinel lymph node biopsy (SNB)                                                  | Yes                      | 26     | 59.1  | 15     | 38.5  | 23     | 54.8  | 8      | 25.8  | 21     | 38.9  | 93        | 44.3  |
|                                                                                   | No                       | 18     | 40.9  | 23     | 59.0  | 19     | 45.2  | 20     | 64.5  | 22     | 40.7  | 102       | 48.6  |
|                                                                                   | Not carried out*         | 0      | -     | 1      | -     | 0      | -     | 3      | -     | 11     | 20.4  | 15        | 7.1   |
| Positive lymph nodes at SNB                                                       | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | No                       | 26     | 100.0 | 15     | 100.0 | 23     | 100.0 | 8      | 100.0 | 21     | 100.0 | 93        | 100.0 |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Diameter of the largest positive lymph node at SNB                                | < 0,3mm                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | 0,3 – 1,0mm              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | > 1.0mm                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;



Table 26: Continued.

| Stage IIC                                                                                                                             |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                                                                       |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Surgical treatment                                                                                                                    |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| SNB completed within 3 months after diagnosis (authorization of pathological report of excision biopsy)                               | Yes                      | -      | -     | -      | -     | -      | -     | 8      | 100.0 | 19     | 90.5  | -         | -     |
|                                                                                                                                       | No                       | -      | -     | -      | -     | -      | -     | 0      | -     | 2      | -     | -         | -     |
| Lymphadenectomy                                                                                                                       | Yes                      | 0      | -     | 1      | -     | 1      | -     | 0      | -     | 0      | -     | 2         | -     |
|                                                                                                                                       | No                       | 44     | 100.0 | 38     | 97.4  | 41     | 97.6  | 31     | 100.0 | 54     | 100.0 | 208       | 99.0  |
|                                                                                                                                       | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Lymphadenectomy completed within 4 months after diagnosis (authorization of pathological report or positive cytology or positive SNB) | Yes                      | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -     |
|                                                                                                                                       | No                       | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -     |
| Adjuvant systemic treatment                                                                                                           |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Adjuvant systemic treatment                                                                                                           | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 5      | 9.3   | 5         | 2.4   |
|                                                                                                                                       | No                       | 43     | 97.7  | 38     | 97.4  | 42     | 100.0 | 31     | 100.0 | 45     | 83.3  | 199       | 94.8  |
|                                                                                                                                       | Not carried out*         | 1      | -     | 1      | -     | 0      | -     | 0      | -     | 4      | -     | 6         | 2.9   |
| Immunotherapy with interferon α2b                                                                                                     |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF inhibitors                                                                                                                       |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| MEK inhibitors                                                                                                                        |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF in MEK inhibitors                                                                                                                |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Ipilimumab                                                                                                                            |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Nivolumab                                                                                                                             |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Pembrolizumab                                                                                                                         |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 5      | 100.0 | 5         | 100.0 |
| Began systemic treatment within 8 weeks after last surgery                                                                            | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -     |
|                                                                                                                                       | No                       | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 4      | -     | 4         | -     |
| Stage IIIA                                                                                                                            |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|                                                                                                                                       |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                                                                    |                          | 9      |       | 12     |       | 9      |       | 10     |       | 9      |       | 49        |       |
| Mean (age)                                                                                                                            |                          | 57.9   |       | 51.3   |       | 58.4   |       | 56.7   |       | 48.4   |       | 54.4      |       |
| Median (age)                                                                                                                          |                          | 62     |       | 54.5   |       | 60     |       | 58     |       | 46     |       | 56        |       |
| Histological type (ICD-O-3 code)                                                                                                      |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                                                                        |                          | 2      | 22.2  | 4      | 33.3  | 1      | 11.1  | 3      | 30.0  | 2      | 22.2  | 12        | 24.5  |
| Nodular melanoma (8721)                                                                                                               |                          | 2      | 22.2  | 1      | 8.3   | 1      | 11.1  | 1      | 10.0  | 1      | 11.1  | 6         | 12.2  |
| Lentigo maligna (8742)                                                                                                                |                          | 0      | 0.0   | 1      | 8.3   | 0      | 0.0   | 0      | 0.0   | 0      | 0.0   | 1         | 2.0   |
| Superficial spreading melanoma (8743)                                                                                                 |                          | 5      | 55.6  | 5      | 41.7  | 6      | 66.7  | 6      | 60.0  | 6      | 66.7  | 28        | 57.1  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770-8772,8780)                                                     |                          | 0      | 0.0   | 1      | 8.3   | 1      | 11.1  | 0      | 0.0   | 0      | 0.0   | 2         | 4.1   |
| All (8720–8780)                                                                                                                       |                          | 9      | 100.0 | 12     | 100.0 | 9      | 100.0 | 10     | 100.0 | 9      | 100.0 | 49        | 100.0 |
| Diagnostic treatment                                                                                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                                                                    | No                       | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                                                                       | PET-CT                   | 2      | -     | 5      | 41.7  | 5      | 55.6  | 7      | 70.0  | 6      | 66.7  | 25        | 51.0  |
|                                                                                                                                       | CT                       | 1      | -     | 3      | -     | 1      | -     | 2      | -     | 1      | -     | 8         | 16.3  |
|                                                                                                                                       | MRI                      | 1      | -     | 0      | -     | 2      | -     | 0      | -     | 0      | -     | 3         | -     |
|                                                                                                                                       | US                       | 3      | -     | 6      | 50.0  | 2      | -     | 2      | -     | 4      | -     | 17        | 34.7  |
|                                                                                                                                       | X-ray                    | 8      | 88.9  | 12     | 100.0 | 7      | 77.8  | 10     | 100.0 | 8      | 88.9  | 45        | 91.8  |
|                                                                                                                                       | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Microscopic confirmation of regional metastases                                                                                       | Metastases not confirmed | 0      | -     | 1      | -     | 0      | -     | 1      | -     | 1      | -     | 3         | -     |
|                                                                                                                                       | Cytologically confirmed  | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1         | -     |
|                                                                                                                                       | Histologically confirmed | 9      | 100.0 | 11     | 91.7  | 9      | 100.0 | 8      | 80.0  | 8      | 88.9  | 45        | 91.8  |
|                                                                                                                                       | No metastases            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IIIA                                                                                                                            |                      |        |       |        |       |        |       |        |       |        |       |           |       |
|---------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                                                                       |                      | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Diagnostic treatment                                                                                                                  |                      | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| BRAF status determination                                                                                                             | Negative             | 2      | -     | 2      | -     | 4      | -     | 3      | -     | 3      | -     | 14        | 28.6  |
|                                                                                                                                       | Positive             | 2      | -     | 7      | 58.3  | 1      | -     | 6      | 60.0  | 3      | -     | 19        | 38.8  |
|                                                                                                                                       | Unknown              | 5      | 55.6  | 3      | -     | 4      | -     | 1      | -     | 1      | -     | 14        | 28.6  |
|                                                                                                                                       | Testing unsuccessful | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2      | -     | 2         | -     |
| Surgical treatment                                                                                                                    |                      | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                                                                              | Yes                  | 7      | 77.8  | 12     | 100.0 | 8      | 88.9  | 9      | 90.0  | 8      | 88.9  | 44        | 89.8  |
|                                                                                                                                       | No                   | 2      | -     | 0      | -     | 1      | -     | 1      | -     | 1      | -     | 5         | 10.2  |
|                                                                                                                                       | Not carried out*     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                                                                                  | < 20mm               | 7      | 100.0 | 12     | 100.0 | 8      | 100.0 | 9      | 100.0 | 8      | 100.0 | 44        | 100.0 |
|                                                                                                                                       | 20mm and more        | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | Unknown              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Deep surgical margin                                                                                                                  | < 20mm               | 7      | 100.0 | 9      | 75.0  | 6      | 75.0  | 8      | 88.9  | 7      | 87.5  | 37        | 84.1  |
|                                                                                                                                       | 20mm and more        | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                                                                       | Unknown              | 0      | -     | 3      | -     | 1      | -     | 1      | -     | 1      | -     | 6         | 13.6  |
| Re-excision if diagnostic excision margin < 20mm                                                                                      | Yes                  | 6      | 85.7  | 12     | 100.0 | 6      | 75.0  | 9      | 100.0 | 8      | 100.0 | 41        | 93.2  |
|                                                                                                                                       | No                   | 1      | -     | 0      | -     | 2      | -     | 0      | -     | 0      | -     | 3         | -     |
|                                                                                                                                       | Not carried out*     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Sentinel lymph node biopsy (SNB)                                                                                                      | Yes                  | 8      | 88.9  | 11     | 91.7  | 8      | 88.9  | 9      | 90.0  | 7      | 77.8  | 43        | 87.8  |
|                                                                                                                                       | No                   | 1      | -     | 1      | -     | 1      | -     | 1      | -     | 2      | -     | 6         | 12.2  |
|                                                                                                                                       | Not carried out*     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Positive lymph nodes at SNB                                                                                                           | Yes                  | 8      | 100.0 | 11     | 100.0 | 8      | 100.0 | 9      | 100.0 | 7      | 100.0 | 43        | 100.0 |
|                                                                                                                                       | No                   | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                                                                       | Unknown              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Diameter of the largest positive lymph node at SNB                                                                                    | < 0,3mm              | 1      | -     | 2      | -     | 2      | -     | 0      | -     | 2      | -     | 7         | 16.3  |
|                                                                                                                                       | 0,3 – 1,0mm          | 1      | -     | 3      | -     | 2      | -     | 2      | -     | 4      | -     | 12        | 27.9  |
|                                                                                                                                       | > 1,0mm              | 6      | 75.0  | 6      | 54.5  | 4      | -     | 7      | 77.8  | 1      | -     | 24        | 55.8  |
| Lymphadenectomy                                                                                                                       | Yes                  | 7      | 77.8  | 5      | 41.7  | 4      | -     | 2      | -     | 2      | -     | 20        | 40.8  |
|                                                                                                                                       | No                   | 2      | -     | 7      | 58.3  | 5      | 55.6  | 8      | 80.0  | 7      | 77.8  | 29        | 59.2  |
|                                                                                                                                       | Not carried out*     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Lymphadenectomy completed within 4 months after diagnosis (authorization of pathological report or positive cytology or positive SNB) | Yes                  | -      | -     | -      | -     | -      | -     | 1      | -     | 1      | -     | -         | -     |
|                                                                                                                                       | No                   | -      | -     | -      | -     | -      | -     | 1      | -     | 1      | -     | -         | -     |
| Adjuvant systemic treatment                                                                                                           |                      | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Adjuvant systemic treatment                                                                                                           | Yes                  | 2      | -     | 9      | 75.0  | 5      | 55.6  | 5      | 50.0  | 8      | 88.9  | 29        | 59.2  |
|                                                                                                                                       | No                   | 5      | 55.6  | 3      | -     | 2      | -     | 5      | 50.0  | 1      | -     | 16        | 32.7  |
|                                                                                                                                       | Not carried out*     | 2      | -     | 0      | -     | 2      | -     | 0      | -     | 0      | -     | 4         | -     |
| Immunotherapy with interferon α2b                                                                                                     |                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF inhibitors                                                                                                                       |                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| MEK inhibitors                                                                                                                        |                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF in MEK inhibitors                                                                                                                |                      | 0      | -     | 6      | 66.7  | 0      | -     | 1      | -     | 1      | -     | 8         | 27.6  |
| Ipilimumab                                                                                                                            |                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Nivolumab                                                                                                                             |                      | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 2         | -     |
| Pembrolizumab                                                                                                                         |                      | 1      | -     | 3      | -     | 5      | 100.0 | 4      | -     | 6      | 75.0  | 19        | 65.5  |
| Began systemic treatment within 8 weeks after last surgery                                                                            | Yes                  | 2      | -     | 7      | 77.8  | 5      | 100.0 | 2      | -     | 6      | 75.0  | 22        | 75.9  |
|                                                                                                                                       | No                   | 0      | -     | 2      | -     | 0      | -     | 3      | -     | 2      | -     | 7         | 24.1  |

Continued. —&gt;

Table 26: Continued.

| Stage IIIB                                                                        |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|-----------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                          | 23     |       | 20     |       | 19     |       | 21     |       | 23     |       | 106       |       |
| Mean (age)                                                                        |                          | 69.5   |       | 54.1   |       | 64.6   |       | 64.9   |       | 63.4   |       | 63.5      |       |
| Median (age)                                                                      |                          | 70     |       | 53.5   |       | 63     |       | 61     |       | 64     |       | 62        |       |
| Histological type (ICD-O-3 code)                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                          | 4      | -     | 6      | 30.0  | 4      | -     | 5      | 23.8  | 4      | -     | 23        | 21.7  |
| Nodular melanoma (8721)                                                           |                          | 4      | -     | 2      | -     | 1      | -     | 5      | 23.8  | 9      | 39.1  | 21        | 19.8  |
| Lentigo maligna (8742)                                                            |                          | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
| Superficial spreading melanoma (8743)                                             |                          | 13     | 56.5  | 11     | 55.0  | 13     | 68.4  | 9      | 42.9  | 9      | 39.1  | 55        | 51.9  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770–8772,8780) |                          | 2      | -     | 1      | -     | 0      | -     | 2      | -     | 1      | -     | 6         | 5.7   |
| All (8720–8780)                                                                   |                          | 23     | 100.0 | 20     | 100.0 | 19     | 100.0 | 21     | 100.0 | 23     | 100.0 | 106       | 100.0 |
| Diagnostic treatment                                                              |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                | No                       | 3      | -     | 1      | -     | 1      | -     | 1      | -     | 0      | -     | 6         | -     |
|                                                                                   | PET-CT                   | 11     | 47.8  | 11     | 55.0  | 11     | 57.9  | 15     | 71.4  | 16     | 69.6  | 64        | 60.4  |
|                                                                                   | CT                       | 4      | -     | 0      | -     | 3      | -     | 9      | 42.9  | 6      | 26.1  | 22        | 20.8  |
|                                                                                   | MRI                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | US                       | 8      | 34.8  | 13     | 65.0  | 7      | 36.8  | 9      | 42.9  | 7      | 30.4  | 44        | 41.5  |
|                                                                                   | X-ray                    | 20     | 87.0  | 16     | 80.0  | 16     | 84.2  | 19     | 90.5  | 21     | 91.3  | 92        | 86.8  |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Microscopic confirmation of regional metastases                                   | Metastases not confirmed | 0      | -     | 0      | -     | 0      | -     | 3      | -     | 1      | -     | 4         | -     |
|                                                                                   | Cytologically confirmed  | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
|                                                                                   | Histologically confirmed | 21     | 91.3  | 17     | 85.0  | 12     | 63.2  | 15     | 71.4  | 20     | 87.0  | 85        | 80.2  |
|                                                                                   | No metastases            | 1      | -     | 1      | -     | 4      | -     | 1      | -     | 0      | -     | 7         | 6.6   |
|                                                                                   | Unknown                  | 1      | -     | 1      | -     | 3      | -     | 2      | -     | 2      | -     | 9         | 8.5   |
| BRAF status determination                                                         | Negative                 | 5      | 21.7  | 3      | -     | 8      | 42.1  | 4      | -     | 8      | 34.8  | 28        | 26.4  |
|                                                                                   | Positive                 | 5      | 21.7  | 10     | 50.0  | 5      | 26.3  | 8      | 38.1  | 8      | 34.8  | 36        | 34.0  |
|                                                                                   | Unknown                  | 13     | 56.5  | 7      | 35.0  | 6      | 31.6  | 8      | 38.1  | 6      | 26.1  | 40        | 37.7  |
|                                                                                   | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1      | -     | 2         | -     |
| Surgical treatment                                                                |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                          | Yes                      | 19     | 82.6  | 15     | 75.0  | 17     | 89.5  | 19     | 90.5  | 22     | 95.7  | 92        | 86.8  |
|                                                                                   | No                       | 4      | -     | 5      | 25.0  | 2      | -     | 2      | -     | 1      | -     | 14        | 13.2  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                              | < 20mm                   | 19     | 100.0 | 15     | 100.0 | 16     | 94.1  | 19     | 100.0 | 20     | 90.9  | 89        | 96.7  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -     |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1      | -     | 2         | -     |
| Deep surgical margin                                                              | < 20mm                   | 17     | 89.5  | 14     | 93.3  | 16     | 94.1  | 16     | 84.2  | 17     | 77.3  | 80        | 87.0  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Unknown                  | 2      | -     | 1      | -     | 1      | -     | 3      | -     | 5      | 22.7  | 12        | 13.0  |
| Re-excision if diagnostic excision margin < 20mm                                  | Yes                      | 16     | 84.2  | 15     | 100.0 | 15     | 88.2  | 17     | 89.5  | 20     | 90.9  | 83        | 90.2  |
|                                                                                   | No                       | 3      | -     | 0      | -     | 2      | -     | 2      | -     | 2      | -     | 9         | 9.8   |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Sentinel lymph node biopsy (SNB)                                                  | Yes                      | 14     | 60.9  | 14     | 70.0  | 16     | 84.2  | 17     | 81.0  | 19     | 82.6  | 80        | 75.5  |
|                                                                                   | No                       | 9      | 39.1  | 6      | 30.0  | 3      | -     | 4      | -     | 4      | -     | 26        | 24.5  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Positive lymph nodes at SNB                                                       | Yes                      | 13     | 92.9  | 11     | 78.6  | 12     | 75.0  | 13     | 76.5  | 15     | 78.9  | 64        | 80.0  |
|                                                                                   | No                       | 1      | -     | 3      | -     | 4      | -     | 4      | -     | 4      | -     | 16        | 20.0  |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IIIB                                                                                                                        |                  |        |      |        |       |        |       |        |       |        |       |           |      |
|-----------------------------------------------------------------------------------------------------------------------------------|------------------|--------|------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|------|
|                                                                                                                                   |                  | 2018   |      | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |      |
| Surgical treatment                                                                                                                |                  | Number | %    | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %    |
| Diameter of the largest positive lymph node at SNB                                                                                | < 0,3mm          | 0      | -    | 2      | -     | 0      | -     | 2      | -     | 3      | -     | 7         | 10.9 |
|                                                                                                                                   | 0,3 – 1,0mm      | 7      | 53.8 | 4      | -     | 3      | -     | 6      | 46.2  | 2      | -     | 22        | 34.4 |
|                                                                                                                                   | > 1,0mm          | 6      | 46.2 | 5      | 45.5  | 9      | 75.0  | 5      | 38.5  | 10     | 66.7  | 35        | 54.7 |
| Lymphadenectomy                                                                                                                   | Yes              | 12     | 52.2 | 9      | 45.0  | 2      | -     | 4      | -     | 1      | -     | 28        | 26.4 |
|                                                                                                                                   | No               | 11     | 47.8 | 11     | 55.0  | 17     | 89.5  | 17     | 81.0  | 22     | 95.7  | 78        | 73.6 |
|                                                                                                                                   | Not carried out* | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| ILP                                                                                                                               | Yes              | 1      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -    |
|                                                                                                                                   | No               | 22     | 95.7 | 20     | 100.0 | 19     | 100.0 | 21     | 100.0 | 23     | 100.0 | 105       | 99.1 |
|                                                                                                                                   | Not carried out* | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| Surgery (lymphadenectomy, excision, ILP) within 4 weeks after diagnosis (authorization of pathological report of excision biopsy) | Yes              | -      | -    | -      | -     | -      | -     | 19     | 90.5  | 22     | 95.7  | -         | -    |
|                                                                                                                                   | No               | -      | -    | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -    |
| Adjuvant RT treatment                                                                                                             |                  | Number | %    | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %    |
| Radiotherapy                                                                                                                      | Yes              | 4      | -    | 3      | -     | 1      | -     | 0      | -     | 1      | -     | 9         | 8.5  |
|                                                                                                                                   | No               | 19     | 82.6 | 17     | 85.0  | 18     | 94.7  | 21     | 100.0 | 22     | 95.7  | 97        | 91.5 |
|                                                                                                                                   | Not carried out* | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| Radiotherapy type                                                                                                                 | Primary          | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
|                                                                                                                                   | Postoperative    | 4      | -    | 3      | -     | 1      | -     | 0      | -     | 0      | -     | 8         | 88.9 |
|                                                                                                                                   | Palliative       | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -    |
| Began radiotherapy within 6 weeks after diagnosis (authorization of pathological report of excision biopsy)                       | Yes              | -      | -    | -      | -     | -      | -     | 0      | -     | 1      | -     | -         | -    |
|                                                                                                                                   | No               | -      | -    | -      | -     | -      | -     | 0      | -     | 0      | -     | -         | -    |
| Adjuvant systemic treatment                                                                                                       |                  | Number | %    | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %    |
| Adjuvant systemic treatment                                                                                                       | Yes              | 4      | -    | 8      | 40.0  | 7      | 36.8  | 10     | 47.6  | 14     | 60.9  | 43        | 40.6 |
|                                                                                                                                   | No               | 18     | 78.3 | 12     | 60.0  | 12     | 63.2  | 9      | 42.9  | 6      | 26.1  | 57        | 53.8 |
|                                                                                                                                   | Not carried out* | 1      | -    | 0      | -     | 0      | -     | 2      | -     | 3      | -     | 6         | 5.7  |
| Immunotherapy with interferon α2b                                                                                                 |                  | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| BRAF inhibitors                                                                                                                   |                  | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| MEK inhibitors                                                                                                                    |                  | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| BRAF in MEK inhibitors                                                                                                            |                  | 1      | -    | 6      | 75.0  | 1      | -     | 1      | -     | 2      | -     | 11        | 25.6 |
| Ipilimumab                                                                                                                        |                  | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| Nivolumab                                                                                                                         |                  | 3      | -    | 2      | -     | 1      | -     | 2      | -     | 0      | -     | 8         | 18.6 |
| Pembrolizumab                                                                                                                     |                  | 0      | -    | 0      | -     | 5      | 71.4  | 7      | 70.0  | 12     | 85.7  | 24        | 55.8 |
| Began systemic treatment within 8 weeks after last surgery                                                                        | Yes              | 2      | -    | 6      | 75.0  | 7      | 100.0 | 9      | 90.0  | 8      | 57.1  | 32        | 74.4 |
|                                                                                                                                   | No               | 2      | -    | 2      | -     | 0      | -     | 1      | -     | 6      | 42.9  | 11        | 25.6 |

Continued. —&gt;

Table 26: Continued.

| Stage IIIC                                                                        |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|-----------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                          | 48     |       | 53     |       | 44     |       | 62     |       | 44     |       | 251       |       |
| Mean (age)                                                                        |                          | 68.5   |       | 66.8   |       | 67.3   |       | 68.7   |       | 70.5   |       | 68.3      |       |
| Median (age)                                                                      |                          | 72.5   |       | 68     |       | 71     |       | 70     |       | 71     |       | 70        |       |
| Histological type (ICD-O-3 code)                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                          | 15     | 31.3  | 11     | 20.8  | 10     | 22.7  | 16     | 25.8  | 10     | 22.7  | 62        | 24.7  |
| Nodular melanoma (8721)                                                           |                          | 15     | 31.3  | 18     | 34.0  | 18     | 40.9  | 32     | 51.6  | 17     | 38.6  | 100       | 39.8  |
| Lentigo maligna (8742)                                                            |                          | 2      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2         | -     |
| Superficial spreading melanoma (8743)                                             |                          | 15     | 31.3  | 21     | 39.6  | 12     | 27.3  | 14     | 22.6  | 13     | 29.5  | 75        | 29.9  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770–8772,8780) |                          | 1      | -     | 3      | -     | 4      | -     | 0      | -     | 4      | -     | 12        | 4.8   |
| All (8720–8780)                                                                   |                          | 48     | 100.0 | 53     | 100.0 | 44     | 100.0 | 62     | 100.0 | 44     | 100.0 | 251       | 100.0 |
| Diagnostic treatment                                                              |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                | No                       | 1      | -     | 2      | -     | 3      | -     | 1      | -     | 3      | -     | 10        | 4.0   |
|                                                                                   | PET-CT                   | 26     | 54.2  | 31     | 58.5  | 33     | 75.0  | 34     | 54.8  | 29     | 65.9  | 153       | 61.0  |
|                                                                                   | CT                       | 7      | 14.6  | 7      | 13.2  | 9      | 20.5  | 31     | 50.0  | 12     | 27.3  | 66        | 26.3  |
|                                                                                   | MRI                      | 0      | -     | 0      | -     | 2      | -     | 5      | 8.1   | 1      | -     | 8         | 3.2   |
|                                                                                   | US                       | 23     | 47.9  | 31     | 58.5  | 25     | 56.8  | 34     | 54.8  | 23     | 52.3  | 136       | 54.2  |
|                                                                                   | X-ray                    | 39     | 81.3  | 44     | 83.0  | 34     | 77.3  | 47     | 75.8  | 33     | 75.0  | 197       | 78.5  |
|                                                                                   | Unknown                  | 2      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2         | -     |
| Microscopic confirmation of regional metastases                                   | Metastases not confirmed | 0      | -     | 3      | -     | 5      | 11.4  | 8      | 12.9  | 5      | 11.4  | 21        | 8.4   |
|                                                                                   | Cytologically confirmed  | 0      | -     | 1      | -     | 2      | -     | 4      | -     | 3      | -     | 10        | 4.0   |
|                                                                                   | Histologically confirmed | 41     | 85.4  | 42     | 79.2  | 33     | 75.0  | 44     | 71.0  | 32     | 72.7  | 192       | 76.5  |
|                                                                                   | No metastases            | 3      | -     | 3      | -     | 1      | -     | 3      | -     | 0      | -     | 10        | 4.0   |
|                                                                                   | Unknown                  | 4      | -     | 4      | -     | 3      | -     | 3      | -     | 4      | -     | 18        | 7.2   |
| BRAF status determination                                                         | Negative                 | 7      | 14.6  | 14     | 26.4  | 17     | 38.6  | 16     | 25.8  | 22     | 50.0  | 76        | 30.3  |
|                                                                                   | Positive                 | 10     | 20.8  | 18     | 34.0  | 16     | 36.4  | 30     | 48.4  | 14     | 31.8  | 88        | 35.1  |
|                                                                                   | Unknown                  | 31     | 64.6  | 21     | 39.6  | 11     | 25.0  | 16     | 25.8  | 8      | 18.2  | 87        | 34.7  |
|                                                                                   | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Surgical treatment                                                                |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                          | Yes                      | 45     | 93.8  | 49     | 92.5  | 39     | 88.6  | 56     | 90.3  | 38     | 86.4  | 227       | 90.4  |
|                                                                                   | No                       | 3      | -     | 4      | -     | 5      | 11.4  | 6      | 9.7   | 6      | 13.6  | 24        | 9.6   |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                              | < 20mm                   | 41     | 91.1  | 43     | 87.8  | 34     | 87.2  | 52     | 92.9  | 33     | 86.8  | 203       | 89.4  |
|                                                                                   | 20mm and more            | 1      | -     | 1      | -     | 0      | -     | 0      | -     | 2      | -     | 4         | -     |
|                                                                                   | Unknown                  | 3      | -     | 5      | 10.2  | 5      | 12.8  | 4      | -     | 3      | -     | 20        | 8.8   |
| Deep surgical margin                                                              | < 20mm                   | 38     | 84.4  | 40     | 81.6  | 32     | 82.1  | 49     | 87.5  | 31     | 81.6  | 190       | 83.7  |
|                                                                                   | 20mm and more            | 2      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2         | -     |
|                                                                                   | Unknown                  | 5      | 11.1  | 9      | 18.4  | 7      | 17.9  | 7      | 12.5  | 7      | 18.4  | 35        | 15.4  |
| Re-excision if diagnostic excision margin < 20mm                                  | Yes                      | 29     | 65.9  | 41     | 83.7  | 28     | 71.8  | 45     | 81.8  | 29     | 76.3  | 172       | 76.4  |
|                                                                                   | No                       | 15     | 34.1  | 8      | 16.3  | 11     | 28.2  | 10     | 18.2  | 9      | 23.7  | 53        | 23.6  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Sentinel lymph node biopsy (SNB)                                                  | Yes                      | 29     | 60.4  | 32     | 60.4  | 26     | 59.1  | 38     | 61.3  | 25     | 56.8  | 150       | 59.8  |
|                                                                                   | No                       | 19     | 39.6  | 21     | 39.6  | 18     | 40.9  | 23     | 37.1  | 16     | 36.4  | 97        | 38.6  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 3      | -     | 4         | -     |
| Positive lymph nodes at SNB                                                       | Yes                      | 24     | 82.8  | 26     | 81.3  | 21     | 80.8  | 32     | 84.2  | 23     | 92.0  | 126       | 84.0  |
|                                                                                   | No                       | 5      | 17.2  | 6      | 18.8  | 5      | 19.2  | 6      | 15.8  | 2      | 8.0   | 24        | 16.0  |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IIIC                                                                                                                        |                  |        |      |        |       |        |       |        |       |        |       |           |      |
|-----------------------------------------------------------------------------------------------------------------------------------|------------------|--------|------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|------|
|                                                                                                                                   |                  | 2018   |      | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |      |
| Surgical treatment                                                                                                                |                  | Number | %    | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %    |
| Diameter of the largest positive lymph node at SNB                                                                                | < 0,3mm          | 0      | -    | 1      | -     | 1      | -     | 2      | -     | 3      | -     | 7         | 5.6  |
|                                                                                                                                   | 0,3 – 1,0mm      | 4      | -    | 4      | -     | 7      | 33.3  | 7      | 21.9  | 8      | 34.8  | 30        | 23.8 |
|                                                                                                                                   | > 1,0mm          | 20     | 83.3 | 21     | 80.8  | 13     | 61.9  | 23     | 71.9  | 12     | 52.2  | 89        | 70.6 |
| Lymphadenectomy                                                                                                                   | Yes              | 30     | 62.5 | 29     | 54.7  | 17     | 38.6  | 21     | 33.9  | 11     | 25.0  | 108       | 43.0 |
|                                                                                                                                   | No               | 18     | 37.5 | 24     | 45.3  | 25     | 56.8  | 41     | 66.1  | 30     | 68.2  | 138       | 55.0 |
|                                                                                                                                   | Not carried out* | 0      | -    | 0      | -     | 2      | -     | 0      | -     | 3      | -     | 5         | 2.0  |
| ILP                                                                                                                               | Yes              | 1      | -    | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 2         | -    |
|                                                                                                                                   | No               | 47     | 97.9 | 52     | 98.1  | 44     | 100.0 | 62     | 100.0 | 44     | 100.0 | 249       | 99.2 |
|                                                                                                                                   | Not carried out* | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| Surgery (lymphadenectomy, excision, ILP) within 4 weeks after diagnosis (authorization of pathological report of excision biopsy) | Yes              | -      | -    | -      | -     | -      | -     | 56     | 90.3  | 38     | 86.4  | -         | -    |
|                                                                                                                                   | No               | -      | -    | -      | -     | -      | -     | 0      | 0.0   | 0      | 0.0   | -         | -    |
| Radiotherapeutic treatment                                                                                                        |                  | Number | %    | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %    |
| Radiotherapy                                                                                                                      | Yes              | 13     | 27.1 | 20     | 37.7  | 13     | 29.5  | 12     | 19.4  | 9      | 20.5  | 67        | 26.7 |
|                                                                                                                                   | No               | 35     | 72.9 | 33     | 62.3  | 29     | 65.9  | 50     | 80.6  | 34     | 77.3  | 181       | 72.1 |
|                                                                                                                                   | Not carried out* | 0      | -    | 0      | -     | 2      | -     | 0      | -     | 1      | -     | 3         | -    |
| Radiotherapy type                                                                                                                 | Primary          | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -    |
|                                                                                                                                   | Postoperative    | 12     | 92.3 | 20     | 100.0 | 12     | 92.3  | 12     | 100.0 | 7      | 77.8  | 63        | 94.0 |
|                                                                                                                                   | Palliative       | 1      | -    | 0      | -     | 1      | -     | 0      | -     | 1      | -     | 3         | -    |
| Adjuvant systemic treatment                                                                                                       |                  | Number | %    | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %    |
| Adjuvant systemic treatment                                                                                                       | Yes              | 13     | 27.1 | 28     | 52.8  | 18     | 40.9  | 33     | 53.2  | 15     | 34.1  | 107       | 42.6 |
|                                                                                                                                   | No               | 34     | 70.8 | 25     | 47.2  | 23     | 52.3  | 24     | 38.7  | 23     | 52.3  | 129       | 51.4 |
|                                                                                                                                   | Not carried out* | 1      | -    | 0      | -     | 3      | -     | 5      | 8.1   | 6      | 13.6  | 15        | 6.0  |
| Immunotherapy with interferon α2b                                                                                                 |                  | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| BRAF inhibitors                                                                                                                   |                  | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| MEK inhibitors                                                                                                                    |                  | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| BRAF in MEK inhibitors                                                                                                            |                  | 2      | -    | 9      | 32.1  | 6      | 33.3  | 8      | 24.2  | 1      | -     | 26        | 24.3 |
| Ipilimumab                                                                                                                        |                  | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| Nivolumab                                                                                                                         |                  | 9      | 69.2 | 12     | 42.9  | 3      | -     | 3      | -     | 0      | -     | 27        | 25.2 |
| Pembrolizumab                                                                                                                     |                  | 2      | -    | 7      | 25.0  | 9      | 50.0  | 22     | 66.7  | 14     | 93.3  | 54        | 50.5 |
| Began systemic treatment within 8 weeks after last surgery                                                                        | Yes              | 12     | 92.3 | 21     | 75.0  | 14     | 77.8  | 23     | 69.7  | 6      | 40.0  | 76        | 71.0 |
|                                                                                                                                   | No               | 1      | -    | 7      | 25.0  | 4      | -     | 10     | 30.3  | 9      | 60.0  | 31        | 29.0 |

Continued. —&gt;

Table 26: Continued.

| Stage IIID                                                                        |                          |        |       |        |       |        |       |        |       |        |      |           |       |
|-----------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|------|-----------|-------|
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |      | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                          | 6      |       | 9      |       | 6      |       | 12     |       | 4      |      | 37        |       |
| Mean (age)                                                                        |                          | 80.0   |       | 65.8   |       | 73.0   |       | 68.1   |       | 61.8   |      | 69.6      |       |
| Median (age)                                                                      |                          | 78.5   |       | 69     |       | 78     |       | 68     |       | 60     |      | 70        |       |
| Histological type (ICD-O-3 code)                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %    | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                          | 0      | -     | 2      | -     | 0      | -     | 1      | -     | 0      | -    | 3         | -     |
| Nodular melanoma (8721)                                                           |                          | 5      | 83.3  | 5      | 55.6  | 4      | 66.7  | 6      | 50.0  | 3      | 75.0 | 23        | 62.2  |
| Lentigo maligna (8742)                                                            |                          | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -    | 1         | -     |
| Superficial spreading melanoma (8743)                                             |                          | 1      | -     | 2      | -     | 1      | -     | 4      | -     | 1      | -    | 9         | 24.3  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770–8772,8780) |                          | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -    | 1         | -     |
| All (8720–8780)                                                                   |                          | 6      | 100.0 | 9      | 100.0 | 6      | 100.0 | 12     | 100.0 | 4      | -    | 37        | 100.0 |
| Diagnostic treatment                                                              |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %    | Number    | %     |
| Diagnostic staging                                                                | No                       | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | PET-CT                   | 4      | -     | 6      | 66.7  | 4      | -     | 12     | 100.0 | 3      | -    | 29        | 78.4  |
|                                                                                   | CT                       | 0      | -     | 3      | -     | 2      | -     | 4      | -     | 2      | -    | 11        | 29.7  |
|                                                                                   | MRI                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | US                       | 2      | -     | 5      | 55.6  | 2      | -     | 9      | 75.0  | 2      | -    | 20        | 54.1  |
|                                                                                   | X-ray                    | 6      | 100.0 | 8      | 88.9  | 5      | 83.3  | 11     | 91.7  | 4      | -    | 34        | 91.9  |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
| Microscopic confirmation of regional metastases                                   | Metastases not confirmed | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | Cytologically confirmed  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | Histologically confirmed | 6      | 100.0 | 9      | 100.0 | 6      | 100.0 | 12     | 100.0 | 4      | -    | 37        | 100.0 |
|                                                                                   | No metastases            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
| BRAF status determination                                                         | Negative                 | 0      | -     | 2      | -     | 2      | -     | 3      | -     | 2      | -    | 9         | 24.3  |
|                                                                                   | Positive                 | 2      | -     | 2      | -     | 3      | -     | 7      | 58.3  | 2      | -    | 16        | 43.2  |
|                                                                                   | Unknown                  | 4      | -     | 5      | 55.6  | 1      | -     | 2      | -     | 0      | -    | 12        | 32.4  |
|                                                                                   | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
| Surgical treatment                                                                |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %    | Number    | %     |
| Excision                                                                          | Yes                      | 6      | 100.0 | 9      | 100.0 | 6      | 100.0 | 12     | 100.0 | 4      | -    | 37        | 100.0 |
|                                                                                   | No                       | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
| Side surgical margin                                                              | < 20mm                   | 6      | 100.0 | 8      | 88.9  | 4      | -     | 9      | 75.0  | 4      | -    | 31        | 83.8  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | Unknown                  | 0      | -     | 1      | -     | 2      | -     | 3      | -     | 0      | -    | 6         | 16.2  |
| Deep surgical margin                                                              | < 20mm                   | 6      | 100.0 | 7      | 77.8  | 3      | -     | 9      | 75.0  | 4      | -    | 29        | 78.4  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | Unknown                  | 0      | -     | 2      | -     | 3      | -     | 3      | -     | 0      | -    | 8         | 21.6  |
| Re-excision if diagnostic excision margin < 20mm                                  | Yes                      | 4      | -     | 7      | 77.8  | 5      | 83.3  | 9      | 75.0  | 1      | -    | 26        | 70.3  |
|                                                                                   | No                       | 2      | -     | 2      | -     | 1      | -     | 3      | -     | 3      | -    | 11        | 29.7  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
| Sentinel lymph node biopsy                                                        | Yes                      | 1      | -     | 1      | -     | 2      | -     | 2      | 16.7  | 0      | -    | 6         | 16.2  |
|                                                                                   | No                       | 5      | 83.3  | 8      | 88.9  | 4      | -     | 10     | 83.3  | 4      | -    | 31        | 83.8  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
| Positive lymph nodes at SNB                                                       | Yes                      | 1      | -     | 1      | -     | 2      | -     | 2      | -     | 0      | -    | 6         | 100.0 |
|                                                                                   | No                       | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -    | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IIID                                                                                                                        |                  |        |       |        |       |        |       |        |       |        |   |           |       |
|-----------------------------------------------------------------------------------------------------------------------------------|------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|---|-----------|-------|
|                                                                                                                                   |                  | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |   | 2018–2022 |       |
| Surgical treatment                                                                                                                |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | % | Number    | %     |
| Diameter of the largest positive lymph node at SNB                                                                                | < 0,3mm          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
|                                                                                                                                   | 0,3 – 1,0mm      | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | - | 1         | -     |
|                                                                                                                                   | > 1,0mm          | 1      | -     | 1      | -     | 1      | -     | 2      | -     | 0      | - | 5         | 83.3  |
| Lymphadenectomy                                                                                                                   | Yes              | 6      | 100.0 | 9      | 100.0 | 4      | -     | 12     | 100.0 | 3      | - | 34        | 91.9  |
|                                                                                                                                   | No               | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1      | - | 2         | -     |
|                                                                                                                                   | Not carried out* | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | - | 1         | -     |
| ILP                                                                                                                               | Yes              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
|                                                                                                                                   | No               | 6      | 100.0 | 9      | 100.0 | 6      | 100.0 | 12     | 100.0 | 4      | - | 37        | 100.0 |
|                                                                                                                                   | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
| Surgery (lymphadenectomy, excision, ILP) within 4 weeks after diagnosis (authorization of pathological report of excision biopsy) | Yes              | -      | -     | -      | -     | -      | -     | 12     | 100.0 | 4      | - | -         | -     |
|                                                                                                                                   | No               | -      | -     | -      | -     | -      | -     | 0      | -     | 0      | - | -         | -     |
| Radiotherapeutic treatment                                                                                                        |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | % | Number    | %     |
| Radiotherapy                                                                                                                      | Yes              | 4      | -     | 8      | 88.9  | 2      | -     | 8      | 66.7  | 1      | - | 23        | 62.2  |
|                                                                                                                                   | No               | 2      | -     | 1      | -     | 4      | -     | 3      | -     | 3      | - | 13        | 35.1  |
|                                                                                                                                   | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | - | 1         | -     |
| Radiotherapy type                                                                                                                 | Primary          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
|                                                                                                                                   | Postoperative    | 4      | -     | 8      | 100.0 | 2      | -     | 8      | 100.0 | 1      | - | 23        | 100.0 |
|                                                                                                                                   | Palliative       | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
| Adjuvant systemic treatment                                                                                                       |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | % | Number    | %     |
| Adjuvant systemic treatment                                                                                                       | Yes              | 1      | -     | 3      | -     | 4      | -     | 4      | -     | 2      | - | 14        | 37.8  |
|                                                                                                                                   | No               | 5      | 83.3  | 5      | 55.6  | 1      | -     | 7      | 58.3  | 2      | - | 20        | 54.1  |
|                                                                                                                                   | Not carried out* | 0      | -     | 1      | -     | 1      | -     | 1      | -     | 0      | - | 3         | -     |
| Immunotherapy with interferon α2b                                                                                                 |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
| BRAF inhibitors                                                                                                                   |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
| MEK inhibitors                                                                                                                    |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
| BRAF in MEK inhibitors                                                                                                            |                  | 0      | -     | 2      | -     | 1      | -     | 3      | -     | 1      | - | 7         | 50.0  |
| Ipilimumab                                                                                                                        |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | - | 0         | -     |
| Nivolumab                                                                                                                         |                  | 1      | -     | 1      | -     | 1      | -     | 1      | -     | 0      | - | 4         | -     |
| Pembrolizumab                                                                                                                     |                  | 0      | -     | 0      | -     | 2      | -     | 0      | -     | 1      | - | 3         | -     |
| Began systemic treatment within 8 weeks after last surgery                                                                        | Yes              | 1      | -     | 2      | -     | 4      | -     | 2      | -     | 1      | - | 10        | 71.4  |
|                                                                                                                                   | No               | 0      | -     | 1      | -     | 0      | -     | 2      | -     | 1      | - | 4         | -     |

Continued. —&gt;



Table 26: Continued.

| Stage IV                                                                          |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|-----------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                          | 21     |       | 17     |       | 13     |       | 23     |       | 19     |       | 93        |       |
| Mean (age)                                                                        |                          | 61.2   |       | 70.4   |       | 66.1   |       | 69.3   |       | 68.2   |       | 67.0      |       |
| Median (age)                                                                      |                          | 65     |       | 72     |       | 71     |       | 65     |       | 69     |       | 68        |       |
| Histological type (ICD-O-3 code)                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                          | 10     | 47.6  | 10     | 58.8  | 9      | 69.2  | 10     | 43.5  | 4      | 21.1  | 43        | 46.2  |
| Nodular melanoma (8721)                                                           |                          | 8      | 38.1  | 5      | 29.4  | 1      | -     | 7      | 30.4  | 10     | 52.6  | 31        | 33.3  |
| Lentigo maligna (8742)                                                            |                          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Superficial spreading melanoma (8743)                                             |                          | 1      | -     | 2      | -     | 3      | -     | 4      | -     | 4      | -     | 14        | 15.1  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770-8772,8780) |                          | 2      | -     | 0      | -     | 0      | -     | 2      | -     | 1      | -     | 5         | 5.4   |
| All (8720–8780)                                                                   |                          | 21     | 100.0 | 17     | 100.0 | 13     | 100.0 | 23     | 100.0 | 19     | 100.0 | 93        | 100.0 |
| Diagnostic treatment                                                              |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                | No                       | 1      | -     | 1      | -     | 1      | -     | 1      | -     | 0      | -     | 4         | -     |
|                                                                                   | PET-CT                   | 17     | 81.0  | 12     | 70.6  | 8      | 61.5  | 16     | 69.6  | 11     | 57.9  | 64        | 68.8  |
|                                                                                   | CT                       | 11     | 52.4  | 6      | 35.3  | 7      | 53.8  | 10     | 43.5  | 14     | 73.7  | 48        | 51.6  |
|                                                                                   | MRI                      | 2      | -     | 3      | -     | 2      | -     | 2      | -     | 4      | -     | 13        | 14.0  |
|                                                                                   | US                       | 6      | 28.6  | 6      | 35.3  | 6      | 46.2  | 16     | 69.6  | 10     | 52.6  | 44        | 47.3  |
|                                                                                   | X-ray                    | 7      | 33.3  | 11     | 64.7  | 8      | 61.5  | 17     | 73.9  | 13     | 68.4  | 56        | 60.2  |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1         | -     |
| Microscopic confirmation of regional metastases                                   | Metastases not confirmed | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 2      | -     | 3         | -     |
|                                                                                   | Cytologically confirmed  | 9      | 42.9  | 3      | -     | 3      | -     | 10     | 43.5  | 6      | 31.6  | 31        | 33.3  |
|                                                                                   | Histologically confirmed | 4      | -     | 4      | -     | 3      | -     | 8      | 34.8  | 3      | -     | 22        | 23.7  |
|                                                                                   | No metastases            | 1      | -     | 0      | -     | 1      | -     | 0      | -     | 2      | -     | 4         | -     |
|                                                                                   | Unknown                  | 7      | 33.3  | 9      | 52.9  | 6      | 46.2  | 5      | 21.7  | 6      | 31.6  | 33        | 35.5  |
| BRAF status determination                                                         | Negative                 | 10     | 47.6  | 3      | -     | 4      | -     | 11     | 47.8  | 5      | 26.3  | 33        | 35.5  |
|                                                                                   | Positive                 | 8      | 38.1  | 8      | 47.1  | 5      | 38.5  | 7      | 30.4  | 8      | 42.1  | 36        | 38.7  |
|                                                                                   | Unknown                  | 3      | -     | 6      | 35.3  | 4      | -     | 5      | 21.7  | 6      | 31.6  | 24        | 25.8  |
|                                                                                   | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Surgical treatment                                                                |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                          | Yes                      | 11     | 52.4  | 9      | 52.9  | 9      | 69.2  | 18     | 78.3  | 16     | 84.2  | 63        | 67.7  |
|                                                                                   | No                       | 10     | 47.6  | 8      | 47.1  | 4      | -     | 5      | 21.7  | 3      | -     | 30        | 32.3  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Side surgical margin                                                              | < 20mm                   | 10     | 90.9  | 7      | 77.8  | 8      | 88.9  | 13     | 72.2  | 16     | 100.0 | 54        | 85.7  |
|                                                                                   | 20mm and more            | 1      | -     | 0      | -     | 0      | -     | 2      | -     | 0      | -     | 3         | -     |
|                                                                                   | Unknown                  | 0      | -     | 2      | -     | 1      | -     | 3      | -     | 0      | -     | 6         | 9.5   |
| Deep surgical margin                                                              | < 20mm                   | 8      | 72.7  | 7      | 77.8  | 8      | 88.9  | 11     | 61.1  | 16     | 100.0 | 50        | 79.4  |
|                                                                                   | 20mm and more            | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | Unknown                  | 3      | -     | 2      | -     | 1      | -     | 7      | 38.9  | 0      | -     | 13        | 20.6  |
| Re-excision if diagnostic excision margin < 20mm                                  | Yes                      | 3      | -     | 1      | -     | 4      | -     | 3      | -     | 5      | 31.3  | 16        | 25.8  |
|                                                                                   | No                       | 8      | 72.7  | 8      | 88.9  | 5      | 55.6  | 14     | 82.4  | 11     | 68.8  | 46        | 74.2  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Sentinel lymph node biopsy (SNB)                                                  | Yes                      | 3      | -     | 0      | -     | 3      | -     | 6      | 26.1  | 3      | -     | 15        | 16.1  |
|                                                                                   | No                       | 18     | 85.7  | 17     | 100.0 | 10     | 76.9  | 17     | 73.9  | 16     | 84.2  | 78        | 83.9  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Positive lymph nodes at SNB                                                       | Yes                      | 3      | -     | 0      | -     | 2      | -     | 5      | 83.3  | 2      | -     | 12        | 80.0  |
|                                                                                   | No                       | 0      | -     | 0      | -     | 1      | -     | 1      | -     | 1      | -     | 3         | -     |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage IV                                           |                  |        |       |        |       |        |       |        |       |        |       |           |       |
|----------------------------------------------------|------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                    |                  | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Surgical treatment                                 |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diameter of the largest positive lymph node at SNB | < 0,3mm          | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                    | 0,3 – 1,0mm      | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1         | -     |
|                                                    | > 1,0mm          | 3      | -     | 0      | -     | 2      | -     | 4      | -     | 2      | -     | 11        | 91.7  |
| Lymphadenectomy                                    | Yes              | 4      | -     | 4      | -     | 1      | -     | 1      | -     | 2      | -     | 12        | 12.9  |
|                                                    | No               | 17     | 81.0  | 12     | 70.6  | 11     | 84.6  | 20     | 87.0  | 17     | 89.5  | 77        | 82.8  |
|                                                    | Not carried out* | 0      | -     | 1      | -     | 1      | -     | 2      | -     | 0      | -     | 4         | -     |
| ILP                                                | Yes              | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                    | No               | 21     | 100.0 | 17     | 100.0 | 13     | 100.0 | 23     | 100.0 | 19     | 100.0 | 93        | 100.0 |
|                                                    | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Radiotherapeutic treatment                         |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Radiotherapy                                       | Yes              | 6      | 28.6  | 4      | -     | 2      | -     | 3      | -     | 4      | -     | 19        | 20.4  |
|                                                    | No               | 15     | 71.4  | 13     | 76.5  | 11     | 84.6  | 20     | 87.0  | 15     | 78.9  | 74        | 79.6  |
|                                                    | Not carried out* | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Radiotherapy type                                  | Primary          | 2      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2         | -     |
|                                                    | Postoperative    | 3      | -     | 3      | -     | 1      | -     | 1      | -     | 1      | -     | 9         | 47.4  |
|                                                    | Palliative       | 1      | -     | 1      | -     | 1      | -     | 2      | -     | 3      | -     | 8         | 42.1  |
| Systemic treatment                                 |                  | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Systemic treatment                                 | Yes              | 15     | 71.4  | 9      | 52.9  | 6      | 46.2  | 13     | 56.5  | 11     | 57.9  | 54        | 58.1  |
|                                                    | No               | 6      | 28.6  | 7      | 41.2  | 6      | 46.2  | 4      | 17.4  | 7      | 36.8  | 30        | 32.3  |
|                                                    | Not carried out* | 0      | -     | 1      | -     | 1      | -     | 6      | 26.1  | 1      | -     | 9         | 9.7   |
| Monochemotherapy                                   |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Combination chemotherapy                           |                  | 1      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1         | -     |
| Chemoimmunotherapy                                 |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF inhibitors                                    |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| MEK inhibitors                                     |                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| BRAF in MEK inhibitors                             |                  | 6      | 40.0  | 7      | 77.8  | 2      | -     | 2      | -     | 1      | -     | 18        | 33.3  |
| Combination immunotherapy                          |                  | 0      | -     | 0      | -     | 1      | -     | 2      | -     | 1      | -     | 4         | -     |
| Anti PD-1                                          |                  | 8      | 53.3  | 2      | -     | 3      | -     | 9      | 69.2  | 9      | 81.8  | 31        | 57.4  |

Continued. —&gt;

Table 26: Continued.

| Stage unknown or unspecified                                                      |                          |        |       |        |       |        |       |        |       |        |       |           |       |
|-----------------------------------------------------------------------------------|--------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                   |                          | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                          | 11     |       | 15     |       | 28     |       | 22     |       | 18     |       | 94        |       |
| Mean (age)                                                                        |                          | 72.8   |       | 65.9   |       | 72.8   |       | 61.0   |       | 72.0   |       | 68.8      |       |
| Median (age)                                                                      |                          | 76     |       | 72     |       | 75     |       | 62.5   |       | 71.5   |       | 70.5      |       |
| Histological type (ICD-O-3 code)                                                  |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                          | 11     | 100.0 | 15     | 100.0 | 23     | 82.1  | 20     | 90.9  | 14     | 77.8  | 83        | 88.3  |
| Nodular melanoma (8721)                                                           |                          | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 0      | -     | 1         | -     |
| Lentigo maligna (8742)                                                            |                          | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1         | -     |
| Superficial spreading melanoma (8743)                                             |                          | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 2      | -     | 3         | -     |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770-8772,8780) |                          | 0      | -     | 0      | -     | 3      | -     | 1      | -     | 2      | -     | 6         | 6.4   |
| All (8720–8780)                                                                   |                          | 11     | 100.0 | 15     | 100.0 | 28     | 100.0 | 22     | 100.0 | 18     | 100.0 | 94        | 100.0 |
| Diagnostic treatment                                                              |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Diagnostic staging                                                                | No                       | 2      | -     | 2      | -     | 4      | -     | 2      | -     | 2      | -     | 12        | 12.8  |
|                                                                                   | PET-CT                   | 5      | 45.5  | 7      | 46.7  | 12     | 42.9  | 9      | 40.9  | 10     | 55.6  | 43        | 45.7  |
|                                                                                   | CT                       | 6      | 54.5  | 7      | 46.7  | 15     | 53.6  | 17     | 77.3  | 11     | 61.1  | 56        | 59.6  |
|                                                                                   | MRI                      | 2      | -     | 6      | 40.0  | 5      | 17.9  | 4      | -     | 5      | 27.8  | 22        | 23.4  |
|                                                                                   | US                       | 3      | -     | 7      | 46.7  | 13     | 46.4  | 14     | 63.6  | 12     | 66.7  | 49        | 52.1  |
|                                                                                   | X-ray                    | 3      | -     | 5      | 33.3  | 12     | 42.9  | 12     | 54.5  | 11     | 61.1  | 43        | 45.7  |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 0      | -     | 1         | -     |
| Microscopic confirmation of regional metastases                                   | Metastases not confirmed | 1      | -     | 2      | -     | 1      | -     | 0      | -     | 0      | -     | 4         | -     |
|                                                                                   | Cytologically confirmed  | 2      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 2         | -     |
|                                                                                   | Histologically confirmed | 1      | -     | 1      | -     | 3      | -     | 1      | -     | 0      | -     | 6         | 6.4   |
|                                                                                   | No metastases            | 1      | -     | 0      | -     | 2      | -     | 2      | -     | 2      | -     | 7         | 7.4   |
|                                                                                   | Unknown                  | 6      | 54.5  | 12     | 80.0  | 22     | 78.6  | 19     | 86.4  | 16     | 88.9  | 75        | 79.8  |
| BRAF status determination                                                         | Negative                 | 3      | -     | 6      | 40.0  | 6      | 21.4  | 6      | 27.3  | 7      | 38.9  | 28        | 29.8  |
|                                                                                   | Positive                 | 2      | -     | 2      | -     | 5      | 17.9  | 9      | 40.9  | 1      | -     | 19        | 20.2  |
|                                                                                   | Unknown                  | 6      | 54.5  | 7      | 46.7  | 17     | 60.7  | 7      | 31.8  | 10     | 55.6  | 47        | 50.0  |
|                                                                                   | Testing unsuccessful     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Surgical treatment                                                                |                          | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Excision                                                                          | Yes                      | 1      | -     | 2      | -     | 4      | -     | 2      | -     | 2      | -     | 11        | 11.7  |
|                                                                                   | No                       | 10     | 90.9  | 13     | 86.7  | 24     | 85.7  | 20     | 90.9  | 16     | 88.9  | 83        | 88.3  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Re-excision                                                                       | Yes                      | 1      | -     | 0      | -     | 2      | -     | 2      | -     | 2      | -     | 7         | 63.6  |
|                                                                                   | No                       | 0      | -     | 2      | -     | 2      | -     | 0      | -     | 0      | -     | 4         | -     |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
| Sentinel lymph node biopsy (SNB)                                                  | Yes                      | 1      | -     | 0      | -     | 3      | -     | 3      | -     | 1      | -     | 8         | 8.5   |
|                                                                                   | No                       | 10     | 90.9  | 15     | 100.0 | 25     | 89.3  | 19     | 86.4  | 16     | 88.9  | 85        | 90.4  |
|                                                                                   | Not carried out*         | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 1      | -     | 1         | -     |
| Positive lymph nodes at SNB                                                       | Yes                      | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |
|                                                                                   | No                       | 1      | -     | 0      | -     | 3      | -     | 3      | -     | 1      | -     | 8         | 100.0 |
|                                                                                   | Unknown                  | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0      | -     | 0         | -     |

Continued. —&gt;

Table 26: Continued.

| Stage unknown or unspecified                       |                  |        |       |        |      |        |       |        |       |        |       |           |      |
|----------------------------------------------------|------------------|--------|-------|--------|------|--------|-------|--------|-------|--------|-------|-----------|------|
|                                                    |                  | 2018   |       | 2019   |      | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |      |
| Surgical treatment                                 |                  | Number | %     | Number | %    | Number | %     | Number | %     | Number | %     | Number    | %    |
| Diameter of the largest positive lymph node at SNB | < 0,3mm          | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
|                                                    | 0,3 – 1,0mm      | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
|                                                    | > 1,0mm          | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| Lymphadenectomy                                    | Yes              | 1      | -     | 1      | -    | 3      | -     | 1      | -     | 4      | -     | 10        | 10.6 |
|                                                    | No               | 10     | 90.9  | 14     | 93.3 | 25     | 89.3  | 21     | 95.5  | 14     | 77.8  | 84        | 89.4 |
|                                                    | Not carried out* | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| ILP                                                | Yes              | 0      | -     | 1      | -    | 0      | -     | 0      | -     | 0      | -     | 1         | -    |
|                                                    | No               | 11     | 100.0 | 14     | 93.3 | 28     | 100.0 | 22     | 100.0 | 18     | 100.0 | 93        | 98.9 |
|                                                    | Not carried out* | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| Radiotherapeutic treatment                         |                  | Number | %     | Number | %    | Number | %     | Number | %     | Number | %     | Number    | %    |
| Radiotherapy                                       | Yes              | 1      | -     | 4      | -    | 9      | 32.1  | 3      | -     | 8      | 44.4  | 25        | 26.6 |
|                                                    | No               | 10     | 90.9  | 11     | 73.3 | 19     | 67.9  | 19     | 86.4  | 7      | 38.9  | 66        | 70.2 |
|                                                    | Not carried out* | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 3      | -     | 3         | -    |
| Radiotherapy type                                  | Primary          | 0      | -     | 1      | -    | 1      | -     | 0      | -     | 2      | -     | 4         | -    |
|                                                    | Postoperative    | 1      | -     | 2      | -    | 5      | 55.6  | 2      | -     | 5      | 62.5  | 15        | 60.0 |
|                                                    | Palliative       | 0      | -     | 1      | -    | 3      | -     | 1      | -     | 1      | -     | 6         | 24.0 |
| Systemic treatment                                 |                  | Number | %     | Number | %    | Number | %     | Number | %     | Number | %     | Number    | %    |
| Systemic treatment                                 | Yes              | 2      | -     | 5      | 33.3 | 8      | 28.6  | 12     | 54.5  | 5      | 27.8  | 32        | 34.0 |
|                                                    | No               | 9      | 81.8  | 10     | 66.7 | 19     | 67.9  | 10     | 45.5  | 11     | 61.1  | 59        | 62.8 |
|                                                    | Not carried out* | 0      | -     | 0      | -    | 1      | -     | 0      | -     | 2      | -     | 3         | -    |
| Monotherapy                                        |                  | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| Combination chemotherapy                           |                  | 0      | -     | 1      | -    | 0      | -     | 0      | -     | 0      | -     | 1         | -    |
| Chemoimmunotherapy                                 |                  | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| BRAF inhibitors                                    |                  | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| MEK inhibitors                                     |                  | 0      | -     | 0      | -    | 0      | -     | 0      | -     | 0      | -     | 0         | -    |
| BRAF in MEK inhibitors                             |                  | 0      | -     | 0      | -    | 2      | -     | 5      | 41.7  | 1      | -     | 8         | 25.0 |
| Combination immunotherapy                          |                  | 0      | -     | 1      | -    | 1      | -     | 2      | -     | 2      | -     | 6         | 18.8 |
| Anti PD-1                                          |                  | 2      | -     | 3      | -    | 5      | 62.5  | 5      | 41.7  | 2      | -     | 17        | 53.1 |

\* Patient declined treatment, present contraindications to treatment, poor general condition of the patient, death of the patient, unknown.

\*\* New treatment guidelines.

\*\*\* The histological types were recoded in 2023, which is why the numbers differ from previous reports.

Table 27: Treatment of recurrence in patients with skin melanoma (C43, C51, C60, C63, C77–C80, D03) by year of diagnosis (for progresses of main lesions up to and including Dec 31 2023), Slovenia 2018–2022.

| Treatment of recurrence                                                           |                         |        |       |        |       |        |       |        |       |        |       |           |       |
|-----------------------------------------------------------------------------------|-------------------------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-----------|-------|
|                                                                                   |                         | 2018   |       | 2019   |       | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |       |
| Number of new cases (main lesions)                                                |                         | 100    |       | 106    |       | 81     |       | 78     |       | 64     |       | 429       |       |
| Mean (age)                                                                        |                         | 66,0   |       | 64,8   |       | 71,6   |       | 69,0   |       | 71,2   |       | 68,1      |       |
| Median (age)                                                                      |                         | 67     |       | 68     |       | 73     |       | 68     |       | 74     |       | 70        |       |
| Histological type (ICD-O-3 code)                                                  |                         | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Malignant melanoma, NOS (8720)                                                    |                         | 26     | 26,0  | 30     | 28,3  | 21     | 25,9  | 25     | 32,1  | 14     | 21,9  | 116       | 27,0  |
| Nodular melanoma (8721)                                                           |                         | 33     | 33,0  | 30     | 28,3  | 22     | 27,2  | 23     | 29,5  | 25     | 39,1  | 133       | 31,0  |
| Lentigo maligna (8742)                                                            |                         | 3      | 3,0   | 5      | 4,7   | 1      | 1,2   | 3      | 3,8   | 0      | 0,0   | 12        | 2,8   |
| Superficial spreading melanoma (8743)                                             |                         | 35     | 35,0  | 40     | 37,7  | 30     | 37,0  | 23     | 29,5  | 19     | 29,7  | 147       | 34,3  |
| Other histological types (8722,8723,8730,8740,8741,8744,8745,8761,8770-8772,8780) |                         | 3      | –     | 1      | –     | 7      | 8,6   | 4      | –     | 6      | 9,4   | 21        | 4,9   |
| All (8720–8780)                                                                   |                         | 100    | 100,0 | 106    | 100,0 | 81     | 100,0 | 78     | 100,0 | 64     | 100,0 | 429       | 100,0 |
| Stage at diagnosis                                                                |                         | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| 0                                                                                 |                         | 0      | –     | 0      | –     | 0      | –     | 0      | –     | 0      | –     | 0         | –     |
| IA                                                                                |                         | 4      | –     | 6      | 5,7   | 3      | –     | 3      | –     | 0      | –     | 16        | 3,7   |
| IB                                                                                |                         | 4      | –     | 4      | –     | 1      | –     | 2      | –     | 2      | –     | 13        | 3,0   |
| IIA                                                                               |                         | 9      | 9,0   | 15     | 14,2  | 8      | 9,9   | 1      | –     | 4      | –     | 37        | 8,6   |
| IIB                                                                               |                         | 10     | 10,0  | 13     | 12,3  | 10     | 12,3  | 2      | –     | 8      | 12,5  | 43        | 10,0  |
| IIC                                                                               |                         | 13     | 13,0  | 13     | 12,3  | 13     | 16,0  | 11     | 14,1  | 15     | 23,4  | 65        | 15,2  |
| IIIA                                                                              |                         | 3      | –     | 3      | –     | 3      | –     | 1      | –     | 1      | –     | 11        | 2,6   |
| IIIB                                                                              |                         | 11     | 11,0  | 7      | 6,6   | 2      | 2,5   | 3      | 3,8   | 4      | 6,3   | 27        | 6,3   |
| IIIC                                                                              |                         | 25     | 25,0  | 24     | 22,6  | 23     | 28,4  | 23     | 29,5  | 14     | 21,9  | 109       | 25,4  |
| IIID                                                                              |                         | 4      | –     | 7      | 6,6   | 4      | –     | 9      | 11,5  | 2      | –     | 26        | 6,1   |
| IV                                                                                |                         | 12     | 12,0  | 7      | 6,6   | 6      | 7,4   | 10     | 12,8  | 8      | 12,5  | 43        | 10,0  |
| Stage unknown or unspecified                                                      |                         | 5      | 5,0   | 7      | 6,6   | 8      | 9,9   | 13     | 16,7  | 6      | 9,4   | 39        | 9,1   |
| First recurrence                                                                  |                         | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Type of disease recurrence                                                        | Local                   | 11     | 11,0  | 13     | 12,3  | 8      | 9,9   | 10     | 12,8  | 9      | 14,1  | 51        | 65,4  |
|                                                                                   | In transit              | 13     | 13,0  | 10     | 9,4   | 9      | 11,1  | 6      | 7,7   | 11     | 17,2  | 49        | 62,8  |
|                                                                                   | In transit and regional | 1      | –     | 2      | –     | 1      | –     | 2      | –     | 0      | –     | 6         | 7,7   |
|                                                                                   | Regional                | 16     | 16,0  | 20     | 18,9  | 17     | 21,0  | 16     | 20,5  | 10     | 15,6  | 79        | 101,3 |
|                                                                                   | Systemic                | 59     | 59,0  | 61     | 57,5  | 46     | 56,8  | 44     | 56,4  | 34     | 53,1  | 244       | 312,8 |
| Surgical treatment at first recurrence                                            |                         | Number | %     | Number | %     | Number | %     | Number | %     | Number | %     | Number    | %     |
| Sentinel lymph node biopsy (SNB)                                                  | Yes                     | 1      | –     | 1      | –     | 1      | –     | 1      | –     | 0      | –     | 4         | –     |
|                                                                                   | No                      | 99     | 99,0  | 105    | 99,1  | 80     | 98,8  | 77     | 98,7  | 64     | 100,0 | 425       | 99,1  |
|                                                                                   | Not carried out*        | 0      | –     | 0      | –     | 0      | –     | 0      | –     | 0      | –     | 0         | –     |
| Positive lymph nodes at SNB                                                       | Yes                     | 0      | –     | 1      | –     | 0      | –     | 1      | –     | 0      | –     | 2         | –     |
|                                                                                   | No                      | 1      | –     | 0      | –     | 1      | –     | 0      | –     | 0      | –     | 2         | –     |
|                                                                                   | Unknown                 | 0      | –     | 0      | –     | 0      | –     | 0      | –     | 0      | –     | 0         | –     |
| Lymphadenectomy                                                                   | Yes                     | 15     | 15,0  | 17     | 16,0  | 8      | 9,9   | 7      | 9,0   | 6      | 9,4   | 53        | 12,4  |
|                                                                                   | No                      | 85     | 85,0  | 89     | 84,0  | 72     | 88,9  | 70     | 89,7  | 58     | 90,6  | 374       | 87,2  |
|                                                                                   | Not carried out*        | 0      | –     | 0      | –     | 1      | –     | 1      | –     | 0      | –     | 2         | –     |
| ILP                                                                               | Yes                     | 1      | –     | 1      | –     | 0      | –     | 0      | –     | 0      | –     | 2         | –     |
|                                                                                   | No                      | 99     | 99,0  | 105    | 99,1  | 81     | 100,0 | 78     | 100,0 | 64     | 100,0 | 427       | 99,5  |
|                                                                                   | Not carried out*        | 0      | –     | 0      | –     | 0      | –     | 0      | –     | 0      | –     | 0         | –     |

Continued. —>

Table 27: Continued.

| Treatment of recurrence                        |                  |        |      |        |      |        |       |        |       |        |       |           |      |
|------------------------------------------------|------------------|--------|------|--------|------|--------|-------|--------|-------|--------|-------|-----------|------|
|                                                |                  | 2018   |      | 2019   |      | 2020** |       | 2021   |       | 2022   |       | 2018–2022 |      |
| Radiotherapeutic treatment at first recurrence |                  | Number | %    | Number | %    | Number | %     | Number | %     | Number | %     | Number    | %    |
| Radiotherapy                                   | Yes              | 25     | 25,0 | 25     | 23,6 | 14     | 17,3  | 10     | 12,8  | 16     | 25,0  | 90        | 21,0 |
|                                                | No               | 73     | 73,0 | 80     | 75,5 | 67     | 82,7  | 68     | 87,2  | 48     | 75,0  | 336       | 78,3 |
|                                                | Not carried out* | 2      | –    | 1      | –    | 0      | –     | 0      | –     | 0      | –     | 3         | –    |
| Radiotherapy type                              | Primary          | 0      | –    | 0,0    | –    | 0      | –     | 0      | –     | 0      | –     | 0         | –    |
|                                                | Postoperative    | 12     | 48,0 | 13     | 52,0 | 5      | 35,7  | 6      | 60,0  | 7      | 43,8  | 43        | 47,8 |
|                                                | Palliative       | 13     | 52,0 | 12     | 48,0 | 9      | 64,3  | 4      | 40,0  | 9      | 56,3  | 47        | 52,2 |
| Systemic treatment at first recurrence         |                  | Number | %    | Number | %    | Number | %     | Number | %     | Number | %     | Number    | %    |
| Systemic treatment at first recurrence         | Yes              | 32     | 32,0 | 30     | 28,3 | 32     | 39,5  | 22     | 28,2  | 22     | 34,4  | 138       | 32,2 |
|                                                | No               | 35     | 35,0 | 42     | 39,6 | 28     | 34,6  | 36     | 46,2  | 19     | 29,7  | 160       | 37,3 |
|                                                | Not carried out* | 33     | 33,0 | 34     | 32,1 | 21     | 25,9  | 20     | 25,6  | 23     | 35,9  | 131       | 30,5 |
| Monotherapy                                    |                  | 4      | –    | 4      | –    | 7      | 8,6   | 1      | –     | 2      | –     | 18        | 4,2  |
| Combination chemotherapy                       |                  | 96     | 96,0 | 102    | 96,2 | 74     | 91,4  | 77     | 98,7  | 62     | 96,9  | 411       | 95,8 |
| Chemoimmunotherapy                             |                  | 0      | –    | 0      | –    | 0      | –     | 0      | –     | 0      | –     | 0         | –    |
| BRAF inhibitors                                |                  | 2      | –    | 1      | –    | 0      | –     | 0      | –     | 0      | –     | 3         | –    |
| BRAF in MEK inhibitors                         |                  | 98     | 98,0 | 105    | 99,1 | 81     | 100,0 | 78     | 100,0 | 64     | 100,0 | 426       | 99,3 |
| Combination immunotherapy                      |                  | 0      | –    | 0      | –    | 0      | –     | 0      | –     | 0      | –     | 0         | –    |
| Anti PD-1                                      |                  | 0      | –    | 0      | –    | 0      | –     | 0      | –     | 0      | –     | 0         | –    |

\* Patient declined treatment, present contraindications to treatment, poor general condition of the patient, death of the patient, unknown.

\*\* New treatment guidelines.

# Quality Indicators

Table 28a: Quality indicators for skin melanoma, Slovenia 2018–2022.

| Quality indicator                     |    |                                                                               | Target value | Year  |       |       |       |       |           |
|---------------------------------------|----|-------------------------------------------------------------------------------|--------------|-------|-------|-------|-------|-------|-----------|
|                                       |    |                                                                               |              | 2018  | 2019  | 2020* | 2021  | 2022  | 2018–2022 |
| 1. Excision                           | 1a | Diagnosis with excision biopsy (EB)                                           | 95%          | 96.0  | 96.4  | 95.8  | 96.2  | 97.7  | 96.4      |
|                                       | 1b | EB was performed by a surgeon or a dermatologist                              | 95%          | 99.2  | 98.8  | 98.8  | 99.4  | 99.1  | 99.1      |
| 2. Standardised histopathology report | 2a | Histopathology report was issued within three months after sample removal     | 95%          |       |       |       | 97.0  | 95.8  | /         |
|                                       | 2b | Histopathology report includes complete data                                  | 95%          | 43.2  | 52.1  | 76.1  | 80.3  | 74.0  | 65.2      |
| 3. Re-excision                        | 3a | Re-excision of primary scar at T1 or higher stage                             | 95%          |       |       |       |       |       |           |
|                                       | 3b | Same surgeon as for excision                                                  | 95%          |       |       |       |       |       |           |
|                                       | 3c | Within three months from diagnosis                                            | 95%          |       |       |       |       |       |           |
| 4. Sentinel lymph node biopsy (SNB)   | 4a | SNB at T1b stage or higher                                                    | 80%          | 76.9  | 79.4  | 78.4  | 77.0  | 70.6  | 76.5      |
|                                       | 4b | SNB was performed by a surgical oncologist                                    | 95%          | 100.0 | 99.1  | 98.6  | 98.5  | 99.6  | 99.2      |
|                                       | 4c | Within three months from diagnosis                                            | 95%          |       |       |       | 96.6  | 93.2  | /         |
|                                       | 4d | Standardised histopathology report SNB has complete data                      | 95%          | 94.3  | 94.5  | 95.3  | 92.9  | 95.1  | 94.4      |
| 5. Multidisciplinary council          | 5  | Multidisciplinary council for all patients with stage III or IV               | 95%          |       |       | 67.9  | 72.6  | 89.3  |           |
| 6. Lymphadenectomy                    | 6a | Lymphadenectomy at stage III                                                  | 85%          | 70.9  | 64.9  |       |       |       | /         |
|                                       |    |                                                                               | 45%*         |       |       | 44.9  | 46.7  | 28.8  | /         |
|                                       | 6b | Lymphadenectomy was performed by a surgical oncologist                        | 95%          | 100.0 | 100.0 | 96.3  | 97.4  | 100.0 | 98.7      |
|                                       | 6c | Within four weeks after finding date                                          | 95%          |       |       |       | 33.3  | 18.8  | /         |
| 7. Diagnostic staging                 | 7  | Diagnostic staging for stage III and IV (PET-CT or CT)                        | 95%          | 66.4  | 70.2  | 81.2  | 93.3  | 90.3  | 80.3      |
| 8. BRAF status                        | 8  | BRAF status identified at stages III and IV                                   | 75%          | 49.1  | 62.3  | 68.3  | 73.9  | 78.8  | 66.5      |
| 9. Adjuvant radiotherapy (RT)         | 9  | Proportion of high-risk patients that received adjuvant RT                    | 80%          | 60.0  | 87.5  |       |       |       | /         |
|                                       |    |                                                                               | 60%*         |       |       | 70.6  | 80.0  | 60.0  | /         |
| 10. Radiotherapy                      | 10 | Proportion of completed radiation treatments                                  | 80%          | 93.5  | 97.4  | 96.5  | 95.3  | 93.5  | 95.2      |
| 11. Adjuvant systemic therapy**       | 11 | Proportion of patients that received adjuvant systemic therapy                | 60%*         | 22.7  | 46.6  | 36.5  | 42.2  | 40.8  | 37.8      |
| 12. Systemic therapy                  | 12 | Proportion of patients that received systemic treatment at stage IV (1. line) | 60%          | 66.7  | 50.0  | 30.4  | 48.3  | 50.0  | 49.1      |
| 13. Systemic treatment complications  | 13 | Follow-up of systemic treatment complications                                 | 85%          | 100.0 | 98.0  | 96.7  | 100.0 | 100.0 | 98.9      |
| 14. Completed systemic treatment      | 14 | Proportion of prematurely terminated systemic treatments***                   | < 15%        | 20.7  | 20.9  | 12.2  | 13.2  | 9.0   | 15.2      |
| 15. Clinical research                 | 15 | Participation of patients in clinical research                                | 15%          | 6.3   | 4.0   | 5.7   | 12.8  | 18.7  | 9.5       |

\* New clinical guidelines are issued.

\*\* Major changes in systemic treatments (new treatment or drug; abandoning of treatment or drug usage) in the period 2018–2022.

\*\*\* The proportion of prematurely terminated systemic treatments does not include treatments terminated prematurely due to side effects. In the period 2018–2022, the share of these was 19% on average.

■ Target value is achieved or surpassed

■ Target value is not achieved

□ Conditions for evaluating the quality indicator have changed or are not yet established

Table 28b: Calculation methodology of quality indicators for skin melanoma, Slovenija 2018–2022.

| Quality indicator                     |    |                                                                           | Indicator calculation                                                                                                                                                                                                                                                                             |
|---------------------------------------|----|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Excision                           | 1a | Diagnosis with excision biopsy (EB)                                       | <b>Numerator:</b> Number of new cases of skin melanoma where diagnostic EB was performed<br><b>Denominator:</b> All new cases of skin melanoma                                                                                                                                                    |
|                                       | 1b | EB was performed by a surgeon or a dermatologist                          | <b>Numerator:</b> Number of new cases of skin melanoma where diagnostic EB was performed by a surgeon or a dermatologist<br><b>Denominator:</b> All new cases of skin melanoma where diagnostic EB was performed                                                                                  |
| 2. Standardised histopathology report | 2a | Histopathology report was issued within three months after sample removal | <b>Numerator:</b> Number of new cases of skin melanoma where diagnostic EB was performed and the histopathology report was issued within three months after sample removal (date of report authorisation)<br><b>Denominator:</b> All new cases of skin melanoma where diagnostic EB was performed |
|                                       | 2b | Histopathology report includes complete data                              | <b>Numerator:</b> Number of new cases of primary invasive skin melanoma where diagnostic EB was performed and histopathology report includes all the prognostically relevant data<br><b>Denominator:</b> All new cases of primary invasive skin melanoma where diagnostic EB was performed        |

Continued. —>

Table 28b: Continued.

| Quality indicator                    |    | Indicator calculation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3. Re-excision                       | 3a | Re-excision of primary scar at T1 or higher stage<br><b>Numerator:</b> Number of new cases of skin melanoma with stage IA or higher where diagnostic EB and re-excision of primary scar were performed or the side and deep surgical margins at EB were 10mm or larger for stages IA and IB or 20mm or larger for higher stages<br><b>Denominator:</b> All new cases of stage IA or higher skin melanoma, where diagnostic EB was performed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                      | 3b | Same surgeon as for excision<br><b>Numerator:</b> Number of new cases of stage IA skin melanoma where re-excision of primary scar was performed by the same surgeon that performed the diagnostic EB<br><b>Denominator:</b> All new cases of stage IA skin melanoma where re-excision of primary scar was performed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                      | 3c | Within three months from finding date<br><b>Numerator:</b> Number of new cases of stage IA skin melanoma where re-excision of primary scar was performed within three months from the date of authorisation of the EB pathology report<br><b>Denominator:</b> All new cases of stage IA skin melanoma diagnostic EB was performed with a side or deep surgical margin smaller than 10mm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 4. Sentinel lymph node biopsy (SNB)  | 4a | SNB at T1b stage or higher<br><b>Numerator:</b> Number of new cases of skin melanoma with stages IB-IIC or IIIC where SNB was performed and with stages IIIA, IIIB, IIID or IB with SNB positive lymph nodes<br><b>Denominator:</b> All new cases of skin melanoma with stages IB-IIC or IIIC where diagnostic EB was performed (excluding cases where lymphadenectomy was performed without previous SNB) and stages IIIA, IIIB, IIID and IV with SNB positive lymph nodes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                      | 4b | SNB was performed by a surgical oncologist<br><b>Numerator:</b> Number of new cases of skin melanoma with stage IB or higher where SB was performed at the IOL<br><b>Denominator:</b> All new cases of skin melanoma with stage IB or higher where SB was performed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                      | 4c | Within three months from diagnosis<br><b>Numerator:</b> Number of new cases of skin melanoma with stage IB or higher where SB was performed within three months from the date of the authorisation of the EB pathology report<br><b>Denominator:</b> All new cases of skin melanoma with stage IB or higher where SB was performed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                      | 4d | Standardised histopathology report SNB has complete data<br><b>Numerator:</b> Number of cases of skin melanoma where SB was performed and the histopathology SNB report has complete data<br><b>Denominator:</b> All cases of skin melanoma where SB was performed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 5. Multidisciplinary council         | 5  | Multidisciplinary council for all patients with stage III or IV<br><b>Numerator:</b> Number of new cases of skin melanoma with stage III or IV with a multidisciplinary council (before surgical treatment (excluding excision, re-excision and SNB), systemic treatment or radiotherapy)<br><b>Denominator:</b> All new cases of skin melanoma with stage III or IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 6. Lymphadenectomy                   | 6a | Lymphadenectomy at stage III<br><b>Numerator:</b> Number of new cases of stage III skin melanoma where lymphadenectomy was performed or SNB was performed and there were zero positive lymph nodes<br><b>Denominator:</b> All new cases of stage III skin melanoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                      | 6b | Lymphadenectomy was performed by a surgical oncologist<br><b>Numerator:</b> Number of new cases of stage III skin where lymphadenectomy was performed at the Institute of Oncology Ljubljana<br><b>Denominator:</b> All new cases of stage III skin melanoma where lymphadenectomy was performed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                      | 6c | Within four weeks after finding date<br><b>Numerator:</b> Number of new cases of stage III skin melanoma where lymphadenectomy was performed within four weeks after the diagnosis of metastasis in a lymph node (date of report authorisation or positive cytology or positive SNB)<br><b>Denominator:</b> Number of new cases of stage III skin melanoma where lymphadenectomy was performed after the diagnosis of metastasis in a lymph node (date of report authorisation or positive cytology or positive SNB)<br>Note: cases with neoadjuvant systemic treatment are excluded from the indicator                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 7. Diagnostic staging                | 7  | Diagnostic staging for stage III and IV (PET-CT or CT)<br><b>Numerator:</b> Number of new cases of skin melanoma with stage III or IV where diagnostic staging (PET-CT or CT) was performed<br><b>Denominator:</b> All new cases of skin melanoma with stage III or IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 8. BRAF status                       | 8  | BRAF status identified at stages III and IV<br><b>Numerator:</b> Number of new cases of skin melanoma with stage III or IV with BRAF status identified<br><b>Denominator:</b> All new cases of skin melanoma with stage III or IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 9. Adjuvant radiotherapy (RT)        | 9  | Proportion of high-risk patients that received adjuvant RT<br><b>Numerator:</b> Number of new cases of skin melanoma with stage IIIA, IIIB, IIIC, IIID or with stage IV and lymphadenectomy was performed at first treatment with high risk*, where adjuvant RT was performed<br><b>Denominator:</b> Number of new cases of skin melanoma with stage IIIA, IIIB, IIIC, IIID or with stage IV and lymphadenectomy was performed at first treatment with high risk*<br>*Superficial parotidectomy and neck dissection, number of positive lymph nodes $\geq 1$ , functional neck dissection level II to V or functional neck dissection level I to V or posterolateral neck dissection – number of positive lymph nodes $\geq 2$ , axillary lymphadenectomy – number of positive lymph nodes $\geq 3$ , inguinal lymphadenectomy and/or inguino-iliac lymphadenectomy – number of positive lymph nodes $\geq 3$ , functional neck dissection level II to V or functional neck dissection level I to V or axillary lymphadenectomy – diameter of largest metastasis $\geq 30$ mm, inguinal lymphadenectomy or inguino-iliac lymphadenectomy – diameter of largest metastasis $\geq 40$ mm, lymphadenectomy – extracapsular extension present, lymphadenectomy – tumour in adipose or connective tissue outside of lymph nodes or blood vessels |
| 10. Radiotherapy                     | 10 | Proportion of completed radiation treatments<br><b>Numerator:</b> Number of RT treatments where intended RT was completed<br><b>Denominator:</b> All RT treatments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 11. Adjuvant systemic therapy        | 11 | Proportion of patients that received adjuvant systemic therapy<br><b>Numerator:</b> Number of new cases of skin melanoma with stage IIB, IIC in III with adjuvant systemic treatment (excluding cases where SNB was performed and the number of positive lymph nodes was zero, but including cases where SNB was and the number of positive lymph nodes was zero and there was disease recurrence and treatment with lymphadenectomy)<br><b>Denominator:</b> Number of new cases of skin melanoma with stage IIB, IIC in III (excluding cases where SNB was performed and the number of positive lymph nodes was zero, but including cases where SNB was and the number of positive lymph nodes was zero and there was disease recurrence and treatment with lymphadenectomy)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 12. Systemic therapy                 | 12 | Proportion of patients that received systemic treatment at stage IV (1. line)<br><b>Numerator:</b> Number of new cases of stage IV skin melanoma that received systemic treatment (1. line)<br><b>Denominator:</b> All new cases of stage IV skin melanoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 13. Systemic treatment complications | 13 | Follow-up of systemic treatment complications<br><b>Numerator:</b> Number of systemic treatment therapies for which systemic treatment side effects were recorded<br><b>Denominator:</b> All systemic treatment therapies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 14. Completed systemic treatment     | 14 | Proportion of prematurely terminated systemic treatments<br><b>Numerator:</b> Number of prematurely terminated systemic treatments<br><b>Denominator:</b> All systemic treatments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 15. Clinical research                | 15 | Participation of patients in clinical research<br><b>Numerator:</b> Number of patients with stages II, III and IV, that were included in clinical research<br><b>Denominator:</b> Number of patients with stages II, III and IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |





